Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

ABSTRACT

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

This application claims benefit to International Application No. PCT/US2008/063621, filed May 15, 2008, under 35 U.S.C. §365(a); which claims priority to provisional application U.S. Serial No. 60/938,570, filed May 17, 2007; under 35 U.S.C. §119(e). The entire teachings of the referenced applications are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to the field of pharmacogenomics, and more specifically, to methods and procedures used to monitor response or determine sensitivity in patients to allow the identification of individualized genetic profiles which will aid in treating diseases and disorders.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

Incorporated herein by reference in its entirety is a Sequence Listing entitled, “11082USPCT ST25.txt”, comprising SEQ ID NO:1 through SEQ ID NO:286, which include amino acid sequences disclosed herein. The Sequence Listing has been submitted herewith in ASCII text format via EFS, and thus constitutes both the paper and computer readable form thereof. The Sequence Listing was first created using PatentIn on May 7, 2012, and is 52 KB in size.

BACKGROUND OF THE INVENTION

Cancer is a disease with extensive histoclinical heterogeneity. Although conventional histological and clinical features have been correlated to prognosis, the same apparent prognostic type of tumors varies widely in its responsiveness to therapy and consequent survival of the patient.

New prognostic and predictive markers, which would facilitate an individualization of therapy for each patient, are needed to accurately predict patient response to treatments, such as small molecule or biological molecule drugs, in the clinic. The problem may be solved by the identification of new parameters that could better predict the patient's sensitivity to treatment. The classification of patient samples is a crucial aspect of cancer diagnosis and treatment. The association of a patient's response to a treatment with molecular and genetic markers can open up new opportunities for treatment development in non-responding patients, or distinguish a treatment's indication among other treatment choices because of higher confidence in the efficacy. Further, the pre-selection of patients who are likely to respond well to a medicine, drug, or combination therapy may reduce the number of patients needed in a clinical study or accelerate the time needed to complete a clinical development program (M. Cockett et al., Current Opinion in Biotechnology, 11:602-609 (2000)).

The ability to determine which patients are responding to anti-angiogenesis therapies (such as IGF1R modulators) or predict drug sensitivity in patients is particularly challenging because drug responses reflect not only properties intrinsic to the target cells, but also a host's metabolic properties. Efforts to use genetic information to predict or monitor drug response have primarily focused on individual genes that have broad effects, such as the multidrug resistance genes mdr1 and mrp1 (P. Sonneveld, J. Intern. Med., 247:521-534 (2000)).

The development of microarray technologies for large scale characterization of gene mRNA expression pattern has made it possible to systematically search for molecular markers and to categorize cancers into distinct subgroups not evident by traditional histopathological methods (J. Khan et al., Cancer Res., 58:5009-5013 (1998); A. A. Alizadeh et al., Nature, 403:503-511 (2000); M. Bittner et al., Nature, 406:536-540 (2000); J. Khan et al., Nature Medicine, 7(6):673-679 (2001); and T. R. Golub et al., Science, 286:531-537 (1999); U. Alon et al., P.N.A.S. USA, 96:6745-6750 (1999)). Such technologies and molecular tools have made it possible to monitor the expression level of a large number of transcripts within a cell population at any given time (see, e.g., Schena et al., Science, 270:467-470 (1995); Lockhart et al., Nature Biotechnology, 14:1675-1680 (1996); Blanchard et al., Nature Biotechnology, 14:1649 (1996); U.S. Pat. No. 5,569,588 to Ashby et al.).

Recent studies demonstrate that gene expression information generated by microarray analysis of human tumors can predict clinical outcome (L. J. van't Veer et al., Nature, 415:530-536 (2002); M. Shipp et al., Nature Medicine, 8(1):68-74 (2002); G. Glinsky et al., The Journal of Clin. Invest., 113(6):913-923 (2004)). These findings bring hope that cancer treatment will be vastly improved by better predicting and monitoring the response of individual tumors to therapy.

PCT Application No. PCT/US2006/034201 provides biomarkers useful for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator.

Needed are new and alternative methods and procedures to determine drug sensitivity or monitor response in patients to allow the development of individualized diagnostics which are necessary to treat diseases and disorders based on patient response at a molecular level.

SUMMARY OF THE INVENTION

The invention provides methods and procedures for determining patient sensitivity or monitor response at the molecular level to one or more insulin growth factor 1 receptor (IGF1R) modulators. The invention also provides methods of determining or predicting whether an individual requiring therapy for a disease state such as cancer will or will not respond to treatment, prior to administration of the treatment, wherein the treatment comprises administration of one or more IGF1R modulators. The one or more IGF1R modulators are compounds that can be selected from, for example, one or more IGF1R specific ligands, one or more small molecule IGF1R inhibitors, or one or more IGF1R binding monoclonal antibodies.

In one aspect, the invention provides a method for predicting the likelihood a mammal will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises: (a) measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8; (b) exposing a biological sample from said mammal to the IGF1R modulator; (c) following the exposing of step (b), measuring in said biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a), indicates an increased likelihood that the mammal will respond therapeutically to said method of treating cancer when said at least one biomarker is a sensitivity biomarker, and indicates an increased likelihood that the mammal will not respond therapeutically to said method of treating cancer when said at least one biomarker is a resistance biomarker.

In another aspect, the invention provides a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises: (a) measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8; (b) exposing a biological sample from the mammal to the IGF1R modulator; (c) following the exposing in step (b), measuring in said biological sample the level of the at least one biomarker and using said measurement to determine whether the mammal is likely to respond therapeutically to said method of treating cancer.

A difference in the level of the biomarker that is sufficient to indicate whether the mammal will or will not respond therapeutically to the method of treating cancer can be readily determined by one of skill in the art using known techniques. The increase or decrease in the level of the biomarker can be correlated to determine whether the difference is sufficient to identify a mammal that will respond therapeutically. The difference in the level of the biomarker that is sufficient can, in one aspect, be predetermined prior to determining whether the mammal will respond therapeutically to the treatment. In one aspect, the difference in the level of the biomarker is a difference in the mRNA level (measured, for example, by RT-PCR or a microarray), such as at least a two-fold difference, at least a three-fold difference, or at least a four-fold difference in the level of expression. In another aspect, the difference in the level of the biomarker is determined by IHC. In another aspect, the difference in the level of the biomarker refers to a p-value of <0.05 in Anova analysis. In yet another aspect, the difference is determined in an ELISA assay.

As used herein, respond therapeutically refers to the alleviation or abrogation of the cancer. This means that the life expectancy of an individual affected with the cancer will be increased or that one or more of the symptoms of the cancer will be reduced or ameliorated. The term encompasses a reduction in cancerous cell growth or tumor volume. Whether a mammal responds therapeutically can be measured by many methods well known in the art, such as PET imaging.

The mammal can be, for example, a human, rat, mouse, dog rabbit, pig sheep, cow, horse, cat, primate, or monkey.

The method of the invention can be, for example, an in vitro method wherein the step of measuring in the mammal the level of at least one biomarker comprises taking a biological sample from the mammal and then measuring the level of the biomarker(s) in the biological sample. The biological sample can comprise, for example, at least one of serum, whole fresh blood, peripheral blood mononuclear cells, frozen whole blood, fresh plasma, frozen plasma, urine, saliva, skin, hair follicle, bone marrow, or tumor tissue.

The level of the at least one biomarker can be, for example, the level of protein and/or mRNA transcript of the biomarker(s).

In another aspect, the invention provides a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises: (a) exposing a biological sample from the mammal to the IGF1R modulator; (b) following the exposing of step (a), measuring in said biological sample the level of at least one biomarker selected from the biomarkers of Tables 2-8, wherein a difference in the level of the at least one biomarker measured in step (b), compared to the level of the biomarker in a mammal that has not been exposed to said IGF1R modulator, indicates that the mammal will respond therapeutically to said method of treating cancer.

In yet another aspect, the invention provides a method for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises: (a) measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8; (b) exposing the mammal to the IGF1R modulator; (c) following the exposing of step (b), measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates that the mammal will respond therapeutically to said method of treating cancer.

In another aspect, the invention provides a method for determining whether a compound inhibits IGF1R activity in a mammal, comprising: (a) exposing the mammal to the compound; and (b) following the exposing of step (a), measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8, wherein a difference in the level of said biomarker measured in step (b), compared to the level of the biomarker in a mammal that has not been exposed to said compound, indicates that the compound inhibits IGF1R activity in the mammal

In yet another aspect, the invention provides a method for determining whether a mammal has been exposed to a compound that inhibits IGF1R activity, comprising (a) exposing the mammal to the compound; and (b) following the exposing of step (a), measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8, wherein a difference in the level of said biomarker measured in step (b), compared to the level of the biomarker in a mammal that has not been exposed to said compound, indicates that the mammal has been exposed to a compound that inhibits IGF1R activity.

In another aspect, the invention provides a method for determining whether a mammal is responding to a compound that inhibits IGF1R activity, comprising (a) exposing the mammal to the compound; and (b) following the exposing of step (a), measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8, wherein a difference in the level of the at least one biomarker measured in step (b), compared to the level of the at least one biomarker in a mammal that has not been exposed to said compound, indicates that the mammal is responding to the compound that inhibits IGF1R activity.

As used herein, “responding” encompasses responding by way of a biological and cellular response, as well as a clinical response (such as improved symptoms, a therapeutic effect, or an adverse event), in a mammal

The invention also provides an isolated biomarker selected from the biomarkers of Tables 2-8. The biomarkers of the invention comprise sequences selected from the nucleotide and amino acid sequences provided in Tables 2-8 and the Sequence Listing, as well as fragments and variants thereof.

The invention also provides a biomarker set comprising two or more biomarkers selected from the biomarkers of Tables 2-8.

The invention also provides kits for determining or predicting whether a patient would be susceptible or resistant to a treatment that comprises one or more IGF1R modulators. The patient may have a cancer or tumor such as, for example, a colon cancer or tumor.

In one aspect, the kit comprises a suitable container that comprises one or more specialized microarrays of the invention, one or more IGF1R modulators for use in testing cells from patient tissue specimens or patient samples, and instructions for use. The kit may further comprise reagents or materials for monitoring the expression of a biomarker set at the level of mRNA or protein.

In another aspect, the invention provides a kit comprising two or more biomarkers selected from the biomarkers of Tables 2-8.

In yet another aspect, the invention provides a kit comprising at least one of an antibody and a nucleic acid for detecting the presence of at least one of the biomarkers selected from the biomarkers of Tables 2-8. In one aspect, the kit further comprises instructions for determining whether or not a mammal will respond therapeutically to a method of treating cancer comprising administering a compound that inhibits IGF1R activity. In another aspect, the instructions comprise the steps of (a) measuring in the mammal the level of at least one biomarker selected from the biomarkers of Tables 2-8, (b) exposing the mammal to the compound, (c) following the exposing of step (b), measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates that the mammal will respond therapeutically to said method of treating cancer.

The invention also provides screening assays for determining if a patient will be susceptible or resistant to treatment with one or more IGF1R modulators.

The invention also provides a method of monitoring the treatment of a patient having a disease, wherein said disease is treated by a method comprising administering one or more IGF1R modulators.

The invention also provides individualized genetic profiles which are necessary to treat diseases and disorders based on patient response at a molecular level.

The invention also provides specialized microarrays, e.g., oligonucleotide microarrays or cDNA microarrays, comprising one or more biomarkers having expression profiles that correlate with either sensitivity or resistance to one or more IGF1R modulators.

The invention also provides antibodies, including polyclonal or monoclonal, directed against one or more biomarkers of the invention.

The invention will be better understood upon a reading of the detailed description of the invention when considered in connection with any accompanying figures.

DETAILED DESCRIPTION OF THE INVENTION

Identification of biomarkers that provide rapid and accessible readouts of efficacy, drug exposure, or clinical response is increasingly important in the clinical development of drug candidates. Embodiments of the invention include measuring changes in the levels of secreted proteins, or plasma biomarkers, which represent one category of biomarker. In one aspect, plasma samples, which represent a readily accessible source of material, serve as surrogate tissue for biomarker analysis.

The invention provides biomarkers that respond to the modulation of a specific signal transduction pathway and also correlate with IGF1R modulator sensitivity or resistance. These biomarkers can be employed for predicting and monitoring response to one or more IGF1R modulators. In one aspect, the biomarkers of the invention are those provided in Tables 2-8 and the Sequence Listing, including both polynucleotide and polypeptide sequences. In another aspect, the biomarkers of the invention are nucleotide sequences that, due to the degeneracy of the genetic code, encodes for a polypeptide sequence provided in the sequence listing.

The biomarkers serve as useful molecular tools for predicting and monitoring response to IGF1R modulators that affect IGF1R activity or the IGF1R signal transduction pathway.

In addition to playing an important role in normal cell growth, maintenance and development, insulin-like growth factor receptor (IGF1R) and its ligands are also important in the establishment and maintenance of the malignant phenotype. Binding of IGF-1 and IGF-II ligands to the IGF1R initiates a cascade of events leading to activation of mitogenic signaling pathway (Ras/Raf/MAPK) and antiapoptotic/survival pathway (PI3K-Akt/mTor), resulting in proliferation, transformation and survival in tumor cells (D. LeRoith, et al., Cancer Lett., 195(2):127-37 (2003), R. Baserga, et al., Int. J. Cancer;107:873-7 (2003)). IGF1R overexpression and/or enhanced activity have been observed in diverse tumor types suggesting that the potential therapeutic use of agents targeting this pathway is broad. IGF1R provides a critical survival signal in multiple tumor types. The expression of this receptor is an indicator of poor prognosis, thus, it has emerged as an attractive and compelling target for cancer therapy to inhibit the progression of multiple tumor types in cancer patients. Various drug discovery approaches have been explored in recent years to modulate the function of IGF1R. Approaches aimed at the reduction of receptor number or enzymatic activity using a variety of strategies in preclinical models have been shown to reverse the malignant phenotype in tumor cells. These strategies include antisense (L. Long, et al., Cancer Res, 55(5):1006-9 (1995), D. Andrews et al., J. Clin. Oncol., 19(8):2189-200 (2001)), monoclonal antibody (C. Arteaga, et al., Cancer Res., 49(22):6237-41 (1989)), small molecule inhibitors (M. Wittman, et al., J. Med. Chem., September 8;48(18):5639-43 (2005), C. Garcia-Echeverria, et al., Cancer Cell, 5(3):231-9 (2004)), IGF-1 mimetic peptides (Z. Pietrzkowski, et al., Cancer Res., 53(5):1102-6 (1993)) as well as dominant negative mutants that lack enzyme activity (C. D'Ambrosio, et al., Cancer Res, 56(17): 4013-20 (1996)).

However, this targeted therapy may only be successful if the receptor is absolutely necessary for pathogenesis and tumor progression. IGF1R and its ligands have been shown to be important in the mesenchymal originated soft tissue sarcomas and neuroblastoma (G. Merlino, et al., Oncogene;18:5340-8 (1999), K. Scotlandi, et al., Cancer Res.;56:4570-4 (1996), S. Burrow, et al., J. Surg. Oncol.;69:21-7 (1998), D. Yee, et al., J. Clin. Invest., 86(6) : 1806-14 (1990)). These rare tumors have distinctive biological characteristics including aggressive local behavior and a predilection for metastasis. With multimodal treatments and very aggressive chemotherapeutic regimens, the survival rate is disappointingly low and, thus, there is a high unmet medical need for the treatment of patients with these tumor types. Inhibition of IGF1R by antibody or small molecule either alone or in combination with other chemotherapeutic agents have demonstrated antitumor activity in sarcomas (S. Benini, et al., Clinical Cancer Res., 7, 1790-97 (2001), K. Scotlandi, et al., Cancer Res., May 1;65(9):3868-76 (2005), M. Manara, et al., Clinical Cancer Res.; 13(4) 1322-30 (2007)).

One of the integral goals in the development of these targeted cancer therapies is to identify the targeted patients population who are most likely to benefit from the drug treatment. Utilizing biomarkers has successfully guided the development of Herceptin® and EGFR inhibitors (J. Baselga, et al., J Clin Oncol. 14, 737-744 (2005), T. Lynch, et al., N. Engl. J. Med., 350, 2129-2139 (2004)). More recently, gene expression profiling studies have demonstrated the advantages of molecular “signatures” or marker sets generated by microarray analysis in predicting chemotherapeutic response and guiding the targeted therapies (K. Iwao-Koizumi, et al., J. Clin. Oncol.;23:422-31 (2005), H. Dressman, et al., Clin. Cancer Res.;12:819-26 (2006), R. Rouzier, et al., Clin. Cancer Res.;11:5678-85 (2005), K. Hess, et al., J. Clin. Oncol.;24:4236-44 (2006), H. Dressman, et al., J. Clin. Oncol., February 10;25(5):517-25 (2007), A. Potti, et al., Nat. Med., November;12(11):1294-300 (2006)). These findings provide hope that cancer treatments of the future will be vastly improved by using molecular “signatures” to choose the most effective drug for patient targeting. One of the challenges is to determine the targeted patient population for the drug before clinical data is available.

To overcome this challenge, as described previously (F. Huang F, et al., Cancer Res., March 1;67(5):2226-38 (2007)), cultured cancer cell lines can be used as models to identify biomarkers that correlate with response to a therapy assuming these markers identified in vitro are ultimately applicable in clinical studies to select targeted patient population.

To this end, in this study, the gene and protein profiling by both microarray and LC/MS based “bottom-up” protein profiling (M. Lipton, et al., Proc. Natl. Acad. Sci. USA., August 20;99(17):11049-54 (2002), H. Prokisch et al., PLoS Biol., June;2(6):e160 (2004)) were conduced in parallel using a panel of 29 cell lines to identify genes or proteins whose basal expression levels are correlated with the in vitro sensitivity of cells to compound 1 or compound 2 (as defined below) and potentially could be used as predictive markers. To gain insights of acquired resistance of compound 1, gene expression profiles of a pair of sensitive and acquired resistant cell lines were compared to identify genes correlated with the acquired resistance. These genes were then compared to the genes over expressed in the resistant cell lines at basal level (correlated with the de novo resistance to the drug). Common mechanism of de novo resistance and acquired resistance to IGF1R inhibitor compound 1 was explored. Furthermore, genes/proteins modulated by drug treatment of compound 1 were identified and linked to the possible mechanisms of the drug action. These markers could be useful to monitor the biological effects of the drug and to select the optimal dose in the clinical studies. To explore the relation between these biomarkers and the drug target IGF1R, pathway analyses were performed and cross-talk between the IGF1R and other kinases was evident, this led us to propose the hypothesis for the potential synergistic activity between compound 1 and other agents targeting these kinases. Drug combination studies of compound 1 with other agents, such as EGFR inhibitors, were performed and synergy in tumor growth inhibition in vitro was observed with combined inhibition of multiple pathways. In this study, we identified the biomarkers of potentially predictive the targeted sub-population of patient with sarcomas that would be benefit from the treatment of IGF1R inhibitor.

IGF1R Modulators:

As used herein, the term “IGF1R modulator” is intended to mean a compound or drug that is a biological molecule or a small molecule that directly or indirectly modulates IGF1R activity or the IGF1R signal transduction pathway. Thus, compounds or drugs as used herein is intended to include both small molecules and biological molecules. Direct or indirect modulation includes activation or inhibition of IGF1R activity or the IGF1R signal transduction pathway. In one aspect, inhibition refers to inhibition of the binding of IGF1R to an IGF1R ligand such as, for example, VEGF. In another aspect, inhibition refers to inhibition of the kinase activity of IGF1R.

IGF1R modulators include, for example, IGF1R specific ligands, small molecule IGF1R inhibitors, and IGF1R monoclonal antibodies. In one aspect, the IGF1R modulator inhibits IGF1R activity and/or inhibits the IGF1R signal transduction pathway. In another aspect, the IGF1R modulator is an IGF1R monoclonal antibody that inhibits IGF1R activity and/or inhibits the IGF1R signal transduction pathway.

IGF1R modulators include biological molecules or small molecules.

Biological molecules include all lipids and polymers of monosaccharides, amino acids, and nucleotides having a molecular weight greater than 450. Thus, biological molecules include, for example, oligosaccharides and polysaccharides; oligopeptides, polypeptides, peptides, and proteins; and oligonucleotides and polynucleotides. Oligonucleotides and polynucleotides include, for example, DNA and RNA.

Biological molecules further include derivatives of any of the molecules described above. For example, derivatives of biological molecules include lipid and glycosylation derivatives of oligopeptides, polypeptides, peptides, and proteins.

Derivatives of biological molecules further include lipid derivatives of oligosaccharides and polysaccharides, e.g., lipopolysaccharides. Most typically, biological molecules are antibodies, or functional equivalents of antibodies. Functional equivalents of antibodies have binding characteristics comparable to those of antibodies, and inhibit the growth of cells that express IGF1R. Such functional equivalents include, for example, chimerized, humanized, and single chain antibodies as well as fragments thereof

Functional equivalents of antibodies also include polypeptides with amino acid sequences substantially the same as the amino acid sequence of the variable or hypervariable regions of the antibodies. An amino acid sequence that is substantially the same as another sequence, but that differs from the other sequence by means of one or more substitutions, additions, and/or deletions, is considered to be an equivalent sequence. Preferably, less than 50%, more preferably less than 25%, and still more preferably less than 10%, of the number of amino acid residues in a sequence are substituted for, added to, or deleted from the protein.

The functional equivalent of an antibody is preferably a chimerized or humanized antibody. A chimerized antibody comprises the variable region of a non-human antibody and the constant region of a human antibody. A humanized antibody comprises the hypervariable region (CDRs) of a non-human antibody. The variable region other than the hypervariable region, e.g., the framework variable region, and the constant region of a humanized antibody are those of a human antibody.

Suitable variable and hypervariable regions of non-human antibodies may be derived from antibodies produced by any non-human mammal in which monoclonal antibodies are made. Suitable examples of mammals other than humans include, for example, rabbits, rats, mice, horses, goats, or primates.

Functional equivalents further include fragments of antibodies that have binding characteristics that are the same as, or are comparable to, those of the whole antibody. Suitable fragments of the antibody include any fragment that comprises a sufficient portion of the hypervariable (i.e., complementarity determining) region to bind specifically, and with sufficient affinity, to IGF1R tyrosine kinase to inhibit growth of cells that express such receptors.

Such fragments may, for example, contain one or both Fab fragments or the F(ab′)2 fragment. Preferably, the antibody fragments contain all six complementarity determining regions of the whole antibody, although functional fragments containing fewer than all of such regions, such as three, four, or five CDRs, are also included.

In one aspect, the fragments are single chain antibodies, or Fv fragments. Single chain antibodies are polypeptides that comprise at least the variable region of the heavy chain of the antibody linked to the variable region of the light chain, with or without an interconnecting linker. Thus, Fv fragment comprises the entire antibody combining site. These chains may be produced in bacteria or in eukaryotic cells.

The antibodies and functional equivalents may be members of any class of immunoglobulins, such as IgG, IgM, IgA, IgD, or IgE, and the subclasses thereof.

In one aspect, the antibodies are members of the IgG1 subclass. The functional equivalents may also be equivalents of combinations of any of the above classes and subclasses.

In one aspect, the IGF1R antibody is provided in PCT publication nos. WO2005/016970, WO02/53596, WO2004/71529, WO2005/16967, WO2004/83248, WO03/106621, WO03/100008, WO03/59951, WO2004/87756, or WO2005/05635.

In another aspect, the IGF1R modulator is derived from fibronectin, such as an AdNectin (Adnexus Therapeutics) (See, PCT publication nos. WO00/34784, WO01/64942, WO02/32925).

In addition to the biological molecules discussed above, the IGF1R modulators useful in the invention may also be small molecules. Any molecule that is not a biological molecule is considered herein to be a small molecule. Some examples of small molecules include organic compounds, organometallic compounds, salts of organic and organometallic compounds, saccharides, amino acids, and nucleotides. Small molecules further include molecules that would otherwise be considered biological molecules, except their molecular weight is not greater than 450. Thus, small molecules may be lipids, oligosaccharides, oligopeptides, and oligonucleotides and their derivatives, having a molecular weight of 450 or less.

It is emphasized that small molecules can have any molecular weight. They are merely called small molecules because they typically have molecular weights less than 450. Small molecules include compounds that are found in nature as well as synthetic compounds. In one embodiment, the IGF1R modulator is a small molecule that inhibits the growth of tumor cells that express IGF1R. In another embodiment, the IGF1R modulator is a small molecule that inhibits the growth of refractory tumor cells that express IGF1R.

Numerous small molecules have been described as being useful to inhibit IGF1R.

In one aspect, the IGF1R modulator is selected from PCT publication nos. WO02/79192, WO2004/30620, WO2004/31401 WO2004/63151, and WO2005/21510, and from U.S. provisional application Nos. 60/819,171, 60/870,872, 60/883,601, and 60/912,446.

In another aspect, the IGF1R modulator is selected from (S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)-pyridin-2(1-H)-one and (2S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-2-pyrrolidinecarboxamide.

In another aspect, the IGF1R modulator is selected from XL-228 (Exelixis), AEW-541 (Novartis), and OSI-906 (OSI).

Biomarkers and Biomarker Sets:

The invention includes individual biomarkers and biomarker sets having both diagnostic and prognostic value in disease areas in which signaling through IGF1R or the IGF1R pathway is of importance, e.g., in cancers or tumors, in immunological disorders, conditions or dysfunctions, or in disease states in which cell signaling and/or cellular proliferation controls are abnormal or aberrant. The biomarker sets comprise a plurality of biomarkers such as, for example, a plurality of the biomarkers provided in Tables 2-8 that highly correlate with resistance or sensitivity to one or more IGF1R modulators.

The biomarkers and biomarker sets of the invention enable one to predict or reasonably foretell the likely effect of one or more IGF1R modulators in different biological systems or for cellular responses. The biomarkers and biomarker sets can be used in in vitro assays of IGF1R modulator response by test cells to predict in vivo outcome. In accordance with the invention, the various biomarkers and biomarker sets described herein, or the combination of these biomarker sets with other biomarkers or markers, can be used, for example, to predict and monitor how patients with cancer might respond to therapeutic intervention with one or more IGF1R modulators.

A biomarker and biomarker set of cellular gene expression patterns correlating with sensitivity or resistance of cells following exposure of the cells to one or more IGF1R modulators provides a useful tool for screening one or more tumor samples before treatment with the IGF1R modulator. The screening allows a prediction of cells of a tumor sample exposed to one or more IGF1R modulators, based on the expression results of the biomarker and biomarker set, as to whether or not the tumor, and hence a patient harboring the tumor, will or will not respond to treatment with the IGF1R modulator.

The biomarker or biomarker set can also be used as described herein for monitoring the progress of disease treatment or therapy in those patients undergoing treatment for a disease involving an IGF1R modulator.

The biomarkers also serve as targets for the development of therapies for disease treatment. Such targets may be particularly applicable to treatment of cancer, such as, for example, hepatocellular carcinoma, colorectal cancer (CRC), NSCLC, and metastatic breast cancer.

Indeed, because these biomarkers are differentially expressed in sensitive and resistant cells, their expression patterns are correlated with relative intrinsic sensitivity of cells to treatment with IGF1R modulators. Accordingly, the biomarkers highly expressed in resistant cells may serve as targets for the development of new therapies for the tumors which are resistant to IGF1R modulators, particularly IGF1R inhibitors. The level of biomarker protein and/or mRNA can be determined using methods well known to those skilled in the art. For example, quantification of protein can be carried out using methods such as ELISA, 2-dimensional SDS PAGE, Western blot, immunopreciptation, immunohistochemistry, fluorescence activated cell sorting (FACS), or flow cytometry. Quantification of mRNA can be carried out using methods such as PCR, array hybridization, Northern blot, in-situ hybridization, dot-blot, Taqman, or RNAse protection assay.

Microassays:

The invention also includes specialized microarrays, e.g., oligonucleotide microarrays or cDNA microarrays, comprising one or more biomarkers, showing expression profiles that correlate with either sensitivity or resistance to one or more IGF1R modulators. Such microarrays can be employed in in vitro assays for assessing the expression level of the biomarkers in the test cells from tumor biopsies, and determining whether these test cells are likely to be resistant or sensitive to IGF1R modulators. For example, a specialized microarray can be prepared using all the biomarkers, or subsets thereof, as described herein and shown in Tables 2-8. Cells from a tissue or organ biopsy can be isolated and exposed to one or more of the IGF1R modulators. In one aspect, following application of nucleic acids isolated from both untreated and treated cells to one or more of the specialized microarrays, the pattern of gene expression of the tested cells can be determined and compared with that of the biomarker pattern from the control panel of cells used to create the biomarker set on the microarray. Based upon the gene expression pattern results from the cells that underwent testing, it can be determined if the cells show a resistant or a sensitive profile of gene expression. Whether or not the tested cells from a tissue or organ biopsy will respond to one or more of the IGF1R modulators and the course of treatment or therapy can then be determined or evaluated based on the information gleaned from the results of the specialized microarray analysis.

Antibodies:

The invention also includes antibodies, including polyclonal or monoclonal, directed against one or more of the polypeptide biomarkers. Such antibodies can be used in a variety of ways, for example, to purify, detect, and target the biomarkers of the invention, including both in vitro and in vivo diagnostic, detection, screening, and/or therapeutic methods.

Kits:

The invention also includes kits for determining or predicting whether a patient would be susceptible or resistant to a treatment that comprises one or more IGF1R modulators. The patient may have a cancer or tumor such as, for example, a breast cancer or tumor. Such kits would be useful in a clinical setting for use in testing a patient's biopsied tumor or cancer samples, for example, to determine or predict if the patient's tumor or cancer will be resistant or sensitive to a given treatment or therapy with an IGF1R modulator. The kit comprises a suitable container that comprises: one or more microarrays, e.g., oligonucleotide microarrays or cDNA microarrays, that comprise those biomarkers that correlate with resistance and sensitivity to IGF1R modulators, particularly IGF1R inhibitors; one or more IGF1R modulators for use in testing cells from patient tissue specimens or patient samples; and instructions for use. In addition, kits contemplated by the invention can further include, for example, reagents or materials for monitoring the expression of biomarkers of the invention at the level of mRNA or protein, using other techniques and systems practiced in the art such as, for example, RT-PCR assays, which employ primers designed on the basis of one or more of the biomarkers described herein, immunoassays, such as enzyme linked immunosorbent assays (ELISAs), immunoblotting, e.g., Western blots, or in situ hybridization, and the like, as further described herein.

Application of Biomarkers and Biomarker Sets:

The biomarkers and biomarker sets may be used in different applications. Biomarker sets can be built from any combination of biomarkers listed in Tables 2-8 to make predictions about the likely effect of any IGF1R modulator in different biological systems. The various biomarkers and biomarkers sets described herein can be used, for example, as diagnostic or prognostic indicators in disease management, to predict how patients with cancer might respond to therapeutic intervention with compounds that modulate the IGF1R, and to predict how patients might respond to therapeutic intervention that modulates signaling through the entire IGF1R regulatory pathway.

While the data described herein were generated in cell lines that are routinely used to screen and identify compounds that have potential utility for cancer therapy, the biomarkers have both diagnostic and prognostic value in other diseases areas in which signaling through IGF1R or the IGF1R pathway is of importance, e.g., in immunology, or in cancers or tumors in which cell signaling and/or proliferation controls have gone awry.

In accordance with the invention, cells from a patient tissue sample, e.g., a tumor or cancer biopsy, can be assayed to determine the expression pattern of one or more biomarkers prior to treatment with one or more IGF1R modulators. Success or failure of a treatment can be determined based on the biomarker expression pattern of the cells from the test tissue (test cells), e.g., tumor or cancer biopsy, as being relatively similar or different from the expression pattern of a control set of the one or more biomarkers. Thus, if the test cells show a biomarker expression profile which corresponds to that of the biomarkers in the control panel of cells which are sensitive to the IGF1R modulator, it is highly likely or predicted that the individual's cancer or tumor will respond favorably to treatment with the IGF1R modulator. By contrast, if the test cells show a biomarker expression pattern corresponding to that of the biomarkers of the control panel of cells which are resistant to the IGF1R modulator, it is highly likely or predicted that the individual's cancer or tumor will not respond to treatment with the IGF1R modulator.

The invention also provides a method of monitoring the treatment of a patient having a disease treatable by one or more IGF1R modulators. The isolated test cells from the patient's tissue sample, e.g., a tumor biopsy or blood sample, can be assayed to determine the expression pattern of one or more biomarkers before and after exposure to an IGF1R modulator wherein, preferably, the IGF1R modulator is an IGF1R inhibitor. The resulting biomarker expression profile of the test cells before and after treatment is compared with that of one or more biomarkers as described and shown herein to be highly expressed in the control panel of cells that are either resistant or sensitive to an IGF1R modulator. Thus, if a patient's response is sensitive to treatment by an IGF1R modulator, based on correlation of the expression profile of the one or biomarkers, the patient's treatment prognosis can be qualified as favorable and treatment can continue. Also, if, after treatment with an IGF1R modulator, the test cells don't show a change in the biomarker expression profile corresponding to the control panel of cells that are sensitive to the IGF1R modulator, it can serve as an indicator that the current treatment should be modified, changed, or even discontinued. This monitoring process can indicate success or failure of a patient's treatment with an IGF1R modulator and such monitoring processes can be repeated as necessary or desired.

The biomarkers of the invention can be used to predict an outcome prior to having any knowledge about a biological system. Essentially, a biomarker can be considered to be a statistical tool. Biomarkers are useful primarily in predicting the phenotype that is used to classify the biological system. In an embodiment of the invention, the goal of the prediction is to classify cancer cells as having an active or inactive IGF1R pathway. Cancer cells with an inactive IGF1R pathway can be considered resistant to treatment with an IGF1R modulator.

EXAMPLES

Methods and Samples:

In the following examples, the compound (S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)-pyridin-2(1-H)-one was used:

This compound is referred to herein as “compound 1.”

In the following examples, the compound (2S)-1-(4-((5-cyclopropy1-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-2-pyrrolidinecarboxamide was used:

This compound is referred to herein as “compound 2.”

Example 1 Identification of Biomarkers

Methods and Materials

Cell Lines:

All pediatric sarcoma and neuroblastoma cell lines were obtained from Dr. Lee Helman at NIH. All cell lines were grown in RPMI medium supplemented with Glutamax (Gibco/Invitrogen #61870-036), 10% inactivated fetal bovine serum (Gibco/Invitrogen #16140-071), 10 mM Hepes, penicillin and streptomycin. For the baseline profiling study, cells were harvested at 70-80% confluence; and for drug treatment study, two rhabdomyosarcoma (RMS) cell lines Rh36 and Rh41 were treated with 0.35 μM compound 1 for 6, 36 and 72 hours before harvest. To develop the compound 1-resistant RD1, the sensitive RD-1 cells (IC₅₀=0.238 μM to compound 1) were first exposed to the dug at the IC₅₀ concentration and passed as the cultures reached 70-80% confluence. The concentration of compound 1 was increased gradually every other culture passage and the IC₅₀ value for the compound in these cells was measured periodically during this treatment time until the resistance level reached a plateau. The resulted RD1-Resist cells has IC₅₀=1.999 μM to compound 1, more than 8 fold of the parental RD1.

In vitro Cellular Proliferation Assays:

Proliferation was evaluated by incorporation of [3H]-thymidine into DNA after exposure to IGF1R inhibitor compound 1 or compound 2 to determine the sensitivity of cell lines to these compounds. Cells were plated at an optimized density for each cell line per well in 96-well microtiter Falcon plates, incubated overnight, and then exposed to a serial dilution of drug. After 72 hours incubation with drug at 37° C., cells were pulsed with 4 μCi/ml [6-3H] thymidine (Amersham Pharmacia Biotech, UK) for 3 hours, trypsinized, harvested onto UniFilter-96, GF/B plates (PerkinElmer, Boston, Mass.) and scintillation was measured on a TopCount NXT (Packard, Conn.). Results were expressed as an IC₅₀, which is the drug concentration required to inhibit cell proliferation by 50% to that of untreated control cells. The mean IC₅₀ and standard deviation (SD) from multiple tests for each cell line were calculated.

Drug Combination Study:

A Dilution of Ratios Drug Combination method was used in cellular proliferation assays to determine whether there was synergy, additivity or antagonism when two compounds were added simultaneously to a variety of human tumor cells in vitro (R. Tallarida, R. J., Drug Synergism and Dose-Effect Data Analysis. 1st edition ed. Chapman & Hall/CRC (2000)). Drug stock solutions for two compounds, are combined in ratios of 10:1, 5:1, 3:1, 1:1, 1:3, 1:5. These ratios, as well as the individual compound stock solutions, are diluted in a serial manner, using 70% DMSO. These serial dilutions are then mixed with RPMI growth medium, and added to cells to test the IC50 values of single agent as well as two compounds in the cellular proliferation assays. Combination Indexes with 95% confidence intervals were used to determine if the combination results represented synergistic, additive, or antagonistic effect.

Gene Expression Profiling:

RNA was isolated from the cultured cells using the RNeasy™ kits from Qiagen (Valencia, Calif.). 10 μg of total RNA from each cell line was used to prepare biotinylated probe according to the Affymetrix GeneChip® Expression Analysis Technical Manual, 2001. Targets were hybridized to Affymetrix high density oligonucleotide array human HG-U133A 2.0 GeneChip® (Affymetrix, Santa Clara, Calif.). The arrays were then washed and stained using the GeneChip® Fluidics station and quantitated with GeneChip® Operating Software (GCOS) V1.0 according to the manufacture's instructions.

Protein Extraction and Tryptic Digestion:

Total protein content for each cell lysate was determined by the bicinchoninic acid assay (Pierce, Rockford, Ill.). An aliquot from each lysate containing 200 μg total protein was withdrawn for further processing.

The normalized samples were chloroform-methanol precipitated using a protein extraction kit (Calbiochem, San Diego, Calif.). Pellets were solublized in a solution containing 8M urea, 200 mM ammonium bicarbonate, and 40 mM DTT. Samples were diluted 4-fold, trypsin was added at 1:50 enyzme:substrate ratio and incubated overnight at 37° C.

Solid Phase Extraction:

Solid phase extraction was performed using an Empore C18 SPE plate (3M, St Paul, Minn.) on a Quadr3 liquid handling workstation (Tomtec, Hamden, Conn.). Sample sequence on the plate was randomized to minimize systemic bias during processing. After sample loading, the SPE plate was washed with 450 μl water in 0.1% trifluoroacetic acid twice and eluted with 300 μl 95% acetonitrile in 0.1% trifluoroacetic acid twice.

Randomization, Duplication, and Lyophilization:

Samples were then split across two separate 96-well plates (VWR, West Chester, Pa.) in a separate randomized order. This process generated two technical replicates for each sample. Following lyophilization on a SpeedVac (Thermo Savant, Holbrook, N.Y.), samples were stored at −80° C. before analysis.

Liquid Chromatography—Mass Spectrometry:

Samples of tryptic peptides were separated on an Zorbax 300SB-C18 column (0.5×150 mm, 3.5 nm) from Agilent (Santa Clara, Calif.) equipped with a 0.5 μm pre-column filter (Opti-solve). The mobile phases were delivered at a total flow rate of 12 μl/min by an Agilent 1100 Capillary HPLC system. Mobile phase A was water in 0.2% isopropyl alcohol, 0.1% acetic acid and 0.001% trifluoroacetic acid; Mobile B was 95% acetonitrile in 0.2% isopropyl alcohol, 0.1% acetic acid and 0.001% trifluoroacetic acid. The following gradient was used to separate the peptides:

Time (min) 0 2 4 64 69 71 71.1 80 % B 0 0 10 40 100 100 0 Stop

Samples were re-dissolved in 40 μl reconstitution solution in 0.2% isopropyl alcohol, 5% acetic acid and 0.001% trifluoroacetic acid. Six microliters of sample was injected for each run using an Agilent 1100 micro well plate sampler chilled at 4° C. To achieve optimum mass accuracy, a peptide standard Glu-Fibrinopeptide B (Sigma, St. Louis, Mo.) was introduced through a Valco-type mixing tee into the flowing system immediately after the HPLC column outlet at 1 μl/min. The HPLC eluent was detected on a Qtof Ultima QqTOF hybrid mass spectrometer (Waters, Manchester, UK) operated in the electrospray positive ionization mode. Mass spectra were acquired for the mass range of 300 to 1800 Da. Each acquisition was 80 minutes long, with 1 second scan time and 0.1 second inter scan delay. Accuracy of the mass measurement was typically within 20 parts per million. A collection of proprietary algorithms (Extractor, Cluster and Time Adjustment) written in-house were applied to extract and quantify peptide peak information, adjust peaks for retention time shifts that may occur during HPLC separation and match peaks across runs. This preprocessing resulted the raw peptide expression measures for each sample.

Peptide Identification:

The peptide ions generated from statistical analyses were sequenced by tandem mass spectrometry (MS/MS). Samples were rerun onto the same LC-MS system in data dependant mode in which the MS survey scan would switch to MSMS product scan when targeted peptide ions were found at the same retention time and mass. MS/MS spectra were generated and submitted to SEQUEST search (J. Eng, et al., J. Am. Soc. Mass. Spectrom., 5: 976-989 (1994)) to yield protein identifications.

Statistical Analysis

Analysis of Baseline Gene and Protein Expression of 29 Cell Lines:

The gene expression raw data were normalized by the Robust Multichip Average (RMA, R. Irizarry, et al., Biostatistics;4(2):249-64 (2003)) method and log₂ transformed, while the protein profiling data was quantile normalized and log2 transformed. To identify genes or proteins whose expression level significantly correlation with the drug sensitivity for the compounds, two separate statistic analyses were performed. First, a two-sample t-test between the resistant and sensitive cell lines (based on a threshold IC₅₀ cutoff of 0.35 μM) was performed. Second, Pearson correlation between the normalized expression level of each gene/protein and the log2(IC₅₀) values of the 29 cell lines was calculated to identify genes/proteins correlated with the drug sensitivity (IC₅₀).

Analysis of Gene and Protein Expression Data of Cells with Drug Treatment:

Pre-filter was applied to both gene and protein expression data. Lowly expressed probe sets with normalized and log₂ transformed expression values less than 5 cross all samples were removed resulting probe sets of 10,479 for gene expression data. For peptide, it must be found in at least 15 LCMS experimental runs and for subsequent statistical analysis in at least 20 cell lines. This filter reduced the number of overall peptides to 9022 for further analysis. A two-way ANOVA mixed model was applied to each probe set in the gene expression profiling data, as well as each peptide in the protein expression profiling data, separately. The model that was applied to each dataset was nearly identical except for a single term in the model applied to the protein expression data which appropriately accounted for the existence of the technical replicates. The analysis was run using SAS version 9.1 (SAS Institute Inc., Cary, N.C., USA). The general form of the model was as follows: (Intensity˜Treatment+Time+Treatment×Time+Error) where Intensity represents the normalized, log2 transformed intensity; Treatment is a term that captures candidates that display significant differential expression upon treatment; Time is a term that captures candidates that display significant differential expression over time; and the Treatment×Time term captures candidates that display significant differential expression upon treatment with compound over time as compared with control. The multiple testing with False Discovery Rate (FDR; Y. Benjamini, et al., J. Roy. Stat. Soc. B.; 57:289-300 (1995)) was apply to each dataset separately, the total of 2056 probe sets with FDR p value<0.05 in either the Treatment effect or Treatment×Time interaction and the fold change between treatment group vs. DMSO control group is greater than 1.2 fold or less than −1.2 fold were selected.

Globaltest Pathway Analysis:

RMA normalized baseline expression data for 28 sarcoma cell lines was first filtered based on following criteria: 1) Maximal expression level across all samples must be greater than 5; 2) Coefficient of Variation (CV) must by greater than 0.03. These resulted a total of 17276 probe sets for further analysis. Globaltest was carried out with Bioconductor (www.bioconductor.org) package (Version 4.4.0) using this filtered dataset and compound 1 resistant/sensitive classification for each cell line against a collection of 183 KEGG pathways. The p value indicating the association between expression values and resistant/sensitive classifications, as well as its multiplicity-adjusted version, FWER (Holm's method), were reported for each pathway. Gene plots were generated for interesting pathways according to user's guide (J. Geoman, et al., Testing association of a pathway with a clinical variable. Package globaltest. Version 4.4.0. (October 2006)) and used to assess the influence of each gene in a specific pathway on the drug sensitivity classification. For Rh41 drug treatment study, expression datasets were first filtered to remove probe sets whose maximal expression level less than 5, which resulted 9269 probe sets. Globaltest was carried out similar as above, with treatment (DMSO control vs. compound 1) as grouping factor. It gives a bar and a reference line for each gene tested. The reference line for each bar gives the expected height under the null hypothesis that the gene is not associated with the sensitivity classification. Marks indicate with how many standard deviations (under the null hypothesis) the bar exceeds the reference line. Bars are colored based on sensitivity classification. The test statistic for a pathway is the average of the bars for all the genes tested.

Ingenuity Pathway Analysis:

497 baseline markers correlated with sensitivity to compound 1 were imported into Ingenuity pathway analysis. Network nodes were colored by the fold change between sensitive and resistant cells. For the drug modulated markers, treatment-induced probe sets in the sensitive cell line Rh41 (FDR adjusted treatment effect less than 0.05, or FDR adjusted treatment-time-interaction less than 0.05) were used for pathway analysis. Genes on canonical pathways were colored based on the fold change between cells with compound 1 treatment and DMSO control.

Results

The Sensitivity Classification of the 29 Pediatric Sarcoma Cell Lines to IGF1R Inhibitors:

The sensitivity to IGF1R inhibitors compound 1 and compound 2 for each of the 29 pediatric sarcoma and neuroblastoma cell lines was determined by cellular proliferation assays and expressed in term of drug concentration required for 50% cell proliferation inhibition (IC₅₀). The results are summarized in Table 1, and a wide range of activity in this panel of cancer cell lines was observed for both compound 1 and compound 2 compounds.

TABLE 1 The IC₅₀ of each cell line and sensitive/resistant classification to compounds 2 and 1. Compound 2 Compound 1 Compound 2 Sensitivity Compound Sensitivity Cell Type Cell Line IC₅₀ (uM) Classification 1 IC₅₀ (uM) Classification Ewing TC32 0.0084 S 0.055 S Ewing RDES 0.0117 S 0.123 S Ewing TC71 0.0143 S 0.119 S Ewing VW 0.019 S 0.101 S Ewing 5838 0.034 S 0.172 S Ewing LG 0.0375 S 0.063 S Ewing JD 0.391 R 0.232 S Ewing KAG 1.665 R 2.113 R Fibrosarcoma HT1080/S 0.531 R 1.409 R Fibrosarcoma SW-684 5 R 5 R Leiomyosarcoma SK- 0.6866 R 0.5 R LMS-1 Liposarcoma To184.T 0.4695 R not tested not tested Liposarcoma HTB-92 1.0199 R 0.584 R Liposarcoma SA-4 1.3007 R 0.779 R Melignant Pleural H211 0.733 R 0.418 R Mesothelioma Melignant Pleural H2052 1.0502 R 0.403 R Mesothelioma Melignant Pleural H513 4.448 R 3.117 R Mesothelioma Melignant Pleural H2595 4.4752 R 5 R Mesothelioma Neuroblastoma LAN-1 0.04 S 0.136 S Neuroblastoma SHSY5Y 0.106 S 0.149 S Neuroblastoma SK-NSH 0.139 S 0.196 S Neuroblastoma IMR-32 0.261 S 0.277 S Neuroblastoma SK-NAS 0.497 R 0.192 S Rhabdomyosarcoma Rh4 0.004 S 0.027 S Rhabdomyosarcoma Rh41 0.0047 S 0.069 S Rhabdomyosarcoma ME 0.015 S 0.163 S Rhabdomyosarcoma Rh1 0.0267 S 0.135 S Rhabdomyosarcoma CTR 0.2526 S 0.37 R Rhabdomyosarcoma Rh36 1.432 R 1.6 R “S” means sensitive and “R” means resistant to the corresponding compounds. The cell subtypes are also indicated. Comparing the IC₅₀ data of these two compounds, compound 2 is more potent than compound 1 in most of the cell lines tested. To classify the cell lines as sensitive or resistant to the compounds, the IC₅₀ value for each cell line was log-transformed, and the mean of log₁₀(IC₅₀) across all cell lines was calculated. The sensitivity/resistance phenotype of the cell lines to compound 1 or compound 2 was classified as follows: the cell lines with log₁₀(IC₅₀) below the mean log₁₀(IC₅₀) of all cell lines were defined as sensitive to the compound, while those with log₁₀(IC₅₀) above the mean log₁₀(IC₅₀) were considered to be resistant to the compound. As shown in Table 1, 16 cell lines were classified as sensitive and 12 cell lines classified as resistant (To184-T was not tested) for compound 1; whereas 15 and 14 cell lines were classified as either sensitive or resistant to compound 2, respectively. Although the sensitivity/resistance demarcation is arbitrary, apparently, the cut off is around 0.35 μM for both compounds. In general, both compounds have a similar sensitivity/resistance profile in this panel of cell lines with the exception of three cell lines that having IC₅₀ values around the borderline of the sensitive/resistant demarcation: CTR was defined as sensitive to compound 2 (IC₅₀=0.2526 μM) but resistant to compound 1 (IC₅₀=0.37 μM), whereas JD and SK-NAS were defined as resistant to compound 2 but resistant to compound 1. Relation Between the Drug Sensitivity and Cell Subtypes:

The correlation between the sensitive/resistant classification and different subtypes of cell lines was further explored. Interestingly, the sensitivity of these cell lines to IGF1R inhibitor compounds was found to be closely related to specific subtypes. As shown in Table 1, most of Ewing's, RMS and neuroblastoma cells are sensitive to the compounds, whereas all fibrosarcoma, leiomyosarcoma, liposarcoma and malignant pleural mesothelioma cells are resistant. The distribution of cell sub-types is significantly different in sensitive and resistant classes with p-value=0.011 for compound 2 and p-value=0.004 for compound 1, respectively in the chi-square test. Although the sample size for each subtype is not big enough to be conclusive, the results may suggest that certain subtypes of sarcoma are more responsive than others, and these responsive tumor types may represent patient subpopulations to be targeted in clinical studies for IGF1R inhibitors.

Identification of Genes/Proteins with Expression Significantly Correlated with the Sensitivity to IGF1R Inhibitors:

The expression level of the drug target IGF1R was evaluated and apparently did not significantly correlate to the sensitivity of compound 2 and/or compound 1 in the 29 cancer cell lines, so IGF1R level is not useful to predict response to compound 2 and/or compound 1 in cancer cells or in patients. Other predictive biomarkers are needed for selecting the potential targeted patient population.

To identify genes or proteins whose basal expression patterns were strongly correlated with the sensitivity to compounds 1 and 2, gene expression profiling and proteomics were performed in parallel using the 29 pediatric sarcoma and neuroblastoma cancer cell lines (RDES and Rh4 were not included in protein profiling). Two statistical methods were used in analyzing both expression datasets: first, two sample t-test was performed to identify genes differentially expressed between sensitive and resistant cell line groups (p<0.001, 2-fold); second, to avoid the bias of arbitrary cut off for the sensitive/resistant demarcation, the Pearson correlations between the log2(IC₅₀) value and the expression level of each gene or protein in all cell lines were calculated to identify genes/proteins significantly correlated with the drug sensitivity (p<0.001). The overlap between these two analyses led to selection of genes/proteins that are significantly correlated with the drug sensitivity/resistance classification for compound 1 or compound 2. For gene expression profiling, there are a total of 497 probe sets with 386 unique genes significantly correlated with the sensitivity to compound 1 (Table 2), and 368 probe sets with 282 unique genes significantly correlated with the sensitivity to compound 2 (Table 3); and. There are 98 or 124 genes highly expressed in the cell lines sensitive to compound 2 or to compound 1, conversely, 184 or 262 genes are highly expressed in the cell lines resistant to compound 2 or compound 1, respectively, with 227 common markers for these two compounds.

TABLE 2 Genes correlated with the sensitivity of 28 sarcoma cell lines to compound 1 as identified by Affymetrix gene array. Gene p-value Fold p-value probe Accession # Gene Title Symbol in t-test (S/R) (correlation) Genes higher expressed in the group of sensitive cell lines 214451_at NM_003221 transcription factor AP- TFAP2B 1.3E−05 56.6 4.3E−04 2 beta (activating enhancer binding protein 2 beta) 212713_at R72286 microfibrillar- MFAP4 1.7E−06 14.5 9.9E−05 associated protein 4 204915_s_at AB028641 SRY (sex determining SOX11 1.7E−07 13.4 4.3E−05 region Y)-box 11 216623_x_at AK025084 trinucleotide repeat TNRC9 3.2E−04 13.2 5.5E−04 containing 9 221011_s_at NM_030915 limb bud and heart LBH 7.1E−05 12.2 4.7E−04 development homolog (mouse) /// limb bud and heart development homolog (mouse) 202517_at NM_001313 collapsin response CRMP1 3.0E−06 11.3 4.1E−04 mediator protein 1 205888_s_at AI962693 janus kinase and JAKMIP2 /// 3.1E−08 9.3 1.1E−05 microtubule interacting MYT1L protein 2 /// myelin transcription factor 1- like 207781_s_at NM_021998 zinc finger protein 711 ZNF711 9.2E−12 8.1 3.6E−07 221748_s_at AL046979 tensin 1 /// tensin 1 TNS1 5.4E−05 7.8 4.3E−04 213170_at AA406605 glutathione peroxidase 7 GPX7 2.0E−05 7.4 1.6E−04 205123_s_at NM_003692 transmembrane protein TMEFF1 1.2E−05 6.9 1.0E−04 with EGF-like and two follistatin-like domains 1 203999_at AV731490 — — 1.6E−06 6.7 9.2E−04 218445_at NM_018649 H2A histone family, H2AFY2 1.2E−07 6.3 9.7E−05 member Y2 215043_s_at X83301 SMA3 /// SMA5 SMA3 /// 4.0E−07 6.2 1.5E−05 SMA5 209598_at AB020690 paraneoplastic antigen PNMA2 2.5E−05 6.1 1.4E−04 MA2 212382_at BF433429 Transcription factor 4 TCF4 1.3E−06 5.8 1.0E−04 212386_at BF592782 CDNA FLJ11918 fis, — 1.6E−06 5.7 6.0E−06 clone HEMBB1000272 205889_s_at NM_014790 janus kinase and JAKMIP2 9.6E−08 5.5 4.5E−06 microtubule interacting protein 2 205830_at NM_004362 calmegin CLGN 5.6E−08 5.4 4.4E−07 211071_s_at BC006471 myeloid/lymphoid or MLLT11 1.9E−05 5.3 5.7E−04 mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 /// myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 212599_at AK025298 autism susceptibility AUTS2 2.1E−05 5.3 1.8E−05 candidate 2 206440_at NM_004664 lin-7 homolog A (C. elegans) LIN7A 9.1E−04 4.8 3.2E−04 206565_x_at NM_006780 SMA3 SMA3 9.0E−07 4.7 4.6E−06 219855_at NM_018159 nudix (nucleoside NUDT11 3.8E−04 4.7 8.1E−04 diphosphate linked moiety X)-type motif 11 213131_at R38389 olfactomedin 1 OLFM1 1.6E−04 4.7 6.0E−04 200884_at NM_001823 creatine kinase, brain CKB 2.8E−07 4.6 9.8E−07 206655_s_at NM_000407 glycoprotein Ib GP1BB /// 1.2E−05 4.5 9.1E−04 (platelet), beta SEPT5 polypeptide /// septin 5 214023_x_at AL533838 tubulin, beta 2B TUBB2B 5.4E−04 4.5 1.5E−04 204860_s_at AI817801 NLR family, apoptosis NAIP /// 3.0E−05 4.2 1.1E−04 inhibitory protein /// LOC728519 similar to Baculoviral IAP repeat-containing protein 1 (Neuronal apoptosis inhibitory protein) 208998_at U94592 uncoupling protein 2 UCP2 2.6E−06 4.2 6.1E−06 (mitochondrial, proton carrier) 204165_at NM_003931 WAS protein family, WASF1 2.7E−07 4.1 1.1E−05 member 1 212847_at AL036840 Far upstream element FUBP1 1.0E−07 4.1 1.2E−04 (FUSE) binding protein 1 213216_at AL537463 OTU domain OTUD3 9.8E−06 3.9 1.9E−05 containing 3 213547_at AB014567 cullin-associated and CAND2 3.3E−05 3.7 2.1E−05 neddylation-dissociated 2 (putative) 204742_s_at NM_015032 androgen-induced APRIN 8.9E−06 3.5 1.5E−05 proliferation inhibitor 213605_s_at AL049987 Similar to Beta- LOC728411 1.6E−05 3.5 3.5E−05 glucuronidase precursor 204457_s_at NM_002048 growth arrest-specific 1 GAS1 1.4E−04 3.4 1.1E−04 214102_at AK023737 centaurin, delta 1 CENTD1 1.9E−06 3.4 5.6E−06 201449_at AL567227 TIA1 cytotoxic TIA1 1.3E−08 3.4 2.4E−05 granule-associated RNA binding protein 205347_s_at NM_021992 thymosin-like 8 TMSL8 7.6E−05 3.3 1.2E−04 212816_s_at BE613178 cystathionine-beta- CBS 5.8E−05 3.2 5.6E−04 synthase 214850_at X75940 glucuronidase, beta GUSBP1 4.9E−06 3.2 1.4E−04 pseudogene 1 212731_at U79297 ankyrin repeat domain ANKRD46 1.8E−07 3.2 2.2E−06 46 221965_at AI990326 M-phase MPHOSPH9 1.6E−07 3.1 8.2E−06 phosphoprotein 9 213283_s_at BG285616 sal-like 2 (Drosophila) SALL2 2.7E−06 3.1 2.4E−05 200644_at NM_023009 MARCKS-like 1 MARCKSL1 2.8E−05 3.1 1.8E−05 210882_s_at U04811 trophinin TRO 2.2E−05 3.0 4.4E−05 204040_at NM_014746 ring finger protein 144 RNF144 1.8E−04 3.0 1.9E−04 203069_at NM_014849 synaptic vesicle SV2A 3.1E−04 3.0 8.0E−04 glycoprotein 2A 215146_s_at AB028966 tetratricopeptide repeat TTC28 7.9E−07 3.0 1.4E−08 domain 28 213610_s_at BE326381 kelch-like 23 KLHL23 7.0E−06 2.9 5.1E−05 (Drosophila) 202967_at NM_001512 glutathione S- GSTA4 1.2E−04 2.9 3.1E−04 transferase A4 218223_s_at NM_016274 pleckstrin homology PLEKHO1 5.9E−07 2.9 1.2E−07 domain containing, family O member 1 221261_x_at NM_030801 melanoma antigen MAGED4 1.9E−05 2.9 9.3E−06 family D, 4 /// melanoma antigen family D, 4 212624_s_at BF339445 chimerin (chimaerin) 1 CHN1 9.7E−05 2.9 1.5E−04 215599_at X83300 SMA4 /// similar to SMA4 /// 9.8E−06 2.8 1.3E−04 SMA4 LOC730390 212126_at BG391282 CDNA clone — 1.4E−07 2.8 7.4E−05 IMAGE: 4842353 209153_s_at M31523 transcription factor 3 TCF3 1.4E−06 2.8 9.7E−05 (E2A immunoglobulin enhancer binding factors E12/E47) 214724_at AF070621 DIX domain containing 1 DIXDC1 1.8E−05 2.7 2.8E−04 208986_at AL559478 transcription factor 12 TCF12 2.3E−06 2.7 2.7E−07 (HTF4, helix-loop-helix transcription factors 4) 213626_at AL049442 carbonyl reductase 4 CBR4 9.6E−06 2.7 3.3E−04 218868_at NM_020445 ARP3 actin-related ACTR3B 6.8E−06 2.6 6.9E−04 protein 3 homolog B (yeast) 203298_s_at NM_004973 jumonji, AT rich JARID2 1.3E−07 2.6 1.6E−04 interactive domain 2 37577_at U79256 Rho GTPase activating ARHGAP19 4.1E−05 2.6 1.1E−04 protein 19 212482_at BF671894 required for meiotic RMND5A 1.8E−06 2.5 1.9E−04 nuclear division 5 homolog A (S. cerevisiae) 204173_at NM_002475 myosin, light chain 6B, MYL6B 9.9E−04 2.5 7.4E−04 alkali, smooth muscle and non-muscle 203151_at AW296788 microtubule-associated MAP1A 2.3E−04 2.5 7.7E−04 protein 1A 212919_at AV715578 DCP2 decapping DCP2 1.1E−06 2.5 3.3E−05 enzyme homolog (S. cerevisiae) 213694_at AW027347 round spermatid basic RSBN1 9.2E−07 2.5 2.8E−04 protein 1 203625_x_at BG105365 melanoma cell adhesion MCAM 1.8E−04 2.5 1.4E−04 molecule 204795_at NM_025263 proline rich 3 PRR3 1.0E−05 2.5 2.0E−04 212670_at AA479278 elastin (supravalvular ELN 2.0E−05 2.5 1.4E−04 aortic stenosis, Williams-Beuren syndrome) 212547_at N34842 FLJ35348 FLJ35348 9.4E−07 2.5 7.2E−05 210567_s_at BC001441 S-phase kinase- SKP2 6.7E−04 2.4 4.1E−04 associated protein 2 (p45) 209748_at AB029006 spastin SPAST 4.0E−07 2.4 3.8E−04 215128_at AV704232 CDNA FLJ11682 fis, — 4.7E−05 2.4 4.5E−04 clone HEMBA1004880 203825_at NM_007371 bromodomain BRD3 1.2E−06 2.4 4.5E−05 containing 3 214220_s_at AW003635 Alstrom syndrome 1 ALMS1 1.4E−06 2.4 1.6E−05 210045_at AU151428 isocitrate IDH2 6.1E−06 2.4 5.7E−04 dehydrogenase 2 (NADP+), mitochondrial 218683_at NM_021190 polypyrimidine tract PTBP2 1.5E−06 2.4 5.8E−04 binding protein 2 218457_s_at NM_022552 DNA (cytosine-5-)- DNMT3A 2.2E−06 2.4 7.2E−05 methyltransferase 3 alpha 204061_at NM_005044 protein kinase, X- PRKX 6.2E−06 2.4 2.3E−05 linked 210649_s_at AF231056 AT rich interactive ARID1A 7.1E−07 2.4 7.2E−08 domain 1A (SWI-like) 212153_at AB007930 pogo transposable POGZ 8.7E−08 2.4 6.1E−05 element with ZNF domain 218265_at NM_024077 SECIS binding protein 2 SECISBP2 1.1E−06 2.4 2.2E−05 210543_s_at U34994 protein kinase, DNA- PRKDC 5.0E−04 2.3 1.3E−04 activated, catalytic polypeptide 220443_s_at NM_012476 ventral anterior VAX2 2.0E−04 2.3 5.1E−04 homeobox 2 202561_at AF070613 tankyrase, TRF1- TNKS 1.4E−04 2.3 4.6E−04 interacting ankyrin- related ADP-ribose polymerase 203795_s_at NM_020993 B-cell CLL/lymphoma BCL7A 3.1E−06 2.3 3.3E−04 7A 213387_at AB033066 ATPase family, AAA ATAD2B 2.5E−06 2.3 1.0E−04 domain containing 2B 203046_s_at NM_003920 timeless homolog TIMELESS 6.7E−07 2.3 7.1E−06 (Drosophila) 211929_at AA527502 heterogeneous nuclear HNRPA3 1.8E−05 2.3 1.8E−04 ribonucleoprotein A3 222101_s_at BF222893 dachsous 1 DCHS1 5.2E−04 2.3 2.3E−04 (Drosophila) 203940_s_at NM_014909 vasohibin 1 VASH1 6.0E−04 2.3 1.8E−04 203026_at NM_014872 zinc finger and BTB ZBTB5 3.7E−08 2.3 5.5E−05 domain containing 5 212164_at AL522296 transmembrane protein TMEM183A 1.1E−06 2.2 1.7E−04 183A 207705_s_at NM_025176 KIAA0980 protein RP4- 1.4E−04 2.2 9.6E−05 691N24.1 210962_s_at AB019691 A kinase (PRKA) AKAP9 5.2E−08 2.2 2.0E−05 anchor protein (yotiao) 9 210555_s_at U85430 nuclear factor of NFATC3 5.4E−07 2.2 5.1E−05 activated T-cells, cytoplasmic, calcineurin-dependent 3 220040_x_at NM_018684 KIAA1166 KIAA1166 1.8E−05 2.2 8.6E−04 220735_s_at NM_020654 SUMO1/sentrin SENP7 1.0E−04 2.2 2.3E−04 specific peptidase 7 220143_x_at NM_018032 LUC7-like (S. cerevisiae) LUC7L 3.0E−06 2.2 2.0E−04 221203_s_at NM_018023 YEATS domain YEATS2 6.8E−08 2.2 1.1E−08 containing 2 212710_at AL043774 calmodulin regulated CAMSAP1 2.0E−05 2.2 8.7E−04 spectrin-associated protein 1 208838_at AB020636 — — 1.4E−04 2.2 5.7E−06 218724_s_at NM_021809 TGFB-induced factor 2 TGIF2 3.2E−04 2.2 7.7E−05 (TALE family homeobox) 206554_x_at NM_006515 SET domain and SETMAR 6.6E−04 2.2 1.7E−04 mariner transposase fusion gene 202540_s_at NM_000859 3-hydroxy-3- HMGCR 4.0E−05 2.2 4.6E−05 methylglutaryl- Coenzyme A reductase 204060_s_at NM_005044 protein kinase, X- PRKX /// 6.8E−05 2.2 4.9E−05 linked /// protein PRKY kinase, Y-linked 203859_s_at NM_002579 paralemmin PALM 2.4E−05 2.1 7.1E−04 209431_s_at AF254083 POZ (BTB) and AT PATZ1 5.4E−06 2.1 4.5E−04 hook containing zinc finger 1 212704_at AI049962 zinc finger, CCHC ZCCHC11 5.6E−06 2.1 5.2E−05 domain containing 11 207401_at NM_002763 prospero-related PROX1 3.7E−04 2.1 5.1E−04 homeobox 1 204557_s_at NM_014934 DAZ interacting protein 1 DZIP1 6.7E−04 2.1 6.8E−06 212753_at AI692203 polycomb group ring PCGF3 8.9E−08 2.1 1.9E−04 finger 3 201051_at BE560202 acidic (leucine-rich) ANP32A 5.9E−05 2.1 5.0E−04 nuclear phosphoprotein 32 family, member A 212693_at BE670928 MDN1, midasin MDN1 2.3E−04 2.1 9.3E−04 homolog (yeast) 201741_x_at M69040 splicing factor, SFRS1 2.4E−07 2.1 7.8E−05 arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) 208644_at M32721 poly (ADP-ribose) PARP1 2.0E−05 2.0 1.3E−04 polymerase family, member 1 218306_s_at NM_003922 hect (homologous to HERC1 1.2E−05 2.0 1.0E−04 the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 213743_at BE674119 cyclin T2 CCNT2 8.7E−07 2.0 4.2E−04 208073_x_at NM_003316 tetratricopeptide repeat TTC3 1.6E−06 2.0 9.5E−04 domain 3 209043_at AF033026 3′-phosphoadenosine 5′- PAPSS1 6.6E−06 2.0 3.4E−05 phosphosulfate synthase 1 209715_at L07515 chromobox homolog 5 CBX5 9.9E−05 2.0 3.1E−05 (HP1 alpha homolog, Drosophila) Genes higher expressed in the group of resistant cell lines 209016_s_at BC002700 keratin 7 KRT7 8.9E−05 −81.0 3.5E−06 222108_at AC004010 adhesion molecule AMIGO2 1.0E−06 −46.4 1.6E−05 with Ig-like domain 2 209008_x_at U76549 keratin 8 /// keratin 8 KRT8 1.1E−05 −45.6 2.5E−04 202858_at NM_006758 U2 small nuclear RNA U2AF1 1.3E−08 −42.3 4.4E−06 auxiliary factor 1 204070_at NM_004585 retinoic acid receptor RARRES3 4.1E−04 −40.9 3.0E−05 responder (tazarotene induced) 3 201324_at NM_001423 epithelial membrane EMP1 6.9E−12 −40.0 3.4E−06 protein 1 211506_s_at AF043337 interleukin 8 IL8 1.7E−06 −39.6 3.5E−05 209835_x_at BC004372 CD44 molecule CD44 2.5E−11 −38.7 3.3E−06 (Indian blood group) 201858_s_at J03223 proteoglycan 1, PRG1 7.6E−07 −37.9 1.5E−04 secretory granule 202638_s_at NM_000201 intercellular adhesion ICAM1 1.8E−04 −34.2 2.6E−04 molecule 1 (CD54), human rhinovirus receptor 201596_x_at NM_000224 keratin 18 KRT18 2.3E−07 −33.3 2.0E−05 204855_at NM_002639 serpin peptidase SERPINB5 9.3E−04 −30.4 5.9E−05 inhibitor, clade B (ovalbumin), member 5 217901_at BF031829 Desmoglein 2 DSG2 8.6E−05 −30.2 7.5E−04 205083_at NM_001159 aldehyde oxidase 1 AOX1 7.5E−07 −28.3 3.1E−05 202855_s_at AL513917 solute carrier family SLC16A3 6.4E−08 −25.5 3.1E−06 16, member 3 (monocarboxylic acid transporter 4) 215034_s_at AI189753 transmembrane 4 L six TM4SF1 2.5E−06 −25.1 1.1E−04 family member 1 221530_s_at BE857425 basic helix-loop-helix BHLHB3 1.1E−06 −24.5 3.6E−07 domain containing, class B, 3 202854_at NM_000194 hypoxanthine HPRT1 2.6E−08 −24.1 3.5E−06 phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) 201798_s_at NM_013451 fer-1-like 3, myoferlin FER1L3 2.4E−10 −23.5 2.5E−06 (C. elegans) 209803_s_at AF001294 pleckstrin homology- PHLDA2 2.2E−11 −23.2 3.3E−06 like domain, family A, member 2 210916_s_at AF098641 CD44 molecule CD44 /// 5.1E−11 −21.7 1.1E−05 (Indian blood group) MAPK10 /// mitogen-activated protein kinase 10 203108_at NM_003979 G protein-coupled GPRC5A 5.8E−09 −20.7 1.3E−05 receptor, family C, group 5, member A 204420_at BG251266 FOS-like antigen 1 FOSL1 6.7E−09 −20.5 4.7E−05 206632_s_at NM_004900 apolipoprotein B APOBEC3B 3.2E−09 −20.3 1.5E−05 mRNA editing enzyme, catalytic polypeptide-like 3B 212444_at AA156240 CDNA clone — 1.2E−07 −18.4 1.0E−04 IMAGE: 6025865 204470_at NM_001511 chemokine (C—X—C CXCL1 1.1E−04 −17.7 2.8E−05 motif) ligand 1 (melanoma growth stimulating activity, alpha) 201109_s_at AV726673 thrombospondin 1 THBS1 4.0E−04 −17.5 9.9E−04 205627_at NM_001785 cytidine deaminase CDA 5.9E−05 −17.5 5.4E−05 209278_s_at L27624 tissue factor pathway TFPI2 3.3E−04 −15.7 4.7E−04 inhibitor 2 208747_s_at M18767 complement C1S 1.5E−04 −15.3 8.1E−04 component 1, s subcomponent 201842_s_at AI826799 EGF-containing EFEMP1 8.3E−04 −14.0 8.7E−04 fibulin-like extracellular matrix protein 1 210592_s_at M55580 spermidine/spermine SAT1 1.2E−08 −13.9 6.3E−06 N1-acetyltransferase 1 204222_s_at NM_006851 GLI pathogenesis- GLIPR1 2.6E−05 −13.8 5.6E−04 related 1 (glioma) 202627_s_at AL574210 serpin peptidase SERPINE1 1.6E−04 −13.2 6.7E−04 inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 203851_at NM_002178 insulin-like growth IGFBP6 1.8E−06 −13.2 3.0E−04 factor binding protein 6 208949_s_at BC001120 lectin, galactoside- LGALS3 2.3E−04 −13.1 6.4E−04 binding, soluble, 3 (galectin 3) 210042_s_at AF073890 cathepsin Z CTSZ 3.0E−07 −12.9 2.1E−05 206513_at NM_004833 absent in melanoma 2 AIM2 1.1E−04 −12.6 1.9E−04 202202_s_at NM_002290 laminin, alpha 4 LAMA4 2.5E−05 −12.2 8.0E−04 204363_at NM_001993 coagulation factor III F3 3.0E−04 −11.9 5.4E−04 (thromboplastin, tissue factor) 202832_at NM_014635 GRIP and coiled-coil GCC2 6.1E−04 −11.9 5.5E−05 domain containing 2 202267_at NM_005562 laminin, gamma 2 LAMC2 3.7E−04 −11.7 1.6E−04 219759_at NM_022350 leukocyte-derived LRAP 1.2E−06 −11.6 1.5E−05 arginine aminopeptidase 217744_s_at NM_022121 PERP, TP53 apoptosis PERP 1.0E−06 −11.4 4.0E−05 effector 204279_at NM_002800 proteasome (prosome, PSMB9 1.3E−05 −11.2 8.0E−06 macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 201474_s_at NM_002204 integrin, alpha 3 ITGA3 2.2E−08 −11.1 3.3E−07 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 201468_s_at NM_000903 NAD(P)H NQO1 3.8E−05 −10.8 2.4E−05 dehydrogenase, quinone 1 205798_at NM_002185 interleukin 7 receptor IL7R 3.2E−07 −10.7 7.5E−04 /// interleukin 7 receptor 221059_s_at NM_021615 coactosin-like 1 COTL1 3.8E−09 −10.5 2.5E−06 (Dictyostelium) 218211_s_at NM_024101 melanophilin MLPH 6.2E−06 −10.4 6.7E−05 201042_at AL031651 transglutaminase 2 (C TGM2 1.4E−04 −10.1 6.7E−04 polypeptide, protein- glutamine-gamma- glutamyltransferase) 212473_s_at BE965029 microtubule associated MICAL2 1.8E−05 −10.1 9.7E−04 monoxygenase, calponin and LIM domain containing 2 201631_s_at NM_003897 immediate early IER3 1.9E−06 −9.3 4.3E−05 response 3 210896_s_at AF306765 aspartate beta- ASPH 9.8E−08 −9.2 1.4E−04 hydroxylase 208581_x_at NM_005952 metallothionein 1X MT1X 3.8E−06 −8.9 1.9E−04 214446_at NM_012081 elongation factor, ELL2 4.9E−10 −8.7 3.2E−05 RNA polymerase II, 2 201170_s_at NM_003670 basic helix-loop-helix BHLHB2 2.5E−07 −8.5 3.5E−06 domain containing, class B, 2 202862_at NM_000137 fumarylacetoacetate FAH 4.0E−07 −8.5 1.6E−05 hydrolase (fumarylacetoacetase) 203234_at NM_003364 uridine phosphorylase 1 UPP1 1.7E−06 −8.5 2.2E−05 218322_s_at NM_016234 acyl-CoA synthetase ACSL5 9.4E−05 −8.3 1.9E−06 long-chain family member 5 206461_x_at NM_005951 metallothionein 1H MT1H 1.1E−06 −8.2 8.6E−05 212185_x_at NM_005953 metallothionein 2A MT2A 1.4E−06 −8.1 1.9E−04 208790_s_at AF312393 polymerase I and PTRF 3.4E−05 −7.8 8.7E−04 transcript release factor 36711_at AL021977 v-maf MAFF 7.4E−09 −7.7 9.7E−07 musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 218084_x_at NM_014164 FXYD domain FXYD5 5.2E−06 −7.6 5.1E−06 containing ion transport regulator 5 217996_at AA576961 pleckstrin homology- PHLDA1 3.8E−07 −7.5 2.5E−04 like domain, family A, member 1 211456_x_at AF333388 metallothionein 1H- LOC645745 1.3E−06 −7.4 1.1E−04 like protein 213865_at AI378788 discoidin, CUB and DCBLD2 2.3E−07 −7.4 5.7E−04 LCCL domain containing 2 209514_s_at BE502030 RAB27A, member RAB27A 2.3E−05 −7.3 3.2E−04 RAS oncogene family 209310_s_at U25804 caspase 4, apoptosis- CASP4 1.4E−05 −7.1 1.3E−04 related cysteine peptidase 209040_s_at U17496 proteasome (prosome, PSMB8 1.8E−05 −7.1 6.9E−06 macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 205100_at NM_005110 glutamine-fructose-6- GFPT2 3.3E−06 −7.1 2.1E−04 phosphate transaminase 2 213572_s_at AI554300 serpin peptidase SERPINB1 1.4E−07 −7.0 1.4E−07 inhibitor, clade B (ovalbumin), member 1 209679_s_at BC003379 small trans-membrane LOC57228 2.4E−06 −7.0 1.1E−04 and glycosylated protein 203821_at NM_001945 heparin-binding EGF- HBEGF 3.8E−05 −6.9 9.8E−05 like growth factor 220016_at NM_024060 AHNAK AHNAK 5.1E−05 −6.9 2.4E−05 nucleoprotein (desmoyokin) 212070_at AL554008 G protein-coupled GPR56 6.1E−05 −6.8 1.6E−07 receptor 56 211429_s_at AF119873 serpin peptidase SERPINA1 5.0E−04 −6.8 5.1E−05 inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 202863_at NM_003113 SP100 nuclear antigen SP100 1.7E−07 −6.7 1.4E−05 216336_x_at AL031602 metallothionein 1M MT1M 5.3E−06 −6.6 1.3E−05 217165_x_at M10943 metallothionein 1F MT1F 5.6E−06 −6.6 1.9E−04 (functional) 201983_s_at AW157070 epidermal growth EGFR 1.6E−06 −6.5 2.8E−04 factor receptor (erythroblastic leukemia viral (v-erb- b) oncogene homolog, avian) 210538_s_at U37546 baculoviral IAP BIRC3 1.6E−04 −6.5 5.4E−05 repeat-containing 3 201926_s_at BC001288 CD55 molecule, decay CD55 3.6E−06 −6.5 3.4E−04 accelerating factor for complement (Cromer blood group) 208944_at D50683 transforming growth TGFBR2 1.2E−06 −6.5 9.7E−04 factor, beta receptor II (70/80 kDa) 208690_s_at BC000915 PDZ and LIM domain PDLIM1 1.6E−04 −6.4 5.6E−05 1 (elfin) 210117_at AF311312 sperm associated SPAG1 3.6E−05 −6.4 4.2E−04 antigen 1 210138_at AF074979 regulator of G-protein RGS20 5.9E−06 −6.3 1.4E−05 signalling 20 217478_s_at X76775 major HLA-DMA 2.9E−04 −6.2 1.3E−04 histocompatibility complex, class II, DM alpha 202499_s_at NM_006931 solute carrier family 2 SLC2A3 1.1E−06 −6.2 2.0E−04 (facilitated glucose transporter), member 3 214791_at AK023116 hypothetical protein LOC93349 1.1E−06 −6.1 2.6E−06 BC004921 209457_at U16996 dual specificity DUSP5 1.5E−05 −6.1 1.7E−04 phosphatase 5 207574_s_at NM_015675 growth arrest and GADD45B 1.2E−06 −6.0 1.6E−04 DNA-damage- inducible, beta 214866_at X74039 plasminogen activator, PLAUR 8.1E−07 −5.8 3.8E−04 urokinase receptor 211612_s_at U62858 interleukin 13 IL13RA1 1.5E−07 −5.7 1.1E−05 receptor, alpha 1 /// interleukin 13 receptor, alpha 1 207265_s_at NM_016657 KDEL (Lys-Asp-Glu- KDELR3 1.4E−07 −5.6 5.0E−04 Leu) endoplasmic reticulum protein retention receptor 3 213274_s_at AA020826 cathepsin B CTSB 6.6E−05 −5.6 2.2E−04 200632_s_at NM_006096 N-myc downstream NDRG1 5.2E−05 −5.5 2.1E−04 regulated gene 1 222150_s_at AK026747 hypothetical protein LOC54103 8.8E−07 −5.5 1.1E−06 LOC54103 210136_at AW070431 myelin basic protein MBP 1.8E−06 −5.4 5.9E−04 216985_s_at AJ002077 syntaxin 3 STX3 1.7E−06 −5.4 3.5E−06 201412_at NM_014045 low density LRP10 3.9E−06 −5.3 1.2E−04 lipoprotein receptor- related protein 10 205579_at NM_000861 histamine receptor H1 HRH1 1.0E−06 −5.3 9.3E−06 202733_at NM_004199 procollagen-proline, 2- P4HA2 5.2E−04 −5.3 3.8E−04 oxoglutarate 4- dioxygenase (proline 4-hydroxylase), alpha polypeptide II 210987_x_at M19267 tropomyosin 1 (alpha) TPM1 1.7E−04 −5.2 3.2E−04 204032_at NM_003567 breast cancer anti- BCAR3 2.8E−06 −5.1 7.4E−04 estrogen resistance 3 209706_at AF247704 NK3 transcription NKX3-1 2.0E−05 −5.1 2.3E−05 factor related, locus 1 (Drosophila) 205499_at NM_014467 sushi-repeat- SRPX2 6.7E−06 −5.0 1.2E−05 containing protein, X- linked 2 202085_at NM_004817 tight junction protein 2 TJP2 9.4E−04 −4.9 5.0E−04 (zona occludens 2) 219620_x_at NM_017723 hypothetical protein FLJ20245 7.0E−07 −4.9 2.3E−04 FLJ20245 212923_s_at AK024828 chromosome 6 open C6orf145 2.4E−08 −4.9 6.1E−05 reading frame 145 212463_at BE379006 CD59 molecule, CD59 1.8E−07 −4.8 2.4E−04 complement regulatory protein 201506_at NM_000358 transforming growth TGFBI 1.9E−04 −4.8 6.6E−04 factor, beta-induced, 68 kDa 202180_s_at NM_017458 major vault protein MVP 6.1E−05 −4.7 9.6E−05 203726_s_at NM_000227 laminin, alpha 3 LAMA3 9.8E−04 −4.6 6.6E−04 212543_at U83115 absent in melanoma 1 AIM1 4.0E−04 −4.6 1.4E−04 205266_at NM_002309 leukemia inhibitory LIF 2.5E−07 −4.6 3.7E−06 factor (cholinergic differentiation factor) 203939_at NM_002526 5′-nucleotidase, ecto NT5E 8.0E−04 −4.6 6.7E−04 (CD73) 222294_s_at AW971415 CDNA clone — 4.1E−05 −4.6 1.2E−04 IMAGE: 5745639 206034_at NM_002640 serpin peptidase SERPINB8 5.9E−06 −4.6 5.9E−04 inhibitor, clade B (ovalbumin), member 8 214459_x_at M12679 major HLA-C 9.7E−04 −4.6 1.3E−04 histocompatibility complex, class I, C 202990_at NM_002863 phosphorylase, PYGL 1.5E−05 −4.6 8.0E−04 glycogen; liver (Hers disease, glycogen storage disease type VI) 205896_at NM_003059 solute carrier family SLC22A4 2.3E−05 −4.5 1.8E−04 22 (organic cation transporter), member 4 203041_s_at J04183 lysosomal-associated LAMP2 1.2E−04 −4.5 2.7E−05 membrane protein 2 201471_s_at NM_003900 sequestosome 1 SQSTM1 3.9E−06 −4.5 2.0E−04 218631_at NM_021732 arginine vasopressin- AVPI1 2.9E−05 −4.5 3.1E−05 induced 1 204981_at NM_002555 solute carrier family SLC22A18 6.9E−06 −4.5 1.1E−04 22 (organic cation transporter), member 18 203005_at NM_002342 lymphotoxin beta LTBR 2.5E−07 −4.5 2.8E−07 receptor (TNFR superfamily, member 3) 200766_at NM_001909 cathepsin D CTSD 3.4E−05 −4.4 9.5E−06 204745_x_at NM_005950 metallothionein 1G MT1G 4.0E−06 −4.4 2.8E−04 219165_at NM_021630 PDZ and LIM domain PDLIM2 9.2E−06 −4.3 9.7E−04 2 (mystique) 201482_at NM_002826 quiescin Q6 QSCN6 1.7E−05 −4.3 6.1E−05 218368_s_at NM_016639 tumor necrosis factor TNFRSF12A 7.6E−07 −4.2 6.7E−05 receptor superfamily, member 12A 209873_s_at AF053719 plakophilin 3 PKP3 3.2E−04 −4.2 7.3E−05 204254_s_at NM_000376 vitamin D (1,25- VDR 3.1E−05 −4.2 5.6E−06 dihydroxyvitamin D3) receptor 203430_at NM_014320 heme binding protein 2 HEBP2 4.5E−05 −4.2 9.1E−05 202531_at NM_002198 interferon regulatory IRF1 4.4E−05 −4.1 3.0E−05 factor 1 205398_s_at NM_005902 SMAD family member 3 SMAD3 4.4E−06 −4.1 7.5E−04 203518_at NM_000081 lysosomal trafficking LYST 5.2E−04 −4.1 2.4E−04 regulator 218273_s_at NM_018444 protein phosphatase PPM2C 8.3E−08 −4.0 2.1E−04 2C, magnesium- dependent, catalytic subunit 202087_s_at NM_001912 cathepsin L CTSL 9.0E−05 −4.0 1.6E−04 218764_at NM_024064 protein kinase C, eta PRKCH 7.8E−05 −3.9 1.2E−05 201422_at NM_006332 interferon, gamma- IFI30 7.7E−04 −3.9 2.7E−04 inducible protein 30 212196_at AW242916 Interleukin 6 signal IL6ST 4.5E−05 −3.9 8.0E−04 transducer (gp130, oncostatin M receptor) 202201_at NM_000713 biliverdin reductase B BLVRB 3.3E−05 −3.8 4.3E−06 (flavin reductase (NADPH)) 209417_s_at BC001356 interferon-induced IFI35 6.6E−05 −3.8 2.9E−04 protein 35 203329_at NM_002845 protein tyrosine PTPRM 3.9E−06 −3.8 5.8E−05 phosphatase, receptor type, M 200701_at NM_006432 Niemann-Pick disease, NPC2 1.2E−04 −3.7 8.2E−04 type C2 219622_at NM_017817 RAB20, member RAS RAB20 8.5E−04 −3.7 8.7E−04 oncogene family 207467_x_at NM_001750 calpastatin CAST 6.6E−06 −3.6 4.1E−04 205640_at NM_000694 aldehyde ALDH3B1 7.4E−07 −3.6 1.5E−07 dehydrogenase 3 family, member B1 203215_s_at AA877789 myosin VI MYO6 9.1E−04 −3.5 4.0E−05 217998_at NM_007350 pleckstrin homology- PHLDA1 /// 4.5E−07 −3.4 2.1E−04 like domain, family A, LOC652993 member 1 /// hypothetical LOC652993 204158_s_at NM_006019 T-cell, immune TCIRG1 5.4E−05 −3.4 7.5E−04 regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 208637_x_at BC003576 actinin, alpha 1 ACTN1 1.2E−07 −3.4 4.4E−05 218844_at NM_025149 hypothetical protein FLJ20920 1.5E−04 −3.4 8.3E−05 FLJ20920 219716_at NM_030641 apolipoprotein L, 6 APOL6 1.4E−05 −3.4 2.2E−08 204747_at NM_001549 interferon-induced IFIT3 1.7E−06 −3.4 4.2E−04 protein with tetratricopeptide repeats 3 202693_s_at AW194730 serine/threonine kinase STK17A 1.6E−04 −3.3 6.4E−04 17a (apoptosis- inducing) 210276_s_at AF281030 TRIO and F-actin TRIOBP 2.5E−04 −3.3 3.4E−04 binding protein 205730_s_at NM_014945 actin binding LIM ABLIM3 3.2E−05 −3.3 1.2E−04 protein family, member 3 202861_at NM_002616 period homolog 1 PER1 4.8E−05 −3.3 5.6E−05 (Drosophila) 217739_s_at NM_005746 pre-B-cell colony PBEF1 7.8E−06 −3.3 1.4E−04 enhancing factor 1 221044_s_at NM_021616 tripartite motif- TRIM34 /// 4.7E−06 −3.3 3.1E−04 containing 34 /// TRIM6-TRIM34 tripartite motif- containing 6 and tripartite motif- containing 34 207375_s_at NM_002189 interleukin 15 IL15RA 1.1E−05 −3.3 1.3E−04 receptor, alpha 213816_s_at AA005141 met proto-oncogene MET 1.8E−06 −3.2 9.9E−04 (hepatocyte growth factor receptor) 221843_s_at AA195017 KIAA1609 KIAA1609 4.6E−05 −3.2 3.4E−05 218983_at NM_016546 complement C1RL 3.6E−04 −3.2 3.1E−04 component 1, r subcomponent-like 207357_s_at NM_017540 UDP-N-acetyl-alpha- GALNT10 3.9E−06 −3.2 7.3E−05 D- galactosamine:polypeptide N- acetylgalactosaminyltransferase 10 (GalNAc- T10) 218292_s_at NM_016203 protein kinase, AMP- PRKAG2 1.2E−06 −3.2 1.4E−04 activated, gamma 2 non-catalytic subunit 207643_s_at NM_001065 tumor necrosis factor TNFRSF1A 1.5E−05 −3.2 2.6E−04 receptor superfamily, member 1A 204629_at NM_013327 parvin, beta PARVB 1.1E−04 −3.1 7.5E−04 212552_at BE617588 hippocalcin-like 1 HPCAL1 1.5E−04 −3.1 3.1E−04 204682_at NM_000428 latent transforming LTBP2 1.1E−05 −3.1 4.0E−06 growth factor beta binding protein 2 219691_at NM_017654 sterile alpha motif SAMD9 6.1E−05 −3.1 3.5E−05 domain containing 9 200885_at NM_005167 ras homolog gene RHOC 1.6E−06 −3.1 2.0E−04 family, member C 212737_at AL513583 GM2 ganglioside GM2A 1.7E−05 −3.0 7.2E−06 activator 210514_x_at AF226990 HLA-G HLA-G 7.8E−04 −3.0 7.4E−04 histocompatibility antigen, class I, G 201944_at NM_000521 hexosaminidase B HEXB 9.4E−07 −2.9 4.2E−04 (beta polypeptide) 218849_s_at NM_006663 protein phosphatase 1, PPP1R13L 4.5E−05 −2.9 2.4E−04 regulatory (inhibitor) subunit 13 like 204693_at NM_007061 CDC42 effector CDC42EP1 5.0E−05 −2.9 2.8E−04 protein (Rho GTPase binding) 1 209546_s_at AF323540 apolipoprotein L, 1 APOL1 3.7E−06 −2.9 1.2E−05 204034_at NM_014297 ethylmalonic ETHE1 3.8E−06 −2.9 4.2E−05 encephalopathy 1 202307_s_at NM_000593 transporter 1, ATP- TAP1 3.3E−04 −2.9 2.4E−04 binding cassette, sub- family B (MDR/TAP) 210978_s_at BC002616 transgelin 2 TAGLN2 2.5E−04 −2.9 8.6E−05 202275_at NM_000402 glucose-6-phosphate G6PD 3.7E−04 −2.9 3.0E−04 dehydrogenase 217150_s_at S73854 neurofibromin 2 NF2 3.3E−05 −2.9 1.2E−04 (bilateral acoustic neuroma) 202545_at NM_006254 protein kinase C, delta PRKCD 1.5E−05 −2.9 7.9E−04 214783_s_at BG177920 annexin A11 ANXA11 7.0E−07 −2.8 6.2E−05 214077_x_at H15129 Meis1 homolog 3 MEIS3P1 7.1E−04 −2.8 9.5E−04 (mouse) pseudogene 1 213083_at AJ005866 solute carrier family SLC35D2 4.3E−04 −2.8 4.9E−04 35, member D2 220049_s_at NM_025239 programmed cell death PDCD1LG2 2.7E−04 −2.8 3.1E−05 1 ligand 2 211926_s_at AI827941 myosin, heavy chain 9, MYH9 1.6E−05 −2.8 6.2E−04 non-muscle 221291_at NM_025217 UL16 binding protein 2 ULBP2 1.6E−04 −2.8 2.4E−04 208613_s_at AV712733 filamin B, beta (actin FLNB 5.2E−04 −2.7 6.0E−04 binding protein 278) 218747_s_at NM_018009 TAP binding protein- TAPBPL 3.6E−04 −2.7 7.4E−05 like 219684_at NM_022147 receptor RTP4 1.4E−04 −2.7 8.0E−04 (chemosensory) transporter protein 4 206284_x_at NM_001834 clathrin, light chain CLTB 2.0E−04 −2.6 1.5E−06 (Lcb) 201847_at NM_000235 lipase A, lysosomal LIPA 3.7E−05 −2.6 9.1E−04 acid, cholesterol esterase (Wolman disease) 205192_at NM_003954 mitogen-activated MAP3K14 3.4E−05 −2.6 2.4E−04 protein kinase kinase kinase 14 221473_x_at U49188 serine incorporator 3 SERINC3 1.5E−07 −2.6 6.7E−05 218194_at NM_015523 REX2, RNA REXO2 8.9E−06 −2.6 6.6E−04 exonuclease 2 homolog (S. cerevisiae) 205084_at NM_018844 B-cell receptor- BCAP29 2.8E−06 −2.6 4.9E−04 associated protein 29 202996_at NM_021173 polymerase (DNA- POLD4 6.3E−05 −2.6 5.3E−04 directed), delta 4 208872_s_at AA814140 receptor accessory REEP5 4.6E−05 −2.6 2.8E−04 protein 5 60471_at AA625133 Ras and Rab interactor 3 RIN3 1.5E−05 −2.6 6.8E−05 203925_at NM_002061 glutamate-cysteine GCLM 6.8E−05 −2.5 5.9E−06 ligase, modifier subunit 201587_s_at NM_001569 interleukin-1 receptor- IRAK1 1.1E−05 −2.5 8.4E−05 associated kinase 1 204769_s_at M74447 transporter 2, ATP- TAP2 9.5E−06 −2.5 9.6E−06 binding cassette, sub- family B (MDR/TAP) 201953_at NM_006384 calcium and integrin CIB1 2.1E−06 −2.5 5.0E−04 binding 1 (calmyrin) 215723_s_at AJ276230 phospholipase D1, PLD1 8.6E−06 −2.5 4.7E−05 phosphatidylcholine- specific 205032_at NM_002203 integrin, alpha 2 ITGA2 6.5E−04 −2.5 7.1E−04 (CD49B, alpha 2 subunit of VLA-2 receptor) 203045_at NM_004148 ninjurin 1 NINJ1 2.9E−05 −2.5 4.0E−04 221641_s_at AF241787 acyl-CoA thioesterase 9 ACOT9 8.9E−05 −2.5 5.5E−04 209039_x_at AF001434 EH-domain containing 1 EHD1 5.2E−05 −2.5 8.8E−04 209179_s_at BC003164 leukocyte receptor LENG4 3.1E−06 −2.4 1.5E−04 cluster (LRC) member 4 206670_s_at NM_013445 glutamate GAD1 /// 2.9E−04 −2.4 8.0E−04 decarboxylase 1 LASS6 (brain, 67 kDa) /// LAG1 homolog, ceramide synthase 6 (S. cerevisiae) 201360_at NM_000099 cystatin C (amyloid CST3 5.6E−05 −2.4 7.7E−04 angiopathy and cerebral hemorrhage) 53720_at AI862559 hypothetical protein FLJ11286 3.2E−04 −2.4 4.4E−04 FLJ11286 201975_at NM_002956 restin (Reed-Steinberg RSN 1.4E−04 −2.4 3.7E−04 cell-expressed intermediate filament- associated protein) 200618_at NM_006148 LIM and SH3 protein 1 LASP1 3.8E−05 −2.4 8.0E−04 209575_at BC001903 interleukin 10 IL10RB 4.2E−04 −2.3 9.6E−06 receptor, beta 220761_s_at NM_016281 TAO kinase 3 TAOK3 3.7E−04 −2.3 5.2E−06 208659_at AF034607 chloride intracellular CLIC1 1.9E−08 −2.3 4.1E−05 channel 1 213272_s_at AF070596 transmembrane protein TMEM159 2.0E−05 −2.3 1.1E−04 159 219710_at NM_024577 SH3 domain and SH3TC2 3.3E−04 −2.3 5.1E−05 tetratricopeptide repeats 2 203258_at NM_006442 DR1-associated DRAP1 1.9E−05 −2.3 5.7E−04 protein 1 (negative cofactor 2 alpha) 221534_at AF073483 chromosome 11 open C11orf68 2.1E−04 −2.3 1.5E−04 reading frame 68 202122_s_at NM_005817 mannose-6-phosphate M6PRBP1 6.5E−07 −2.3 4.4E−04 receptor binding protein 1 202205_at NM_003370 vasodilator-stimulated VASP 7.5E−06 −2.2 1.6E−05 phosphoprotein 203920_at NM_005693 nuclear receptor NR1H3 3.6E−04 −2.2 5.5E−04 subfamily 1, group H, member 3 207196_s_at NM_006058 TNFAIP3 interacting TNIP1 1.1E−05 −2.2 4.1E−04 protein 1 218881_s_at NM_024530 FOS-like antigen 2 FOSL2 1.1E−07 −2.2 1.8E−06 204398_s_at NM_012155 echinoderm EML2 4.9E−05 −2.2 2.5E−06 microtubule associated protein like 2 202378_s_at NM_017526 leptin receptor LEPROT 3.7E−04 −2.2 1.3E−04 overlapping transcript 219332_at NM_024723 MICAL-like 2 MICALL2 4.4E−05 −2.2 6.4E−04 203454_s_at NM_004045 ATX1 antioxidant ATOX1 5.9E−06 −2.2 3.0E−04 protein 1 homolog (yeast) 208757_at BC001123 transmembrane emp24 TMED9 7.9E−07 −2.2 8.7E−05 protein transport domain containing 9 209584_x_at AF165520 apolipoprotein B APOBEC3C 4.1E−05 −2.2 2.0E−04 mRNA editing enzyme, catalytic polypeptide-like 3C 220174_at NM_025061 leucine rich repeat LRRC8E 9.7E−05 −2.2 6.2E−04 containing 8 family, member E 200709_at NM_000801 FK506 binding protein FKBP1A 2.7E−06 −2.2 5.8E−05 1A, 12 kDa 215037_s_at U72398 BCL2-like 1 BCL2L1 5.9E−04 −2.2 4.3E−04 221926_s_at BF196320 interleukin 17 receptor C IL17RC 2.2E−06 −2.2 5.7E−06 203279_at NM_014674 ER degradation EDEM1 8.4E−06 −2.2 5.7E−04 enhancer, mannosidase alpha-like 1 218109_s_at NM_022736 major facilitator MFSD1 1.7E−04 −2.2 1.5E−04 superfamily domain containing 1 221561_at L21934 sterol O- SOAT1 5.8E−05 −2.2 8.8E−04 acyltransferase (acyl- Coenzyme A: cholesterol acyltransferase) 1 214703_s_at AW954107 mannosidase, alpha, MAN2B2 2.4E−04 −2.1 9.9E−04 class 2B, member 2 202377_at AW026535 — — 1.5E−04 −2.1 7.5E−05 202908_at NM_006005 Wolfram syndrome 1 WFS1 7.7E−05 −2.1 5.1E−04 (wolframin) 40420_at AB015718 serine/threonine kinase STK10 1.6E−07 −2.1 1.1E−04 10 209940_at AF083068 poly (ADP-ribose) PARP3 7.4E−06 −2.1 1.7E−04 polymerase family, member 3 208701_at BC000373 Amyloid beta (A4) APLP2 1.2E−04 −2.1 8.5E−05 precursor-like protein 2 218065_s_at NM_020644 TMEM9 domain TMEM9B 6.5E−06 −2.1 1.3E−04 family, member B 204458_at AL110209 lysophospholipase 3 LYPLA3 8.0E−05 −2.1 5.9E−04 (lysosomal phospholipase A2) 218749_s_at NM_024959 solute carrier family SLC24A6 2.0E−07 −2.1 2.1E−05 24 (sodium/potassium/calcium exchanger), member 6 220189_s_at NM_014275 mannosyl (alpha-1,3-)- MGAT4B 7.0E−05 −2.1 1.4E−04 glycoprotein beta-1,4- N- acetylglucosaminyltransferase, isozyme B 218498_s_at NM_014584 ERO1-like (S. cerevisiae) ERO1L 1.5E−06 −2.1 8.2E−05 201022_s_at NM_006870 destrin (actin DSTN 5.2E−06 −2.1 3.3E−06 depolymerizing factor) 208407_s_at NM_001331 catenin (cadherin- CTNND1 4.0E−04 −2.1 7.8E−04 associated protein), delta 1 336_at D38081 thromboxane A2 TBXA2R 4.7E−04 −2.0 8.4E−05 receptor 221087_s_at NM_014349 apolipoprotein L, 3 APOL3 1.5E−04 −2.0 2.1E−05 218154_at NM_024736 gasdermin domain GSDMDC1 9.5E−06 −2.0 1.3E−04 containing 1 The genes were selected by two statistic analyses: t-test (p < 0.001 and 2 fold between the groups of 16 sensitive cell lines and 12 resistant cell lines) and the Pearson correlations between the log2 (IC₅₀) data and the expression level of each gene in the 28 cell lines (p < 0.001). The overlapped genes listed here with p values and fold change indicated. The genes are rank ordered by the fold changes. The positive fold changes indicate the genes have higher expression level in the sensitive cell lines and the negative fold changes indicate the genes have higher expression level in the resistant cell lines.

**TABLE 3 Genes correlated with the sensitivity of 29 sarcoma cell lines to compound 2 as identified by Affymetrix gene array. Gene p-value Fold p-value probe Accession # Gene Title Symbol in t-test (S/R) (correlation) Genes higher expressed in the group of sensitive cell lines 214451_at NM_003221 transcription TFAP2B 7.2E−05 18.4 2.3E−04 factor AP-2 beta (activating enhancer binding protein 2 beta) 216623_x_at AK025084 trinucleotide TNRC9 5.3E−04 15.1 3.0E−05 repeat containing 9 219740_at NM_024749 vasohibin 2 VASH2 2.8E−04 10.4 4.7E−04 211341_at L20433 POU domain, POU4F1 6.8E−04 9.5 3.9E−05 class 4, transcription factor 1 212713_at R72286 microfibrillar- MFAP4 2.6E−04 8.3 5.8E−04 associated protein 4 206440_at NM_004664 lin-7 homolog A LIN7A 4.8E−04 5.6 3.3E−05 (C. elegans) 204914_s_at AW157202 SRY (sex SOX11 6.9E−05 5.5 5.5E−04 determining region Y)-box 11 218824_at NM_018215 hypothetical FLJ10781 5.1E−05 5.4 7.6E−04 protein FLJ10781 204457_s_at NM_002048 growth arrest- GAS1 8.9E−04 5.1 4.9E−05 specific 1 215043_s_at X83301 SMA3 /// SMA5 SMA3 7.9E−05 4.8 3.9E−05 /// SMA5 203139_at NM_004938 death-associated DAPK1 6.9E−05 4.8 9.6E−05 protein kinase 1 212599_at AK025298 autism AUTS2 1.5E−04 4.7 2.4E−04 susceptibility candidate 2 205888_s_at AI962693 janus kinase and JAKMIP2 2.6E−04 4.7 1.6E−06 microtubule /// interacting MYT1L protein 2 /// myelin transcription factor 1-like 206565_x_at NM_006780 SMA3 SMA3 6.9E−05 4.2 1.5E−05 207781_s_at NM_021998 zinc finger ZNF711 7.7E−06 4.0 9.7E−06 protein 711 204860_s_at AI817801 NLR family, NAIP /// 9.0E−04 4.0 2.5E−04 apoptosis LOC728519 inhibitory protein /// similar to Baculoviral IAP repeat- containing protein 1 (Neuronal apoptosis inhibitory protein) 213657_s_at BE858194 Zinc finger ZNF710 1.7E−05 4.0 9.2E−04 protein 710 /// /// MRNA full DOCK4 length insert cDNA clone EUROIMAGE 375854 /// Dedicator of cytokinesis 4 213216_at AL537463 OTU domain OTUD3 8.5E−04 3.9 1.4E−05 containing 3 204165_at NM_003931 WAS protein WASF1 1.6E−04 3.8 1.6E−04 family, member 1 200884_at NM_001823 creatine kinase, CKB 9.4E−05 3.6 1.1E−04 brain 212847_at AL036840 Far upstream FUBP1 9.3E−06 3.5 7.4E−05 element (FUSE) binding protein 1 205889_s_at NM_014790 janus kinase and JAKMIP2 2.3E−04 3.5 9.4E−07 microtubule interacting protein 2 213605_s_at AL049987 Similar to Beta- LOC728411 5.5E−04 3.4 1.2E−04 glucuronidase precursor 208998_at U94592 uncoupling UCP2 7.2E−04 3.3 6.5E−05 protein 2 (mitochondrial, proton carrier) 212731_at U79297 ankyrin repeat ANKRD46 5.0E−06 3.2 8.5E−06 domain 46 213058_at AL033538 tetratricopeptide TTC28 4.8E−05 3.1 5.0E−05 repeat domain 28 204742_s_at NM_015032 androgen- APRIN 2.7E−04 3.0 7.4E−06 induced proliferation inhibitor 201449_at AL567227 TIA1 cytotoxic TIA1 5.5E−06 3.0 5.6E−05 granule- associated RNA binding protein 203117_s_at NM_014871 ubiquitin USP52 8.9E−05 2.9 6.5E−05 specific peptidase 52 37577_at U79256 Rho GTPase ARHGAP19 5.0E−04 2.9 3.0E−04 activating protein 19 213283_s_at BG285616 sal-like 2 SALL2 4.1E−04 2.9 3.8E−04 (Drosophila) 200644_at NM_023009 MARCKS-like 1 MARCKSL1 3.4E−04 2.9 4.3E−04 210045_at AU151428 isocitrate IDH2 5.7E−07 2.8 4.8E−05 dehydrogenase 2 (NADP+), mitochondrial 218457_s_at NM_022552 DNA (cytosine- DNMT3A 2.2E−06 2.8 1.2E−04 5-)- methyltransferase 3 alpha 208986_at AL559478 transcription TCF12 1.6E−05 2.8 7.2E−07 factor 12 (HTF4, helix- loop-helix transcription factors 4) 213891_s_at AI927067 CDNA — 4.0E−04 2.7 6.5E−04 FLJ11918 fis, clone HEMBB1000272 210882_s_at U04811 trophinin TRO 1.9E−04 2.6 9.5E−04 218223_s_at NM_016274 pleckstrin PLEKHO1 1.3E−04 2.6 3.7E−06 homology domain containing, family O member 1 212547_at N34842 FLJ35348 FLJ35348 2.4E−06 2.6 1.5E−05 203825_at NM_007371 bromodomain BRD3 1.7E−06 2.6 6.7E−06 containing 3 212126_at BG391282 CDNA clone — 4.3E−05 2.6 2.1E−05 IMAGE: 4842353 206554_x_at NM_006515 SET domain and SETMAR 1.3E−04 2.6 1.9E−04 mariner transposase fusion gene 221261_x_at NM_030801 melanoma MAGED4 1.8E−04 2.6 6.8E−05 antigen family D, 4 /// melanoma antigen family D, 4 212386_at BF592782 CDNA — 4.8E−04 2.6 4.3E−04 FLJ11918 fis, clone HEMBB1000272 215599_at X83300 SMA4 /// similar SMA4 6.5E−04 2.6 1.5E−04 to SMA4 /// LOC730390 209715_at L07515 chromobox CBX5 1.2E−05 2.6 1.7E−06 homolog 5 (HP1 alpha homolog, Drosophila) 221260_s_at NM_030809 chromosome 12 C12orf22 9.9E−04 2.5 1.7E−04 open reading frame 22 /// chromosome 12 open reading frame 22 212966_at AL043112 hypermethylated HIC2 2.4E−04 2.5 7.4E−04 in cancer 2 215128_at AV704232 CDNA — 3.2E−04 2.5 5.8E−05 FLJ11682 fis, clone HEMBA1004880 212670_at AA479278 elastin ELN 2.1E−04 2.4 3.3E−04 (supravalvular aortic stenosis, Williams- Beuren syndrome) 203298_s_at NM_004973 jumonji, AT rich JARID2 1.5E−04 2.4 5.3E−05 interactive domain 2 220443_s_at NM_012476 ventral anterior VAX2 6.6E−05 2.4 7.2E−06 homeobox 2 204799_at NM_014838 zinc finger, ZBED4 1.6E−06 2.4 5.0E−04 BED-type containing 4 209153_s_at M31523 transcription TCF3 1.4E−04 2.4 1.8E−04 factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) 203625_x_at BG105365 melanoma cell MCAM 7.4E−04 2.4 5.6E−05 adhesion molecule 213387_at AB033066 ATPase family, ATAD2B 2.0E−05 2.3 3.0E−05 AAA domain containing 2B 213694_at AW027347 round spermatid RSBN1 2.8E−04 2.3 6.5E−04 basic protein 1 203046_s_at NM_003920 timeless TIMELESS 1.2E−05 2.3 2.7E−07 homolog (Drosophila) 214877_at BE794663 CDK5 CDKAL1 5.5E−05 2.3 9.2E−04 regulatory subunit associated protein 1-like 1 208838_at AB020636 — — 2.6E−04 2.3 8.3E−06 213610_s_at BE326381 kelch-like 23 KLHL23 7.7E−04 2.3 8.3E−04 (Drosophila) 221965_at AI990326 M-phase MPHOSPH9 5.8E−04 2.3 1.1E−04 phosphoprotein 9 203026_at NM_014872 zinc finger and ZBTB5 1.6E−06 2.3 2.9E−05 BTB domain containing 5 210555_s_at U85430 nuclear factor of NFATC3 5.7E−07 2.3 5.8E−06 activated T- cells, cytoplasmic, calcineurin- dependent 3 211929_at AA527502 heterogeneous HNRPA3 3.5E−04 2.2 6.2E−04 nuclear ribonucleoprotein A3 212704_at AI049962 zinc finger, ZCCHC11 2.9E−05 2.2 7.8E−06 CCHC domain containing 11 208664_s_at AU131711 tetratricopeptide TTC3 1.7E−05 2.2 4.7E−04 repeat domain 3 210649_s_at AF231056 AT rich ARID1A 9.6E−05 2.2 4.1E−07 interactive domain 1A (SWI-like) 204060_s_at NM_005044 protein kinase, PRKX 8.2E−04 2.2 1.4E−04 X-linked /// /// protein kinase, PRKY Y-linked 212153_at AB007930 pogo POGZ 6.5E−04 2.2 6.9E−04 transposable element with ZNF domain 221902_at AL567940 G protein- GPR153 5.3E−04 2.2 4.4E−04 coupled receptor 153 213302_at AL044326 phosphoribosylformylglycinamidine PFAS 3.7E−04 2.2 4.1E−04 synthase (FGAR amidotransferase) 52975_at AA534894 family with FAM125B 7.3E−04 2.1 1.1E−04 sequence similarity 125, member B 212164_at AL522296 transmembrane TMEM183A 1.5E−04 2.1 4.2E−05 protein 183A 208990_s_at AF132362 heterogeneous HNRPH3 5.8E−07 2.1 7.7E−06 nuclear ribonucleoprotein H3 (2H9) 221883_at AA133342 PBX/knotted 1 PKNOX1 3.0E−05 2.1 1.2E−04 homeobox 1 202540_s_at NM_000859 3-hydroxy-3- HMGCR 1.8E−04 2.1 3.1E−04 methylglutaryl- Coenzyme A reductase 217025_s_at AL110225 drebrin 1 DBN1 2.3E−04 2.1 4.3E−05 218683_at NM_021190 polypyrimidine PTBP2 1.9E−04 2.1 8.9E−05 tract binding protein 2 210962_s_at AB019691 A kinase AKAP9 5.9E−05 2.1 2.1E−06 (PRKA) anchor protein (yotiao) 9 212482_at BF671894 required for RMND5A 3.8E−04 2.1 1.5E−04 meiotic nuclear division 5 homolog A (S. cerevisiae) 212919_at AV715578 DCP2 DCP2 2.0E−04 2.1 1.1E−04 decapping enzyme homolog (S. cerevisiae) 219800_s_at NM_024838 — — 5.5E−04 2.1 3.9E−04 201741_x_at M69040 splicing factor, SFRS1 3.6E−06 2.1 1.4E−04 arginine/serine- rich 1 (splicing factor 2, alternate splicing factor) 218875_s_at NM_012177 F-box protein 5 FBXO5 8.3E−04 2.1 6.8E−04 212170_at BF447705 RNA binding RBM12 2.5E−04 2.1 6.4E−05 motif protein 12 214221_at AI825212 Alstrom ALMS1 5.9E−04 2.1 4.2E−05 syndrome 1 210473_s_at M37712 G protein- GPR125 1.8E−04 2.1 2.6E−04 coupled receptor 125 208839_s_at AL136810 cullin-associated CAND1 4.8E−04 2.1 1.2E−05 and neddylation- dissociated 1 208644_at M32721 poly (ADP- PARP1 3.3E−04 2.0 6.2E−05 ribose) polymerase family, member 1 205256_at NM_014830 zinc finger and ZBTB39 1.5E−05 2.0 3.4E−06 BTB domain containing 39 202455_at NM_005474 histone HDAC5 4.1E−04 2.0 2.3E−05 deacetylase 5 213677_s_at BG434893 PMS1 PMS1 7.1E−06 2.0 6.4E−05 postmeiotic segregation increased 1 (S. cerevisiae) 206128_at AI264306 adrenergic, ADRA2C 9.1E−04 2.0 3.0E−05 alpha-2C-, receptor 201833_at NM_001527 histone HDAC2 2.1E−06 2.0 7.8E−05 deacetylase 2 202051_s_at NM_005095 zinc finger, ZMYM4 2.8E−04 2.0 3.8E−04 MYM-type 4 204520_x_at NM_014577 bromodomain BRD1 7.5E−06 2.0 8.3E−04 containing 1 201235_s_at BG339064 BTG family, BTG2 9.3E−04 2.0 5.9E−04 member 2 Genes higher expressed in the group of resistant cell lines 222108_at AC004010 adhesion AMIGO2 4.8E−05 −40.9 7.8E−05 molecule with Ig-like domain 2 209835_x_at BC004372 CD44 molecule CD44 1.3E−06 −33.2 5.0E−06 (Indian blood group) 201858_s_at J03223 proteoglycan 1, PRG1 3.0E−05 −30.8 2.6E−04 secretory granule 202638_s_at NM_000201 intercellular ICAM1 3.6E−04 −30.3 4.0E−04 adhesion molecule 1 (CD54), human rhinovirus receptor 217901_at BF031829 Desmoglein 2 DSG2 9.6E−04 −25.6 5.7E−04 205083_at NM_001159 aldehyde AOX1 6.5E−05 −24.1 1.7E−04 oxidase 1 213010_at AI088622 protein kinase PRKCDBP 3.8E−04 −21.8 7.5E−04 C, delta binding protein 202855_s_at AL513917 solute carrier SLC16A3 1.5E−05 −21.5 1.2E−05 family 16, member 3 (monocarboxylic acid transporter 4) 202854_at NM_000194 hypoxanthine HPRT1 1.4E−05 −20.0 8.7E−06 phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) 215034_s_at AI189753 transmembrane TM4SF1 2.0E−04 −20.0 1.1E−04 4 L six family member 1 210916_s_at AF098641 CD44 molecule CD44 1.0E−06 −18.7 7.2E−06 (Indian blood /// group) /// MAPK10 mitogen- activated protein kinase 10 221530_s_at BE857425 basic helix-loop- BHLHB3 3.5E−04 −18.1 4.7E−06 helix domain containing, class B, 3 209803_s_at AF001294 pleckstrin PHLDA2 1.6E−06 −17.4 2.0E−06 homology-like domain, family A, member 2 204420_at BG251266 FOS-like FOSL1 1.6E−06 −17.2 9.8E−06 antigen 1 201596_x_at NM_000224 keratin 18 KRT18 2.3E−05 −16.8 1.6E−05 209278_s_at L27624 tissue factor TFPI2 3.0E−04 −16.1 7.4E−05 pathway inhibitor 2 203108_at NM_003979 G protein- GPRC5A 5.0E−05 −15.9 1.2E−04 coupled receptor, family C, group 5, member A 211864_s_at AF207990 fer-1-like 3, FER1L3 1.3E−05 −15.7 3.8E−06 myoferlin (C. elegans) 204470_at NM_001511 chemokine CXCL1 9.1E−04 −15.4 2.5E−04 (C—X—C motif) ligand 1 (melanoma growth stimulating activity, alpha) 204279_at NM_002800 proteasome PSMB9 2.4E−07 −15.0 9.1E−07 (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) 205627_at NM_001785 cytidine CDA 7.0E−04 −14.9 4.8E−04 deaminase 212444_at AA156240 CDNA clone — 7.8E−05 −14.8 3.2E−04 IMAGE: 6025865 201842_s_at AI826799 EGF-containing EFEMP1 4.2E−04 −14.3 5.7E−04 fibulin-like extracellular matrix protein 1 208747_s_at M18767 complement C1S 4.6E−04 −14.1 6.9E−04 component 1, s subcomponent 204602_at NM_012242 dickkopf DKK1 2.0E−04 −13.9 6.6E−04 homolog 1 (Xenopus laevis) 201468_s_at NM_000903 NAD(P)H NQO1 5.6E−06 −13.7 5.1E−05 dehydrogenase, quinone 1 201631_s_at NM_003897 immediate early IER3 1.1E−06 −13.7 5.8E−05 response 3 204222_s_at NM_006851 GLI GLIPR1 7.3E−05 −13.0 4.2E−04 pathogenesis- related 1 (glioma) 210592_s_at M55580 spermidine/spermine SAT1 5.6E−07 −12.6 3.7E−06 N1- acetyltransferase 1 208949_s_at BC001120 lectin, LGALS3 8.9E−04 −11.3 2.3E−04 galactoside- binding, soluble, 3 (galectin 3) 206513_at NM_004833 absent in AIM2 8.3E−04 −11.0 7.4E−04 melanoma 2 203851_at NM_002178 insulin-like IGFBP6 1.7E−04 −11.0 1.7E−04 growth factor binding protein 6 202627_s_at AL574210 serpin peptidase SERPINE1 7.1E−04 −10.9 6.4E−04 inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 210042_s_at AF073890 cathepsin Z CTSZ 4.4E−05 −10.8 3.2E−05 202858_at NM_006758 U2 small U2AF1 9.2E−04 −10.7 2.2E−04 nuclear RNA auxiliary factor 1 208510_s_at NM_015869 peroxisome PPARG 8.7E−05 −10.2 1.6E−04 proliferator- activated receptor gamma 202202_s_at NM_002290 laminin, alpha 4 LAMA4 4.8E−04 −10.2 2.6E−04 219759_at NM_022350 leukocyte- LRAP 6.1E−05 −9.8 6.4E−05 derived arginine aminopeptidase 205798_at NM_002185 interleukin 7 IL7R 1.5E−05 −9.8 2.6E−04 receptor /// interleukin 7 receptor 202862_at NM_000137 fumarylacetoacetate FAH 1.3E−06 −9.8 9.7E−06 hydrolase (fumarylacetoacetase) 201474_s_at NM_002204 integrin, alpha 3 ITGA3 3.9E−06 −9.7 6.8E−07 (antigen CD49C, alpha 3 subunit of VLA- 3 receptor) 221059_s_at NM_021615 coactosin-like 1 COTL1 5.7E−06 −9.6 8.2E−06 (Dictyostelium) 217744_s_at NM_022121 PERP, TP53 PERP 3.6E−05 −9.3 2.9E−04 apoptosis effector 211367_s_at U13699 caspase 1, CASP1 7.1E−05 −9.1 7.4E−04 apoptosis- related cysteine peptidase (interleukin 1, beta, convertase) 209040_s_at U17496 proteasome PSMB8 5.8E−09 −9.1 1.1E−06 (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) 201042_at AL031651 transglutaminase TGM2 6.7E−04 −9.1 3.7E−04 2 (C polypeptide, protein- glutamine- gamma- glutamyltransferase) 212473_s_at BE965029 microtubule MICAL2 2.3E−04 −8.9 8.0E−04 associated monoxygenase, calponin and LIM domain containing 2 218211_s_at NM_024101 melanophilin MLPH 2.1E−04 −8.8 2.5E−05 210896_s_at AF306765 aspartate beta- ASPH 3.2E−06 −8.2 1.5E−04 hydroxylase 210951_x_at AF125393 RAB27A, RAB27A 6.0E−06 −8.1 1.7E−05 member RAS oncogene family 203234_at NM_003364 uridine UPP1 1.9E−05 −8.0 2.1E−05 phosphorylase 1 209310_s_at U25804 caspase 4, CASP4 1.2E−07 −7.8 8.3E−05 apoptosis- related cysteine peptidase 212268_at NM_030666 serpin peptidase SERPINB1 5.6E−06 −7.6 1.2E−07 inhibitor, clade B (ovalbumin), member 1 201324_at NM_001423 epithelial EMP1 4.0E−05 −7.4 4.2E−06 membrane protein 1 218084_x_at NM_014164 FXYD domain FXYD5 6.8E−06 −7.3 2.4E−05 containing ion transport regulator 5 201170_s_at NM_003670 basic helix-loop- BHLHB2 8.1E−05 −7.3 8.4E−05 helix domain containing, class B, 2 218322_s_at NM_016234 acyl-CoA ACSL5 9.0E−04 −7.2 2.3E−04 synthetase long- chain family member 5 202863_at NM_003113 SP100 nuclear SP100 3.4E−06 −7.1 2.0E−05 antigen 214791_at AK023116 hypothetical LOC93349 2.7E−06 −7.1 2.8E−05 protein BC004921 206461_x_at NM_005951 metallothionein MT1H 6.4E−05 −7.1 6.7E−04 1H 209679_s_at BC003379 small trans- LOC57228 2.9E−06 −6.9 1.5E−05 membrane and glycosylated protein 202510_s_at NM 006291 tumor necrosis TNFAIP2 9.7E−04 −6.9 3.8E−04 factor, alpha- induced protein 2 36711_at AL021977 v-maf MAFF 2.0E−07 −6.8 4.6E−08 musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 206632_s_at NM_004900 apolipoprotein B APOBEC3B 1.6E−04 −6.6 5.0E−05 mRNA editing enzyme, catalytic polypeptide-like 3B 211456_x_at AF333388 metallothionein LOC645745 7.3E−05 −6.4 8.8E−04 1H-like protein 214446_at NM_012081 elongation ELL2 1.9E−05 −6.3 2.1E−05 factor, RNA polymerase II, 2 220016_at NM_024060 AHNAK AHNAK 9.7E−04 −6.0 2.9E−04 nucleoprotein (desmoyokin) 205100_at NM_005110 glutamine- GFPT2 1.3E−04 −5.9 2.7E−04 fructose-6- phosphate transaminase 2 210538_s_at U37546 baculoviral IAP BIRC3 8.8E−04 −5.8 2.3E−04 repeat- containing 3 216336_x_at AL031602 metallothionein MT1M 1.2E−04 −5.8 1.8E−04 1M 210117_at AF311312 sperm SPAG1 1.2E−04 −5.7 5.8E−04 associated antigen 1 216985_s_at AJ002077 syntaxin 3 STX3 1.4E−06 −5.6 5.3E−06 217165_x_at M10943 metallothionein MT1F 2.8E−04 −5.6 9.8E−04 1F (functional) 204017_at NM_006855 KDEL (Lys- KDELR3 1.2E−05 −5.5 3.9E−04 Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 217996_at AA576961 pleckstrin PHLDA1 2.2E−04 −5.3 3.8E−04 homology-like domain, family A, member 1 202733_at NM_004199 procollagen- P4HA2 3.7E−05 −5.3 6.9E−05 proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), alpha polypeptide II 209457_at U16996 dual specificity DUSP5 1.3E−04 −5.0 9.8E−04 phosphatase 5 214866_at X74039 plasminogen PLAUR 4.5E−05 −5.0 1.2E−04 activator, urokinase receptor 211612_s_at U62858 interleukin 13 IL13RA1 1.5E−04 −5.0 4.3E−04 receptor, alpha 1 /// interleukin 13 receptor, alpha 1 210987_x_at M19267 tropomyosin 1 TPM1 7.4E−04 −5.0 2.3E−05 (alpha) 213274_s_at AA020826 cathepsin B CTSB 7.9E−04 −5.0 1.6E−04 202949_s_at NM_001450 four and a half FHL2 5.6E−05 −4.9 5.2E−04 LIM domains 2 203939_at NM_002526 5′-nucleotidase, NT5E 9.5E−04 −4.9 6.1E−05 ecto (CD73) 222294_s_at AW971415 CDNA clone — 8.3E−06 −4.9 1.2E−05 IMAGE: 5745639 202085_at NM_004817 tight junction TJP2 1.4E−04 −4.9 2.8E−04 protein 2 (zona occludens 2) 209706_at AF247704 NK3 NKX3-1 6.0E−05 −4.9 1.8E−04 transcription factor related, locus 1 (Drosophila) 222150_s_at AK026747 hypothetical LOC54103 1.8E−05 −4.8 2.6E−06 protein LOC54103 200632_s_at NM_006096 N-myc NDRG1 6.2E−04 −4.8 4.1E−04 downstream regulated gene 1 210136_at AW070431 myelin basic MBP 1.6E−05 −4.6 1.0E−04 protein 205579_at NM_000861 histamine HRH1 6.3E−05 −4.6 1.5E−04 receptor H1 201412_at NM_014045 low density LRP10 8.4E−05 −4.6 2.8E−04 lipoprotein receptor-related protein 10 211799_x_at U62824 major HLA-C 5.4E−04 −4.6 8.6E−04 histocompatibility complex, class I, C 203005_at NM_002342 lymphotoxin LTBR 1.1E−06 −4.5 4.4E−06 beta receptor (TNFR superfamily, member 3) 209417_s_at BC001356 interferon- IFI35 1.7E−05 −4.3 7.7E−05 induced protein 35 203041_s_at J04183 lysosomal- LAMP2 8.4E−04 −4.3 9.0E−04 associated membrane protein 2 213865_at AI378788 discoidin, CUB DCBLD2 8.1E−04 −4.2 3.6E−04 and LCCL domain containing 2 201649_at NM_004223 ubiquitin- UBE2L6 2.6E−04 −4.2 6.4E−05 conjugating enzyme E2L 6 202180_s_at NM_017458 major vault MVP 3.1E−04 −4.1 2.7E−04 protein 211000_s_at AB015706 interleukin 6 IL6ST 1.8E−04 −4.1 8.0E−04 signal transducer (gp 130, oncostatin M receptor) 203518_at NM_000081 lysosomal LYST 4.9E−05 −4.0 4.4E−05 trafficking regulator 205896_at NM_003059 solute carrier SLC22A4 3.2E−04 −4.0 6.6E−04 family 22 (organic cation transporter), member 4 201482_at NM_002826 quiescin Q6 QSCN6 2.1E−05 −4.0 6.0E−05 218631_at NM_021732 arginine AVPI1 8.6E−04 −3.9 2.6E−04 vasopressin- induced 1 201471_s_at NM_003900 sequestosome 1 SQSTM1 1.4E−04 −3.9 4.8E−04 212463_at BE379006 CD59 molecule, CD59 2.6E−04 −3.8 3.5E−04 complement regulatory protein 205266_at NM_002309 leukemia LIF 8.2E−05 −3.8 5.1E−05 inhibitory factor (cholinergic differentiation factor) 204745_x_at NM_005950 metallothionein MT1G 1.6E−04 −3.7 4.4E−04 1G 202087_s_at NM_001912 cathepsin L CTSL 2.7E−04 −3.7 6.1E−04 202531_at NM_002198 interferon IRF1 2.3E−04 −3.7 3.1E−04 regulatory factor 1 205398_s_at NM_005902 SMAD family SMAD3 1.9E−05 −3.7 6.4E−04 member 3 202201_at NM_000713 biliverdin BLVRB 2.5E−05 −3.6 3.6E−05 reductase B (flavin reductase (NADPH)) 202499_s_at NM_006931 solute carrier SLC2A3 4.8E−04 −3.6 5.9E−05 family 2 (facilitated glucose transporter), member 3 203329_at NM_002845 protein tyrosine PTPRM 2.2E−05 −3.6 8.0E−05 phosphatase, receptor type, M 218273_s_at NM_018444 protein PPM2C 1.8E−05 −3.6 2.0E−05 phosphatase 2C, magnesium- dependent, catalytic subunit 202948_at NM_000877 interleukin 1 IL1R1 4.3E−04 −3.5 6.5E−04 receptor, type I 204158_s_at NM_006019 T-cell, immune TCIRG1 3.1E−06 −3.4 1.8E−04 regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 202861_at NM_002616 period homolog PER1 5.6E−05 −3.4 3.8E−05 1 (Drosophila) 219691_at NM_017654 sterile alpha SAMD9 1.1E−05 −3.4 8.9E−05 motif domain containing 9 202074_s_at NM_021980 optineurin OPTN 9.9E−04 −3.3 6.4E−04 204981_at NM_002555 solute carrier SLC22A18 7.4E−04 −3.3 7.4E−06 family 22 (organic cation transporter), member 18 202693_s_at AW194730 serine/threonine STK17A 1.6E−04 −3.3 1.0E−04 kinase 17a (apoptosis- inducing) 207467_x_at NM_001750 calpastatin CAST 3.4E−05 −3.2 1.6E−04 218552_at NM_018281 enoyl Coenzyme ECHDC2 1.0E−04 −3.2 3.0E−04 A hydratase domain containing 2 204863_s_at BE856546 interleukin 6 IL6ST 4.3E−04 −3.2 9.8E−04 signal /// transducer MAGEA4 (gp130, oncostatin M receptor) /// melanoma antigen family A, 4 218983_at NM_016546 complement C1RL 5.1E−05 −3.2 6.4E−05 component 1, r subcomponent- like 205640_at NM_000694 aldehyde ALDH3B1 6.0E−05 −3.1 2.3E−05 dehydrogenase 3 family, member B1 212737_at AL513583 GM2 GM2A 3.9E−04 −3.1 3.2E−05 ganglioside activator 203430_at NM_014320 heme binding HEBP2 3.5E−04 −3.1 1.9E−05 protein 2 210978_s_at BC002616 transgelin 2 TAGLN2 3.3E−04 −3.1 3.1E−05 209304_x_at AF087853 growth arrest GADD45B 5.5E−04 −3.0 9.4E−04 and DNA- damage- inducible, beta 211528_x_at M90685 HLA-G HLA-G 3.1E−04 −3.0 9.7E−04 histocompatibility antigen, class I, G 204747_at NM_001549 interferon- IFIT3 3.5E−05 −3.0 4.0E−04 induced protein with tetratricopeptide repeats 3 217739_s_at NM_005746 pre-B-cell PBEF1 3.6E−05 −3.0 1.2E−04 colony enhancing factor 1 202307_s_at NM_000593 transporter 1, TAP1 1.2E−05 −3.0 6.1E−04 ATP-binding cassette, sub- family B (MDR/TAP) 207375_s_at NM_002189 interleukin 15 IL15RA 1.6E−04 −3.0 8.1E−04 receptor, alpha 219716_at NM_030641 apolipoprotein APOL6 4.1E−04 −2.9 4.2E−05 L, 6 212552_at BE617588 hippocalcin-like 1 HPCAL1 2.2E−04 −2.9 1.0E−04 217998_at NM_007350 pleckstrin PHLDA1 9.7E−05 −2.9 3.6E−04 homology-like /// domain, family LOC652993 A, member 1 /// hypothetical LOC652993 202275_at NM_000402 glucose-6- G6PD 6.9E−05 −2.9 1.2E−04 phosphate dehydrogenase 201954_at NM_005720 actin related ARPC1B 7.2E−04 −2.9 5.3E−04 protein 2/3 /// complex, LOC653888 subunit 1B, 41 kDa /// similar to Actin- related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41- ARC) 214447_at NM_005238 v-ets ETS1 2.5E−04 −2.8 8.3E−04 erythroblastosis virus E26 oncogene homolog 1 (avian) 221044_s_at NM_021616 tripartite motif- TRIM34 2.7E−04 −2.8 8.1E−04 containing 34 /// /// tripartite motif- TRIM6- containing 6 and TRIM34 tripartite motif- containing 34 221843_s_at AA195017 KIAA1609 KIAA1609 6.9E−04 −2.8 7.7E−05 213083_at AJ005866 solute carrier SLC35D2 2.0E−04 −2.7 2.2E−05 family 35, member D2 208637_x_at BC003576 actinin, alpha 1 ACTN1 2.9E−04 −2.7 1.7E−04 53720_at AI862559 hypothetical FLJ11286 2.4E−05 −2.7 6.6E−06 protein FLJ11286 208829_at AF029750 TAP binding TAPBP 6.8E−04 −2.6 8.3E−04 protein (tapasin) 204682_at NM_000428 latent LTBP2 5.9E−04 −2.6 2.4E−04 transforming growth factor beta binding protein 2 208613_s_at AV712733 filamin B, beta FLNB 2.1E−04 −2.6 2.4E−04 (actin binding protein 278) 201944_at NM_000521 hexosaminidase HEXB 3.2E−05 −2.6 4.4E−04 B (beta polypeptide) 208872_s_at AA814140 receptor REEP5 1.6E−05 −2.6 2.0E−04 accessory protein 5 218747_s_at NM_018009 TAP binding TAPBPL 9.1E−04 −2.6 2.7E−04 protein-like 209546_s_at AF323540 apolipoprotein APOL1 2.4E−04 −2.6 7.1E−05 L, 1 205032_at NM_002203 integrin, alpha 2 ITGA2 7.2E−05 −2.5 4.9E−04 (CD49B, alpha 2 subunit of VLA-2 receptor) 204769_s_at M74447 transporter 2, TAP2 1.6E−05 −2.5 1.4E−05 ATP-binding cassette, sub- family B (MDR/TAP) 206284_x_at NM_001834 clathrin, light CLTB 3.9E−04 −2.4 4.3E−05 chain (Lcb) 204034_at NM_014297 ethylmalonic ETHE1 5.5E−04 −2.4 2.2E−05 encephalopathy 1 219684_at NM_022147 receptor RTP4 7.9E−04 −2.4 5.4E−04 (chemosensory) transporter protein 4 211769_x_at BC006088 serine SERINC3 1.7E−06 −2.4 1.1E−04 incorporator 3 /// serine incorporator 3 213272_s_at AF070596 transmembrane TMEM159 5.6E−05 −2.4 7.6E−05 protein 159 201587_s_at NM_001569 interleukin-1 IRAK1 1.3E−04 −2.4 1.4E−04 receptor- associated kinase 1 203925_at NM_002061 glutamate- GCLM 2.3E−04 −2.4 4.2E−04 cysteine ligase, modifier subunit 220761_s_at NM_016281 TAO kinase 3 TAOK3 8.4E−05 −2.3 2.0E−07 214783_s_at BG177920 annexin A11 ANXA11 2.4E−04 −2.3 8.6E−04 217751_at NM_015917 glutathione S- GSTK1 7.3E−04 −2.3 5.4E−04 transferase kappa 1 203045_at NM_004148 ninjurin 1 NINJ1 3.8E−05 −2.3 2.7E−04 203167_at NM_003255 TIMP TIMP2 9.0E−04 −2.3 5.5E−04 metallopeptidase inhibitor 2 60471_at AA625133 Ras and Rab RIN3 5.9E−05 −2.2 2.7E−04 interactor 3 209179_s_at BC003164 leukocyte LENG4 7.8E−06 −2.2 1.8E−04 receptor cluster (LRC) member 4 202013_s_at NM_000401 exostoses EXT2 4.7E−05 −2.2 4.2E−04 (multiple) 2 218739_at NM_016006 abhydrolase ABHD5 3.0E−04 −2.2 9.1E−04 domain containing 5 219677_at NM_025106 splA/ryanodine SPSB1 3.9E−06 −2.2 1.1E−04 receptor domain and SOCS box containing 1 209575_at BC001903 interleukin 10 IL10RB 2.8E−04 −2.2 2.9E−05 receptor, beta 218154_at NM_024736 gasdermin GSDMDC1 5.0E−09 −2.2 7.2E−06 domain containing 1 201847_at NM_000235 lipase A, LIPA 3.3E−04 −2.2 2.2E−05 lysosomal acid, cholesterol esterase (Wolman disease) 201953_at NM_006384 calcium and CIB1 1.2E−04 −2.2 6.5E−04 integrin binding 1 (calmyrin) 200752_s_at NM_005186 calpain 1, (mu/I) CAPN1 3.3E−04 −2.2 4.9E−04 large subunit 205084_at NM_018844 B-cell receptor- BCAP29 8.0E−04 −2.1 6.6E−04 associated protein 29 221827_at BE788439 RanBP-type and RBCK1 2.6E−06 −2.1 1.9E−04 C3HC4-type zinc finger containing 1 203258_at NM_006442 DR1-associated DRAP1 1.6E−04 −2.1 5.1E−04 protein 1 (negative cofactor 2 alpha) 201360_at NM_000099 cystatin C CST3 6.0E−04 −2.1 4.6E−04 (amyloid angiopathy and cerebral hemorrhage) 200709_at NM_000801 FK506 binding FKBP1A 8.6E−06 −2.0 9.5E−05 protein 1A, 12 kDa 218109_s_at NM_022736 major facilitator MFSD1 2.9E−04 −2.0 4.0E−04 superfamily domain containing 1 203454_s_at NM_004045 ATX1 ATOX1 6.3E−05 −2.0 3.3E−04 antioxidant protein 1 homolog (yeast) The genes were selected by two statistic analyses: t-test (p < 0.001 and 2 fold between the groups of 15 sensitive cell lines and 14 resistant cell lines) and the Pearson correlations between the log2 (IC₅₀) data and the expression level of each gene in the 29 cell lines (p < 0.001). The overlapped genes listed here with p values and fold change indicated. The genes are rank ordered by the fold changes. The positive fold changes indicate the genes have higher expression level in the sensitive cell lines and the negative fold changes indicate the genes have higher expression level in the resistant cell lines.

The same two statistical methods were applied to protein profiling data to identify proteins that correlated with the sensitivity of the cell lines to IGF1R inhibitors. This yielded 251 unique peptide ions for compound 1, and 228 unique peptide ions for compound 2, 153 of which overlap between the two compounds. These unique peptide ions were then sequenced by tandem mass spectrometry to obtain the identity of the corresponding protein markers. As shown in Table 4, 76 peptides were identified to represent 46 proteins that were differentially expressed between the sensitive and resistant cell line groups for compound 1; and 70 peptides representing 45 proteins (Table 5) for compound 2, with 39 proteins common for both compounds.

TABLE 4 Proteins correlated with the sensitivity of 26 sarcoma cell lines to compound 1 as identified by LC/MS based protein profiling. Swiss- Identified protein by Gene Protein name ID microarray name Peptide sequence actinin, alpha P12814 Yes ACTN1 VGWEQLLTTIAR (SEQ ID NO: 1) FAIQDISVEETSAK (SEQ ID NO: 2) TINEVENQILTR (SEQ ID NO: 3) actinin, alpha O43707 Yes ACTN4 DYETATLSDIK (SEQ ID NO: 4) AHNAK Q09666 Yes AHNAK VPGIDATTK (SEQ ID NO: 5) nucleoprotein GEGPEVDVNLPK (SEQ ID NO: 6) FSMPGFK (SEQ ID NO: 7) IGFSGPKLEGGEVDLKGPK (SEQ ID NO: 8 ISMPDFDLHLK (SEQ ID NO: 9 ISMPDIDLNLK: (SEQ ID NO: 10) GEGPDVHMTLPKGDISISGPK (SEQ ID NO: 11) Plasma P23634 ATP2B4 SMSTVIRNPNGGFR (SEQ ID NO: 12) membrane calcium- transporting ATPase 4 TSPVEGLSGNPADLEK (SEQ ID NO: 13) PADGILIQGNDLK (SEQ ID NO: 14) ATP synthase, Q9Y653 Yes ATP5G TIAMDGTEGLVR (SEQ ID NO: 15) H+ transporting, mitochondrial F1 complex calpain CAPN2 SMVAVMDSDTTGK (SEQ ID NO: 16) Creatine Kinase, Yes CKB FCTGLTQIETLFK (SEQ ID NO: 17) brain chloride O00299 Yes CLIC1 GVTFNVTTVDTK (SEQ ID NO: 18) intracelluar protein 1 heat shock CPN60 VGEVIVTK (SEQ ID NO: 19) protein 60 catenin Yes CTNNA1 TLAVER (SEQ ID NO: 20) HVNPVQALSEFK (SEQ ID NO: 21) destrin P60981 Yes DSTN YALYDASFETK (SEQ ID NO: 22) myoferlin Q9NZM1 Yes FER1L3 VGETIIDLENR (SEQ ID NO: 23) filamin B Yes FLNB GDYVLAVK (SEQ ID NO: 24) G protein- Yes GPR56 SSLHYKPTPDLR (SEQ ID NO: 25) coupled receptor 56 histone 2 Yes H2AFY2 EIQTAVR (SEQ ID NO: 26) histone 3 Yes H3F3B EIAQDFK (SEQ ID NO: 27) histone 1 HIST1H4I TLYGFGG (SEQ ID NO: 28) DAVTYTEHAK (SEQ ID NO: 29) histone 3 Yes HIST3H3 YRPGTVALR (SEQ ID NO: 30) high mobility HMGB1 KHPDASVNFSEFSK (SEQ ID NO: 31) protein 1 high mobility P26583 Yes HMGB2 LGEMWSEQSAK (SEQ ID NO: 32) protein 2 MSSYAFFVQTCR (SEQ ID NO: 33) heterogeneous Yes HNRPA2 IDTIEIITDR (SEQ ID NO: 34) nuclear ribonucleoprotein heterogeneous Yes HNRPA3 LTDCVVMR (SEQ ID NO: 35) nuclear ribonucleoprotein heterogeneous Q14103 Yes HNRPD IFVGGLSPDTPEEK (SEQ ID NO: 36) nuclear ribonucleoprotein heterogeneous P09651 Yes HRNPA1 NQGGYGGSSSSSSYGSGR (SEQ ID NO: 37) nuclear ribonucleoprotein EDSQRPGAHLTVK (SEQ ID NO: 38) heterogeneous P22626 Yes HRNPA2 GFGFVTFDDHDPVDK (SEQ ID NO: 39) nuclear ribonucleoprotein heterogeneous Q14103 Yes HNRPD MFIGGLSWDTTK (SEQ ID NO: 40) nuclear ribonucleoprotein GFGFVLFK (SEQ ID NO: 41) heterogeneous Yes HRNPK IILDLISESPIK (SEQ ID NO: 42) nuclear ribonucleoprotein heterogeneous Yes HRNPM AFITNIPFDVK (SEQ ID NO: 43) nuclear ribonucleoprotein KH domain Q07666 Yes KHDRBS1 DSLDPSFTHAMQLLTAEIEK (SEQ ID NO: 44) containing, RNA binding, signal transduction associated 1 LIM domain and Q9UHB6 LIMA1 YPHIKDGEDLK (SEQ ID NO: 45) actin binding SNTENLSQHFR (SEQ ID NO: 46) matrin 3 Yes MATR3 MKSQAFIEMETR (SEQ ID NO: 47) YQLLQLVEPFGVISNHLILNK (SEQ ID NO: 48) DLSAAGIGLLAAATQSLSMPASLGR (SEQ ID NO: 49) myosin heavy Yes MYH9 VVFQEFR (SEQ ID NO: 50) chain LQQELDDLLVDLDHQR (SEQ ID NO: 51) VISGVLQLGNIVFK (SEQ ID NO: 52) LDPHLVLDQLR (SEQ ID NO: 53) myosin light O00159 Yes MYL6 HVLVTLGEK (SEQ ID NO: 54) chain ELLTTMGDR (SEQ ID NO: 55) EAFQLFDR (SEQ ID NO: 56) DGFIDKEDLHDMLASLGK (SEQ ID NO: 57) IAEFTTNLTEEEEK (SEQ ID NO: 58) VLDFEHFLPMLQTVAK (SEQ ID NO: 59) lactate LDHB IVVVTAGVR (SEQ ID NO: 60) dehydrogenase histone H2B Yes NP_00351 AMGIMNSFVNDIFER (SEQ ID NO: 61) tublin, alpha NP_006073 FDLMYAK (SEQ ID NO: 62) cleavage and Q10570 Yes CPSF1 MYAVYK (SEQ ID NO: 63) polyadenylation specific factor 1 poly rC binding Yes PCBP2 IITLTGPTNAIFK (SEQ ID NO: 64) protein peroxiredoxin Yes PRDX6 LPFPIIDDR (SEQ ID NO: 65) protein tyrosine PTPRF TFALHK (SEQ ID NO: 66) phosphatase, receptor type, F YANVIAYDHSR (SEQ ID NO: 67) Radixin P35241 RDX KALELDQER (SEQ ID NO: 68) KENPLQFKFR (SEQ ID NO: 69) splicing factor SFPQ LFVGNLPADITEDEFKR (SEQ ID NO: 70) proline/glutamine rich spectrin, beta SPTBN2 ALAVEGK (SEQ ID NO: 71) AAMRETWLSENQR (SEQ ID NO: 72) Stathmin P16949 Yes STMN1 DLSLEEIQK (SEQ ID NO: 73) Syntaxin O15400 Yes STX7 TLNQLGTPQDSPELR (SEQ ID NO: 74) thymoprotein TMPO YGVNPGPIVGTTR (SEQ ID NO: 75) The peptide ions were selected by the overlaps between the two statistic analyses: t-test (p < 0.001 and 2 fold between the groups of 14 sensitive cell lines and 12 resistant cell lines) and the Pearson correlations between the log2(IC₅₀) data and the expression level of each peptide ion in the 26 cell lines (p < 0.001). The peptide ions generated from statistical analyses were sequenced by tandem mass spectrometry to get the identification of the proteins which are listed in this Table. The name of protein and gene, the sequence of each peptide ion associated with identified protein are listed. The overlap with Affymetrix gene expression results also indicated.

TABLE 5 Proteins correlated with the sensitivity of 27 sarcoma cell lines to compound 2 as identified by LC/MS based protein profiling. Swiss- Identified protein by Gene Protein name ID microarray name Peptide sequence Septin 7 Q16181 SEPT7 IKIYEFPETDDEEENKLVK (SEQ ID NO: 76) actinin, alpha P12814 Yes ACTN1 VGWEQLLTTIAR (SEQ ID NO: 77) FAIQDISVEETSAK (SEQ ID NO: 78) TINEVENQILTR (SEQ ID NO: 79) RDQALTEEHAR (SEQ ID NO: 80) actinin, alpha O43707 Yes ACTN4 DYETATLSDIK (SEQ ID NO: 81) ISNRPAFMPSEGK (SEQ ID NO: 82) AHNAK Q09666 Yes AHNAK VPGIDATTK (SEQ ID NO: 83) nucleoprotein GEGPEVDVNLPK (SEQ ID NO: 84) FSMPGFK (SEQ ID NO: 85) IGFSGPKLEGGEVDLKGPK (SEQ ID NO: 86) ISMPDFDLHLK (SEQ ID NO: 87) ISMPDIDLNLK (SEQ ID NO: 88) GEGPDVHMTLPKGDISISGPK (SEQ ID NO: 89) GDLDASVPSMK (SEQ ID NO: 90) Plasma P23634 ATP2B4 TSPVEGLSGNPADLEK (SEQ ID NO: 91) membrane calcium- transporting ATPase 4 PADGILIQGNDLK (SEQ ID NO: 92) ATP synthase, Q9Y653 Yes ATP5G TIAMDGTEGLVR (SEQ ID NO: 93) H+ transporting, mitochondrial F1 complex Creatine Yes CKB FCTGLTQIETLFK (SEQ ID NO: 94) Kinase, brain chloride O00299 Yes CLIC1 GVTFNVTTVDTK (SEQ ID NO: 95) intracelluar protein 1 catenin Yes CTNNA1 HVNPVQALSEFK (SEQ ID NO: 96) destrin P60981 Yes DSTN YALYDASFETK (SEQ ID NO: 97) myoferlin Q9NZM1 Yes FER1L3 VGETIIDLENR (SEQ ID NO: 98) filamin B Yes FLNB GDYVLAVK (SEQ ID NO: 99) G protein- Yes GPR56 SSLHYKPTPDLR (SEQ ID NO: 100) coupled receptor 56 histone 2 Q99877 Yes H2AFY2 ESYSVYVYK (SEQ ID NO: 101) histone 3 Yes HIST3H3 YRPGTVALR (SEQ ID NO: 102) high mobility HMGB1 KHPDASVNFSEFSK (SEQ ID NO: 103) protein 1 high mobility Yes HMGB2 MSSYAFFVQTCR (SEQ ID NO: 104) protein 2 heterogeneous Yes HNRPA3 LTDCVVMR (SEQ ID NO: 105) nuclear ribonucleoprotein heterogeneous P09651 Yes HRNPA1 NQGGYGGSSSSSSYGSGR (SEQ ID NO: 106) nuclear ribonucleoprotein EDSQRPGAHLTVK (SEQ ID NO: 107) heterogeneous Yes HRNPA2 GFGFVTFDDHDPVDK (SEQ ID NO: 108) nuclear ribonucleoprotein heterogeneous Q14103 Yes HRNPD GFGFVLFK (SEQ ID NO: 109) nuclear ribonucleoprotein heterogeneous Yes HRNPK IILDLISESPIK (SEQ ID NO: 110) nuclear ribonucleoprotein heterogeneous Yes HRNPM AFITNIPFDVK (SEQ ID NO: 111) nuclear ribonucleoprotein KH domain Q07666 Yes KHDRBS1 DSLDPSFTHAMQLLTAEIEK (SEQ ID NO: 112) containing, RNA binding, signal transduction associated 1 LIM domain Q9UHB6 LIMA1 YPHIKDGEDLK (SEQ ID NO: 113) and actin binding SNTENLSQHFR (SEQ ID NO: 114) matrin 3 Yes MATR3 MKSQAFIEMETR (SEQ ID NO: 115) YQLLQLVEPFGVISNHLILNK (SEQ ID NO: 116) DLSAAGIGLLAAATQSLSMPAS LGR (SEQ ID NO: 117) myosin heavy Yes MYH9 VVFQEFR (SEQ ID NO: 118) chain LQQELDDLLVDLDHQR (SEQ ID NO: 119) VISGVLQLGNIVFK (SEQ ID NO: 120) LDPHLVLDQLR (SEQ ID NO: 121) IVGLDQVTGMTETAFGSAYK (SEQ ID NO: 122) myosin light O00159 Yes MYL6 HVLVTLGEK (SEQ ID NO: 123) chain EAFQLFDR (SEQ ID NO: 124) lactate P07195 LDHB IVVVTAGVR (SEQ ID NO: 125) dehydrogenase histone H2B Yes NP_00351 AMGIMNSFVNDIFER (SEQ ID NO: 126) Annexin A2 P07355 Yes ANXA2 TPAQYDASELK (SEQ ID NO: 127) Clathrin heavy Q00610 Yes CLTC IVLDNSVFSEHR (SEQ ID NO: 128) chain 1 tublin, alpha P68363 NP_006073 FDLMYAK (SEQ ID NO: 129) LDHKFDLMYAK (SEQ ID NO: 130) calcium Q99653 NP_009167 ETGFSHSQITR (SEQ ID NO: 131) binding protein P22 ISRDELLQVLR (SEQ ID NO: 132) cleavage and Q10570 Yes CPSF1 MYAVYK (SEQ ID NO: 133) polyadenylation specific factor 1 poly rC Yes PCBP2 IITLTGPTNAIFK (SEQ ID NO: 134) binding protein peroxiredoxin P30041 Yes PRDX6 LPFPIIDDR (SEQ ID NO: 135) protein PTPRF YANVIAYDHSR (SEQ ID NO: 136) tyrosine phosphatase, receptor type, F Radixin P35241 RDX KALELDQER (SEQ ID NO: 137) KENPLQFK (SEQ ID NO: 138) splicing factor SFPQ LFVGNLPADITEDEFKR (SEQ ID NO: 139) proline/glutamine rich spectrin, beta O15020 SPTBN2 VGDLYSDLRDGR (SEQ ID NO: 140) AAMRETWLSENQR (SEQ ID NO: 141) Stathmin P16949 Yes STMN1 DLSLEEIQK (SEQ ID NO: 142) Syntaxin O15400 Yes STX7 TLNQLGTPQDSPELR (SEQ ID NO: 143) thymoprotein TMPO YGVNPGPIVGTTR (SEQ ID NO: 144) Tubulin beta-2 P05217 Yes TUBB2C EIVHIQAGQCGNQIGAK (SEQ ID NO: 145) chain The peptide ions were selected by the overlaps between the two statistic analyses: t-test (p < 0.001 and 2 fold between the groups of 13 sensitive cell lines and 14 resistant cell lines) and the Pearson correlations between the log2(IC₅₀) data and the expression level of each peptide ion in the 27 cell lines (p < 0.001). The peptide ions generated from statistical analyses were sequenced by tandem mass spectrometry to get the identification of the proteins which are listed in this Table. The name of protein and gene, the sequence of each peptide ion associated with identified protein are listed. The overlap with Affymetrix gene expression results also indicated.

In general, a higher number of genes than proteins was identified using the same statistic analyses due to the complicity of the protein profiling technology. Cross comparing the gene and protein profiling results, the overlaps between identified genes and proteins are significantly large as indicated in Tables 4 and 5. 71.7% (33 out 46) proteins for compound 1 and 73.3% (33 out 45) proteins for compound 2 also identified in gene expression profiling, respectively, suggesting good concordance between the results detected by the two technologies. For some of the markers identified by the protein profiling, for example, ATP2B4, it was also detected as significantly differentially expressed between the sensitive and resistant cell lines (−2.3 fold and p values are 0.0043 and 0.0016 for t-test and correlation test, respectively) by gene profiling, yet did not meet the stringent statistical cutoff of p values of 0.001.

Genes/Proteins Modulated by IGF1R Inhibitor Compound 1 Treatment:

There is differential sensitivity of compound 1 in a pair of human RMS cell lines, Rh36 (resistant, IC₅₀=1.6 μM) and Rh41 (sensitive, IC₅₀=0.069 μM). In order to understand the mechanism of the differential sensitivity, both cell lines were evaluated using gene expression profiling and proteomics analyses to search at genomics scale for genes or proteins that are differentially modulated by IGF1R inhibitor compound 1 in a time course study with the drug treatment for 6, 30 and 72 hours. Cell lysates were subjected in parallel to microarray and LC/MS based “bottom-up” protein profiling analyses. A two-way ANOVA mixed model was utilized to identify drug treatment effect as well as treatment and time interaction on the expression of genes and protein. Overall, there were some mRNA transcripts or peptides with expression change upon the drug treatment in Rh36 cell line at 6 hr, and these changes mainly reflected the initial stress response to the stimuli the cell encountered. However, the drug had little to no effect at later time points, 36 and 72 hrs in Rh36 cells. This makes sense for the given concentration of compound 1 cell treated, Rh36 is highly resistant, so the drug had little effect on cell growth compared to the sensitive cell Rh41, which had dramatic changes in gene/protein expression. The genes and protein that were modulated by compound 1 in the sensitive RH41 cell line are listed in Table 6 and Table 7, respectively.

TABLE 6 Genes modulated by compound 1 treatment in Rh41 cells. fdr p fold_change Gene fdr p value value for (compound probe Accession # Symbol Gene Title for treatment treatment_Time 1 vs DMSO) 213880_at AL524520 LGR5 leucine-rich repeat- 0.0007 0.9280 3.5 containing G protein-coupled receptor 5 203131_at NM_006206 PDGFRA platelet-derived 0.0011 0.6916 3.3 growth factor receptor, alpha polypeptide 219106_s_at NM_006063 KBTBD10 kelch repeat and 0.0007 0.0666 2.6 BTB (POZ) domain containing 10 207558_s_at NM_000325 PITX2 paired-like 0.0130 0.8149 2.3 homeodomain transcription factor 2 212614_at BG285011 ARID5B AT rich interactive 0.0005 0.2446 2.3 domain 5B (MRF1-like) 214375_at AI962377 PPFIBP1 PTPRF interacting 0.0030 0.0721 2.2 /// protein, binding LOC440091 protein 1 (liprin /// beta 1) /// similar to LOC729222 Liprin-beta 1 (Protein tyrosine phosphatase receptor type f polypeptide- interacting protein binding protein 1) (PTPRF-interacting protein binding protein 1) (hSGT2) /// similar to PTPRF interacting protein binding protein 1 isoform 1 209102_s_at AF019214 HBP1 HMG-box 0.0004 0.0424 2.2 transcription factor 1 216321_s_at X03348 NR3C1 nuclear receptor 0.0059 0.2261 2.1 subfamily 3, group C, member 1 (glucocorticoid receptor) 209199_s_at N22468 MEF2C MADS box 0.0022 0.2701 2.1 transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) 202364_at NM_005962 MXI1 MAX interactor 1 0.0014 0.4787 2.0 /// MAX interactor 1 213624_at AA873600 SMPDL3A sphingomyelin 0.0027 0.5082 2.0 phosphodiesterase, acid-like 3A 218258_at NM_015972 POLR1D polymerase (RNA) 0.0006 0.0546 2.0 I polypeptide D, 16 kDa 220416_at NM_024837 ATP8B4 ATPase, Class I, 0.0056 0.4286 2.0 type 8B, member 4 212148_at AL049381 PBX1 Pre-B-cell 0.0024 0.5563 2.0 leukemia transcription factor 1 205923_at NM_005045 RELN reelin 0.0020 0.3396 2.0 213891_s_at AI927067 — CDNA FLJ11918 0.0029 0.3970 2.0 fis, clone HEMBB1000272 206306_at NM_001036 RYR3 ryanodine receptor 3 0.0014 0.2488 1.9 214608_s_at AJ000098 EYA1 eyes absent 0.0007 0.0714 1.9 homolog 1 (Drosophila) 221217_s_at NM_018723 A2BP1 ataxin 2-binding 0.0015 0.0721 1.9 protein 1 213593_s_at AW978896 TRA2A transformer-2 0.0153 0.4675 1.9 alpha 203628_at H05812 IGF1R insulin-like growth 0.0017 0.0401 1.9 factor 1 receptor 212406_s_at AB028973 PCMTD2 protein-L- 0.0007 0.5279 1.9 isoaspartate (D- aspartate) O- methyltransferase domain containing 2 213139_at AI572079 SNAI2 snail homolog 2 0.0064 0.3069 1.9 (Drosophila) 215123_at AL049250 LOC23117 KIAA0220-like 0.0116 0.4345 1.9 /// protein /// LOC339047 hypothetical /// protein LOC642778 LOC339047 /// /// similar to nuclear LOC642799 pore complex /// interacting protein LOC728888 /// similar to nuclear pore complex interacting protein /// similar to Protein KIAA0220 220751_s_at NM_016348 C5orf4 chromosome 5 0.0038 0.3618 1.9 open reading frame 4 205619_s_at NM_004527 MEOX1 mesenchyme 0.0072 0.1300 1.8 homeobox 1 218694_at NM_016608 ARMCX1 armadillo repeat 0.0021 0.2291 1.8 containing, X- linked 1 201739_at NM_005627 SGK serum/glucocorticoid 0.0025 0.3263 1.8 regulated kinase 221899_at AI809961 PFAAP5 Phosphonoformate 0.0076 0.5328 1.8 immuno-associated protein 5 217989_at NM_016245 HSD17B11 hydroxysteroid 0.0010 0.2141 1.8 (17-beta) dehydrogenase 11 204030_s_at NM_014575 SCHIP1 schwannomin 0.0019 0.5363 1.8 interacting protein 1 205741_s_at NM_001392 DTNA dystrobrevin, alpha 0.0038 0.5200 1.8 203753_at NM_003199 TCF4 transcription factor 4 0.0034 0.0971 1.8 219961_s_at NM_018474 C20orf19 chromosome 20 0.0043 0.7121 1.8 open reading frame 19 201384_s_at NM_005899 NBR1 /// neighbor of 0.0015 0.8006 1.8 LOC727732 BRCA1 gene 1 /// similar to neighbor of BRCA1 gene 1 211341_at L20433 POU4F1 POU domain, class 0.0030 0.0990 1.8 4, transcription factor 1 203408_s_at NM_002971 SATB1 special AT-rich 0.0011 0.0695 1.8 sequence binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's) 200632_s_at NM_006096 NDRG1 N-myc downstream 0.0057 0.0839 1.7 regulated gene 1 204019_s_at NM_015677 SH3YL1 SH3 domain 0.0079 0.1130 1.7 containing, Ysc84- like 1 (S. cerevisiae) 207327_at NM_004100 EYA4 eyes absent 0.0058 0.1761 1.7 homolog 4 (Drosophila) 213435_at AB028957 SATB2 SATB family 0.0081 0.5816 1.7 member 2 219935_at NM_007038 ADAMTS5 ADAM 0.0030 0.0441 1.7 metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) 209112_at BC001971 CDKN1B cyclin-dependent 0.0044 0.2948 1.7 kinase inhibitor 1B (p27, Kip1) 201294_s_at N24643 WSB1 WD repeat and 0.0100 0.1315 1.7 SOCS box- containing 1 221589_s_at AW612403 ALDH6A1 aldehyde 0.0135 0.6528 1.7 dehydrogenase 6 family, member A1 209479_at BC000758 CCDC28A coiled-coil domain 0.0071 0.2439 1.7 containing 28A 200921_s_at NM_001731 BTG1 B-cell translocation 0.0085 0.7445 1.7 gene 1, anti- proliferative 212179_at AW157501 C6orf111 chromosome 6 0.0238 0.4713 1.7 open reading frame 111 203824_at NM_004616 TSPAN8 tetraspanin 8 0.0167 0.6494 1.7 204297_at NM_002647 PIK3C3 phosphoinositide- 0.0051 0.5000 1.7 3-kinase, class 3 209185_s_at AF073310 IRS2 insulin receptor 0.0021 0.8649 1.7 substrate 2 202551_s_at BG546884 CRIM1 cysteine rich 0.0111 0.1974 1.7 transmembrane BMP regulator 1 (chordin-like) 213782_s_at BF939176 MYOZ2 myozenin 2 0.0121 0.8529 1.7 212761_at AI949687 TCF7L2 transcription factor 0.0012 0.1631 1.7 7-like 2 (T-cell specific, HMG- box) 202028_s_at BC000603 RPL38 ribosomal protein 0.0118 0.1143 1.7 L38 207401_at NM_002763 PROX1 prospero-related 0.0305 0.2292 1.7 homeobox 1 204851_s_at AF040254 DCX doublecortex; 0.0302 0.0565 1.7 lissencephaly, X- linked (doublecortin) 202553_s_at NM_015484 SYF2 SYF2 homolog, 0.0015 0.2787 1.7 RNA splicing factor (S. cerevisiae) 209034_at AF279899 PNRC1 proline-rich 0.0093 0.6717 1.7 nuclear receptor coactivator 1 217906_at NM_014315 KLHDC2 kelch domain 0.0017 0.6814 1.7 containing 2 208671_at AF164794 SERINC1 serine incorporator 1 0.0044 0.3841 1.7 206854_s_at NM_003188 MAP3K7 mitogen-activated 0.0007 0.0592 1.6 protein kinase kinase kinase 7 221841_s_at BF514079 KLF4 Kruppel-like factor 0.0068 0.1692 1.6 4 (gut) 203810_at BG252490 DNAJB4 DnaJ (Hsp40) 0.0037 0.2405 1.6 homolog, subfamily B, member 4 210858_x_at U26455 ATM ataxia 0.0045 0.0493 1.6 telangiectasia mutated (includes complementation groups A, C and D) 218645_at NM_021994 ZNF277P zinc finger protein 0.0030 0.1008 1.6 277 pseudogene 218142_s_at NM_016302 CRBN cereblon 0.0012 0.1954 1.6 206363_at NM_005360 MAF v-maf 0.0089 0.5222 1.6 musculoaponeurotic fibrosarcoma oncogene homolog (avian) 220917_s_at NM_025132 WDR19 WD repeat domain 0.0010 0.2438 1.6 19 213413_at BG434174 STON1 stonin 1 0.0079 0.7123 1.6 203227_s_at NM_005981 TSPAN31 tetraspanin 31 0.0079 0.3100 1.6 222273_at AI419423 PAPOLG poly(A) 0.0365 0.6023 1.6 polymerase gamma 202160_at NM_004380 CREBBP CREB binding 0.0026 0.3771 1.6 protein (Rubinstein-Taybi syndrome) 202105_at NM_001551 IGBP1 immunoglobulin 0.0004 0.0261 1.6 (CD79A) binding protein 1 215450_at W87901 — — 0.0185 0.1143 1.6 217988_at NM_021178 CCNB1IP1 cyclin B1 0.0005 0.0571 1.6 interacting protein 1 212956_at AI348094 TBC1D9 TBC1 domain 0.0005 0.0274 1.6 family, member 9 (with GRAM domain) 212448_at AB007899 NEDD4L neural precursor 0.0043 0.4684 1.6 cell expressed, developmentally down-regulated 4- like 203789_s_at NM_006379 SEMA3C sema domain, 0.0051 0.3375 1.6 immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C 214683_s_at AI251890 CLK1 CDC-like kinase 1 0.0358 0.7292 1.6 201008_s_at AA812232 TXNIP thioredoxin 0.0060 0.3503 1.6 interacting protein 209212_s_at AB030824 KLF5 Kruppel-like factor 0.0074 0.4147 1.6 5 (intestinal) 215043_s_at X83301 SMA3 /// SMA3 /// SMA5 0.0240 0.8101 1.6 SMA5 218603_at NM_016217 HECA headcase homolog 0.0026 0.3544 1.6 (Drosophila) 219599_at NM_018507 PRO1843 hypothetical 0.0213 0.5078 1.6 protein PRO1843 212616_at BF668950 CHD9 chromodomain 0.0061 0.6115 1.6 helicase DNA binding protein 9 210111_s_at AF277175 KIAA0265 KIAA0265 protein 0.0024 0.5594 1.6 213258_at BF511231 TFPI tissue factor 0.0050 0.2677 1.6 pathway inhibitor (lipoprotein- associated coagulation inhibitor) 217627_at BE515346 ZNF573 zinc finger protein 0.0188 0.3191 1.6 573 213032_at AI186739 NFIB nuclear factor I/B 0.0041 0.0563 1.6 215071_s_at AL353759 HIST1H2AC histone cluster 1, 0.0021 0.1437 1.6 H2ac 206059_at NM_003430 ZNF91 zinc finger protein 0.0109 0.0953 1.6 91 218168_s_at NM_020247 CABC1 chaperone, ABC1 0.0046 0.3869 1.6 activity of bc1 complex homolog (S. pombe) 201465_s_at BC002646 JUN jun oncogene 0.0055 0.0800 1.6 218643_s_at NM_014171 CRIPT cysteine-rich PDZ- 0.0078 0.7762 1.6 binding protein 213655_at AA502643 PAFAH1B1 Platelet-activating 0.0017 0.0157 1.6 factor acetylhydrolase, isoform Ib, alpha subunit 45 kDa 206565_x_at NM_006780 SMA3 SMA3 0.0055 0.8548 1.6 203298_s_at NM_004973 JARID2 jumonji, AT rich 0.0007 0.0705 1.6 interactive domain 2 216623_x_at AK025084 TNRC9 trinucleotide repeat 0.0255 0.7718 1.6 containing 9 204485_s_at NM_005486 TOM1L1 target of myb1-like 0.0016 0.3551 1.6 1 (chicken) 205431_s_at NM_021073 BMP5 bone 0.0075 0.3673 1.6 morphogenetic protein 5 205054_at NM_004543 NEB nebulin 0.0015 0.2275 1.6 209750_at N32859 NR1D2 nuclear receptor 0.0270 0.0803 1.6 subfamily 1, group D, member 2 208131_s_at NM_000961 PTGIS prostaglandin I2 0.0025 0.0783 1.6 (prostacyclin) synthase /// prostaglandin I2 (prostacyclin) synthase 219679_s_at NM_018604 WAC WW domain 0.0129 0.1806 1.6 containing adaptor with coiled-coil 221763_at AI694023 JMJD1C jumonji domain 0.0007 0.0389 1.6 containing 1C 203420_at NM_016255 FAM8A1 family with 0.0043 0.1789 1.6 sequence similarity 8, member A1 210102_at BC001234 LOH11CR2A loss of 0.0183 0.4585 1.5 heterozygosity, 11, chromosomal region 2, gene A 212936_at AI927701 C5orf21 chromosome 5 0.0020 0.1531 1.5 open reading frame 21 204726_at NM_001257 CDH13 cadherin 13, H- 0.0388 0.7671 1.5 cadherin (heart) 202832_at NM_014635 GCC2 GRIP and coiled- 0.0047 0.2332 1.5 coil domain containing 2 203510_at BG170541 MET met proto- 0.0049 0.3651 1.5 oncogene (hepatocyte growth factor receptor) 207186_s_at NM_004459 BPTF bromodomain PHD 0.0135 0.2421 1.5 finger transcription factor 212593_s_at N92498 PDCD4 programmed cell 0.0059 0.7650 1.5 death 4 (neoplastic transformation inhibitor) 203491_s_at AI123527 CEP57 centrosomal 0.0149 0.1552 1.5 protein 57 kDa 217100_s_at AK026451 UBXD7 UBX domain 0.0069 0.2624 1.5 containing 7 210346_s_at AF212224 CLK4 CDC-like kinase 4 0.0007 0.0252 1.5 218277_s_at NM_024612 DHX40 DEAH (Asp-Glu- 0.0049 0.6421 1.5 Ala-His) box polypeptide 40 212764_at AI806174 — — 0.0031 0.1646 1.5 207170_s_at NM_015416 LETMD1 LETM1 domain 0.0020 0.4216 1.5 containing 1 213939_s_at AI871641 RUFY3 RUN and FYVE 0.0143 0.7780 1.5 domain containing 3 210962_s_at AB019691 AKAP9 A kinase (PRKA) 0.0062 0.7228 1.5 anchor protein (yotiao) 9 201637_s_at NM_005087 FXR1 fragile X mental 0.0100 0.6502 1.5 retardation, autosomal homolog 1 200965_s_at NM_006720 ABLIM1 actin binding LIM 0.0017 0.0274 1.5 protein 1 203139_at NM_004938 DAPK1 death-associated 0.0051 0.8963 1.5 protein kinase 1 201737_s_at NM_005885 6-Mar membrane- 0.0112 0.5449 1.5 associated ring finger (C3HC4) 6 221190_s_at NM_013326 C18orf8 chromosome 18 0.0095 0.4956 1.5 open reading frame 8 218330_s_at NM_018162 NAV2 neuron navigator 2 0.0163 0.7871 1.5 217783_s_at NM_016061 YPEL5 yippee-like 5 0.0033 0.1201 1.5 (Drosophila) 205824_at NM_001541 HSPB2 heat shock 27 kDa 0.0139 0.6070 1.5 protein 2 211675_s_at AF054589 MDFIC MyoD family 0.0029 0.1408 1.5 inhibitor domain containing /// MyoD family inhibitor domain containing 218625_at NM_016588 NRN1 neuritin 1 0.0465 0.5695 1.5 214016_s_at AL558875 SFPQ splicing factor 0.0146 0.5232 1.5 proline/glutamine- rich (polypyrimidine tract binding protein associated) 212634_at AW298092 KIAA0776 KIAA0776 0.0198 0.0537 1.5 213002_at AA770596 MARCKS Myristoylated 0.0105 0.1001 1.5 alanine-rich protein kinase C substrate 212654_at AL566786 TPM2 /// tropomyosin 2 0.0166 0.6932 1.5 PPIL5 (beta) /// peptidylprolyl isomerase (cyclophilin)-like 5 200962_at AI348010 RPL31 /// ribosomal protein 0.0047 0.3069 1.5 LOC285260 L31 /// similar to /// ribosomal protein RPL31P4 L31 /// ribosomal /// protein L31 RPL31P10 pseudogene 4 /// /// ribosomal protein LOC641790 L31 pseudogene 10 /// /// similar to LOC646841 ribosomal protein /// L31 /// similar to LOC648737 ribosomal protein /// L31 /// similar to LOC653773 ribosomal protein /// L31 /// similar to LOC727792 ribosomal protein /// L31 /// similar to LOC729646 ribosomal protein /// L31 /// LOC732015 hypothetical protein LOC729646 /// similar to ribosomal protein L31 217591_at BF725121 SKIL SKI-like oncogene 0.0284 0.1213 1.5 211161_s_at AF130082 COL3A1 collagen, type III, 0.0016 0.4548 1.5 alpha 1 (Ehlers- Danlos syndrome type IV, autosomal dominant) 208796_s_at BC000196 CCNG1 cyclin G1 0.0018 0.2131 1.5 214042_s_at AW071997 RPL22 ribosomal protein 0.0007 0.0592 1.5 L22 220755_s_at NM_016947 C6orf48 chromosome 6 0.0005 0.1746 1.5 open reading frame 48 212665_at AL556438 TIPARP TCDD-inducible 0.0025 0.2295 1.5 poly(ADP-ribose) polymerase 212773_s_at BG165094 TOMM20 translocase of outer 0.0188 0.1173 1.5 mitochondrial membrane 20 homolog (yeast) 212455_at N36997 YTHDC1 YTH domain 0.0010 0.0732 1.5 containing 1 201285_at NM_013446 MKRN1 makorin, ring 0.0045 0.9558 1.5 finger protein, 1 /// makorin, ring finger protein, 1 203140_at NM_001706 BCL6 B-cell 0.0135 0.6753 1.5 CLL/lymphoma 6 (zinc finger protein 51) /// B-cell CLL/lymphoma 6 (zinc finger protein 51) 212451_at N52532 KIAA0256 KIAA0256 gene 0.0190 0.0968 1.5 product 203002_at NM_016201 AMOTL2 angiomotin like 2 0.0311 0.1937 1.5 208886_at BC000145 H1F0 H1 histone family, 0.0008 0.2034 1.5 member 0 204094_s_at NM_014779 TSC22D2 TSC22 domain 0.0034 0.5023 1.5 family, member 2 204822_at NM_003318 TTK TTK protein kinase 0.0086 0.1596 1.5 213241_at AF035307 PLXNC1 plexin C1 0.0283 0.9168 1.5 209286_at AI754416 CDC42EP3 CDC42 effector 0.0050 0.2353 1.5 protein (Rho GTPase binding) 3 206572_x_at NM_003429 ZNF85 zinc finger protein 0.0206 0.6963 1.5 85 222288_at AI004009 — Transcribed locus, 0.0045 0.2761 1.5 weakly similar to NP_001013658.1 protein LOC387873 [Homo sapiens] 206829_x_at NM_025189 ZNF430 zinc finger protein 0.0074 0.4605 1.5 430 214280_x_at X79536 HNRPA1 heterogeneous 0.0029 0.1967 1.5 nuclear ribonucleoprotein A1 217936_at AW044631 ARHGAP5 Rho GTPase 0.0214 0.5528 1.5 activating protein 5 212463_at BE379006 CD59 CD59 molecule, 0.0012 0.1864 1.5 complement regulatory protein 208835_s_at AW089673 CROP cisplatin 0.0311 0.1778 1.5 resistance- associated overexpressed protein 203640_at BE328496 MBNL2 muscleblind-like 2 0.0030 0.0670 1.4 (Drosophila) 218316_at NM_012460 TIMM9 translocase of inner 0.0042 0.1350 1.4 mitochondrial membrane 9 homolog (yeast) 204920_at AF154830 CPS1 carbamoyl- 0.0095 0.7685 1.4 phosphate synthetase 1, mitochondrial 205022_s_at NM_005197 CHES1 checkpoint 0.0085 0.2652 1.4 suppressor 1 205443_at NM_003082 SNAPC1 small nuclear RNA 0.0038 0.0942 1.4 activating complex, polypeptide 1, 43 kDa 204215_at NM_024315 C7orf23 chromosome 7 0.0100 0.3811 1.4 open reading frame 23 202023_at NM_004428 EFNA1 ephrin-A1 0.0135 0.5642 1.4 203538_at NM_001745 CAMLG calcium 0.0082 0.0804 1.4 /// modulating ligand FAM39DP /// family with sequence similarity 39, member D pseudogene 202976_s_at NM_014899 RHOBTB3 Rho-related BTB 0.0039 0.1116 1.4 domain containing 3 205811_at NM_007215 POLG2 polymerase (DNA 0.0160 0.7714 1.4 directed), gamma 2, accessory subunit 218253_s_at NM_006893 LGTN ligatin 0.0064 0.2044 1.4 210312_s_at BC002640 IFT20 intraflagellar 0.0087 0.2350 1.4 transport 20 homolog (Chlamydomonas) 217990_at NM_016576 GMPR2 guanosine 0.0035 0.2297 1.4 monophosphate reductase 2 204633_s_at AF074393 RPS6KA5 ribosomal protein 0.0232 0.5765 1.4 S6 kinase, 90 kDa, polypeptide 5 221499_s_at AK026970 STX16 syntaxin 16 0.0114 0.1455 1.4 205954_at NM_006917 RXRG retinoid X receptor, 0.0050 0.0389 1.4 gamma 202956_at NM_006421 ARFGEF1 ADP-ribosylation 0.0270 0.6102 1.4 factor guanine nucleotide- exchange factor 1(brefeldin A- inhibited) 213844_at NM_019102 HOXA5 homeobox A5 0.0046 0.1113 1.4 220924_s_at NM_018976 SLC38A2 solute carrier 0.0060 0.6814 1.4 family 38, member 2 209656_s_at AL136550 TMEM47 transmembrane 0.0015 0.3325 1.4 protein 47 208204_s_at NM_001234 CAV3 caveolin 3 0.0078 0.9326 1.4 205872_x_at NM_022359 PDE4DIP phosphodiesterase 0.0299 0.0719 1.4 4D interacting protein (myomegalin) 213605_s_at AL049987 LOC728411 Similar to Beta- 0.0399 0.3946 1.4 glucuronidase precursor 201417_at AL136179 SOX4 SRY (sex 0.0121 0.4154 1.4 determining region Y)-box 4 200912_s_at NM_001967 EIF4A2 eukaryotic 0.0005 0.0721 1.4 translation initiation factor 4A, isoform 2 217987_at NM_019048 ASNSD1 asparagine 0.0226 0.2254 1.4 synthetase domain containing 1 212689_s_at AA524505 JMJD1A jumonji domain 0.0012 0.1485 1.4 containing 1A 218268_at NM_022771 TBC1D15 TBC1 domain 0.0245 0.3320 1.4 family, member 15 201616_s_at AL577531 CALD1 caldesmon 1 0.0442 0.2187 1.4 212675_s_at AB011154 — — 0.0149 0.7153 1.4 218397_at NM_018062 FANCL Fanconi anemia, 0.0064 0.1684 1.4 complementation group L 209181_s_at U49245 RABGGTB Rab 0.0031 0.1108 1.4 geranylgeranyltransferase, beta subunit 215983_s_at D83768 UBXD6 UBX domain 0.0214 0.2921 1.4 containing 6 209781_s_at AF069681 KHDRBS3 KH domain 0.0013 0.3269 1.4 containing, RNA binding, signal transduction associated 3 201200_at NM_003851 CREG1 cellular repressor 0.0121 0.2634 1.4 of E1A-stimulated genes 1 213619_at AV753392 HNRPH1 Heterogeneous 0.0052 0.0417 1.4 nuclear ribonucleoprotein H1 (H) 201549_x_at NM_006618 JARID1B jumonji, AT rich 0.0176 0.5037 1.4 interactive domain 1B 200899_s_at NM_012215 MGEA5 meningioma 0.0261 0.5721 1.4 expressed antigen 5 (hyaluronidase) 218718_at NM_016205 PDGFC platelet derived 0.0007 0.0280 1.4 growth factor C 201289_at NM_001554 CYR61 cysteine-rich, 0.0154 0.4485 1.4 angiogenic inducer, 61 202118_s_at AA541758 CPNE3 copine III 0.0079 0.0589 1.4 200620_at NM_004872 TMEM59 transmembrane 0.0007 0.2260 1.4 protein 59 213645_at AF305057 ENOSF1 enolase 0.0273 0.6899 1.4 superfamily member 1 202906_s_at AF049895 NBN nibrin 0.0383 0.0964 1.4 209205_s_at BC003600 LMO4 LIM domain only 4 0.0029 0.1916 1.4 205361_s_at AI718295 PFDN4 prefoldin subunit 4 0.0037 0.0482 1.4 208697_s_at BC000734 EIF3S6 eukaryotic 0.0012 0.0582 1.4 translation initiation factor 3, subunit 6 48 kDa 203881_s_at NM_004010 DMD dystrophin 0.0152 0.0504 1.4 (muscular dystrophy, Duchenne and Becker types) 202227_s_at NM_006696 BRD8 bromodomain 0.0046 0.0774 1.4 containing 8 201166_s_at NM_014676 PUM1 pumilio homolog 1 0.0007 0.5211 1.4 (Drosophila) 213967_at AI634532 LOC138046 hypothetical 0.0337 0.4178 1.4 protein LOC138046 203117_s_at NM_014871 USP52 ubiquitin specific 0.0177 0.5403 1.4 peptidase 52 212209_at AL133033 THRAP2 thyroid hormone 0.0041 0.6494 1.4 receptor associated protein 2 204588_s_at NM_003982 SLC7A7 solute carrier 0.0051 0.1846 1.4 family 7 (cationic amino acid transporter, y+ system), member 7 214451_at NM_003221 TFAP2B transcription factor 0.0190 0.1948 1.4 AP-2 beta (activating enhancer binding protein 2 beta) 215096_s_at AU145746 ESD esterase 0.0032 0.1013 1.4 D/formylglutathione hydrolase 213224_s_at AK025724 LOC92482 hypothetical 0.0079 0.0654 1.4 protein LOC92482 201174_s_at NM_018975 TERF2IP telomeric repeat 0.0222 0.3358 1.4 binding factor 2, interacting protein 201735_s_at NM_001829 CLCN3 chloride channel 3 0.0415 0.3570 1.4 209130_at BC003686 SNAP23 synaptosomal- 0.0124 0.1309 1.4 associated protein, 23 kDa 207992_s_at NM_000480 AMPD3 adenosine 0.0015 0.0645 1.4 monophosphate deaminase (isoform E) 200091_s_at AA888388 RPS25 ribosomal protein 0.0010 0.0877 1.4 S25 /// ribosomal protein S25 221471_at AW173623 SERINC3 serine incorporator 3 0.0041 0.1925 1.4 206132_at NM_002387 MCC mutated in 0.0154 0.2417 1.4 colorectal cancers 207598_x_at NM_005431 XRCC2 X-ray repair 0.0088 0.0663 1.4 complementing defective repair in Chinese hamster cells 2 212530_at AL080111 NEK7 NIMA (never in 0.0110 0.9827 1.4 mitosis gene a)- related kinase 7 218343_s_at NM_012086 GTF3C3 general 0.0404 0.7847 1.4 transcription factor IIIC, polypeptide 3, 102 kDa 217731_s_at NM_021999 ITM2B integral membrane 0.0189 0.3784 1.4 protein 2B 218181_s_at NM_017792 MAP4K4 mitogen-activated 0.0042 0.1923 1.4 protein kinase kinase kinase kinase 4 209285_s_at N38985 C3orf63 chromosome 3 0.0020 0.1860 1.4 open reading frame 63 215245_x_at AA830884 FMR1 fragile X mental 0.0393 0.5658 1.4 retardation 1 201922_at NM_014886 TINP1 TGF beta-inducible 0.0004 0.0197 1.4 nuclear protein 1 214800_x_at R83000 BTF3 basic transcription 0.0015 0.0280 1.4 factor 3 212498_at AF056433 — Full-length cDNA 0.0047 0.7550 1.4 clone CS0DM001YA04 of Fetal liver of Homo sapiens (human) 209004_s_at AF142481 FBXL5 F-box and leucine- 0.0030 0.0800 1.4 rich repeat protein 5 204568_at NM_014924 KIAA0831 KIAA0831 0.0129 0.9702 1.4 216060_s_at AK021890 DAAM1 dishevelled 0.0055 0.0785 1.4 associated activator of morphogenesis 1 201877_s_at NM_002719 PPP2R5C protein 0.0049 0.1367 1.4 phosphatase 2, regulatory subunit B (B56), gamma isoform 203155_at NM_012432 SETDB1 SET domain, 0.0110 0.2112 1.4 bifurcated 1 213762_x_at AI452524 RBMX RNA binding motif 0.0029 0.2264 1.4 protein, X-linked 203638_s_at NM_022969 FGFR2 fibroblast growth 0.0029 0.1774 1.4 factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) 213186_at BG502305 DZIP3 zinc finger DAZ 0.0125 0.4348 1.4 interacting protein 3 218491_s_at NM_014174 THYN1 thymocyte nuclear 0.0107 0.3964 1.4 protein 1 218508_at NM_018403 DCP1A DCP1 decapping 0.0066 0.7693 1.4 enzyme homolog A (S. cerevisiae) 204528_s_at NM_004537 NAP1L1 nucleosome 0.0015 0.0941 1.4 assembly protein 1- like 1 218919_at NM_024699 ZFAND1 zinc finger, AN1- 0.0024 0.0684 1.4 type domain 1 57715_at W72694 FAM26B family with 0.0080 0.1016 1.4 sequence similarity 26, member B 217550_at AA576497 ATF6 Activating 0.0217 0.2505 1.4 transcription factor 6 212943_at AB011100 KIAA0528 KIAA0528 0.0051 0.2420 1.4 219767_s_at NM_005111 CRYZL1 crystallin, zeta 0.0048 0.8085 1.4 (quinone reductase)-like 1 209861_s_at U13261 METAP2 methionyl 0.0166 0.2431 1.4 aminopeptidase 2 201779_s_at AF070558 RNF13 ring finger protein 0.0009 0.0227 1.4 13 214749_s_at AK000818 ARMCX6 armadillo repeat 0.0125 0.1875 1.4 containing, X- linked 6 217266_at Z97353 RPL15 /// ribosomal protein 0.0072 0.5812 1.4 LOC402694 L15 /// similar to /// ribosomal protein LOC646672 L15 /// similar to /// ribosomal protein LOC653232 L15 /// similar to /// ribosomal protein LOC728002 L15 /// similar to /// ribosomal protein LOC728088 L15 /// similar to /// ribosomal protein LOC728576 L15 /// similar to /// ribosomal protein LOC730925 L15 /// similar to /// ribosomal protein LOC731527 L15 /// similar to /// ribosomal protein LOC731822 L15 /// similar to ribosomal protein L15 221954_at AA160474 C20orf111 Chromosome 20 0.0035 0.1674 1.4 open reading frame 111 212074_at BE972774 UNC84A unc-84 homolog A 0.0051 0.2261 1.4 (C. elegans) 204131_s_at N25732 FOXO3A forkhead box O3A 0.0007 0.0981 1.4 222182_s_at BG105204 CNOT2 CCR4-NOT 0.0043 0.1023 1.4 transcription complex, subunit 2 205935_at NM_001451 FOXF1 forkhead box F1 0.0102 0.5190 1.4 212812_at AI700633 SERINC5 Serine incorporator 5 0.0069 0.3193 1.4 221580_s_at BC001972 JOSD3 Josephin domain 0.0323 0.4333 1.4 containing 3 217862_at N24868 PIAS1 protein inhibitor of 0.0247 0.1807 1.4 activated STAT, 1 201133_s_at AA142966 PJA2 praja 2, RING-H2 0.0189 0.0968 1.4 motif containing 208771_s_at J02959 LTA4H leukotriene A4 0.0004 0.0344 1.4 hydrolase 200074_s_at U16738 RPL14 /// ribosomal protein 0.0025 0.0963 1.4 RPL14L L14 /// ribosomal /// protein L14 /// LOC649821 ribosomal protein L14-like /// ribosomal protein L14-like /// similar to 60S ribosomal protein L14 (CAG- ISL 7) /// similar to 60S ribosomal protein L14 (CAG- ISL 7) 212629_s_at AI633689 PKN2 protein kinase N2 0.0106 0.0285 1.4 209786_at BC001282 HMGN4 high mobility 0.0124 0.1345 1.4 group nucleosomal binding domain 4 201738_at NM_005875 EIF1B eukaryotic 0.0100 0.1022 1.4 translation initiation factor 1B 206114_at NM_004438 EPHA4 EPH receptor A4 0.0198 0.1139 1.4 218361_at NM_018178 GOLPH3L golgi 0.0087 0.5276 1.4 phosphoprotein 3- like 202467_s_at NM_004236 COPS2 COP9 constitutive 0.0052 0.0436 1.4 photomorphogenic homolog subunit 2 (Arabidopsis) 219658_at NM_024754 PTCD2 pentatricopeptide 0.0065 0.4391 1.4 repeat domain 2 217971_at NM_021970 MAP2K1IP1 mitogen-activated 0.0183 0.3561 1.4 protein kinase kinase 1 interacting protein 1 212408_at AK023204 TOR1AIP1 torsin A interacting 0.0299 0.1539 1.4 protein 1 212795_at AL137753 KIAA1033 KIAA1033 0.0500 0.9390 1.4 218004_at NM_018045 BSDC1 BSD domain 0.0161 0.1788 1.4 containing 1 205052_at NM_001698 AUH AU RNA binding 0.0042 0.1537 1.4 protein/enoyl- Coenzyme A hydratase 203097_s_at NM_014247 RAPGEF2 Rap guanine 0.0399 0.3291 1.4 nucleotide exchange factor (GEF) 2 219077_s_at NM_016373 WWOX WW domain 0.0069 0.1782 1.4 containing oxidoreductase 201917_s_at AI694452 SLC25A36 solute carrier 0.0420 0.0719 1.4 family 25, member 36 203630_s_at NM_006348 COG5 component of 0.0160 0.5887 1.4 oligomeric golgi complex 5 216348_at AL049693 RPS17 /// ribosomal protein 0.0045 0.2251 1.4 LOC402057 S17 /// similar to 40S ribosomal protein S17 212111_at AA628051 STX12 syntaxin 12 0.0054 0.2425 1.4 202214_s_at NM_003588 CUL4B cullin 4B 0.0074 0.4189 1.4 217807_s_at NM_015710 GLTSCR2 glioma tumor 0.0015 0.0474 1.4 suppressor candidate region gene 2 219138_at BC000606 RPL14 ribosomal protein 0.0084 0.2776 1.4 L14 212358_at AL117468 CLIPR-59 CLIP-170-related 0.0131 0.3968 1.4 protein 221476_s_at AF279903 RPL15 ribosomal protein 0.0016 0.0696 1.4 L15 203781_at NM_004891 MRPL33 mitochondrial 0.0126 0.0635 1.4 ribosomal protein L33 221582_at BC001193 HIST3H2A histone cluster 3, 0.0043 0.3642 1.4 H2a 208667_s_at U17714 ST13 suppression of 0.0140 0.0995 1.4 tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) 201358_s_at NM_016451 COPB1 coatomer protein 0.0100 0.1582 1.4 complex, subunit beta 1 211938_at BF247371 EIF4B eukaryotic 0.0050 0.1793 1.4 translation initiation factor 4B 212044_s_at BE737027 RPL27A Ribosomal protein 0.0457 0.5986 1.4 L27a 215978_x_at AK021514 LOC152719 hypothetical 0.0135 0.1439 1.4 protein LOC152719 203910_at NM_004815 ARHGAP29 Rho GTPase 0.0201 0.5119 1.4 activating protein 29 209682_at U26710 CBLB Cas-Br-M (murine) 0.0128 0.0489 1.3 ecotropic retroviral transforming sequence b 202644_s_at NM_006290 TNFAIP3 tumor necrosis 0.0322 0.0856 1.3 factor, alpha- induced protein 3 212215_at AB007896 PREPL prolyl 0.0076 0.5632 1.3 endopeptidase-like 218428_s_at NM_016316 REV1 REV1 homolog (S. cerevisiae) 0.0211 0.1542 1.3 217954_s_at NM_015153 PHF3 PHD finger protein 3 0.0066 0.2171 1.3 212232_at AB023231 FNBP4 formin binding 0.0204 0.5785 1.3 protein 4 202231_at NM_006360 PCID1 PCI domain 0.0048 0.0923 1.3 containing 1 (herpesvirus entry mediator) 202769_at AW134535 CCNG2 cyclin G2 0.0230 0.3482 1.3 216221_s_at D87078 PUM2 pumilio homolog 2 0.0020 0.5905 1.3 (Drosophila) 213093_at AI471375 PRKCA protein kinase C, 0.0006 0.0721 1.3 alpha 201926_s_at BC001288 CD55 CD55 molecule, 0.0261 0.3374 1.3 decay accelerating factor for complement (Cromer blood group) 218450_at NM_015987 HEBP1 heme binding 0.0057 0.0971 1.3 protein 1 218379_at NM_016090 RBM7 RNA binding motif 0.0013 0.0274 1.3 protein 7 212609_s_at U79271 AKT3 V-akt murine 0.0054 0.0969 1.3 thymoma viral oncogene homolog 3 (protein kinase B, gamma) 215001_s_at AL161952 GLUL glutamate- 0.0245 0.9178 1.3 ammonia ligase (glutamine synthetase) 209120_at AL037401 NR2F2 nuclear receptor 0.0147 0.5417 1.3 subfamily 2, group F, member 2 221593_s_at BC001663 RPL31 ribosomal protein 0.0170 0.1235 1.3 L31 212591_at AA887480 RBM34 RNA binding motif 0.0130 0.1604 1.3 protein 34 207719_x_at NM_014812 CEP170 centrosomal 0.0293 0.3400 1.3 protein 170 kDa 205163_at NM_013292 MYLPF fast skeletal 0.0118 0.1064 1.3 myosin light chain 2 213136_at AI828880 PTPN2 protein tyrosine 0.0039 0.2891 1.3 phosphatase, non- receptor type 2 213750_at AA928506 — Full length insert 0.0015 0.0274 1.3 cDNA YH77E09 201682_at NM_004279 PMPCB peptidase 0.0022 0.4599 1.3 (mitochondrial processing) beta 201448_at AL046419 TIA1 TIA1 cytotoxic 0.0430 0.4300 1.3 granule-associated RNA binding protein 211962_s_at BG250310 ZFP36L1 zinc finger protein 0.0471 0.1958 1.3 36, C3H type-like 1 214722_at AW516297 NOTCH2NL Notch homolog 2 0.0049 0.2858 1.3 (Drosophila) N- terminal like 202723_s_at AW117498 FOXO1A forkhead box O1A 0.0019 0.3257 1.3 (rhabdomyosarcoma) 217993_s_at NM_013283 MAT2B methionine 0.0018 0.0583 1.3 adenosyltransferase II, beta 216342_x_at AL121916 LOC390183 similar to 40S 0.0037 0.5394 1.3 /// ribosomal protein LOC442162 S4, X isoform /// similar to 40S ribosomal protein S4, X isoform 217747_s_at NM_001013 RPS9 ribosomal protein 0.0004 0.0280 1.3 S9 222229_x_at AL121871 LOC392501 similar to 60S 0.0007 0.0664 1.3 ribosomal protein L26 201812_s_at NM_019059 TOMM7 translocase of outer 0.0077 0.1777 1.3 /// mitochondrial LOC201725 membrane 7 homolog (yeast) /// hypothetical protein LOC201725 206506_s_at NM_003599 SUPT3H suppressor of Ty 3 0.0013 0.0389 1.3 homolog (S. cerevisiae) 204093_at NM_001239 CCNH cyclin H 0.0011 0.0264 1.3 211967_at BG538627 TMEM123 transmembrane 0.0049 0.2276 1.3 protein 123 212533_at X62048 WEE1 WEE1 homolog (S. pombe) 0.0014 0.0990 1.3 211713_x_at BC005832 KIAA0101 KIAA0101 /// 0.0035 0.0344 1.3 KIAA0101 206169_x_at NM_025013 ZC3H7B zinc finger CCCH- 0.0199 0.1897 1.3 type containing 7B 221827_at BE788439 RBCK1 RanBP-type and 0.0033 0.1180 1.3 C3HC4-type zinc finger containing 1 212462_at AU144267 MYST4 MYST histone 0.0491 0.9450 1.3 acetyltransferase (monocytic leukemia) 4 204369_at NM_006218 PIK3CA phosphoinositide- 0.0136 0.1909 1.3 3-kinase, catalytic, alpha polypeptide 213438_at AA995925 NFASC neurofascin 0.0177 0.0582 1.3 homolog (chicken) 219001_s_at NM_024345 WDR32 WD repeat domain 0.0159 0.7542 1.3 32 200023_s_at NM_003754 EIF3S5 eukaryotic 0.0004 0.0285 1.3 translation initiation factor 3, subunit 5 epsilon, 47 kDa /// eukaryotic translation initiation factor 3, subunit 5 epsilon, 47 kDa 202679_at NM_000271 NPC1 Niemann-Pick 0.0280 0.5043 1.3 disease, type C1 221735_at H04342 WDR48 WD repeat domain 0.0214 0.1303 1.3 48 205917_at NM_003417 ZNF264 zinc finger protein 0.0289 0.3938 1.3 264 213483_at AK025679 PPWD1 peptidylprolyl 0.0081 0.3358 1.3 isomerase domain and WD repeat containing 1 203255_at NM_018693 FBXO11 F-box protein 11 0.0497 0.1031 1.3 201652_at NM_006837 COPS5 COP9 constitutive 0.0376 0.1262 1.3 photomorphogenic homolog subunit 5 (Arabidopsis) 218499_at NM_016542 RP6- serine/threonine 0.0373 0.3857 1.3 213H19.1 protein kinase MST4 216570_x_at AL096829 LOC646417 similar to 60S 0.0055 0.4385 1.3 ribosomal protein L29 (P23) 212265_at AL031781 QKI quaking homolog, 0.0235 0.2288 1.3 KH domain RNA binding (mouse) 213275_x_at W47179 CTSB cathepsin B 0.0154 0.1777 1.3 208655_at BG530368 CCNI Cyclin I 0.0029 0.1777 1.3 212416_at AV745949 SCAMP1 secretory carrier 0.0035 0.8372 1.3 membrane protein 1 202026_at NM_003002 SDHD succinate 0.0181 0.2574 1.3 dehydrogenase complex, subunit D, integral membrane protein 212897_at AI738802 CDC2L6 cell division cycle 0.0031 0.3399 1.3 2-like 6 (CDK8- like) 201592_at NM_003756 EIF3S3 eukaryotic 0.0016 0.0564 1.3 translation initiation factor 3, subunit 3 gamma, 40 kDa 202076_at NM_001166 BIRC2 baculoviral IAP 0.0033 0.0770 1.3 repeat-containing 2 217799_x_at NM_003344 UBE2H ubiquitin- 0.0304 0.2586 1.3 conjugating enzyme E2H (UBC8 homolog, yeast) 200771_at NM_002293 LAMC1 laminin, gamma 1 0.0012 0.2016 1.3 (formerly LAMB2) 202172_at BG035116 VEZF1 vascular 0.0037 0.2438 1.3 endothelial zinc finger 1 213853_at AL050199 DPH4 DPH4, JJJ3 0.0136 0.0763 1.3 homolog (S. cerevisiae) 209242_at AL042588 PEG3 paternally 0.0184 0.8421 1.3 expressed 3 212604_at AI937794 MRPS31 mitochondrial 0.0044 0.0424 1.3 ribosomal protein S31 209422_at AL109965 PHF20 PHD finger protein 0.0173 0.0571 1.3 20 216380_x_at AC005011 LOC728453 similar to 40S 0.0032 0.7942 1.3 /// ribosomal protein LOC730288 S28 /// similar to /// 40S ribosomal LOC730819 protein S28 /// similar to 40S ribosomal protein S28 213236_at AK025495 SASH1 SAM and SH3 0.0035 0.2189 1.3 domain containing 1 213322_at AL031778 C6orf130 chromosome 6 0.0449 0.5982 1.3 open reading frame 130 205070_at NM_019071 ING3 inhibitor of growth 0.0079 0.0885 1.3 family, member 3 204700_x_at NM_014388 C1orf107 chromosome 1 0.0355 0.5585 1.3 open reading frame 107 210095_s_at M31159 IGFBP3 insulin-like growth 0.0091 0.6408 1.3 factor binding protein 3 222368_at AW972351 — CDNA FLJ37098 0.0041 0.0383 1.3 fis, clone BRACE2019004 219492_at NM_012110 CHIC2 cysteine-rich 0.0254 0.4819 1.3 hydrophobic domain 2 200017_at NM_002954 RPS27A ribosomal protein 0.0019 0.0719 1.3 S27a /// ribosomal protein S27a 214176_s_at AI348545 PBXIP1 Pre-B-cell 0.0039 0.1142 1.3 leukemia transcription factor interacting protein 1 218972_at NM_018259 TTC17 tetratricopeptide 0.0366 0.5363 1.3 repeat domain 17 211337_s_at BC000966 76P gamma tubulin ring 0.0225 0.2023 1.3 complex protein (76p gene) 202668_at BF001670 EFNB2 ephrin-B2 0.0059 0.0951 1.3 209620_s_at AB005289 ABCB7 ATP-binding 0.0129 0.2027 1.3 cassette, sub- family B (MDR/TAP), member 7 212519_at AL518159 UBE2E1 ubiquitin- 0.0098 0.0900 1.3 conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) 203067_at NM_003477 PDHX pyruvate 0.0135 0.3222 1.3 dehydrogenase complex, component X 219641_at NM_017996 DET1 de-etiolated 0.0133 0.8629 1.3 homolog 1 (Arabidopsis) 206090_s_at NM_018662 DISC1 disrupted in 0.0429 0.7391 1.3 schizophrenia 1 200741_s_at NM_001030 RPS27 ribosomal protein 0.0020 0.0582 1.3 S27 (metallopanstimulin 1) 204587_at NM_003951 SLC25A14 solute carrier 0.0055 0.5404 1.3 family 25 (mitochondrial carrier, brain), member 14 202220_at NM_014949 KIAA0907 KIAA0907 0.0018 0.0746 1.3 213269_at N21541 ZNF248 zinc finger protein 0.0112 0.9344 1.3 248 211257_x_at AF273049 ZNF638 zinc finger protein 0.0157 0.1090 1.3 638 219147_s_at NM_017881 C9orf95 chromosome 9 0.0147 0.0770 1.3 open reading frame 95 202973_x_at NM_014883 FAM13A1 family with 0.0169 0.6932 1.3 sequence similarity 13, member A1 213883_s_at AA012917 TM2D1 TM2 domain 0.0148 0.1709 1.3 containing 1 205370_x_at NM_001918 DBT dihydrolipoamide 0.0034 0.1235 1.3 branched chain transacylase E2 219571_s_at NM_016265 ZNF12 zinc finger protein 0.0223 0.0935 1.3 12 219133_at NM_017897 OXSM 3-oxoacyl-ACP 0.0183 0.5794 1.3 synthase, mitochondrial 220988_s_at NM_030945 C1QTNF3 C1q and tumor 0.0079 0.2302 1.3 necrosis factor related protein 3 /// C1q and tumor necrosis factor related protein 3 202454_s_at NM_001982 ERBB3 v-erb-b2 0.0180 0.5119 1.3 erythroblastic leukemia viral oncogene homolog 3 (avian) 203831_at NM_014925 R3HDM2 R3H domain 0.0183 0.7758 1.3 containing 2 210028_s_at AF125507 ORC3L origin recognition 0.0029 0.2383 1.3 complex, subunit 3-like (yeast) 202386_s_at NM_019081 KIAA0430 KIAA0430 0.0377 0.3255 1.3 215628_x_at AL049285 PPP2CA Protein 0.0079 0.4496 1.3 phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 212018_s_at AK000822 RSL1D1 ribosomal L1 0.0054 0.3191 1.3 domain containing 1 203667_at NM_004607 TBCA tubulin folding 0.0025 0.0280 1.3 cofactor A 212327_at AK026815 DKFZP686A01247 hypothetical 0.0038 0.4265 1.3 protein 212334_at BE880245 GNS glucosamine (N- 0.0218 0.1233 1.3 acetyl)-6-sulfatase (Sanfilippo disease IIID) 201164_s_at BG474429 RNF6 /// ring finger protein 0.0026 0.2690 1.3 PUM1 (C3H2C3 type) 6 /// pumilio homolog 1 (Drosophila) 200010_at NM_000975 RPL11 Ribosomal protein 0.0019 0.0441 1.3 L11 /// Ribosomal protein L11 222034_at AA443762 GNB2L1 Guanine nucleotide 0.0167 0.1744 1.3 binding protein (G protein), beta polypeptide 2-like 1 221207_s_at NM_015678 NBEA neurobeachin 0.0076 0.1564 1.3 222122_s_at BG403671 THOC2 THO complex 2 0.0494 0.2813 1.3 213168_at AU145005 SP3 Sp3 transcription 0.0257 0.4889 1.3 factor 221112_at NM_017416 IL1RAPL2 interleukin 1 0.0483 0.9794 1.3 receptor accessory protein-like 2 213229_at BF590131 DICER1 Dicer1, Dcr-1 0.0454 0.0372 1.3 homolog (Drosophila) 221702_s_at AF353992 TM2D3 TM2 domain 0.0049 0.1787 1.3 containing 3 /// TM2 domain containing 3 200897_s_at NM_016081 PALLD palladin, 0.0042 0.0476 1.3 cytoskeletal associated protein 203704_s_at AW118862 — — 0.0495 0.2054 1.3 213065_at AB011118 CCDC131 coiled-coil domain 0.0233 0.9011 1.3 containing 131 207283_at NM_020217 RPL23AP13 ribosomal protein 0.0489 0.6649 1.3 L23a pseudogene 13 202960_s_at NM_000255 MUT methylmalonyl 0.0361 0.1791 1.3 Coenzyme A mutase 221486_at AF067170 ENSA endosulfine alpha 0.0113 0.1876 1.3 212558_at BF508662 SPRY1 sprouty homolog 1, 0.0376 0.8925 1.3 antagonist of FGF signaling (Drosophila) 203481_at AI655902 C10orf6 chromosome 10 0.0137 0.0636 1.3 open reading frame 6 214281_s_at AA524525 RCHY1 ring finger and 0.0048 0.0861 1.3 CHY zinc finger domain containing 1 200062_s_at L05095 RPL30 ribosomal protein 0.0011 0.0383 1.3 L30 /// ribosomal protein L30 203221_at AI758763 TLE1 transducin-like 0.0020 0.0387 1.3 enhancer of split 1 (E(sp1) homolog, Drosophila) 218628_at NM_016053 CCDC53 coiled-coil domain 0.0257 0.0506 1.3 containing 53 214707_x_at AB002326 ALMS1 Alstrom syndrome 1 0.0021 0.0329 1.3 212758_s_at AI373166 TCF8 transcription factor 0.0166 0.0274 1.3 8 (represses interleukin 2 expression) 202557_at AI718418 STCH stress 70 protein 0.0144 0.1063 1.3 chaperone, microsome- associated, 60 kDa 208246_x_at NM_017618 — CDNA FLJ20006 0.0043 0.1221 1.3 fis, clone ADKA02694 202766_s_at NM_000138 FBN1 fibrillin 1 0.0129 0.6308 1.3 201830_s_at NM_005863 NET1 neuroepithelial cell 0.0180 0.0835 1.3 transforming gene 1 212805_at AB002365 KIAA0367 KIAA0367 0.0344 0.3786 1.3 207467_x_at NM_001750 CAST calpastatin 0.0122 0.0990 1.3 201502_s_at AI078167 NFKBIA nuclear factor of 0.0044 0.0499 1.3 kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 209111_at BC004155 RNF5 ring finger protein 5 0.0072 0.9883 1.3 211971_s_at AI653608 LRPPRC leucine-rich PPR- 0.0080 0.1196 1.3 motif containing 210389_x_at BC000258 TUBD1 tubulin, delta 1 0.0199 0.6862 1.3 212982_at AI621223 ZDHHC17 zinc finger, 0.0496 0.4017 1.3 DHHC-type containing 17 210946_at AF014403 PPAP2A phosphatidic acid 0.0123 0.2350 1.3 phosphatase type 2A 203095_at NM_002453 MTIF2 mitochondrial 0.0312 0.2324 1.3 translational initiation factor 2 201857_at NM_016107 ZFR zinc finger RNA 0.0069 0.0656 1.3 binding protein 209390_at AF013168 TSC1 tuberous sclerosis 1 0.0005 0.0554 1.3 213313_at AI922519 RABGAP1 RAB GTPase 0.0129 0.2904 1.3 activating protein 1 209065_at BC005230 UQCRB ubiquinol- 0.0314 0.1143 1.3 cytochrome c reductase binding protein 212244_at AL050091 GRINL1A glutamate receptor, 0.0198 0.4925 1.3 /// Gcom1 ionotropic, N- methyl D- aspartate-like 1A /// GRINL1A combined protein 208021_s_at NM_002913 RFC1 replication factor C 0.0224 0.4152 1.3 (activator 1) 1, 145 kDa /// replication factor C (activator 1) 1, 145 kDa 212542_s_at BF224151 PHIP pleckstrin 0.0244 0.3957 1.3 homology domain interacting protein 213657_s_at BE858194 ZNF710 Zinc finger protein 0.0202 0.5147 1.3 /// 710 /// MRNA full DOCK4 length insert cDNA clone EUROIMAGE 375854 /// Dedicator of cytokinesis 4 212226_s_at AA628586 PPAP2B phosphatidic acid 0.0253 0.1768 1.3 phosphatase type 2B 203038_at NM_002844 PTPRK protein tyrosine 0.0050 0.1699 1.3 phosphatase, receptor type, K 201648_at AL039831 JAK1 Janus kinase 1 (a 0.0364 0.4317 1.3 protein tyrosine kinase) 213542_at AI246730 ZNF710 zinc finger protein 0.0146 0.3325 1.3 710 209684_at AL136924 RIN2 Ras and Rab 0.0097 0.1105 1.3 interactor 2 214003_x_at BF184532 RPS20 ribosomal protein 0.0009 0.0252 1.3 S20 218852_at NM_017917 C14orf10 chromosome 14 0.0433 0.1844 1.3 open reading frame 10 212893_at AL080063 ZZZ3 zinc finger, ZZ- 0.0186 0.1134 1.3 type containing 3 218263_s_at NM_021211 ZBED5 zinc finger, BED- 0.0016 0.0395 1.3 type containing 5 203301_s_at NM_021145 DMTF1 cyclin D binding 0.0400 0.4154 1.3 myb-like transcription factor 1 207730_x_at NM_017932 HDGF2 Hepatoma-derived 0.0045 0.0473 1.3 growth factor- related protein 2 202302_s_at NM_023012 FLJ11021 similar to splicing 0.0085 0.1061 1.3 factor, arginine/serine-rich 4 203020_at NM_014857 RABGAP1L RAB GTPase 0.0038 0.2687 1.3 activating protein 1-like 220352_x_at NM_024305 — — 0.0021 0.1437 1.3 211452_x_at AF130054 LRRFIP1 leucine rich repeat 0.0066 0.0547 1.3 (in FLII) interacting protein 1 200810_s_at NM_001280 CIRBP cold inducible 0.0036 0.0793 1.3 RNA binding protein 212104_s_at N95026 RBM9 RNA binding motif 0.0045 0.1200 1.3 protein 9 213839_at AW028110 KIAA0500 KIAA0500 protein 0.0297 0.2545 1.3 202968_s_at Y09216 DYRK2 dual-specificity 0.0395 0.1646 1.3 tyrosine-(Y)- phosphorylation regulated kinase 2 213074_at BG545769 IRAK1BP1 Interleukin-1 0.0314 0.6649 1.3 receptor-associated kinase 1 binding protein 1 202623_at NM_018453 C14orf11 chromosome 14 0.0073 0.1164 1.3 open reading frame 11 213048_s_at W26593 SET SET translocation 0.0024 0.0197 1.3 (myeloid leukemia- associated) 219392_x_at NM_018304 PRR11 proline rich 11 0.0058 0.1864 1.3 201588_at NM_004786 TXNL1 thioredoxin-like 1 0.0047 0.0284 1.3 200026_at NM_000995 RPL34 /// ribosomal protein 0.0044 0.0681 1.3 LOC342994 L34 /// ribosomal /// protein L34 /// LOC651249 similar to /// ribosomal protein LOC729536 L34 /// similar to /// ribosomal protein LOC731916 L34 /// similar to ribosomal protein L34 /// similar to ribosomal protein L34 /// hypothetical protein LOC729536 /// hypothetical protein LOC729536 /// similar to ribosomal protein L34 /// similar to ribosomal protein L34 213328_at AI936517 NEK1 NIMA (never in 0.0285 0.0844 1.3 mitosis gene a)- related kinase 1 207616_s_at NM_004180 TANK TRAF family 0.0256 0.2643 1.3 member-associated NFKB activator 217797_at NM_016406 UFC1 ubiquitin-fold 0.0025 0.0646 1.3 modifier conjugating enzyme 1 222244_s_at AK000749 TUG1 taurine upregulated 0.0055 0.1914 1.3 gene 1 202673_at NM_003859 DPM1 dolichyl-phosphate 0.0116 0.0642 1.3 mannosyltransferase polypeptide 1, catalytic subunit 204688_at NM_003919 SGCE sarcoglycan, 0.0027 0.1571 1.3 epsilon 207943_x_at NM_006718 PLAGL1 pleiomorphic 0.0133 0.6838 1.3 adenoma gene-like 1 203044_at NM_014918 CHSY1 carbohydrate 0.0272 0.0951 1.3 (chondroitin) synthase 1 201758_at NM_006292 TSG101 tumor 0.0088 0.1664 1.3 susceptibility gene 101 213531_s_at AI040009 RAB3GAP1 RAB3 GTPase 0.0046 0.7605 1.3 activating protein subunit 1 (catalytic) 218598_at NM_021930 RINT1 RAD50 interactor 1 0.0193 0.2781 1.3 214670_at AA653300 ZKSCAN1 zinc finger with 0.0302 0.3630 1.3 KRAB and SCAN domains 1 218989_x_at NM_022902 SLC30A5 solute carrier 0.0118 0.0958 1.3 family 30 (zinc transporter), member 5 200937_s_at NM_000969 RPL5 ribosomal protein 0.0011 0.0539 1.3 L5 213015_at BF448315 — ARTC1 mRNA, 0.0072 0.0197 1.3 complete sequence 211228_s_at AF085736 RAD17 RAD17 homolog 0.0082 0.2369 1.3 (S. pombe) 209505_at AI951185 NR2F1 Nuclear receptor 0.0237 0.7005 1.3 subfamily 2, group F, member 1 204457_s_at NM_002048 GAS1 growth arrest- 0.0055 0.1142 1.3 specific 1 212596_s_at AJ010070 HMG2L1 high-mobility 0.0205 0.2332 1.3 group protein 2- like 1 201256_at NM_004718 COX7A2L cytochrome c 0.0015 0.0271 1.3 oxidase subunit VIIa polypeptide 2 like 205051_s_at NM_000222 KIT v-kit Hardy- 0.0500 0.3862 1.3 Zuckerman 4 feline sarcoma viral oncogene homolog 214739_at AI357539 LRCH3 leucine-rich repeats 0.0255 0.3342 1.3 and calponin homology (CH) domain containing 3 201406_at NM_021029 RPL36A ribosomal protein 0.0039 0.1666 1.3 /// L36a /// similar to LOC729362 large subunit ribosomal protein L36a 208986_at AL559478 TCF12 transcription factor 0.0085 0.1013 1.3 12 (HTF4, helix- loop-helix transcription factors 4) 200743_s_at NM_000391 TPP1 tripeptidyl 0.0024 0.3558 1.3 peptidase I 204725_s_at NM_006153 NCK1 NCK adaptor 0.0084 0.2949 1.3 protein 1 220760_x_at NM_024733 ZNF665 zinc finger protein 0.0279 0.2927 1.3 665 200888_s_at NM_000978 RPL23 ribosomal protein 0.0031 0.1288 1.3 L23 214257_s_at AA890010 SEC22B SEC22 vesicle 0.0340 0.0759 1.3 trafficking protein homolog B (S. cerevisiae) 202811_at NM_006463 STAMBP STAM binding 0.0479 0.1820 1.3 protein 213685_at AA830143 — Gene from PAC 0.0170 0.2067 1.3 886K2, chromosome 1 208936_x_at AF074000 LGALS8 lectin, galactoside- 0.0267 0.5425 1.3 binding, soluble, 8 (galectin 8) 201831_s_at BE875592 PAK1 /// p21/Cdc42/Rac1- 0.0222 0.2437 1.3 VDP activated kinase 1 (STE20 homolog, yeast) /// vesicle docking protein p115 209835_x_at BC004372 CD44 CD44 molecule 0.0124 0.2180 1.3 (Indian blood group) 220176_at NM_025152 NUBPL nucleotide binding 0.0495 0.9762 1.3 protein-like 200038_s_at NM_000985 RPL17 ribosomal protein 0.0019 0.0400 1.3 L17 /// ribosomal protein L17 201989_s_at AL529409 CREBL2 cAMP responsive 0.0147 0.9018 1.3 element binding protein-like 2 207513_s_at NM_003452 ZNF189 zinc finger protein 0.0252 0.1180 1.3 189 217313_at AC004692 — — 0.0166 0.8256 1.3 218549_s_at NM_016033 FAM82B family with 0.0235 0.0666 1.3 sequence similarity 82, member B 217579_x_at AW301806 ARL6IP2 ADP-ribosylation 0.0069 0.0770 1.3 factor-like 6 interacting protein 2 203240_at NM_003890 FCGBP Fc fragment of IgG 0.0085 0.1142 1.3 binding protein 217833_at AL520908 SYNCRIP synaptotagmin 0.0054 0.0968 1.3 binding, cytoplasmic RNA interacting protein 215529_x_at AI590053 DIP2A DIP2 disco- 0.0146 0.1925 1.3 interacting protein 2 homolog A (Drosophila) 210774_s_at AL162047 NCOA4 nuclear receptor 0.0057 0.0763 1.3 coactivator 4 200090_at BG168896 FNTA farnesyltransferase, 0.0047 0.4557 1.3 CAAX box, alpha /// farnesyltransferase, CAAX box, alpha 215504_x_at AF131777 ANKRD10 Ankyrin repeat 0.0117 0.7025 1.3 domain 10 217379_at AL121934 LOC442171 similar to 0.0014 0.1820 1.3 ribosomal protein L10 204454_at NM_012317 LDOC1 leucine zipper, 0.0026 0.0631 1.3 down-regulated in cancer 1 205888_s_at AI962693 JAKMIP2 janus kinase and 0.0374 0.4240 1.3 /// microtubule MYT1L interacting protein 2 /// myelin transcription factor 1-like 212042_x_at BG389744 RPL7 ribosomal protein 0.0010 0.0421 1.3 L7 203306_s_at NM_006416 SLC35A1 solute carrier 0.0322 0.8372 1.3 family 35 (CMP- sialic acid transporter), member A1 214731_at AB037854 CTTNBP2NL CTTNBP2 N- 0.0329 0.3513 1.3 terminal like 208943_s_at U93239 TLOC1 translocation 0.0015 0.0274 1.3 protein 1 203966_s_at NM_021003 PPM1A protein 0.0080 0.3222 1.3 phosphatase 1A (formerly 2C), magnesium- dependent, alpha isoform /// protein phosphatase 1A (formerly 2C), magnesium- dependent, alpha isoform 206323_x_at NM_002547 OPHN1 oligophrenin 1 0.0339 0.2763 1.3 202372_at BF240652 — Full-length cDNA 0.0040 0.0880 1.3 clone CS0DC007YG11 of Neuroblastoma Cot 25-normalized of Homo sapiens (human) 204641_at NM_002497 NEK2 NIMA (never in 0.0060 0.1598 1.3 mitosis gene a)- related kinase 2 218127_at AI804118 NFYB nuclear 0.0298 0.1675 1.3 transcription factor Y, beta 202629_at AV681579 APPBP2 amyloid beta 0.0023 0.4904 1.3 precursor protein (cytoplasmic tail) binding protein 2 210817_s_at BC004130 CALCOCO2 calcium binding 0.0082 0.1515 1.3 and coiled-coil domain 2 208195_at NM_003319 TTN titin 0.0265 0.1949 1.3 205126_at NM_006296 VRK2 vaccinia related 0.0033 0.0365 1.2 kinase 2 219356_s_at NM_016410 CHMP5 chromatin 0.0190 0.1778 1.2 modifying protein 5 200686_s_at NM_004768 SFRS11 splicing factor, 0.0064 0.0719 1.2 arginine/serine-rich 11 204630_s_at NM_004871 GOSR1 golgi SNAP 0.0098 0.3668 1.2 receptor complex member 1 221641_s_at AF241787 ACOT9 acyl-CoA 0.0253 0.1581 1.2 thioesterase 9 217317_s_at AB002391 HERC2P3 hect domain and 0.0403 0.4707 1.2 /// RLD 2 pseudogene HERC2P2 3 /// hect domain /// and RLD 2 LOC440248 pseudogene 2 /// hypothetical LOC440248 213794_s_at AI269117 NGDN neuroguidin, 0.0074 0.1963 1.2 EIF4E binding protein 203621_at NM_002492 NDUFB5 NADH 0.0297 0.1554 1.2 dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa 219940_s_at NM_018386 PCID2 PCI domain 0.0102 0.3122 1.2 containing 2 214715_x_at AK024789 ZNF160 zinc finger protein 0.0117 0.1338 1.2 160 205452_at NM_004855 PIGB phosphatidylinositol 0.0061 0.2509 1.2 glycan anchor biosynthesis, class B 221064_s_at NM_023076 C16orf28 chromosome 16 0.0198 0.9418 1.2 open reading frame 28 220071_x_at NM_018097 CEP27 centrosomal 0.0116 0.1564 1.2 protein 27 kDa 215588_x_at AK024958 RIOK3 RIO kinase 3 0.0028 0.4594 1.2 (yeast) 208717_at BC001669 OXA1L oxidase 0.0197 0.7795 1.2 (cytochrome c) assembly 1-like 203883_s_at BG249608 RAB11FIP2 RAB11 family 0.0049 0.1190 1.2 interacting protein 2 (class I) 218766_s_at NM_015836 WARS2 tryptophanyl tRNA 0.0147 0.1269 1.2 synthetase 2 (mitochondrial) 221527_s_at AF196185 PARD3 par-3 partitioning 0.0232 0.1408 1.2 defective 3 homolog (C. elegans) 200994_at BG291787 IPO7 Importin 7 0.0388 0.6843 1.2 221923_s_at AA191576 NPM1 nucleophosmin 0.0071 0.0636 1.2 (nucleolar phosphoprotein B23, numatrin) 201253_s_at NM_006319 CDIPT CDP- 0.0133 0.1470 1.2 diacylglycerol-- inositol 3- phosphatidyltransferase (phosphatidylinositol synthase) 213687_s_at BE968801 RPL35A ribosomal protein 0.0012 0.0344 1.2 L35a 221419_s_at NM_013307 — — 0.0174 0.1039 1.2 212153_at AB007930 POGZ pogo transposable 0.0024 0.4615 1.2 element with ZNF domain 202021_x_at AF083441 EIF1 eukaryotic 0.0012 0.1070 1.2 translation initiation factor 1 213896_x_at BE856549 KIAA0974 KIAA0974 0.0118 0.1469 1.2 200823_x_at NM_000992 RPL29 ribosomal protein 0.0061 0.2552 1.2 L29 215179_x_at AK023843 PGF Placental growth 0.0085 0.1642 1.2 factor, vascular endothelial growth factor-related protein 203351_s_at AF047598 ORC4L origin recognition 0.0199 0.3619 1.2 complex, subunit 4-like (yeast) 200905_x_at NM_005516 HLA-E major 0.0053 0.1334 1.2 histocompatibility complex, class I, E 219119_at NM_016200 LSM8 LSM8 homolog, 0.0447 0.2301 1.2 U6 small nuclear RNA associated (S. cerevisiae) 214305_s_at AW003030 SF3B1 splicing factor 3b, 0.0061 0.0197 1.2 subunit 1, 155 kDa 200099_s_at AL356115 RPS3A /// ribosomal protein 0.0040 0.0558 1.2 LOC439992 S3A /// ribosomal protein S3A /// similar to ribosomal protein S3a /// similar to ribosomal protein S3a 218007_s_at NM_015920 RPS27L ribosomal protein 0.0046 0.0971 1.2 S27-like 203445_s_at NM_005730 CTDSP2 CTD (carboxy- 0.0057 0.1941 1.2 terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 220796_x_at NM_024881 SLC35E1 solute carrier 0.0136 0.2093 1.2 family 35, member E1 203261_at NM_006571 DCTN6 dynactin 6 0.0322 0.2746 1.2 204362_at NM_003930 SKAP2 src kinase 0.0267 0.5442 1.2 associated phosphoprotein 2 200858_s_at NM_001012 RPS8 ribosomal protein 0.0024 0.0843 1.2 S8 212229_s_at AK001699 FBXO21 F-box protein 21 0.0336 0.1148 1.2 216187_x_at AF222691 KNS2 Kinesin 2 0.0161 0.8431 1.2 201483_s_at BC002802 SUPT4H1 suppressor of Ty 4 0.0079 0.9595 1.2 homolog 1 (S. cerevisiae) 208855_s_at AF083420 STK24 serine/threonine 0.0136 0.0721 1.2 kinase 24 (STE20 homolog, yeast) 207180_s_at NM_006410 HTATIP2 HIV-1 Tat 0.0359 0.8053 1.2 interactive protein 2, 30 kDa 219590_x_at NM_015958 DPH5 DPH5 homolog (S. cerevisiae) 0.0029 0.1068 1.2 218630_at NM_017777 MKS1 Meckel syndrome, 0.0224 0.5271 1.2 type 1 202279_at NM_004894 C14orf2 chromosome 14 0.0155 0.0721 1.2 open reading frame 2 217122_s_at AL031282 SLC35E2 solute carrier 0.0178 0.3398 1.2 /// family 35, member LOC728661 E2 /// similar to solute carrier family 35, member E2 208933_s_at AI659005 — — 0.0027 0.0803 1.2 205327_s_at NM_001616 ACVR2A activin A receptor, 0.0357 0.5733 1.2 type IIA 203448_s_at AI347136 TERF1 telomeric repeat 0.0112 0.0284 1.2 binding factor (NIMA- interacting) 1 218250_s_at NM_013354 CNOT7 CCR4-NOT 0.0049 0.0564 1.2 transcription complex, subunit 7 214097_at AW024383 RPS21 ribosomal protein 0.0345 0.3691 1.2 S21 214802_at AK022397 EXOC7 exocyst complex 0.0299 0.4976 1.2 component 7 202970_at AI192838 — MRNA; cDNA 0.0404 0.1580 1.2 DKFZp667B0924 (from clone DKFZp667B0924) 202317_s_at NM_006048 UBE4B ubiquitination 0.0069 0.5881 1.2 factor E4B (UFD2 homolog, yeast) 209329_x_at BC000587 HIGD2A HIG1 domain 0.0186 0.5037 1.2 family, member 2A 214686_at AA868898 ZNF266 zinc finger protein 0.0199 0.6239 1.2 266 214143_x_at AI560573 RPL24 /// ribosomal protein 0.0022 0.0284 1.2 ACSM3 L24 /// acyl-CoA /// synthetase SLC36A2 medium-chain family member 3 /// solute carrier family 36 (proton/amino acid symporter), member 2 203316_s_at NM_003094 SNRPE small nuclear 0.0241 0.1629 1.2 ribonucleoprotein polypeptide E 221934_s_at BF941492 DALRD3 DALR anticodon 0.0322 0.8698 1.2 binding domain containing 3 221540_x_at AF078847 GTF2H2 general 0.0289 0.1892 1.2 /// transcription factor DKFZP686M0199 IIH, polypeptide 2, /// 44 kDa /// similar to LOC653866 TFIIH basal /// transcription factor LOC728340 complex p44 /// subunit (Basic LOC730394 transcription factor 2 44 kDa subunit) (BTF2-p44) (General transcription factor IIH polypeptide 2) /// similar to TFIIH basal transcription factor complex p44 subunit (Basic transcription factor 2 44 kDa subunit) (BTF2-p44) (General transcription factor IIH polypeptide 2) /// similar to TFIIH basal transcription factor complex p44 subunit (Basic transcription factor 2 44 kDa subunit) (BTF2-p44) (General transcription factor IIH polypeptide 2) /// region containing general transcription factor IIH, polypeptide 2, 44 kDa; similar to TFIIH basal transcription factor complex p44 subunit (Basic transcription factor 2 44 kDa subunit) (BTF2-p44) (General transcription factor IIH polypeptide 2) 202054_s_at NM_000382 ALDH3A2 aldehyde 0.0264 0.2941 1.2 dehydrogenase 3 family, member A2 35436_at L06147 GOLGA2 golgi autoantigen, 0.0143 0.2075 1.2 golgin subfamily a, 2 218988_at NM_018656 SLC35E3 solute carrier 0.0332 0.4575 1.2 family 35, member E3 212632_at N32035 STX7 Syntaxin 7 0.0264 0.4759 1.2 209472_at BC000819 RP11- kynurenine 0.0347 0.1281 1.2 82K18.3 aminotransferase III 204020_at BF739943 PURA purine-rich element 0.0149 0.0874 1.2 binding protein A 208113_x_at NM_030979 PABPC3 poly(A) binding 0.0330 0.2927 1.2 protein, cytoplasmic 3 /// poly(A) binding protein, cytoplasmic 3 214394_x_at AI613383 EEF1D /// eukaryotic 0.0013 0.0326 1.2 LOC126037 translation elongation factor 1 delta (guanine nucleotide exchange protein) /// similar to Elongation factor 1-delta (EF-1- delta) (Antigen NY-CO-4) 213292_s_at AA908770 SNX13 sorting nexin 13 0.0283 0.1715 1.2 220046_s_at NM_020307 CCNL1 cyclin L1 0.0054 0.1498 1.2 202379_s_at AI361805 NKTR natural killer-tumor 0.0226 0.0758 1.2 recognition sequence 221787_at BF431618 C6orf120 chromosome 6 0.0087 0.0877 1.2 open reading frame 120 210296_s_at BC005375 PXMP3 peroxisomal 0.0152 0.5465 1.2 membrane protein 3, 35 kDa (Zellweger syndrome) 209678_s_at L18964 PRKCI protein kinase C, 0.0298 0.0441 1.2 iota 219926_at NM_022361 POPDC3 popeye domain 0.0062 0.0307 1.2 containing 3 212474_at D87682 KIAA0241 KIAA0241 0.0221 0.3172 1.2 217820_s_at NM_018212 ENAH enabled homolog 0.0366 0.1120 1.2 (Drosophila) 212447_at AF161402 KBTBD2 kelch repeat and 0.0089 0.4481 1.2 BTB (POZ) domain containing 2 212368_at AA972711 ZNF292 zinc finger protein 0.0176 0.0861 1.2 292 202829_s_at NM_005638 SYBL1 synaptobrevin-like 1 0.0160 0.1131 1.2 216310_at AK024376 TAOK1 TAO kinase 1 0.0075 0.5594 1.2 211297_s_at L20320 CDK7 cyclin-dependent 0.0359 0.0916 1.2 kinase 7 (MO15 homolog, Xenopus laevis, cdk- activating kinase) 210686_x_at BC001407 SLC25A16 solute carrier 0.0079 0.2001 1.2 family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 201032_at NM_006698 BLCAP bladder cancer 0.0011 0.1159 1.2 associated protein 218467_at NM_020232 TNFSF5IP1 tumor necrosis 0.0055 0.1200 1.2 factor superfamily, member 5-induced protein 1 205526_s_at NM_007044 KATNA1 katanin p60 0.0142 0.0800 1.2 (ATPase- containing) subunit A 1 208066_s_at NM_001514 GTF2B general 0.0333 0.3117 1.2 transcription factor IIB /// general transcription factor IIB 209069_s_at BC001124 H3F3B H3 histone, family 0.0174 0.0958 1.2 3B (H3.3B) 210908_s_at AB055804 PFDN5 prefoldin subunit 5 0.0045 0.0424 1.2 218098_at AL121903 — — 0.0396 0.3857 1.2 208904_s_at BC000354 RPS28 /// ribosomal protein 0.0019 0.1381 1.2 LOC645899 S28 /// similar to /// 40S ribosomal LOC646195 protein S28 /// similar to 40S ribosomal protein S28 201371_s_at AF062537 CUL3 cullin 3 0.0109 0.0933 1.2 219703_at NM_018365 MNS1 meiosis-specific 0.0184 0.0703 1.2 nuclear structural 1 205788_s_at NM_014827 ZC3H11A zinc finger CCCH- 0.0255 0.7984 1.2 type containing 11A 221829_s_at AI307759 TNPO1 transportin 1 0.0043 0.0185 1.2 212600_s_at AV727381 UQCRC2 ubiquinol- 0.0050 0.0383 1.2 cytochrome c reductase core protein II 200034_s_at NM_000970 RPL6 ribosomal protein 0.0060 0.2152 1.2 L6 /// ribosomal protein L6 200036_s_at NM_007104 RPL10A ribosomal protein 0.0020 0.0971 1.2 L10a /// ribosomal protein L10a 216858_x_at AL080112 — — 0.0298 0.1388 1.2 203034_s_at NM_000990 RPL27A ribosomal protein 0.0010 0.0274 1.2 /// L27a /// similar to LOC389435 60S ribosomal protein L27a 200726_at NM_002710 PPP1CC protein 0.0326 0.5063 1.2 phosphatase 1, catalytic subunit, gamma isoform 217941_s_at NM_018695 ERBB2IP erbb2 interacting 0.0195 0.6001 1.2 protein 200018_at NM_001017 RPS13 ribosomal protein 0.0006 0.0252 1.2 S13 /// ribosomal protein S13 200705_s_at NM_001959 EEF1B2 eukaryotic 0.0007 0.0157 1.2 translation elongation factor 1 beta 2 205042_at NM_005476 GNE glucosamine 0.0294 0.2075 1.2 (UDP-N-acetyl)-2- epimerase/N- acetylmannosamine kinase 218654_s_at NM_016071 MRPS33 mitochondrial 0.0011 0.0282 1.2 ribosomal protein S33 212345_s_at BE675139 CREB3L2 cAMP responsive 0.0168 0.1160 1.2 element binding protein 3-like 2 207700_s_at NM_006534 NCOA3 nuclear receptor 0.0380 0.0932 1.2 coactivator 3 202378_s_at NM_017526 LEPROT leptin receptor 0.0092 0.0747 1.2 overlapping transcript 215823_x_at U64661 PABPC3 poly(A) binding 0.0081 0.0893 1.2 /// protein, PABPC1 cytoplasmic 3 /// /// poly(A) binding LOC341315 protein, /// cytoplasmic 1 /// LOC652607 hypothetical LOC341315 /// similar to Polyadenylate- binding protein 1 (Poly(A)-binding protein 1) (PABP 1) 205176_s_at NM_014288 ITGB3BP integrin beta 3 0.0354 0.3312 1.2 binding protein (beta3-endonexin) 217491_x_at AF042165 COX7C cytochrome c 0.0007 0.0452 1.2 oxidase subunit VIIc 209007_s_at AF267856 C1orf63 chromosome 1 0.0468 0.9308 1.2 open reading frame 63 208993_s_at AW340788 PPIG peptidylprolyl 0.0404 0.0424 1.2 isomerase G (cyclophilin G) 212440_at X76302 RY1 putative nucleic 0.0038 0.0285 1.2 acid binding protein RY-1 213179_at BG289914 — — 0.0149 0.7695 1.2 200092_s_at BF216701 RPL37 ribosomal protein 0.0007 0.0197 1.2 L37 /// ribosomal protein L37 208695_s_at BC001019 RPL39 ribosomal protein 0.0035 0.0984 1.2 L39 202265_at NM_005180 BMI1 B lymphoma Mo- 0.0159 0.0499 1.2 MLV insertion region (mouse) 208610_s_at AI655799 SRRM2 serine/arginine 0.0301 0.0441 1.2 repetitive matrix 2 218146_at NM_018446 GLT8D1 glycosyltransferase 0.0261 0.3313 1.2 8 domain containing 1 215424_s_at AV689564 SNW1 SNW domain 0.0168 0.2988 1.2 containing 1 206089_at NM_006157 NELL1 NEL-like 1 0.0451 0.1134 1.2 (chicken) 201041_s_at NM_004417 DUSP1 dual specificity 0.0237 0.9234 1.2 phosphatase 1 204576_s_at AA207013 CLUAP1 clusterin associated 0.0329 0.9377 1.2 protein 1 202710_at BC000899 BET1 BET1 homolog (S. cerevisiae) 0.0267 0.2967 1.2 201653_at NM_005776 CNIH cornichon homolog 0.0011 0.0185 1.2 (Drosophila) 203858_s_at NM_001303 COX10 COX10 homolog, 0.0030 0.0383 1.2 cytochrome c oxidase assembly protein, heme A: farnesyltransferase (yeast) 213049_at BG436400 GARNL1 GTPase activating 0.0416 0.1940 1.2 Rap/RanGAP domain-like 1 217975_at NM_016303 WBP5 WW domain 0.0129 0.0467 1.2 binding protein 5 209760_at AL136932 KIAA0922 KIAA0922 0.0378 0.7343 1.2 217256_x_at Z98950 LOC641903 similar to large 0.0029 0.2079 1.2 /// subunit ribosomal LOC643505 protein L36a /// /// similar to large LOC646175 subunit ribosomal /// protein L36a /// LOC649299 similar to large /// subunit ribosomal LOC651209 protein L36a /// /// similar to large LOC728202 subunit ribosomal /// protein L36a /// LOC732102 similar to large subunit ribosomal protein L36a /// similar to large subunit ribosomal protein L36a /// similar to large subunit ribosomal protein L36a 200847_s_at NM_016127 TMEM66 transmembrane 0.0402 0.3313 1.2 protein 66 203011_at NM_005536 IMPA1 inositol(myo)-1(or 0.0121 0.0452 1.2 4)- monophosphatase 1 209447_at AF043290 SYNE1 spectrin repeat 0.0367 0.1023 1.2 containing, nuclear envelope 1 217846_at NM_005051 QARS glutaminyl-tRNA 0.0008 0.0841 1.2 synthetase 218341_at NM_024664 PPCS phosphopantotheno 0.0369 0.0576 1.2 ylcysteine synthetase 219762_s_at NM_015414 RPL36 ribosomal protein 0.0060 0.1247 1.2 L36 215907_at AK027193 BACH2 BTB and CNC 0.0197 0.2184 1.2 homology 1, basic leucine zipper transcription factor 2 202336_s_at NM_000919 PAM peptidylglycine 0.0451 0.2016 1.2 alpha-amidating monooxygenase 219220_x_at NM_020191 MRPS22 mitochondrial 0.0016 0.0383 1.2 ribosomal protein S22 203292_s_at NM_021729 VPS11 vacuolar protein 0.0249 0.4069 1.2 sorting 11 homolog (S. cerevisiae) 201290_at NM_014300 SEC11A SEC11 homolog A 0.0025 0.0417 1.2 (S. cerevisiae) 219711_at NM_017652 ZNF586 zinc finger protein 0.0476 0.8054 1.2 586 219030_at NM_016058 TPRKB TP53RK binding 0.0354 0.1017 1.2 protein 210139_s_at L03203 PMP22 peripheral myelin 0.0029 0.4411 1.2 protein 22 218991_at NM_022070 ABC1 amplified in breast 0.0406 0.4662 1.2 cancer 1 219563_at NM_024633 C14orf139 chromosome 14 0.0212 0.4167 1.2 open reading frame 139 216960_s_at AL049646 ZNF133 zinc finger protein 0.0140 0.0798 1.2 133 216505_x_at AL118502 RPS10 /// ribosomal protein 0.0045 0.0853 1.2 LOC133569 S10 /// similar to /// ribosomal protein RPS10P3 S10 /// ribosomal /// protein S10 LOC649303 pseudogene 3 /// /// similar to LOC654029 ribosomal protein /// S10 /// similar to LOC728791 40S ribosomal /// protein S10 /// LOC730965 similar to 40S /// ribosomal protein LOC732348 S10 /// similar to 40S ribosomal protein S10 /// similar to ribosomal protein S10 221959_at BE672313 C8orf72 chromosome 8 0.0176 0.3838 1.2 open reading frame 72 216499_at AL137590 — MRNA; cDNA 0.0238 0.4595 1.2 DKFZp434K0610 (from clone DKFZp434K0610) 204274_at AA812215 EBAG9 estrogen receptor 0.0258 0.1645 1.2 binding site associated, antigen, 9 203098_at AL050164 CDYL chromodomain 0.0029 0.1514 1.2 protein, Y-like 221868_at AB032981 KIAA1155 KIAA1155 protein 0.0078 0.3685 1.2 201606_s_at BE796924 PWP1 PWP1 homolog (S. cerevisiae) 0.0206 0.0351 1.2 219740_at NM_024749 VASH2 vasohibin 2 0.0467 0.0197 1.2 209510_at AF064801 RNF139 ring finger protein 0.0064 0.0383 1.2 139 32259_at AB002386 EZH1 enhancer of zeste 0.0294 0.6894 1.2 homolog 1 (Drosophila) 203180_at NM_000693 ALDH1A3 aldehyde 0.0234 0.0537 1.2 dehydrogenase 1 family, member A3 215582_x_at AK022303 MCM3AP MCM3 0.0261 0.6795 1.2 minichromosome maintenance deficient 3 (S. cerevisiae) associated protein 202920_at BF726212 ANK2 ankyrin 2, neuronal 0.0055 0.0418 1.2 221423_s_at NM_030799 YIPF5 Yip1 domain 0.0284 0.2018 1.2 family, member 5 /// Yip1 domain family, member 5 211935_at D31885 ARL6IP1 ADP-ribosylation 0.0025 0.1564 1.2 factor-like 6 interacting protein 1 214129_at AI821791 LOC727942 similar to 0.0262 0.0645 1.2 phosphodiesterase 4D interacting protein isoform 2 202542_s_at NM_004757 SCYE1 small inducible 0.0473 0.3700 1.2 cytokine subfamily E, member 1 (endothelial monocyte- activating) 212505_s_at AL110250 KIAA0892 KIAA0892 0.0415 0.3689 1.2 202495_at NM_003192 TBCC tubulin folding 0.0288 0.1796 1.2 cofactor C 201630_s_at NM_004300 ACP1 acid phosphatase 1, 0.0049 0.7714 1.2 soluble 210027_s_at M80261 APEX1 APEX nuclease 0.0015 0.0441 1.2 (multifunctional DNA repair enzyme) 1 219442_at NM_024048 C16orf67 chromosome 16 0.0205 0.1694 1.2 open reading frame 67 202798_at NM_006323 SEC24B SEC24 related 0.0149 0.4001 1.2 gene family, member B (S. cerevisiae) 200595_s_at NM_003750 EIF3S10 eukaryotic 0.0423 0.3400 1.2 translation initiation factor 3, subunit 10 theta, 150/170 kDa 215373_x_at AK022213 FLJ12151 hypothetical 0.0344 0.2990 1.2 protein FLJ12151 214150_x_at BE043477 ATP6V0E1 ATPase, H+ 0.0097 0.0385 1.2 transporting, lysosomal 9 kDa, V0 subunit e1 213223_at AK025866 RPL28 ribosomal protein 0.0186 0.2522 1.2 L28 206770_s_at NM_012243 SLC35A3 solute carrier 0.0385 0.1965 1.2 family 35 (UDP-N- acetylglucosamine (UDP-GlcNAc) transporter), member A3 200032_s_at NM_000661 RPL9 ribosomal protein 0.0064 0.1269 1.2 L9 /// ribosomal protein L9 200089_s_at AI953886 RPL4 ribosomal protein 0.0011 0.1019 1.2 L4 /// ribosomal protein L4 218936_s_at NM_014167 CCDC59 coiled-coil domain 0.0401 0.1497 1.2 containing 59 200013_at NM_000986 RPL24 ribosomal protein 0.0012 0.0506 1.2 L24 /// ribosomal protein L24 206551_x_at NM_017644 KLHL24 kelch-like 24 0.0102 0.0791 1.2 (Drosophila) 205125_at NM_006225 PLCD1 phospholipase C, 0.0415 0.4391 1.2 delta 1 201352_at NM_014263 YME1L1 YME1-like 1 (S. cerevisiae) 0.0080 0.0645 1.2 209049_s_at BC001004 PRKCBP1 protein kinase C 0.0193 0.1143 1.2 binding protein 1 200781_s_at NM_001019 RPS15A ribosomal protein 0.0012 0.0252 1.2 S15a 208759_at AF240468 IKBKB /// inhibitor of kappa 0.0459 0.9106 1.2 NCSTN light polypeptide gene enhancer in B-cells, kinase beta /// nicastrin 202536_at AK002165 CHMP2B chromatin 0.0369 0.0552 1.2 modifying protein 2B 208025_s_at NM_003483 HMGA2 high mobility 0.0144 0.0506 1.2 group AT-hook 2 /// high mobility group AT-hook 2 208137_x_at NM_030972 ZNF611 zinc finger protein 0.0034 0.0383 1.2 /// 611 /// zinc finger LOC731901 protein 611 /// similar to zinc finger protein 160 /// similar to zinc finger protein 160 200081_s_at BE741754 RPS6 ribosomal protein 0.0029 0.0971 1.2 S6 /// ribosomal protein S6 200862_at NM_014762 DHCR24 24- 0.0001 0.0261 −3.1 dehydrocholesterol reductase 201287_s_at NM_002997 SDC1 syndecan 1 0.0011 0.1550 −2.2 209146_at AV704962 SC4MOL sterol-C4-methyl 0.0013 0.3139 −2.1 oxidase-like 209218_at AF098865 SQLE squalene epoxidase 0.0012 0.6633 −2.1 202613_at NM_001905 CTPS CTP synthase 0.0012 0.3142 −2.0 212218_s_at AI954041 FASN fatty acid synthase 0.0006 0.0369 −2.0 201609_x_at AL578502 ICMT isoprenylcysteine 0.0024 0.8332 −1.9 carboxyl methyltransferase 210950_s_at BC003573 FDFT1 farnesyl- 0.0002 0.0274 −1.9 diphosphate farnesyltransferase 1 201790_s_at AW150953 DHCR7 7- 0.0036 0.9588 −1.9 dehydrocholesterol reductase 201475_x_at NM_004990 MARS methionine-tRNA 0.0005 0.2911 −1.9 synthetase 221750_at BG035985 HMGCS1 3-hydroxy-3- 0.0030 0.4659 −1.9 methylglutaryl- Coenzyme A synthase 1 (soluble) 200832_s_at AB032261 SCD stearoyl-CoA 0.0012 0.1157 −1.8 desaturase (delta-9- desaturase) 202580_x_at NM_021953 FOXM1 forkhead box M1 0.0019 0.0660 −1.8 205534_at NM_002589 PCDH7 BH-protocadherin 0.0012 0.0452 −1.8 (brain-heart) 208002_s_at NM_007274 ACOT7 acyl-CoA 0.0043 0.1221 −1.8 thioesterase 7 208881_x_at BC005247 IDI1 isopentenyl- 0.0012 0.2090 −1.8 diphosphate delta isomerase 1 210793_s_at U41815 NUP98 nucleoporin 98 kDa 0.0014 0.5809 −1.8 211136_s_at BC004865 CLPTM1 cleft lip and palate 0.0007 0.0264 −1.8 associated transmembrane protein 1 201490_s_at NM_005729 PPIF peptidylprolyl 0.0015 0.6082 −1.8 isomerase F (cyclophilin F) 200987_x_at AA758755 PSME3 proteasome 0.0015 0.8757 −1.8 (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) 212009_s_at AL553320 STIP1 stress-induced- 0.0011 0.5636 −1.8 phosphoprotein 1 (Hsp70/Hsp90- organizing protein) 202587_s_at BC001116 AK1 adenylate kinase 1 0.0014 0.8539 −1.8 217943_s_at NM_018067 RPRC1 arginine/proline 0.0036 0.7553 −1.8 rich coiled-coil 1 201564_s_at NM_003088 FSCN1 fascin homolog 1, 0.0007 0.0411 −1.8 actin-bundling protein (Strongylocentrotus purpuratus) 210337_s_at U18197 ACLY ATP citrate lyase 0.0009 0.2586 −1.8 201679_at BE646076 ARS2 ARS2 protein 0.0019 0.2538 −1.7 217992_s_at NM_024329 EFHD2 EF-hand domain 0.0015 0.2671 −1.7 family, member D2 202052_s_at NM_015577 RAI14 retinoic acid 0.0160 0.7493 −1.7 induced 14 201626_at BG292233 INSIG1 insulin induced 0.0071 0.5750 −1.7 gene 1 202743_at BE622627 PIK3R3 phosphoinositide- 0.0007 0.2808 −1.7 3-kinase, regulatory subunit 3 (p55, gamma) 207622_s_at NM_005692 ABCF2 ATP-binding 0.0007 0.5505 −1.7 cassette, sub- family F (GCN20), member 2 210973_s_at M63889 FGFR1 fibroblast growth 0.0017 0.0348 −1.7 factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) 201281_at NM_007002 ADRM1 adhesion regulating 0.0004 0.7557 −1.7 molecule 1 207945_s_at NM_001893 CSNK1D casein kinase 1, 0.0008 0.0981 −1.7 delta 208637_x_at BC003576 ACTN1 actinin, alpha 1 0.0010 0.3106 −1.7 212563_at BG491842 BOP1 /// block of 0.0025 0.1767 −1.7 LOC727967 proliferation 1 /// similar to block of proliferation 1 219894_at NM_019066 MAGEL2 MAGE-like 2 0.0033 0.8372 −1.7 205483_s_at NM_005101 ISG15 ISG15 ubiquitin- 0.0296 0.9106 −1.7 like modifier 218494_s_at NM_020062 SLC2A4RG SLC2A4 regulator 0.0007 0.0645 −1.7 213986_s_at AI805266 C19orf6 chromosome 19 0.0074 0.0807 −1.7 open reading frame 6 212983_at NM_005343 HRAS v-Ha-ras Harvey 0.0011 0.7695 −1.7 rat sarcoma viral oncogene homolog 204285_s_at AI857639 PMAIP1 phorbol-12- 0.0041 0.0964 −1.7 myristate-13- acetate-induced protein 1 201516_at NM_003132 SRM spermidine 0.0005 0.2652 −1.7 synthase 219099_at NM_020375 C12orf5 chromosome 12 0.0099 0.3265 −1.7 open reading frame 5 201695_s_at NM_000270 NP nucleoside 0.0031 0.2128 −1.7 phosphorylase 222155_s_at AK021918 GPR172A G protein-coupled 0.0061 0.3703 −1.7 receptor 172A 217025_s_at AL110225 DBN1 drebrin 1 0.0015 0.5175 −1.6 200720_s_at AL532341 ACTR1A ARP1 actin-related 0.0024 0.3563 −1.6 protein 1 homolog A, centractin alpha (yeast) 205858_at NM_002507 NGFR nerve growth factor 0.0361 0.7526 −1.6 receptor (TNFR superfamily, member 16) 218051_s_at NM_022908 NT5DC2 5′-nucleotidase 0.0007 0.0532 −1.6 domain containing 2 202539_s_at AL518627 HMGCR 3-hydroxy-3- 0.0047 0.7250 −1.6 methylglutaryl- Coenzyme A reductase 207824_s_at NM_002383 MAZ MYC-associated 0.0012 0.0274 −1.6 zinc finger protein (purine-binding transcription factor) 208962_s_at BE540552 FADS1 fatty acid 0.0007 0.0663 −1.6 desaturase 1 212048_s_at AW245400 YARS tyrosyl-tRNA 0.0007 0.0642 −1.6 synthetase 201277_s_at NM_004499 HNRPAB heterogeneous 0.0007 0.0504 −1.6 nuclear ribonucleoprotein A/B 209608_s_at BC000408 ACAT2 acetyl-Coenzyme 0.0015 0.2423 −1.6 A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase) 212907_at AI972416 SLC30A1 Solute carrier 0.0161 0.3563 −1.6 family 30 (zinc transporter), member 1 202852_s_at NM_024666 FLJ11506 hypothetical 0.0069 0.2746 −1.6 protein FLJ11506 200664_s_at BG537255 DNAJB1 DnaJ (Hsp40) 0.0008 0.2350 −1.6 homolog, subfamily B, member 1 213492_at X06268 COL2A1 collagen, type II, 0.0143 0.1963 −1.6 alpha 1 (primary osteoarthritis, spondyloepiphysea 1 dysplasia, congenital) 201874_at BF978611 MPZL1 myelin protein 0.0061 0.3437 −1.6 zero-like 1 200825_s_at NM_006389 HYOU1 hypoxia up- 0.0013 0.0376 −1.6 regulated 1 212125_at NM_002883 RANGAP1 Ran GTPase 0.0124 0.2690 −1.6 activating protein 1 203499_at NM_004431 EPHA2 EPH receptor A2 0.0048 0.7012 −1.6 220892_s_at NM_021154 PSAT1 phosphoserine 0.0130 0.3662 −1.6 aminotransferase 1 201005_at NM_001769 CD9 CD9 molecule 0.0012 0.0733 −1.6 213523_at AI671049 CCNE1 cyclin E1 0.0007 0.1144 −1.6 221503_s_at AF034756 KPNA3 karyopherin alpha 0.0042 0.0834 −1.6 3 (importin alpha 4) 217762_s_at BE789881 RAB31 RAB31, member 0.0068 0.3313 −1.6 RAS oncogene family 206491_s_at NM_003827 NAPA N-ethylmaleimide- 0.0043 0.1666 −1.6 sensitive factor attachment protein, alpha 222231_s_at AK025328 LRRC59 leucine rich repeat 0.0012 0.2297 −1.6 containing 59 201167_x_at D13989 ARHGDIA Rho GDP 0.0069 0.0544 −1.6 dissociation inhibitor (GDI) alpha 204141_at NM_001069 TUBB2A tubulin, beta 2A 0.0031 0.7289 −1.6 200800_s_at NM_005345 HSPA1A heat shock 70 kDa 0.0047 0.0547 −1.6 /// protein 1A /// heat HSPA1B shock 70 kDa protein 1B 213030_s_at AI688418 PLXNA2 plexin A2 0.0019 0.1469 −1.6 200078_s_at BC005876 ATP6V0B ATPase, H+ 0.0007 0.1997 −1.6 transporting, lysosomal 21 kDa, V0 subunit b /// ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit b 212501_at AL564683 CEBPB CCAAT/enhancer 0.0168 0.7928 −1.6 binding protein (C/EBP), beta 201248_s_at NM_004599 SREBF2 sterol regulatory 0.0036 0.0990 −1.6 element binding transcription factor 2 217717_s_at BF246499 YWHAB tyrosine 3- 0.0274 0.9884 −1.6 monooxygenase/tryptophan 5- monooxygenase activation protein, beta polypeptide 205417_s_at NM_004393 DAG1 dystroglycan 1 0.0024 0.1175 −1.6 (dystrophin- associated glycoprotein 1) 208625_s_at AF104913 EIF4G1 eukaryotic 0.0040 0.5095 −1.6 translation initiation factor 4 gamma, 1 205047_s_at NM_001673 ASNS asparagine 0.0034 0.4312 −1.6 synthetase 211899_s_at AF082185 TRAF4 TNF receptor- 0.0152 0.4299 −1.6 associated factor 4 200753_x_at BE866585 SFRS2 splicing factor, 0.0027 0.6707 −1.5 arginine/serine-rich 2 211066_x_at BC006439 PCDHGC3 protocadherin 0.0100 0.7921 −1.5 /// gamma subfamily PCDHGB4 C, 3 /// /// protocadherin PCDHGA8 gamma subfamily /// C, 3 /// PCDHGA12 protocadherin /// gamma subfamily PCDHGC5 B, 4 /// /// protocadherin PCDHGC4 gamma subfamily /// B, 4 /// PCDHGB7 protocadherin /// gamma subfamily PCDHGB6 A, 8 /// /// protocadherin PCDHGB5 gamma subfamily /// A, 8 /// PCDHGB3 protocadherin /// gamma subfamily PCDHGB2 A, 12 /// /// protocadherin PCDHGB1 gamma subfamily /// A, 12 /// PCDHGA11 protocadherin /// gamma subfamily PCDHGA10 C, 5 /// /// protocadherin PCDHGA9 gamma subfamily /// C, 5 /// PCDHGA7 protocadherin /// gamma subfamily PCDHGA6 C, 4 /// /// protocadherin PCDHGA5 gamma subfamily /// C, 4 /// PCDHGA4 protocadherin /// gamma subfamily PCDHGA3 B, 7 /// /// protocadherin PCDHGA2 gamma subfamily /// B, 7 /// PCDHGA1 protocadherin gamma subfamily B, 6 /// protocadherin gamma subfamily B, 6 /// protocadherin gamma subfamily B, 5 /// protocadherin gamma subfamily B, 5 /// protocadherin gamma subfamily B, 3 /// protocadherin gamma subfamily B, 3 /// protocadherin gamma subfamily B, 2 /// protocadherin gamma subfamily B, 2 /// protocadherin gamma subfamily B, 1 /// protocadherin gamma subfamily B, 1 /// protocadherin gamma subfamily A, 11 /// protocadherin gamma subfamily A, 11 /// protoc 221539_at AB044548 EIF4EBP1 eukaryotic 0.0005 0.1625 −1.5 translation initiation factor 4E binding protein 1 212020_s_at AU152107 MKI67 antigen identified 0.0100 0.3569 −1.5 by monoclonal antibody Ki-67 212186_at BE855983 ACACA acetyl-Coenzyme 0.0046 0.7009 −1.5 A carboxylase alpha 200736_s_at NM_000581 GPX1 glutathione 0.0005 0.0958 −1.5 peroxidase 1 212110_at D31887 SLC39A14 solute carrier 0.0039 0.1774 −1.5 family 39 (zinc transporter), member 14 221269_s_at NM_031286 SH3BGRL3 SH3 domain 0.0022 0.1530 −1.5 binding glutamic acid-rich protein like 3 /// SH3 domain binding glutamic acid-rich protein like 3 218866_s_at NM_016310 POLR3K polymerase (RNA) 0.0006 0.0499 −1.5 III (DNA directed) polypeptide K, 12.3 kDa 208998_at U94592 UCP2 uncoupling protein 0.0064 0.2296 −1.5 2 (mitochondrial, proton carrier) 201920_at NM_005415 SLC20A1 solute carrier 0.0127 0.2383 −1.5 family 20 (phosphate transporter), member 1 217140_s_at AJ002428 VDAC1 voltage-dependent 0.0011 0.2544 −1.5 anion channel 1 204178_s_at NM_006328 RBM14 RNA binding motif 0.0012 0.0244 −1.5 protein 14 208977_x_at BC004188 TUBB2C tubulin, beta 2C 0.0007 0.1351 −1.5 55692_at W22924 ELMO2 engulfment and 0.0193 0.7394 −1.5 cell motility 2 201954_at NM_005720 ARPC1B actin related 0.0090 0.6520 −1.5 /// protein 2/3 LOC653888 complex, subunit 1B, 41 kDa /// similar to Actin- related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41- ARC) 52164_at AA065185 C11orf24 chromosome 11 0.0012 0.3796 −1.5 open reading frame 24 200884_at NM_001823 CKB creatine kinase, 0.0141 0.1787 −1.5 brain 200744_s_at AI741124 GNB1 guanine nucleotide 0.0006 0.0653 −1.5 binding protein (G protein), beta polypeptide 1 200617_at NM_014730 KIAA0152 KIAA0152 0.0042 0.6385 −1.5 203085_s_at BC000125 TGFB1 transforming 0.0122 0.2679 −1.5 growth factor, beta 1 (Camurati- Engelmann disease) 222278_at AW969655 — Transcribed locus, 0.0420 0.6056 −1.5 moderately similar to XP_001002661.1 hypothetical protein [Mus musculus] 212300_at AL049795 TXLNA taxilin alpha 0.0028 0.2423 −1.5 211237_s_at AF202063 FGFR4 fibroblast growth 0.0018 0.0648 −1.5 factor receptor 4 201700_at NM_001760 CCND3 cyclin D3 0.0018 0.3480 −1.5 214677_x_at X57812 IGL@ /// immunoglobulin 0.0075 0.3646 −1.5 IGLV4-3 lambda locus /// /// IGLV3- immunoglobulin 25 /// lambda variable 4- IGLV2-14 3 /// /// IGLJ3 immunoglobulin lambda variable 3- 25 /// immunoglobulin lambda variable 2- 14 /// immunoglobulin lambda joining 3 214845_s_at AF257659 CALU calumenin 0.0069 0.6021 −1.5 206463_s_at NM_005794 DHRS2 dehydrogenase/reductase 0.0135 0.4760 −1.5 (SDR family) member 2 204768_s_at NM_004111 FEN1 flap structure- 0.0007 0.1484 −1.5 specific endonuclease 1 213547_at AB014567 CAND2 cullin-associated 0.0025 0.0807 −1.5 and neddylation- dissociated 2 (putative) 217861_s_at NM_013388 PREB prolactin 0.0012 0.8030 −1.5 regulatory element binding 209361_s_at BC004153 PCBP4 poly(rC) binding 0.0022 0.1080 −1.5 protein 4 210317_s_at U28936 YWHAE tyrosine 3- 0.0050 0.0441 −1.5 monooxygenase/tryptophan 5- monooxygenase activation protein, epsilon polypeptide 203968_s_at NM_001254 CDC6 cell division cycle 0.0012 0.1235 −1.5 6 homolog (S. cerevisiae) 218888_s_at NM_018092 NETO2 neuropilin (NRP) 0.0044 0.3076 −1.5 and tolloid (TLL)- like 2 209336_at U56085 PWP2 PWP2 periodic 0.0065 0.9234 −1.5 tryptophan protein homolog (yeast) 203737_s_at NM_015062 PPRC1 peroxisome 0.0136 0.5419 −1.5 proliferator- activated receptor gamma, coactivator-related 1 202478_at NM_021643 TRIB2 tribbles homolog 2 0.0026 0.2666 −1.5 (Drosophila) 208891_at BC003143 DUSP6 dual specificity 0.0069 0.0576 −1.5 phosphatase 6 208815_x_at AB023420 HSPA4 heat shock 70 kDa 0.0025 0.0549 −1.5 protein 4 204087_s_at NM_021095 SLC5A6 solute carrier 0.0035 0.7493 −1.5 family 5 (sodium- dependent vitamin transporter), member 6 203109_at NM_003969 UBE2M ubiquitin- 0.0020 0.7428 −1.5 conjugating enzyme E2M (UBC12 homolog, yeast) 208693_s_at D30658 GARS glycyl-tRNA 0.0016 0.4086 −1.5 synthetase 220651_s_at NM_018518 MCM10 MCM10 0.0017 0.1151 −1.5 minichromosome maintenance deficient 10 (S. cerevisiae) 217808_s_at NM_024117 MAPKAP1 mitogen-activated 0.0007 0.2075 −1.5 protein kinase associated protein 1 201198_s_at AI860431 PSMD1 proteasome 0.0009 0.2829 −1.5 (prosome, macropain) 26S subunit, non- ATPase, 1 201193_at NM_005896 IDH1 isocitrate 0.0049 0.4382 −1.5 dehydrogenase 1 (NADP+), soluble 201551_s_at J03263 LAMP1 lysosomal- 0.0031 0.0506 −1.5 associated membrane protein 1 212680_x_at BE305165 PPP1R14B protein 0.0006 0.2726 −1.5 phosphatase 1, regulatory (inhibitor) subunit 14B 201618_x_at NM_003801 GPAA1 glycosylphosphatidylinositol 0.0100 0.0923 −1.5 anchor attachment protein 1 homolog (yeast) 200886_s_at NM_002629 PGAM1 phosphoglycerate 0.0007 0.4197 −1.5 /// mutase 1 (brain) /// LOC642969 similar to /// Phosphoglycerate LOC643576 mutase 1 (Phosphoglycerate mutase isozyme B) (PGAM-B) (BPG- dependent PGAM 1) /// similar to Phosphoglycerate mutase 1 (Phosphoglycerate mutase isozyme B) (PGAM-B) (BPG- dependent PGAM 1) 212419_at AA131324 C10orf56 chromosome 10 0.0016 0.3823 −1.5 open reading frame 56 212242_at AL565074 TUBA1 tubulin, alpha 1 0.0007 0.1083 −1.5 221640_s_at AF274972 LRDD leucine-rich repeats 0.0071 0.0995 −1.5 and death domain containing 209035_at M69148 MDK midkine (neurite 0.0009 0.0727 −1.5 growth-promoting factor 2) 200787_s_at BC002426 PEA15 phosphoprotein 0.0016 0.4992 −1.5 enriched in astrocytes 15 212041_at AL566172 ATP6V0D1 ATPase, H+ 0.0078 0.7937 −1.5 transporting, lysosomal 38 kDa, V0 subunit d1 218115_at NM_018154 ASF1B ASF1 anti- 0.0066 0.2165 −1.5 silencing function 1 homolog B (S. cerevisiae) 201710_at NM_002466 MYBL2 v-myb 0.0036 0.1147 −1.5 myeloblastosis viral oncogene homolog (avian)- like 2 205748_s_at NM_017876 RNF126 ring finger protein 0.0056 0.6038 −1.5 126 203359_s_at AL525412 MYCBP c-myc binding 0.0071 0.2121 −1.5 protein 212174_at W02312 AK2 adenylate kinase 2 0.0014 0.2498 −1.5 212441_at D86985 KIAA0232 KIAA0232 gene 0.0039 0.0993 −1.5 product 221972_s_at AL571362 SDF4 stromal cell 0.0020 0.0645 −1.5 derived factor 4 207088_s_at NM_003562 SLC25A11 solute carrier 0.0056 0.6504 −1.5 family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 202556_s_at NM_006337 MCRS1 microspherule 0.0042 0.1233 −1.5 protein 1 205512_s_at NM_004208 AIFM1 apoptosis-inducing 0.0035 0.7462 −1.5 factor, mitochondrion- associated, 1 206510_at AF332197 SIX2 sine oculis 0.0060 0.4870 −1.5 homeobox homolog 2 (Drosophila) 210574_s_at AF241788 NUDC nuclear distribution 0.0006 0.1606 −1.5 gene C homolog (A. nidulans) 204695_at AI343459 CDC25A cell division cycle 0.0011 0.1847 −1.5 25 homolog A (S. cerevisiae) 200655_s_at NM_006888 CALM1 calmodulin 1 0.0008 0.0712 −1.5 (phosphorylase kinase, delta) 202939_at NM_005857 ZMPSTE24 zinc 0.0088 0.1153 −1.5 metallopeptidase (STE24 homolog, yeast) 203606_at NM_004553 NDUFS6 NADH 0.0014 0.0990 −1.5 dehydrogenase (ubiquinone) Fe—S protein 6, 13 kDa (NADH-coenzyme Q reductase) 218803_at NM_018223 CHFR checkpoint with 0.0040 0.2666 −1.5 forkhead and ring finger domains 209645_s_at NM_000692 ALDH1B1 aldehyde 0.0026 0.6355 −1.5 dehydrogenase 1 family, member B1 218893_at NM_024710 ISOC2 isochorismatase 0.0057 0.1709 −1.5 domain containing 2 201192_s_at NM_006224 PITPNA phosphatidylinositol 0.0249 0.9184 −1.5 transfer protein, alpha 201478_s_at U59151 DKC1 dyskeratosis 0.0035 0.5159 −1.5 congenita 1, dyskerin 201020_at NM_003405 YWHAH tyrosine 3- 0.0119 0.2666 −1.5 monooxygenase/tryptophan 5- monooxygenase activation protein, eta polypeptide 217785_s_at NM_006555 YKT6 YKT6 v-SNARE 0.0025 0.4852 −1.5 homolog (S. cerevisiae) 203239_s_at NM_014516 CNOT3 CCR4-NOT 0.0144 0.0832 −1.5 transcription complex, subunit 3 208091_s_at NM_030796 ECOP EGFR-coamplified 0.0009 0.0746 −1.5 and overexpressed protein /// EGFR- coamplified and overexpressed protein 202854_at NM_000194 HPRT1 hypoxanthine 0.0096 0.1663 −1.5 phosphoribosyltransferase 1 (Lesch- Nyhan syndrome) 200611_s_at AB010427 WDR1 WD repeat domain 1 0.0024 0.7179 −1.5 200634_at NM_005022 PFN1 profilin 1 0.0007 0.0539 −1.5 209039_x_at AF001434 EHD1 EH-domain 0.0057 0.9870 −1.5 containing 1 221731_x_at BF218922 CSPG2 chondroitin sulfate 0.0043 0.0878 −1.5 proteoglycan 2 (versican) 204364_s_at BE535746 REEP1 receptor accessory 0.0072 0.1344 −1.5 protein 1 216952_s_at M94363 LMNB2 lamin B2 0.0011 0.0274 −1.5 201360_at NM_000099 CST3 cystatin C (amyloid 0.0010 0.0252 −1.5 angiopathy and cerebral hemorrhage) 201420_s_at BF975273 WDR77 WD repeat domain 0.0011 0.9108 −1.5 77 218214_at NM_021934 C12orf44 chromosome 12 0.0095 0.9055 −1.5 open reading frame 44 202581_at NM_005346 HSPA1B heat shock 70 kDa 0.0185 0.1596 −1.5 protein 1B 216733_s_at X86401 GATM glycine 0.0199 0.5609 −1.5 amidinotransferase (L-arginine:glycine amidinotransferase) 201801_s_at AF079117 SLC29A1 solute carrier 0.0140 0.5393 −1.5 family 29 (nucleoside transporters), member 1 202138_x_at NM_006303 JTV1 JTV1 gene 0.0023 0.2414 −1.5 217791_s_at NM_002860 ALDH18A1 aldehyde 0.0064 0.7660 −1.5 dehydrogenase 18 family, member A1 208677_s_at AL550657 BSG basigin (Ok blood 0.0007 0.0428 −1.5 group) 203064_s_at NM_004514 FOXK2 forkhead box K2 0.0090 0.6618 −1.5 204042_at AB020707 WASF3 WAS protein 0.0300 0.4120 −1.5 family, member 3 201377_at NM_014847 UBAP2L ubiquitin 0.0077 0.3919 −1.5 associated protein 2-like 217977_at NM_016332 SEPX1 selenoprotein X, 1 0.0012 0.5433 −1.4 218119_at NM_006327 TIMM23 translocase of inner 0.0054 0.4659 −1.4 /// mitochondrial LOC653252 membrane 23 homolog (yeast) /// similar to Mitochondrial import inner membrane translocase subunit Tim23 214121_x_at AA086229 PDLIM7 PDZ and LIM 0.0029 0.0807 −1.4 domain 7 (enigma) 200895_s_at NM_002014 FKBP4 FK506 binding 0.0037 0.8039 −1.4 protein 4, 59 kDa 205436_s_at NM_002105 H2AFX H2A histone 0.0004 0.0252 −1.4 family, member X 217899_at NM_017727 FLJ20254 hypothetical 0.0129 0.3602 −1.4 protein FLJ20254 204488_at NM_014908 TMEM15 transmembrane 0.0075 0.6853 −1.4 protein 15 217903_at NM_013403 STRN4 striatin, calmodulin 0.0218 0.1914 −1.4 binding protein 4 201645_at NM_002160 TNC tenascin C 0.0395 0.3472 −1.4 (hexabrachion) 212739_s_at AL523860 NME4 non-metastatic 0.0015 0.3553 −1.4 cells 4, protein expressed in 213867_x_at AA809056 ACTB actin, beta 0.0010 0.8642 −1.4 201195_s_at AB018009 SLC7A5 solute carrier 0.0028 0.1293 −1.4 family 7 (cationic amino acid transporter, y+ system), member 5 209100_at BC001327 IFRD2 interferon-related 0.0050 0.2084 −1.4 developmental regulator 2 202771_at NM_014745 FAM38A family with 0.0031 0.0541 −1.4 sequence similarity 38, member A 201523_x_at BE262760 UBE2N ubiquitin- 0.0012 0.5131 −1.4 conjugating enzyme E2N (UBC13 homolog, yeast) 200846_s_at NM_002708 PPP1CA protein 0.0010 0.0395 −1.4 phosphatase 1, catalytic subunit, alpha isoform 210010_s_at U25147 SLC25A1 solute carrier 0.0001 0.0157 −1.4 family 25 (mitochondrial carrier; citrate transporter), member 1 209202_s_at AF001690 EXTL3 exostoses 0.0264 0.4576 −1.4 (multiple)-like 3 201043_s_at NM_006305 ANP32A acidic (leucine- 0.0079 0.2051 −1.4 rich) nuclear phosphoprotein 32 family, member A 210378_s_at BC004118 SSNA1 Sjogren's syndrome 0.0007 0.2575 −1.4 nuclear autoantigen 1 200824_at NM_000852 GSTP1 glutathione S- 0.0019 0.0537 −1.4 transferase pi 212155_at AA085748 RNF187 ring finger protein 0.0016 0.1231 −1.4 187 213011_s_at BF116254 TPI1 triosephosphate 0.0039 0.3558 −1.4 isomerase 1 209482_at BC001430 POP7 processing of 0.0014 0.3306 −1.4 precursor 7, ribonuclease P subunit (S. cerevisiae) 203258_at NM_006442 DRAP1 DR1-associated 0.0012 0.3362 −1.4 protein 1 (negative cofactor 2 alpha) 221637_s_at BC001434 C11orf48 chromosome 11 0.0173 0.3011 −1.4 open reading frame 48 200646_s_at NM_006148 NUCB1 nucleobindin 1 0.0039 0.0452 −1.4 218308_at NM_006342 TACC3 transforming, 0.0011 0.4338 −1.4 acidic coiled-coil containing protein 3 204616_at NM_006002 UCHL3 ubiquitin carboxyl- 0.0045 0.0432 −1.4 terminal esterase L3 (ubiquitin thiolesterase) 205479_s_at NM_002658 PLAU plasminogen 0.0244 0.5956 −1.4 activator, urokinase 212432_at AL542571 GRPEL1 GrpE-like 1, 0.0015 0.4084 −1.4 mitochondrial (E. coli) 208649_s_at AF100752 VCP valosin-containing 0.0035 0.5192 −1.4 protein 200952_s_at AI635187 CCND2 cyclin D2 0.0317 0.1578 −1.4 208478_s_at NM_004324 BAX BCL2-associated X 0.0479 0.9784 −1.4 protein 206703_at NM_000747 CHRNB1 cholinergic 0.0146 0.9472 −1.4 receptor, nicotinic, beta 1 (muscle) 209825_s_at BC002906 UCK2 uridine-cytidine 0.0010 0.0941 −1.4 kinase 2 216251_s_at BF965437 TTLL12 tubulin tyrosine 0.0022 0.7692 −1.4 ligase-like family, member 12 208622_s_at AA670344 VIL2 villin 2 (ezrin) 0.0323 0.6566 −1.4 208941_s_at BC000941 SEPHS1 selenophosphate 0.0013 0.3793 −1.4 synthetase 1 209262_s_at BC002669 NR2F6 nuclear receptor 0.0060 0.3291 −1.4 subfamily 2, group F, member 6 200600_at NM_002444 MSN moesin 0.0025 0.0666 −1.4 200776_s_at AL518328 BZW1 /// basic leucine 0.0085 0.1920 −1.4 LOC151579 zipper and W2 domains 1 /// similar to basic leucine zipper and W2 domains 1 201818_at NM_024830 AYTL2 acyltransferase like 2 0.0071 0.1235 −1.4 201082_s_at NM_004082 DCTN1 dynactin 1 (p150, 0.0118 0.0783 −1.4 glued homolog, Drosophila) 55081_at W46406 MICALL 1 MICAL-like 1 0.0054 0.9766 −1.4 216088_s_at AL078633 PSMA7 proteasome 0.0014 0.6547 −1.4 (prosome, macropain) subunit, alpha type, 7 209231_s_at AI038068 DCTN5 dynactin 5 (p25) 0.0124 0.9715 −1.4 200827_at NM_000302 PLOD1 procollagen-lysine 0.0048 0.0510 −1.4 1,2-oxoglutarate 5-dioxygenase 1 213746_s_at AW051856 FLNA filamin A, alpha 0.0207 0.5615 −1.4 (actin binding protein 280) 220949_s_at NM_024033 C7orf49 chromosome 7 0.0047 0.3132 −1.4 open reading frame 49 202908_at NM_006005 WFS1 Wolfram syndrome 0.0099 0.2926 −1.4 1 (wolframin) 207714_s_at NM_004353 SERPINH 1 serpin peptidase 0.0012 0.0512 −1.4 inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) 217752_s_at NM_018235 CNDP2 CNDP dipeptidase 0.0082 0.5146 −1.4 2 (metallopeptidase M20 family) 208744_x_at BG403660 HSPH1 heat shock 0.0104 0.0536 −1.4 105 kDa/110 kDa protein 1 202111_at NM_003040 SLC4A2 solute carrier 0.0037 0.0681 −1.4 family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1) 212691_at AW131863 NUP188 nucleoporin 0.0061 0.3316 −1.4 188 kDa 210338_s_at AB034951 HSPA8 heat shock 70 kDa 0.0019 0.1113 −1.4 protein 8 202245_at AW084510 LSS lanosterol synthase 0.0219 0.2846 −1.4 (2,3- oxidosqualene- lanosterol cyclase) 201762_s_at NM_002818 PSME2 proteasome 0.0018 0.1893 −1.4 (prosome, macropain) activator subunit 2 (PA28 beta) 218815_s_at NM_018022 TMEM51 transmembrane 0.0079 0.6437 −1.4 protein 51 204147_s_at NM_007111 TFDP1 transcription factor 0.0247 0.6619 −1.4 Dp-1 201204_s_at AA706065 RRBP1 ribosome binding 0.0340 0.7216 −1.4 protein 1 homolog 180 kDa (dog) 50314_i_at AI761506 C20orf27 chromosome 20 0.0025 0.1143 −1.4 open reading frame 27 201584_s_at NM_005804 DDX39 DEAD (Asp-Glu- 0.0024 0.2953 −1.4 Ala-Asp) box polypeptide 39 208928_at AF258341 POR P450 (cytochrome) 0.0269 0.3414 −1.4 oxidoreductase 220326_s_at NM_018071 FLJ10357 hypothetical 0.0005 0.0252 −1.4 protein FLJ10357 201654_s_at AI991033 HSPG2 heparan sulfate 0.0045 0.0396 −1.4 proteoglycan 2 (perlecan) 202737_s_at NM_012321 LSM4 LSM4 homolog, 0.0066 0.6417 −1.4 U6 small nuclear RNA associated (S. cerevisiae) 202528_at NM_000403 GALE UDP-galactose-4- 0.0114 0.5096 −1.4 epimerase 209652_s_at BC001422 PGF placental growth 0.0012 0.0452 −1.4 factor, vascular endothelial growth factor-related protein 203270_at NM_012145 DTYMK deoxythymidylate 0.0049 0.2176 −1.4 /// kinase LOC727761 (thymidylate kinase) /// similar to deoxythymidylate kinase (thymidylate kinase) 218695_at NM_019037 EXOSC4 exosome 0.0046 0.3295 −1.4 component 4 202894_at NM_004444 EPHB4 EPH receptor B4 0.0057 0.6685 −1.4 200700_s_at NM_006854 KDELR2 KDEL (Lys-Asp- 0.0021 0.3528 −1.4 Glu-Leu) endoplasmic reticulum protein retention receptor 2 219526_at NM_024644 C14orf169 chromosome 14 0.0075 0.3181 −1.4 open reading frame 169 209052_s_at BF111870 WHSC1 Wolf-Hirschhorn 0.0039 0.0436 −1.4 syndrome candidate 1 201282_at NM_002541 OGDH oxoglutarate 0.0117 0.0916 −1.4 (alpha- ketoglutarate) dehydrogenase (lipoamide) 221484_at BF691447 B4GALT5 UDP- 0.0078 0.4685 −1.4 Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 200911_s_at NM_006283 TACC1 transforming, 0.0036 0.1542 −1.4 acidic coiled-coil containing protein 1 203039_s_at NM_005006 NDUFS1 NAPH 0.0159 0.2193 −1.4 dehydrogenase (ubiquinone) Fe—S protein 1, 75 kDa (NADH-coenzyme Q reductase) 201168_x_at NM_004309 ARHGDIA Rho GDP 0.0007 0.0451 −1.4 /// dissociation LOC728908 inhibitor (GDI) alpha /// similar to Rho GDP dissociation inhibitor (GDI) alpha 201537_s_at BC002682 DUSP3 dual specificity 0.0061 0.1488 −1.4 phosphatase 3 (vaccinia virus phosphatase VH1- related) 209773_s_at BC001886 RRM2 ribonucleotide 0.0007 0.2822 −1.4 reductase M2 polypeptide 210986_s_at Z24727 TPM1 tropomyosin 1 0.0436 0.6520 −1.4 (alpha) 218493_at NM_024571 C16orf33 chromosome 16 0.0022 0.5112 −1.4 open reading frame 33 202887_s_at NM_019058 DDIT4 DNA-damage- 0.0039 0.1757 −1.4 inducible transcript 4 218857_s_at NM_025080 ASRGL1 asparaginase like 1 0.0047 0.6967 −1.4 209190_s_at AF051782 DIAPH1 diaphanous 0.0057 0.6058 −1.4 homolog 1 (Drosophila) 200650_s_at NM_005566 LDHA lactate 0.0004 0.0344 −1.4 dehydrogenase A 200948_at NM_005439 MLF2 myeloid leukemia 0.0078 0.3850 −1.4 factor 2 200623_s_at NM_005184 CALM3 calmodulin 3 0.0079 0.0721 −1.4 (phosphorylase kinase, delta) 204849_at NM_006602 TCFL5 transcription 0.0088 0.7035 −1.4 factor-like 5 (basic helix-loop-helix) 204331_s_at NM_021107 MRPS12 mitochondrial 0.0060 0.5066 −1.4 ribosomal protein S12 213476_x_at AL565749 TUBB3 tubulin beta 3 0.0076 0.7836 −1.4 209321_s_at AF033861 ADCY3 adenylate cyclase 3 0.0034 0.0856 −1.4 200808_s_at NM_003461 ZYX zyxin 0.0061 0.4333 −1.4 219212_at NM_016299 HSPA14 heat shock 70 kDa 0.0027 0.1403 −1.4 protein 14 206593_s_at NM_006752 SURF5 surfeit 5 0.0363 0.2712 −1.4 201797_s_at NM_006295 VARS valyl-tRNA 0.0159 0.9226 −1.4 synthetase 203190_at NM_002496 NDUFS8 NADH 0.0019 0.8311 −1.4 dehydrogenase (ubiquinone) Fe—S protein 8, 23 kDa (NADH-coenzyme Q reductase) 2028_s_at M96577 E2F1 E2F transcription 0.0227 0.5305 −1.4 factor 1 203392_s_at NM_001328 CTBP1 C-terminal binding 0.0091 0.7822 −1.4 protein 1 217818_s_at NM_005718 ARPC4 actin related 0.0112 0.4886 −1.4 protein 2/3 complex, subunit 4, 20 kDa 208657_s_at AF142408 9-Sep septin 9 0.0041 0.0721 −1.4 201252_at NM_006503 PSMC4 /// proteasome 0.0034 0.2890 −1.4 LOC652826 (prosome, macropain) 26S subunit, ATPase, 4 /// similar to 26S protease regulatory subunit 6B (MIP224) (MB67- interacting protein) (TAT-binding protein 7) (TBP-7) 200880_at AL534104 DNAJA1 DnaJ (Hsp40) 0.0122 0.1190 −1.4 homolog, subfamily A, member 1 201573_s_at M75715 ETF1 eukaryotic 0.0065 0.4236 −1.4 translation termination factor 1 218131_s_at NM_017660 GATAD2A GATA zinc finger 0.0045 0.1527 −1.4 domain containing 2A 207740_s_at NM_012346 NUP62 nucleoporin 62 kDa 0.0302 0.2490 −1.4 217777_s_at NM_016395 PTPLAD1 protein tyrosine 0.0237 0.3399 −1.4 /// phosphatase-like A LOC732402 domain containing 1 /// similar to butyrate-induced transcript 1 218474_s_at NM_018992 KCTD5 potassium channel 0.0314 0.5788 −1.4 tetramerisation domain containing 5 200621_at NM_004078 CSRP1 cysteine and 0.0007 0.1464 −1.4 glycine-rich protein 1 219438_at NM_024522 FAM77C family with 0.0279 0.9563 −1.4 sequence similarity 77, member C 211070_x_at BC006466 DBI diazepam binding 0.0029 0.0800 −1.4 inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein) /// diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein) 212378_at NM_000819 GART phosphoribosylglycinamide 0.0046 0.4656 −1.4 formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase 208453_s_at NM_006523 XPNPEP1 X-prolyl 0.0102 0.6642 −1.4 aminopeptidase (aminopeptidase P) 1, soluble 203489_at NM_006427 SIVA1 SIVA1, apoptosis- 0.0054 0.3864 −1.4 inducing factor 209834_at AB017915 CHST3 carbohydrate 0.0107 0.4595 −1.4 (chondroitin 6) sulfotransferase 3 208700_s_at L12711 TKT transketolase 0.0008 0.0502 −1.4 (Wernicke- Korsakoff syndrome) 202595_s_at AF161461 LEPROTL1 leptin receptor 0.0451 0.8984 −1.4 overlapping transcript-like 1 203252_at NM_005851 CDK2AP2 CDK2-associated 0.0302 0.6607 −1.4 protein 2 205895_s_at NM_004741 NOLC1 nucleolar and 0.0243 0.5497 −1.4 coiled-body phosphoprotein 1 201979_s_at NM_006247 PPP5C protein 0.0271 0.1164 −1.4 phosphatase 5, catalytic subunit 208313_s_at NM_004630 SF1 splicing factor 1 0.0012 0.0284 −1.4 203814_s_at NM_000904 NQO2 NAD(P)H 0.0332 0.6539 −1.4 dehydrogenase, quinone 2 217294_s_at U88968 ENO1 enolase 1, (alpha) 0.0080 0.5283 −1.4 201714_at NM_001070 TUBG1 tubulin, gamma 1 0.0049 0.9428 −1.4 212116_at NM_006510 TRIM27 tripartite motif- 0.0042 0.3418 −1.4 containing 27 218744_s_at NM_016223 PACSIN3 protein kinase C 0.0054 0.8147 −1.4 and casein kinase substrate in neurons 3 201090_x_at NM_006082 K- alpha tubulin 0.0014 0.1096 −1.4 ALPHA-1 219361_s_at NM_022767 ISG20L1 interferon 0.0012 0.0579 −1.4 stimulated exonuclease gene 20 kDa-like 1 211126_s_at U46006 CSRP2 cysteine and 0.0007 0.0582 −1.4 glycine-rich protein 2 202329_at NM_004383 CSK c-src tyrosine 0.0222 0.8338 −1.4 kinase 212712_at BE222901 CAMSAP1 calmodulin 0.0064 0.4040 −1.4 regulated spectrin- associated protein 1 202483_s_at NM_002882 RANBP1 RAN binding 0.0020 0.0727 −1.4 protein 1 201368_at U07802 ZFP36L2 zinc finger protein 0.0165 0.2538 −1.4 36, C3H type-like 2 209526_s_at AB029156 HDGFRP3 hepatoma-derived 0.0034 0.2976 −1.4 growth factor, related protein 3 202407_s_at BF342707 PRPF31 PRP31 pre-mRNA 0.0144 0.1019 −1.4 processing factor 31 homolog (S. cerevisiae) 212126_at BG391282 — CDNA clone 0.0066 0.0714 −1.4 IMAGE: 4842353 202779_s_at NM_014501 UBE2S /// ubiquitin- 0.0007 0.0841 −1.4 LOC731049 conjugating enzyme E2S /// similar to Ubiquitin- conjugating enzyme E2S (Ubiquitin- conjugating enzyme E2-24 kDa) (Ubiquitin- protein ligase) (Ubiquitin carrier protein) (E2-EPF5) 211593_s_at AB047005 MAST2 microtubule 0.0061 0.1211 −1.4 associated serine/threonine kinase 2 /// microtubule associated serine/threonine kinase 2 213787_s_at AV702405 EBP emopamil binding 0.0414 0.3058 −1.4 protein (sterol isomerase) 217796_s_at NM_017921 NPLOC4 nuclear protein 0.0069 0.2545 −1.4 localization 4 homolog (S. cerevisiae) 214507_s_at NM_014285 EXOSC2 exosome 0.0023 0.4634 −1.4 component 2 209233_at U72514 EMG1 EMG1 nucleolar 0.0052 0.4127 −1.4 protein homolog (S. cerevisiae) 221759_at AL583123 G6PC3 glucose 6 0.0069 0.0941 −1.4 phosphatase, catalytic, 3 215121_x_at AA680302 IGL@ /// immunoglobulin 0.0302 0.3171 −1.4 IGLV4-3 lambda locus /// /// IGLV3- immunoglobulin 25 /// lambda variable 4- IGLV2-14 3 /// immunoglobulin lambda variable 3- 25 /// immunoglobulin lambda variable 2- 14 210026_s_at AY028896 CARD10 caspase 0.0193 0.7762 −1.4 recruitment domain family, member 10 211762_s_at BC005978 KPNA2 /// karyopherin alpha 0.0066 0.4069 −1.4 LOC728860 2 (RAG cohort 1, importin alpha 1) /// karyopherin alpha 2 (RAG cohort 1, importin alpha 1) /// similar to Importin alpha-2 subunit (Karyopherin alpha-2 subunit) (SRP1-alpha) (RAG cohort protein 1) /// similar to Importin alpha-2 subunit (Karyopherin alpha-2 subunit) (SRP1-alpha) (RAG cohort protein 1) 218678_at NM_024609 NES nestin 0.0043 0.1063 −1.4 201275_at NM_002004 FDPS farnesyl 0.0014 0.9609 −1.4 diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase) 220011_at NM_024037 C1orf135 chromosome 1 0.0050 0.1904 −1.4 open reading frame 135 201000_at NM_001605 AARS alanyl-tRNA 0.0076 0.6685 −1.4 synthetase 217835_x_at NM_018840 C20orf24 chromosome 20 0.0011 0.0271 −1.4 open reading frame 24 217755_at NM_016185 HN1 hematological and 0.0007 0.0336 −1.4 neurological expressed 1 200734_s_at BG341906 ARF3 ADP-ribosylation 0.0093 0.2784 −1.4 factor 3 203411_s_at NM_005572 LMNA lamin A/C 0.0007 0.1514 −1.4 218661_at NM_024845 FLJ14154 hypothetical 0.0066 0.3772 −1.4 protein FLJ14154 214439_x_at AF043899 BIN1 bridging integrator 1 0.0130 0.4300 −1.4 201953_at NM_006384 CIB1 calcium and 0.0078 0.1914 −1.4 integrin binding 1 (calmyrin) 208540_x_at NM_021039 LOC729659 similar to Putative 0.0057 0.3193 −1.4 /// S100 calcium- LOC730278 binding protein /// A11 pseudogene /// LOC730558 similar to Putative S100 calcium- binding protein A11 pseudogene /// similar to Putative S100 calcium- binding protein A11 pseudogene 202718_at NM_000597 IGFBP2 insulin-like growth 0.0007 0.0157 −1.4 factor binding protein 2, 36 kDa 209567_at BC001811 RRS1 RRS1 ribosome 0.0265 0.1269 −1.4 biogenesis regulator homolog (S. cerevisiae) 212540_at BG476661 CDC34 cell division cycle 0.0110 0.9118 −1.4 34 homolog (S. cerevisiae) 213470_s_at BF983406 HNRPH1 heterogeneous 0.0175 0.5096 −1.4 nuclear ribonucleoprotein H1 (H) 200964_at NM_003334 UBE1 ubiquitin- 0.0009 0.0599 −1.4 activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) 221571_at AI721219 TRAF3 TNF receptor- 0.0065 0.1689 −1.4 associated factor 3 201096_s_at AL537042 ARF4 ADP-ribosylation 0.0093 0.3651 −1.4 factor 4 215714_s_at AF254822 SMARCA4 SWI/SNF related, 0.0135 0.1898 −1.4 matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 202469_s_at AU149367 CPSF6 cleavage and 0.0399 0.2918 −1.4 polyadenylation specific factor 6, 68 kDa 65585_at AA527515 FAM86B1 family with 0.0044 0.0891 −1.4 sequence similarity 86, member B1 213334_x_at BE676218 UCHL5IP UCHL5 interacting 0.0136 0.5765 −1.4 protein 209213_at BC002511 CBR1 carbonyl reductase 1 0.0080 0.9371 −1.4 206441_s_at NM_017828 COMMD4 COMM domain 0.0069 0.0965 −1.4 containing 4 218650_at NM_022775 DGCR8 DiGeorge 0.0166 0.0645 −1.4 syndrome critical region gene 8 218200_s_at NM_004546 NDUFB2 NADH 0.0026 0.3329 −1.4 dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa 202692_s_at NM_014233 UBTF upstream binding 0.0074 0.4143 −1.4 transcription factor, RNA polymerase I 201247_at BE513151 — — 0.0042 0.0441 −1.4 208308_s_at NM_000175 GPI glucose phosphate 0.0014 0.0589 −1.4 isomerase 218028_at NM_016031 ELOVL1 elongation of very 0.0052 0.1335 −1.4 long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)- like 1 204955_at NM_006307 SRPX sushi-repeat- 0.0149 0.0681 −1.4 containing protein, X-linked 201543_s_at NM_020150 SAR1A SAR1 gene 0.0017 0.1483 −1.4 homolog A (S. cerevisiae) 209093_s_at K02920 GBA /// glucosidase, beta; 0.0066 0.1233 −1.4 GBAP acid (includes glucosylceramidase) /// glucosidase, beta; acid, pseudogene 201251_at NM_002654 PKM2 pyruvate kinase, 0.0060 0.0966 −1.3 muscle 209372_x_at BF971587 TUBB2A tubulin, beta 2A /// 0.0382 0.3610 −1.3 /// tubulin, beta 2B TUBB2B 218305_at NM_024658 IPO4 importin 4 0.0192 0.5264 −1.3 202418_at NM_020470 YIF1A Yip1 interacting 0.0156 0.7400 −1.3 factor homolog A (S. cerevisiae) 220966_x_at NM_030978 ARPC5L actin related 0.0059 0.2710 −1.3 protein 2/3 complex, subunit 5-like /// actin related protein 2/3 complex, subunit 5-like 209186_at M23114 ATP2A2 ATPase, Ca++ 0.0041 0.0664 −1.3 transporting, cardiac muscle, slow twitch 2 219646_at NM_017702 FLJ20186 hypothetical 0.0012 0.0732 −1.3 protein FLJ20186 213887_s_at AI554759 POLR2E polymerase (RNA) 0.0006 0.0629 −1.3 II (DNA directed) polypeptide E, 25 kDa 219556_at NM_025108 C16orf59 chromosome 16 0.0047 0.7714 −1.3 open reading frame 59 204975_at NM_001424 EMP2 epithelial 0.0129 0.1233 −1.3 membrane protein 2 200628_s_at M61715 WARS tryptophanyl-tRNA 0.0060 0.5095 −1.3 synthetase 221790_s_at AL545035 LDLRAP1 low density 0.0220 0.1822 −1.3 lipoprotein receptor adaptor protein 1 37996_s_at L08835 DMPK dystrophia 0.0037 0.0582 −1.3 myotonica-protein kinase 208793_x_at AI744900 SMARCA4 SWI/SNF related, 0.0195 0.3604 −1.3 /// matrix associated, MRPL43 actin dependent regulator of chromatin, subfamily a, member 4 /// mitochondrial ribosomal protein L43 202262_x_at NM_013974 DDAH2 dimethylarginine 0.0016 0.2933 −1.3 dimethylaminohydrolase 2 215489_x_at AI871287 HOMER3 homer homolog 3 0.0462 0.6112 −1.3 (Drosophila) 210334_x_at AB028869 BIRC5 baculoviral IAP 0.0111 0.0735 −1.3 repeat-containing 5 (survivin) 213897_s_at AI832239 MRPL23 mitochondrial 0.0054 0.6849 −1.3 ribosomal protein L23 212702_s_at N45111 BICD2 bicaudal D 0.0304 0.4187 −1.3 homolog 2 (Drosophila) 217772_s_at NM_014342 MTCH2 mitochondrial 0.0040 0.6337 −1.3 carrier homolog 2 (C. elegans) 204441_s_at NM_002689 POLA2 polymerase (DNA 0.0049 0.1015 −1.3 directed), alpha 2 (70 kD subunit) 202275_at NM_000402 G6PD glucose-6- 0.0248 0.1383 −1.3 phosphate dehydrogenase 200045_at NM_001090 ABCF1 ATP-binding 0.0051 0.9326 −1.3 cassette, sub- family F (GCN20), member 1 /// ATP- binding cassette, sub-family F (GCN20), member 1 209899_s_at AF217197 SIAHBP1 fuse-binding 0.0015 0.4831 −1.3 protein-interacting repressor 202041_s_at NM_004214 FIBP fibroblast growth 0.0044 0.2432 −1.3 factor (acidic) intracellular binding protein 221853_s_at N39536 NOMO1 NODAL modulator 0.0018 0.2079 −1.3 /// 1 /// NODAL NOMO2 modulator 2 /// /// NODAL modulator 3 NOMO3 208836_at U51478 ATP1B3 ATPase, Na+/K+ 0.0048 0.9938 −1.3 transporting, beta 3 polypeptide 214500_at AF044286 H2AFY H2A histone 0.0050 0.5729 −1.3 family, member Y 203025_at NM_003491 ARD1A ARD1 homolog A, 0.0376 0.7352 −1.3 N-acetyltransferase (S. cerevisiae) 206452_x_at NM_021131 PPP2R4 protein 0.0127 0.2664 −1.3 phosphatase 2A, regulatory subunit B′ (PR 53) 202326_at NM_006709 EHMT2 euchromatic 0.0261 0.4234 −1.3 histone-lysine N- methyltransferase 2 218708_at NM_013248 NXT1 NTF2-dike export 0.0016 0.0699 −1.3 factor 1 208353_x_at NM_020480 ANK1 ankyrin 1, 0.0036 0.5544 −1.3 erythrocytic 218497_s_at NM_002936 RNASEH1 ribonuclease H1 0.0043 0.2176 −1.3 220864_s_at NM_015965 NDUFA13 NADH 0.0101 0.8591 −1.3 dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 212708_at AV721987 MSL-1 male-specific 0.0026 0.2235 −1.3 lethal-1 homolog 218223_s_at NM_016274 PLEKHO1 pleckstrin 0.0247 0.8246 −1.3 homology domain containing, family O member 1 203119_at NM_024098 CCDC86 coiled-coil domain 0.0040 0.1268 −1.3 containing 86 200660_at NM_005620 S100A11 S100 calcium 0.0007 0.1105 −1.3 binding protein A11 218918_at NM_020379 MAN1C1 mannosidase, 0.0076 0.6532 −1.3 alpha, class 1C, member 1 222065_s_at AI830227 FLII flightless I 0.0066 0.2358 −1.3 homolog (Drosophila) 217946_s_at NM_016402 SAE1 SUMO1 activating 0.0007 0.1017 −1.3 enzyme subunit 1 211799_x_at U62824 HLA-C major 0.0098 0.7199 −1.3 histocompatibility complex, class I, C 200055_at NM_006284 TAF10 TAF10 RNA 0.0029 0.2192 −1.3 polymerase II, TATA box binding protein (TBP)- associated factor, 30 kDa /// TAF10 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 30 kDa 209478_at U95006 PCDHGC3 Protocadherin 0.0036 0.4002 −1.3 gamma subfamily C, 3 218897_at NM_030577 TMEM177 transmembrane 0.0063 0.9572 −1.3 protein 177 39835_at U93181 SBF1 SET binding factor 1 0.0015 0.0290 −1.3 212437_at AL109804 CENPB centromere protein 0.0286 0.3415 −1.3 B, 80 kDa 203871_at NM_015670 SENP3 SUMO1/sentrin/SMT3 0.0190 0.2427 −1.3 specific peptidase 3 218358_at NM_024324 CCNK Cyclin K 0.0044 0.3329 −1.3 213892_s_at AA927724 APRT adenine 0.0040 0.8086 −1.3 phosphoribosyltransferase 220789_s_at NM_004749 TBRG4 transforming 0.0323 0.4333 −1.3 growth factor beta regulator 4 202758_s_at NM_003721 RFXANK regulatory factor 0.0032 0.3094 −1.3 X-associated ankyrin-containing protein 208620_at U24223 PCBP1 poly(rC) binding 0.0021 0.1368 −1.3 protein 1 200768_s_at BC001686 MAT2A methionine 0.0073 0.0436 −1.3 adenosyltransferase II, alpha 201937_s_at NM_012100 DNPEP aspartyl 0.0117 0.4038 −1.3 aminopeptidase 209536_s_at AF320070 EHD4 EH-domain 0.0246 0.4627 −1.3 containing 4 201727_s_at NM_001419 ELAVL1 ELAV (embryonic 0.0184 0.5267 −1.3 lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) 202715_at NM_004341 CAD /// carbamoyl- 0.0029 0.1198 −1.3 ARHGEF5 phosphate /// synthetase 2, LOC653691 aspartate transcarbamylase, and dihydroorotase /// Rho guanine nucleotide exchange factor (GEF) 5 /// FLJ40722-like 202330_s_at NM_003362 UNG uracil-DNA 0.0046 0.1330 −1.3 glycosylase 215464_s_at AK001327 TAX1BP3 Tax1 (human T- 0.0038 0.2644 −1.3 cell leukemia virus type I) binding protein 3 204099_at NM_003078 SMARCD3 SWI/SNF related, 0.0047 0.4707 −1.3 matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 203622_s_at NM_020143 PNO1 partner of NOB1 0.0066 0.0727 −1.3 homolog (S. cerevisiae) 203940_s_at NM_014909 VASH1 vasohibin 1 0.0107 0.7646 −1.3 203349_s_at NM_004454 ETV5 ets variant gene 5 0.0074 0.5793 −1.3 (ets-related molecule) 200739_s_at BG338532 SUMO3 SMT3 suppressor 0.0146 0.1657 −1.3 of mif two 3 homolog 3 (S. cerevisiae) 209765_at Y13786 ADAM19 ADAM 0.0079 0.4707 −1.3 metallopeptidase domain 19 (meltrin beta) 200601_at U48734 ACTN4 actinin, alpha 4 0.0062 0.0990 −1.3 208433_s_at NM_017522 LRP8 low density 0.0212 0.7888 −1.3 lipoprotein receptor-related protein 8, apolipoprotein e receptor 200913_at NM_002707 PPM1G protein 0.0107 0.3412 −1.3 phosphatase 1G (formerly 2C), magnesium- dependent, gamma isoform 212185_x_at NM_005953 MT2A metallothionein 2A 0.0015 0.0280 −1.3 212624_s_at BF339445 CHN1 chimerin 0.0259 0.8804 −1.3 (chimaerin) 1 202756_s_at NM_002081 GPC1 glypican 1 0.0074 0.7875 −1.3 201246_s_at NM_017670 OTUB1 OTU domain, 0.0481 0.7828 −1.3 ubiquitin aldehyde binding 1 202761_s_at NM_015180 SYNE2 spectrin repeat 0.0415 0.0995 −1.3 containing, nuclear envelope 2 204317_at BF305380 GTSE1 G-2 and S-phase 0.0250 0.1113 −1.3 expressed 1 217913_at NM_013245 VPS4A vacuolar protein 0.0007 0.1899 −1.3 sorting 4 homolog A (S. cerevisiae) 212005_at AL582808 — — 0.0086 0.1735 −1.3 200075_s_at BC006249 GUK1 guanylate kinase 1 0.0214 0.6352 −1.3 /// guanylate kinase 1 221848_at AL121845 ZGPAT zinc finger, CCCH- 0.0015 0.0424 −1.3 type with G patch domain 218083_at NM_025072 PTGES2 prostaglandin E 0.0123 0.5372 −1.3 synthase 2 206050_s_at NM_002939 RNH1 ribonuclease/angiogenin 0.0018 0.8628 −1.3 inhibitor 1 209468_at AB017498 LRP5 low density 0.0212 0.8184 −1.3 lipoprotein receptor-related protein 5 209103_s_at BC001049 UFD1L ubiquitin fusion 0.0034 0.2084 −1.3 degradation 1 like (yeast) 218070_s_at NM_013335 GMPPA GDP-mannose 0.0192 0.1434 −1.3 pyrophosphorylase A 201389_at NM_002205 ITGA5 integrin, alpha 5 0.0122 0.1383 −1.3 (fibronectin receptor, alpha polypeptide) 215084_s_at AL031427 LRRC42 leucine rich repeat 0.0036 0.4075 −1.3 containing 42 218388_at NM_012088 PGLS 6- 0.0008 0.0332 −1.3 phosphogluconolactonase 201126_s_at NM_002406 MGAT1 mannosyl (alpha- 0.0185 0.7484 −1.3 1,3-)-glycoprotein beta-1,2-N- acetylglucosaminyl transferase 210519_s_at BC000906 NQO1 NAD(P)H 0.0128 0.4020 −1.3 dehydrogenase, quinone 1 218238_at NM_012341 GTPBP4 GTP binding 0.0378 0.1778 −1.3 protein 4 208905_at BC005299 CYCS cytochrome c, 0.0052 0.0872 −1.3 somatic 207332_s_at NM_003234 TFRC transferrin receptor 0.0035 0.4831 −1.3 (p90, CD71) 218069_at NM_024096 XTP3TPA XTP3- 0.0040 0.1290 −1.3 transactivated protein A 211982_x_at AL546600 XPO6 exportin 6 0.0049 0.9166 −1.3 202024_at NM_004317 ASNA1 arsA arsenite 0.0058 0.1066 −1.3 transporter, ATP- binding, homolog 1 (bacterial) 221657_s_at BC001719 ASB6 ankyrin repeat and 0.0233 0.7801 −1.3 SOCS box- containing 6 220964_s_at NM_030981 RAB1B RAB1B, member 0.0162 0.2294 −1.3 RAS oncogene family /// RAB1B, member RAS oncogene family 203931_s_at NM_002949 MRPL12 mitochondrial 0.0045 0.5499 −1.3 ribosomal protein L12 208842_s_at W93787 GORASP2 golgi reassembly 0.0042 0.8638 −1.3 stacking protein 2, 55 kDa 215905_s_at AL157420 WDR57 WD repeat domain 0.0023 0.4162 −1.3 57 (US snRNP specific) 212422_at AL547263 PDCD11 programmed cell 0.0197 0.3396 −1.3 death 11 211730_s_at BC005903 POLR2L polymerase (RNA) 0.0030 0.5416 −1.3 II (DNA directed) polypeptide L, 7.6 kDa /// polymerase (RNA) II (DNA directed) polypeptide L, 7.6 kDa 202264_s_at NM_006114 TOMM40 translocase of outer 0.0150 0.7824 −1.3 mitochondrial membrane 40 homolog (yeast) 209731_at U79718 NTHL1 nth endonuclease 0.0137 0.6042 −1.3 III-like 1 (E. coli) 217897_at NM_022003 FXYD6 FXYD domain 0.0017 0.0447 −1.3 containing ion transport regulator 6 211564_s_at BC003096 PDLIM4 PDZ and LIM 0.0124 0.6209 −1.3 domain 4 203545_at NM_024079 ALG8 asparagine-linked 0.0125 0.2016 −1.3 glycosylation 8 homolog (S. cerevisiae, alpha- 1,3- glucosyltransferase) 217099_s_at AF258545 GEMIN4 gem (nuclear 0.0117 0.5238 −1.3 organelle) associated protein 4 218641_at NM_023941 MGC3032 hypothetical 0.0135 0.6803 −1.3 protein MGC3032 212411_at BE747342 IMP4 IMP4, U3 small 0.0178 0.5931 −1.3 nucleolar ribonucleoprotein, homolog (yeast) 214794_at BF669264 DLST dihydrolipoamide 0.0235 0.9380 −1.3 S- succinyltransferase (E2 component of 2-oxo-glutarate complex) 203311_s_at M57763 ARF6 ADP-ribosylation 0.0425 0.3117 −1.3 factor 6 221676_s_at BC002342 CORO1C coronin, actin 0.0093 0.5425 −1.3 binding protein, 1C 218670_at NM_025215 PUS1 pseudouridylate 0.0305 0.2781 −1.3 synthase 1 212003_at BG171020 C1orf144 chromosome 1 0.0349 0.4840 −1.3 open reading frame 144 211576_s_at BC003068 SLC19A1 solute carrier 0.0047 0.1028 −1.3 family 19 (folate transporter), member 1 201817_at NM_014671 UBE3C ubiquitin protein 0.0429 0.6649 −1.3 ligase E3C 220956_s_at NM_017555 EGLN2 egl nine homolog 2 0.0078 0.7604 −1.3 (C. elegans) 208910_s_at L04636 C1QBP complement 0.0329 0.3231 −1.3 component 1, q subcomponent binding protein 203462_x_at NM_003751 EIF3S9 eukaryotic 0.0017 0.1620 −1.3 translation initiation factor 3, subunit 9 eta, 116 kDa 218834_s_at NM_017870 TMEM132A transmembrane 0.0106 0.1838 −1.3 protein 132A 208932_at BC001416 PPP4C protein 0.0040 0.1494 −1.3 phosphatase 4 (formerly X), catalytic subunit 203228_at NM_002573 PAFAH1B3 platelet-activating 0.0041 0.2248 −1.3 factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa 203031_s_at NM_000375 UROS uroporphyrinogen 0.0130 0.8462 −1.3 III synthase (congenital erythropoietic porphyria) 203647_s_at M18003 FDX1 ferredoxin 1 0.0430 0.8149 −1.3 217225_x_at AL512687 NOMO2 NODAL modulator 2 0.0042 0.2518 −1.3 201095_at NM_004394 DAP death-associated 0.0166 0.2794 −1.3 protein 202128_at NM_014821 KIAA0317 KIAA0317 0.0446 0.9567 −1.3 212129_at AI589507 NIPA2 non imprinted in 0.0163 0.7517 −1.3 Prader- Willi/Angelman syndrome 2 204610_s_at NM_006848 CCDC85B coiled-coil domain 0.0377 0.4333 −1.3 containing 85B 215093_at U82671 NSDHL NAD(P) dependent 0.0159 0.7567 −1.3 steroid dehydrogenase-like 200950_at NM_006409 ARPC1A actin related 0.0115 0.7012 −1.3 protein 2/3 complex, subunit 1A, 41 kDa 217716_s_at NM_013336 SEC61A1 Sec61 alpha 1 0.0045 0.0475 −1.3 subunit (S. cerevisiae) 208132_x_at NM_004638 BAT2 HLA-B associated 0.0051 0.1305 −1.3 transcript 2 203960_s_at NM_016126 C1orf41 chromosome 1 0.0053 0.0645 −1.3 /// open reading frame IL17RB 41 /// interleukin 17 receptor B 201950_x_at NM_004930 CAPZB capping protein 0.0107 0.4512 −1.3 (actin filament) muscle Z-line, beta 210966_x_at BC001460 LARP1 La 0.0155 0.1383 −1.3 ribonucleoprotein domain family, member 1 210983_s_at AF279900 MCM7 MCM7 0.0031 0.0832 −1.3 minichromosome maintenance deficient 7 (S. cerevisiae) 200803_s_at AF033095 TEGT testis enhanced 0.0061 0.0745 −1.3 gene transcript (BAX inhibitor 1) 201554_x_at NM_004130 GYG1 glycogenin 1 0.0267 0.7594 −1.3 205462_s_at NM_002149 HPCAL1 hippocalcin-like 1 0.0193 0.2490 −1.3 211934_x_at W87689 GANAB glucosidase, alpha; 0.0072 0.0476 −1.3 neutral AB 209344_at BC002827 TPM4 tropomyosin 4 0.0239 0.8829 −1.3 217753_s_at NM_001029 RPS26 /// ribosomal protein 0.0010 0.1482 −1.3 LOC644166 S26 /// similar to /// 40S ribosomal LOC644191 protein S26 /// /// similar to 40S LOC728937 ribosomal protein S26 /// similar to 40S ribosomal protein S26 219575_s_at NM_022341 PDF /// peptide 0.0154 0.7836 −1.3 COG8 deformylase (mitochondrial) /// component of oligomeric golgi complex 8 203683_s_at NM_003377 VEGFB vascular 0.0305 0.4504 −1.3 endothelial growth factor B 204608_at NM_000048 ASL argininosuccinate 0.0071 0.2170 −1.3 lyase 202085_at NM_004817 TJP2 tight junction 0.0110 0.3198 −1.3 protein 2 (zona occludens 2) 204275_at AI796687 SOLH small optic lobes 0.0350 0.2001 −1.3 homolog (Drosophila) 212120_at BE897886 RHOQ ras homolog gene 0.0062 0.0571 −1.3 family, member Q 200737_at NM_000291 PGK1 phosphoglycerate 0.0017 0.3518 −1.3 kinase 1 219675_s_at NM_025076 UXS1 UDP-glucuronate 0.0279 0.7782 −1.3 decarboxylase 1 209409_at D86962 GRB10 growth factor 0.0104 0.0935 −1.3 receptor-bound protein 10 200806_s_at BE256479 HSPD1 heat shock 60 kDa 0.0042 0.1925 −1.3 protein 1 (chaperonin) 201614_s_at NM_003707 RUVBL1 RuvB-like 1 (E. coli) 0.0029 0.0941 −1.3 222116_s_at AL157485 TBC1D16 TBC1 domain 0.0107 0.3474 −1.3 family, member 16 203806_s_at NM_000135 FANCA Fanconi anemia, 0.0370 0.5381 −1.3 complementation group A /// Fanconianemia, complementation group A 213180_s_at BE895285 GOSR2 golgi SNAP 0.0408 0.2254 −1.3 receptor complex member 2 203184_at NM_001999 FBN2 fibrillin 2 0.0227 0.1383 −1.3 (congenital contractural arachnodactyly) 201911_s_at NM_005766 FARP1 FERM, RhoGEF 0.0107 0.6444 −1.3 (ARHGEF) and pleckstrin domain protein 1 (chondrocyte- derived) 218057_x_at NM_006067 COX4NB COX4 neighbor 0.0136 0.1344 −1.3 44783_s_at R61374 HEY1 hairy/enhancer-of- 0.0156 0.0964 −1.3 split related with YRPW motif 1 200644_at NM_023009 MARCKSL1 MARCKS-like 1 0.0011 0.4243 −1.3 203276_at NM_005573 LMNB1 lamin B1 0.0156 0.5237 −1.3 212159_x_at AI125280 AP2A2 adaptor-related 0.0342 0.5742 −1.3 protein complex 2, alpha 2 subunit 204839_at NM_015918 POP5 processing of 0.0121 0.4107 −1.3 precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) 201522_x_at NM_003097 SNRPN /// small nuclear 0.0035 0.4870 −1.3 SNURF ribonucleoprotein polypeptide N /// SNRPN upstream reading frame 200727_s_at AA699583 ACTR2 ARP2 actin-related 0.0170 0.1805 −1.3 protein 2 homolog (yeast) 200021_at NM_005507 CFL1 cofilin 1 (non- 0.0039 0.1498 −1.3 muscle) /// cofilin 1 (non-muscle) 201968_s_at NM_002633 PGM1 phosphoglucomutase 1 0.0049 0.2714 −1.3 202593_s_at NM_016641 MIR16 membrane 0.0177 0.1789 −1.3 interacting protein of RGS16 200918_s_at NM_003139 SRPR signal recognition 0.0112 0.3210 −1.3 particle receptor (‘docking protein’) 204238_s_at NM_006443 C6orf108 chromosome 6 0.0494 0.8953 −1.3 open reading frame 108 201704_at NM_001247 ENTPD6 ectonucleoside 0.0358 0.5222 −1.3 triphosphate diphosphohydrolase 6 (putative function) 201267_s_at AL545523 PSMC3 proteasome 0.0010 0.7722 −1.3 (prosome, macropain) 26S subunit, ATPase, 3 201923_at NM_006406 PRDX4 peroxiredoxin 4 0.0044 0.0475 −1.3 211065_x_at BC006422 PFKL phosphofructokinase, 0.0056 0.1200 −1.3 liver /// phosphofructokinase, liver 205002_at NM_015699 AHDC1 AT hook, DNA 0.0301 0.6324 −1.3 binding motif, containing 1 218529_at NM_016579 CD320 CD320 molecule 0.0027 0.2776 −1.3 200640_at NM_003406 YWHAZ tyrosine 3- 0.0023 0.1580 −1.3 monooxygenase/tryptophan 5- monooxygenase activation protein, zeta polypeptide 37384_at D86995 PPM1F protein 0.0244 0.7220 −1.3 phosphatase 1F (PP2C domain containing) 210678_s_at U56418 AGPAT2 1-acylglycerol-3- 0.0380 0.8549 −1.3 phosphate O- acyltransferase 2 (lysophosphatidic acid acyltransferase, beta) 218399_s_at NM_017955 CDCA4 cell division cycle 0.0012 0.5384 −1.3 associated 4 203201_at NM_000303 PMM2 phosphomannomutase 2 0.0020 0.4099 −1.3 212829_at BE878277 — CDNA FLJ13267 0.0007 0.0383 −1.3 fis, clone OVARC1000964 /// CDNA FLJ13267 fis, clone OVARC1000964 214119_s_at AI936769 FKBP1A FK506 binding 0.0045 0.0911 −1.3 protein 1A, 12 kDa 215696_s_at BC001404 KIAA0310 KIAA0310 0.0039 0.2613 −1.3 200020_at NM_007375 TARDBP TAR DNA binding 0.0031 0.1467 −1.3 protein /// TAR DNA binding protein 212723_at AK021780 PTDSR phosphatidylserine 0.0091 0.1709 −1.3 receptor 218890_x_at NM_016622 MRPL35 mitochondrial 0.0170 0.7931 −1.3 ribosomal protein L35 201577_at NM_000269 NME1 non-metastatic 0.0007 0.0699 −1.3 cells 1, protein (NM23A) expressed in 205740_s_at NM_024321 MGC10433 hypothetical 0.0094 0.3321 −1.3 protein MGC10433 221807_s_at BG399562 TRABD TraB domain 0.0359 0.5498 −1.3 containing 217947_at NM_017801 CMTM6 CKLF-like 0.0187 0.1774 −1.3 MARVEL transmembrane domain containing 6 202934_at AI761561 HK2 hexokinase 2 0.0265 0.1646 −1.3 214726_x_at AL556041 ADD1 adducin 1 (alpha) 0.0175 0.0771 −1.3 204328_at NM_007267 TMC6 transmembrane 0.0245 0.6147 −1.3 channel-like 6 47069_at AA533284 PRR5 proline rich 5 0.0045 0.0714 −1.3 (renal) 200830_at NM_002808 PSMD2 proteasome 0.0024 0.1174 −1.3 (prosome, macropain) 26S subunit, non- ATPase, 2 208858_s_at BC004998 FAM62A family with 0.0154 0.5500 −1.3 sequence similarity 62 (C2 domain containing), member A 218596_at NM_018201 TBC1D13 TBC1 domain 0.0433 0.2850 −1.3 family, member 13 212016_s_at AA679988 PTBP1 polypyrimidine 0.0124 0.0659 −1.3 tract binding protein 1 202870_s_at NM_001255 CDC20 cell division cycle 0.0117 0.1758 −1.3 20 homolog (S. cerevisiae) 209714_s_at AF213033 CDKN3 cyclin-dependent 0.0069 0.7689 −1.3 kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) 219051_x_at NM_024042 METRN meteorin, glial cell 0.0107 0.9563 −1.3 differentiation regulator 209365_s_at U65932 ECM1 extracellular matrix 0.0232 0.1288 −1.3 protein 1 202535_at NM_003824 FADD Fas (TNFRSF6)- 0.0366 0.8980 −1.3 associated via death domain 202836_s_at NM_006701 TXNL4A thioredoxin-like 0.0069 0.3942 −1.3 4A 217811_at NM_016275 SELT selenoprotein T 0.0314 0.2573 −1.3 211505_s_at AL136601 STAU1 staufen, RNA 0.0378 0.6525 −1.3 binding protein, homolog 1 (Drosophila) 203664_s_at NM_004805 POLR2D polymerase (RNA) 0.0204 0.3117 −1.3 II (DNA directed) polypeptide D 218291_at NM_014017 MAPBPIP mitogen-activated 0.0034 0.3392 −1.3 protein-binding protein-interacting protein 212858_at AL520675 PAQR4 progestin and 0.0060 0.2961 −1.3 adipoQ receptor family member IV 218391_at NM_007241 SNF8 SNF8, ESCRT-II 0.0056 0.3662 −1.3 complex subunit, homolog (S. cerevisiae) 201724_s_at NM_020474 GALNT1 UDP-N-acetyl- 0.0073 0.0441 −1.3 alpha-D- galactosamine:poly peptide N- acetylgalactosaminyltransferase 1 (GalNAc-T1) 200699_at BE962456 — Full-length cDNA 0.0042 0.6171 −1.3 clone CS0DC014YA20 of Neuroblastoma Cot 25-normalized of Homo sapiens (human) 221436_s_at NM_031299 CDCA3 cell division cycle 0.0140 0.1080 −1.3 associated 3 /// cell division cycle associated 3 204174_at NM_001629 ALOX5AP arachidonate 5- 0.0219 0.4380 −1.3 lipoxygenase- activating protein 212170_at BF447705 RBM12 RNA binding motif 0.0244 0.1083 −1.3 protein 12 217911_s_at NM_004281 BAG3 BCL2-associated 0.0428 0.7171 −1.3 athanogene 3 208445_s_at NM_023005 BAZ1B bromodomain 0.0085 0.7292 −1.3 adjacent to zinc finger domain, 1B 221692_s_at AB049652 MRPL34 mitochondrial 0.0399 0.4826 −1.3 ribosomal protein L34 /// mitochondrial ribosomal protein L34 218555_at NM_013366 ANAPC2 anaphase 0.0039 0.0274 −1.3 promoting complex subunit 2 219203_at NM_016049 C14orf122 chromosome 14 0.0005 0.0911 −1.3 open reading frame 122 220948_s_at NM_000701 ATP1A1 ATPase, Na+/K+ 0.0107 0.3441 −1.3 transporting, alpha 1 polypeptide 201376_s_at AI591354 HNRPF heterogeneous 0.0101 0.3926 −1.3 nuclear ribonucleoprotein F 204133_at NM_004704 RRP9 RRP9, small 0.0445 0.6616 −1.3 subunit (SSU) processome component, homolog (yeast) 201903_at NM_003365 UQCRC1 ubiquinol- 0.0085 0.2404 −1.3 cytochrome c reductase core protein I 205241_at NM_005138 SCO2 SCO cytochrome 0.0071 0.3412 −1.3 oxidase deficient homolog 2 (yeast) 200799_at NM_005345 HSPA1A heat shock 70 kDa 0.0253 0.0476 −1.3 protein 1A 218317_x_at NM_024044 GIYD2 /// GIY-YIG domain 0.0033 0.0441 −1.3 GIYD1 containing 2 /// GIY-YIG domain containing 1 209836_x_at AF060511 BOLA2 /// bolA homolog 2 0.0027 0.0592 −1.3 BOLA2B (E. coli) /// bolA homolog 2B (E. coli) 213244_at AI207792 SCAMP4 secretory carrier 0.0242 0.1143 −1.3 membrane protein 4 201662_s_at D89053 ACSL3 acyl-CoA 0.0245 0.9280 −1.3 synthetase long- chain family member 3 206554_x_at NM_006515 SETMAR SET domain and 0.0298 0.4143 −1.3 mariner transposase fusion gene 203925_at NM_002061 GCLM glutamate-cysteine 0.0146 0.1594 −1.3 ligase, modifier subunit 200707_at NM_002743 PRKCSH protein kinase C 0.0194 0.0567 −1.3 substrate 80K-H 201963_at NM_021122 ACSL1 acyl-CoA 0.0149 0.3605 −1.3 synthetase long- chain family member 1 207856_s_at NM_017951 SMPD4 /// sphingomyelin 0.0201 0.6155 −1.3 FLJ41352 phosphodiesterase 4, neutral membrane (neutral sphingomyelinase- 3) /// FLJ41352 protein 200875_s_at NM_006392 NOL5A nucleolar protein 0.0031 0.4776 −1.3 5A (56 kDa with KKE/D repeat) 202382_s_at NM_005471 GNPDA1 glucosamine-6- 0.0070 0.7544 −1.3 phosphate deaminase 1 203017_s_at R52678 SSX2IP synovial sarcoma, 0.0205 0.5419 −1.3 X breakpoint 2 interacting protein 208702_x_at AI525212 APLP2 amyloid beta (A4) 0.0122 0.2960 −1.3 precursor-like protein 2 201764_at NM_024056 TMEM106C transmembrane 0.0019 0.0834 −1.3 protein 106C 221521_s_at BC003186 GINS2 GINS complex 0.0045 0.2979 −1.3 subunit 2 (Psf2 homolog) 216971_s_at Z54367 PLEC1 plectin 1, 0.0037 0.0894 −1.3 intermediate filament binding protein 500 kDa 217893_s_at NM_024595 C1orf108 chromosome 1 0.0435 0.0434 −1.3 open reading frame 108 219709_x_at NM_023933 C16orf24 chromosome 16 0.0166 0.3879 −1.3 open reading frame 24 205401_at NM_003659 AGPS alkylglycerone 0.0355 0.3570 −1.3 phosphate synthase 209017_s_at U02389 LONP1 lon peptidase 1, 0.0368 0.7567 −1.3 mitochondrial 221815_at BE671816 ABHD2 abhydrolase 0.0233 0.7423 −1.3 domain containing 2 208972_s_at AL080089 ATP5G1 ATP synthase, H+ 0.0066 0.4128 −1.3 transporting, mitochondrial F0 complex, subunit C1 (subunit 9) 213052_at BF246917 PRKAR2A Protein kinase, 0.0180 0.8806 −1.3 cAMP-dependent, regulatory, type II, alpha 208676_s_at U87954 DLST /// dihydrolipoamide 0.0016 0.3528 −1.3 PA2G4 S- succinyltransferase (E2 component of 2-oxo-glutarate complex) /// proliferation- associated 2G4, 38 kDa 210672_s_at BC004185 C16orf35 chromosome 16 0.0151 0.2049 −1.3 open reading frame 35 204766_s_at NM_002452 NUDT1 nudix (nucleoside 0.0048 0.3257 −1.3 diphosphate linked moiety X)-type motif 1 208270_s_at NM_020216 RNPEP arginyl 0.0183 0.2672 −1.3 aminopeptidase (aminopeptidase B) 213937_s_at AV723177 FTSJ1 FtsJ homolog 1 (E. coli) 0.0436 0.9574 −1.3 209444_at BC001851 RAP1GDS1 RAP1, GTP-GDP 0.0280 0.4171 −1.3 dissociation stimulator 1 211071_s_at BC006471 MLLT11 myeloid/lymphoid 0.0021 0.0418 −1.3 or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 /// myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 200637_s_at AI762627 PTPRF protein tyrosine 0.0406 0.2980 −1.3 phosphatase, receptor type, F 202475_at NM_006326 TMEM147 transmembrane 0.0016 0.4204 −1.3 protein 147 221647_s_at AL136935 RIC8A resistance to 0.0132 0.5700 −1.3 inhibitors of cholinesterase 8 homolog A (C. elegans) 204169_at NM_000883 IMPDH1 IMP (inosine 0.0287 0.3633 −1.3 monophosphate) dehydrogenase 1 216969_s_at AC002301 KIF22 /// kinesin family 0.0355 0.0578 −1.3 LOC728037 member 22 /// similar to Kinesin- like protein KIF22 (Kinesin-like DNA-binding protein) (Kinesin- like protein 4) 202459_s_at U55968 LPIN2 lipin 2 0.0083 0.3844 −1.3 204306_s_at NM_004357 CD151 CD151 molecule 0.0015 0.0558 −1.3 (Raph blood group) 218550_s_at NM_018205 LRRC20 leucine rich repeat 0.0145 0.3547 −1.3 containing 20 201388_at NM_002809 PSMD3 proteasome 0.0015 0.0524 −1.3 (prosome, macropain) 26S subunit, non- ATPase, 3 212971_at AI769685 CARS cysteinyl-tRNA 0.0007 0.0665 −1.3 synthetase 200072_s_at AF061832 HNRPM heterogeneous 0.0049 0.2084 −1.3 nuclear ribonucleoprotein M /// heterogeneous nuclear ribonucleoprotein M 218420_s_at NM_025138 C13orf23 chromosome 13 0.0134 0.2363 −1.3 open reading frame 23 218408_at NM_012456 TIMM10 translocase of inner 0.0149 0.4352 −1.3 mitochondrial membrane 10 homolog (yeast) 217973_at NM_016286 DCXR dicarbonyl/L- 0.0025 0.0732 −1.3 xylulose reductase 204033_at NM_004237 TRIP13 thyroid hormone 0.0084 0.7000 −1.3 receptor interactor 13 217871_s_at NM_002415 MIF macrophage 0.0050 0.1736 −1.3 migration inhibitory factor (glycosylation- inhibiting factor) 201932_at NM_006369 LRRC41 leucine rich repeat 0.0294 0.5384 −1.3 containing 41 217923_at NM_012392 PEF1 penta-EF-hand 0.0170 0.2047 −1.3 domain containing 1 211595_s_at AB049944 MRPS11 mitochondrial 0.0027 0.2091 −1.3 ribosomal protein S11 /// mitochondrial ribosomal protein S11 213041_s_at BE798517 ATP5D ATP synthase, H+ 0.0053 0.2420 −1.3 transporting, mitochondrial F1 complex, delta subunit 212219_at D38521 PSME4 proteasome 0.0245 0.5016 −1.3 (prosome, macropain) activator subunit 4 200654_at J02783 P4HB /// procollagen- 0.0151 0.0856 −1.3 LOC728900 proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), beta polypeptide /// similar to prolyl 4- hydroxylase, beta subunit 219997_s_at NM_022730 COPS7B COP9 constitutive 0.0166 0.3902 −1.3 photomorphogenic homolog subunit 7B (Arabidopsis) 201014_s_at NM_006452 PAICS phosphoribosylaminoimidazole 0.0484 0.3181 −1.3 carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase 200954_at NM_001694 ATP6V0C ATPase, H+ 0.0248 0.1232 −1.3 transporting, lysosomal 16 kDa, V0 subunit c 219047_s_at NM_024706 ZNF668 zinc finger protein 0.0026 0.5284 −1.3 668 210125_s_at AF044773 BANF1 barrier to 0.0006 0.0721 −1.3 autointegration factor 1 205439_at NM_000854 GSTT2 glutathione S- 0.0203 0.3127 −1.3 transferase theta 2 218394_at NM_024589 ROGDI rogdi homolog 0.0020 0.0424 −1.3 (Drosophila) 217934_x_at NM_005861 STUB1 STIP1 homology 0.0049 0.2833 −1.3 and U-box containing protein 1 218141_at NM_022066 UBE2O ubiquitin- 0.0077 0.0895 −1.3 conjugating enzyme E2O 221575_at BC000586 SCLY selenocysteine 0.0435 0.4733 −1.3 lyase 218447_at NM_020188 C16orf61 chromosome 16 0.0336 0.1746 −1.3 open reading frame 61 212456_at AB014564 KIAA0664 KIAA0664 0.0143 0.8617 −1.3 202308_at NM_004176 SREBF1 sterol regulatory 0.0441 0.3563 −1.3 element binding transcription factor 1 217782_s_at NM_004127 GPS1 G protein pathway 0.0186 0.1542 −1.3 suppressor 1 208978_at U36190 CRIP2 cysteine-rich 0.0014 0.0604 −1.3 protein 2 212767_at BC004409 MTG1 mitochondrial 0.0015 0.0547 −1.3 GTPase 1 homolog (S. cerevisiae) 202236_s_at NM_003051 SLC16A1 solute carrier 0.0046 0.1925 −1.3 family 16, member 1 (monocarboxylic acid transporter 1) 222118_at AK023669 CENPN centromere protein N 0.0487 0.5572 −1.3 204027_s_at NM_005371 METTL1 methyltransferase 0.0329 0.3662 −1.3 like 1 204514_at NM_001384 DPH2 DPH2 homolog (S. cerevisiae) 0.0114 0.1875 −1.3 218565_at BG223334 C9orf114 chromosome 9 0.0037 0.0721 −1.3 open reading frame 114 202860_at NM_014856 DENND4B DENN/MADD 0.0043 0.0285 −1.3 domain containing 4B 205085_at NM_004153 ORC1L origin recognition 0.0423 0.8149 −1.3 complex, subunit 1-like (yeast) 209191_at BC002654 TUBB6 tubulin, beta 6 0.0018 0.6584 −1.3 213730_x_at BE962186 TCF3 transcription factor 0.0021 0.5366 −1.3 3 (E2A immunoglobulin enhancer binding factors E12/E47) 203612_at NM_004053 BYSL bystin-like 0.0126 0.6728 −1.3 219068_x_at NM_018188 ATAD3A ATPase family, 0.0127 0.3312 −1.3 AAA domain containing 3A 205444_at NM_004320 ATP2A1 ATPase, Ca++ 0.0427 0.1270 −1.3 transporting, cardiac muscle, fast twitch 1 204817_at NM_012291 ESPL1 extra spindle pole 0.0293 0.0418 −1.3 bodies homolog 1 (S. cerevisiae) 208973_at BC001072 PRNPIP prion protein 0.0077 0.3586 −1.3 interacting protein 202055_at AA652173 KPNA1 karyopherin alpha 0.0380 0.6914 −1.3 1 (importin alpha 5) 201853_s_at NM_021873 CDC25B cell division cycle 0.0043 0.1229 −1.3 25 homolog B (S. cerevisiae) 206200_s_at NM_001157 ANXA11 annexin A11 0.0055 0.2452 −1.3 209427_at AF064238 SMTN smoothelin 0.0020 0.0645 −1.3 216591_s_at AF080579 SDHC /// succinate 0.0270 0.4786 −1.3 LOC642502 dehydrogenase complex, subunit C, integral membrane protein, 15 kDa /// similar to succinate dehydrogenase complex, subunit C isoform 3 precursor 208827_at BC000835 PSMB6 proteasome 0.0049 0.3860 −1.3 (prosome, macropain) subunit, beta type, 6 201387_s_at NM_004181 UCHL1 ubiquitin carboxyl- 0.0307 0.1309 −1.3 terminal esterase L1 (ubiquitin thiolesterase) 203536_s_at NM_004804 CIAO1 cytosolic iron- 0.0491 0.4019 −1.3 sulfur protein assembly 1 homolog (S. cerevisiae) 218580_x_at NM_017900 AURKAIP1 aurora kinase A 0.0027 0.4766 −1.3 /// interacting protein LOC727877 1 /// similar to Cyclin-L2 (Paneth cell-enhanced expression protein) 212178_s_at AK022555 POM121 POM121 0.0119 0.0807 −1.3 /// membrane LOC340318 glycoprotein (rat) /// /// nuclear envelope LOC729316 pore membrane LOC340318 /// similar to Nuclear envelope pore membrane protein POM 121 (Pore membrane protein of 121 kDa) (P145) 212285_s_at AW008051 AGRIN agrin 0.0401 0.4488 −1.3 218902_at NM_017617 NOTCH1 Notch homolog 1, 0.0314 0.1325 −1.3 translocation- associated (Drosophila) 220547_s_at NM_019054 FAM35A family with 0.0297 0.1633 −1.3 sequence similarity 35, member A 216602_s_at AD000092 FARSLA phenylalanine- 0.0210 0.1596 −1.3 tRNA synthetase- like, alpha subunit 213358_at AB018345 KIAA0802 KIAA0802 /// 0.0039 0.2086 −1.3 /// chromosome 21 C21orf57 open reading frame 57 202370_s_at NM_001755 CBFB core-binding 0.0351 0.2187 −1.3 factor, beta subunit 200656_s_at NM_000918 P4HB procollagen- 0.0037 0.0558 −1.3 proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), beta polypeptide 212512_s_at AA551784 CARM1 coactivator- 0.0246 0.2430 −1.3 associated arginine methyltransferase 1 212796_s_at BF195608 TBC1D2B TBC1 domain 0.0233 0.4904 −1.3 family, member 2B 221434_s_at NM_031210 C14orf156 chromosome 14 0.0342 0.4605 −1.3 open reading frame 156 /// chromosome 14 open reading frame 156 220358_at NM_018664 SNFT Jun dimerization 0.0209 0.4938 −1.3 protein p21SNFT 203040_s_at NM_000190 HMBS hydroxymethylbilane 0.0077 0.4143 −1.3 synthase 221764_at AL574186 C19orf22 chromosome 19 0.0051 0.0735 −1.3 open reading frame 22 201155_s_at NM_014874 MFN2 mitofusin 2 0.0078 0.5620 −1.3 218492_s_at NM_030573 THAP7 THAP domain 0.0114 0.2235 −1.3 containing 7 208968_s_at BC002568 CIAPIN1 cytokine induced 0.0060 0.3329 −1.3 apoptosis inhibitor 1 211752_s_at BC005954 NDUFS7 NAPH 0.0491 0.3169 −1.3 dehydrogenase (ubiquinone) Fe—S protein 7, 20 kDa (NADH-coenzyme Q reductase) /// NAPH dehydrogenase (ubiquinone) Fe—S protein 7, 20 kDa (NADH-coenzyme Q reductase) 203423_at NM_002899 RBP1 retinol binding 0.0483 0.5702 −1.3 protein 1, cellular 219084_at NM_022455 NSD1 nuclear receptor 0.0310 0.2817 −1.3 binding SET domain protein 1 215159_s_at AI239732 NADK NAD kinase 0.0266 0.3031 −1.3 209413_at BC002431 B4GALT2 UDP- 0.0309 0.5550 −1.3 Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 205293_x_at AB017120 BAIAP2 BAI1-associated 0.0123 0.2614 −1.3 protein 2 202484_s_at AF072242 MBD2 methyl-CpG 0.0457 0.3651 −1.3 binding domain protein 2 214170_x_at AA669797 FH fumarate hydratase 0.0248 0.3513 −1.3 222216_s_at AK026857 MRPL17 mitochondrial 0.0011 0.0990 −1.3 ribosomal protein L17 209461_x_at BC001648 WDR18 WD repeat domain 0.0196 0.1327 −1.3 18 214141_x_at BF033354 SFRS7 splicing factor, 0.0046 0.0350 −1.3 arginine/serine-rich 7, 35 kDa 202927_at NM_006221 PIN1 protein 0.0059 0.2652 −1.3 (peptidylprolyl cis/trans isomerase) NIMA- interacting 1 201400_at NM_002795 PSMB3 proteasome 0.0045 0.1367 −1.3 (prosome, macropain) subunit, beta type, 3 202691_at NM_006938 SNRPD1 small nuclear 0.0014 0.0839 −1.3 ribonucleoprotein D1 polypeptide 16 kDa 205449_at NM_013299 SAC3D1 SAC3 domain 0.0253 0.3329 −1.3 containing 1 208679_s_at AF279893 ARPC2 actin related 0.0015 0.0811 −1.3 protein 2/3 complex, subunit 2, 34 kDa 36936_at U58766 TSTA3 tissue specific 0.0081 0.6356 −1.3 transplantation antigen P35B 209860_s_at J04543 ANXA7 annexin A7 0.0133 0.1925 −1.3 200730_s_at BF576710 PTP4A1 protein tyrosine 0.0038 0.0899 −1.3 phosphatase type IVA, member 1 217118_s_at AK025608 C22orf9 chromosome 22 0.0147 0.2509 −1.3 open reading frame 9 211926_s_at AI827941 MYH9 myosin, heavy 0.0177 0.1399 −1.3 chain 9, non- muscle 202578_s_at NM_018332 DDX19A DEAD (Asp-Glu- 0.0307 0.5964 −1.3 Ala-As) box polypeptide 19A 33307_at AL022316 CTA- CGI-96 protein 0.0138 0.4373 −1.3 126B4.3 204612_at NM_006823 PKIA protein kinase 0.0429 0.6572 −1.3 (cAMP-dependent, catalytic) inhibitor alpha 208541_x_at NM_012251 TFAM transcription factor 0.0101 0.1028 −1.3 A, mitochondrial 209219_at L03411 RDBP RD RNA binding 0.0081 0.4823 −1.3 protein 200687_s_at NM_012426 SF3B3 splicing factor 3b, 0.0053 0.1142 −1.3 subunit 3, 130 kDa 209080_x_at AF118652 TXNL2 thioredoxin-like 2 0.0060 0.3555 −1.3 202415_s_at NM_012267 HSPBP1 hsp70-interacting 0.0110 0.1066 −1.3 protein 210527_x_at L11645 TUBA2 tubulin, alpha 2 0.0299 0.5806 −1.3 213944_x_at BG236220 NCLN Nicalin homolog 0.0265 0.9908 −1.3 (zebrafish) 216080_s_at AC004770 FADS3 fatty acid 0.0429 0.6339 −1.3 desaturase 3 214679_x_at AL110227 GNA11 guanine nucleotide 0.0066 0.0675 −1.3 binding protein (G protein), alpha 11 (Gq class) 218632_at NM_024602 HECTD3 HECT domain 0.0079 0.0819 −1.3 containing 3 203410_at NM_006803 AP3M2 adaptor-related 0.0084 0.6490 −1.3 protein complex 3, mu 2 subunit 212714_at AL050205 LARP4 La 0.0259 0.5696 −1.3 ribonucleoprotein domain family, member 4 203733_at NM_014015 DEXI dexamethasone- 0.0096 0.0775 −1.3 induced transcript 204599_s_at NM_006428 MRPL28 mitochondrial 0.0235 0.7391 −1.3 ribosomal protein L28 213793_s_at BE550452 HOMER1 homer homolog 1 0.0186 0.0395 −1.3 (Drosophila) 218331_s_at NM_017782 C10orf18 chromosome 10 0.0356 0.2221 −1.3 open reading frame 18 204241_at BF055171 ACOX3 acyl-Coenzyme A 0.0303 0.3147 −1.2 oxidase 3, pristanoyl 212165_at AF070537 TMEM183A transmembrane 0.0012 0.2139 −1.2 protein 183A 202296_s_at NM_007033 RER1 RER1 retention in 0.0061 0.7824 −1.2 endoplasmic reticulum 1 homolog (S. cerevisiae) 201481_s_at NM_002862 PYGB phosphorylase, 0.0064 0.1309 −1.2 glycogen; brain 34868_at AB029012 SMG5 Smg-5 homolog, 0.0054 0.3627 −1.2 nonsense mediated mRNA decay factor (C. elegans) 212564_at AA523921 KCTD2 potassium channel 0.0215 0.0579 −1.2 tetramerisation domain containing 2 204117_at NM_002726 PREP prolyl 0.0277 0.4656 −1.2 endopeptidase 211052_s_at BC006364 TBCD tubulin folding 0.0091 0.0783 −1.2 cofactor D /// tubulin folding cofactor D 202440_s_at NM_005418 ST5 suppression of 0.0080 0.0861 −1.2 tumorigenicity 5 202670_at AI571419 MAP2K1 mitogen-activated 0.0255 0.3612 −1.2 protein kinase kinase 1 203452_at NM_012200 B3GAT3 beta-1,3- 0.0172 0.0662 −1.2 glucuronyltransferase 3 (glucuronosyltranserase I) 200837_at NM_005745 BCAP31 B-cell receptor- 0.0100 0.4385 −1.2 associated protein 31 219611_s_at NM_022778 CCDC21 coiled-coil domain 0.0094 0.0843 −1.2 containing 21 213535_s_at AA910614 UBE2I ubiquitin- 0.0011 0.1305 −1.2 conjugating enzyme E2I (UBC9 homolog, yeast) 200852_x_at NM_005273 GNB2 guanine nucleotide 0.0007 0.0274 −1.2 binding protein (G protein), beta polypeptide 2 201578_at NM_005397 PODXL podocalyxin-like 0.0269 0.7420 −1.2 212696_s_at BF968633 RNF4 ring finger protein 4 0.0135 0.5482 −1.2 210869_s_at M29277 MCAM melanoma cell 0.0197 0.3612 −1.2 adhesion molecule 217787_s_at AL525086 GALNT2 UDP-N-acetyl- 0.0500 0.1670 −1.2 alpha-D- galactosamine:poly peptide N- acetylgalactosaminyltransferase 2 (GalNAc-T2) 200774_at BE963765 FAM120A family with 0.0219 0.2718 −1.2 sequence similarity 120A 211037_s_at BC006309 LENG4 leukocyte receptor 0.0266 0.1880 −1.2 cluster (LRC) member 4 /// leukocyte receptor cluster (LRC) member 4 204976_s_at AK023637 AMMECR1 Alport syndrome, 0.0193 0.3064 −1.2 mental retardation, midface hypoplasia and elliptocytosis chromosomal region, gene 1 212978_at AU146004 LRRC8B Leucine rich repeat 0.0233 0.0532 −1.2 containing 8 family, member B 218058_at NM_014593 CXXC1 CXXC finger 1 0.0304 0.1699 −1.2 (PHD domain) 212861_at BF690150 MFSD5 major facilitator 0.0294 0.2091 −1.2 superfamily domain containing 5 218112_at NM_023936 MRPS34 mitochondrial 0.0079 0.5000 −1.2 ribosomal protein S34 221828_s_at AK024432 FAM125B family with 0.0057 0.1233 −1.2 sequence similarity 125, member B 201397_at NM_006623 PHGDH phosphoglycerate 0.0026 0.0935 −1.2 dehydrogenase 202039_at NM_004740 TIAF1 /// TGFB1-induced 0.0138 0.5359 −1.2 MYO18A anti-apoptotic factor 1 /// myosin XVIIIA 204518_s_at NM_000943 PPIC peptidylprolyl 0.0138 0.6379 −1.2 isomerase C (cyclophilin C) 211804_s_at AB012305 CDK2 /// cyclin-dependent 0.0372 0.1019 −1.2 BCDO2 kinase 2 /// beta- carotene dioxygenase 2 208767_s_at AW149681 LAPTM4B lysosomal 0.0287 0.7180 −1.2 associated protein transmembrane 4 beta 201912_s_at NM_002094 GSPT1 G1 to S phase 0.0415 0.9318 −1.2 transition 1 /// G1 to S phase transition 1 201272_at NM_001628 AKR1B1 aldo-keto reductase 0.0052 0.0958 −1.2 family 1, member B1 (aldose reductase) 201144_s_at NM_004094 EIF2S1 eukaryotic 0.0018 0.0260 −1.2 translation initiation factor 2, subunit 1 alpha, 35 kDa 208999_at D86957 8-Sep septin 8 0.0370 0.3680 −1.2 202848_s_at BG423052 GRK6 G protein-coupled 0.0124 0.2148 −1.2 receptor kinase 6 218653_at NM_014252 SLC25A15 solute carrier 0.0290 0.9035 −1.2 family 25 (mitochondrial carrier; ornithine transporter) member 15 202640_s_at NM_003624 RANBP3 RAN binding 0.0202 0.3932 −1.2 protein 3 201559_s_at AF109196 CLIC4 chloride 0.0481 0.5454 −1.2 intracellular channel 4 201414_s_at NM_005969 NAP1L4 nucleosome 0.0127 0.0843 −1.2 assembly protein 1- like 4 200790_at NM_002539 ODC1 ornithine 0.0076 0.7147 −1.2 decarboxylase 1 219076_s_at NM_018663 PXMP2 peroxisomal 0.0101 0.0783 −1.2 membrane protein 2, 22 kDa 204123_at NM_013975 LIG3 ligase III, DNA, 0.0209 0.5066 −1.2 ATP-dependent 209208_at AF059752 MPDU1 mannose-P- 0.0105 0.1514 −1.2 dolichol utilization defect 1 202348_s_at BC000674 TOR1A torsin family 1, 0.0155 0.9365 −1.2 member A (torsin A) 212115_at AK023154 HN1L hematological and 0.0039 0.8034 −1.2 neurological expressed 1-like 201851_at NM_003025 SH3GL1 SH3-domain 0.0389 0.8279 −1.2 GRB2-like 1 211714_x_at BC005838 TUBB tubulin, beta /// 0.0210 0.4381 −1.2 tubulin, beta 209094_at AL078459 DDAH1 dimethylarginine 0.0015 0.0447 −1.2 dimethylaminohydrolase 1 201715_s_at NM_014977 ACIN1 apoptotic 0.0426 0.1405 −1.2 chromatin condensation inducer 1 218774_at NM_014026 DCPS decapping enzyme, 0.0055 0.0571 −1.2 scavenger 218629_at NM_005631 SMO smoothened 0.0234 0.1969 −1.2 homolog (Drosophila) 218016_s_at NM_018119 POLR3E polymerase (RNA) 0.0244 0.4851 −1.2 III (DNA directed) polypeptide E (80 kD) 218741_at NM_024053 CENPM centromere protein M 0.0144 0.4422 −1.2 218586_at NM_018270 C20orf20 chromosome 20 0.0036 0.3145 −1.2 open reading frame 20 219260_s_at NM_015362 C17orf81 chromosome 17 0.0105 0.2294 −1.2 open reading frame 81 220094_s_at NM_022102 CCDC90A coiled-coil domain 0.0461 0.2205 −1.2 containing 90A 208831_x_at D79984 SUPT6H suppressor of Ty 6 0.0222 0.1216 −1.2 homolog (S. cerevisiae) 214828_s_at AL157851 dJ222E13.2 similar to CGI-96 0.0105 0.1409 −1.2 209014_at AF217963 MAGED1 melanoma antigen 0.0008 0.0299 −1.2 family D, 1 212766_s_at AW294587 ISG20L2 interferon 0.0111 0.8419 −1.2 stimulated exonuclease gene 20 kDa-like 2 204266_s_at NM_001277 CHKA /// choline kinase 0.0249 0.3418 −1.2 LOC650122 alpha /// similar to choline kinase alpha isoform a 214869_x_at AK021533 GAPVD1 GTPase activating 0.0205 0.7717 −1.2 protein and VPS9 domains 1 221877_at BF508835 — CDNA FLJ38849 0.0086 0.5431 −1.2 fis, clone MESAN2008936 200697_at NM_000188 HK1 hexokinase 1 0.0416 0.6041 −1.2 211750_x_at BC005946 TUBA6 tubulin, alpha 6 /// 0.0011 0.0549 −1.2 tubulin, alpha 6 201587_s_at NM_001569 IRAK1 interleukin-1 0.0035 0.2935 −1.2 receptor-associated kinase 1 209663_s_at AF072132 ITGA7 integrin, alpha 7 0.0417 0.0631 −1.2 221247_s_at NM_030798 WBSCR16 Williams-Beuren 0.0295 0.1278 −1.2 syndrome chromosome region 16 /// Williams-Beuren syndrome chromosome region 16 201271_s_at NM_016732 RALY RNA binding 0.0275 0.2379 −1.2 protein, autoantigenic (hnRNP-associated with lethal yellow homolog (mouse)) 217754_at NM_019082 DDX56 DEAD (Asp-Glu- 0.0050 0.1143 −1.2 Ala-Asp) box polypeptide 56 217838_s_at NM_016337 EVL Enah/Vasp-like 0.0362 0.0971 −1.2 200762_at NM_001386 DPYSL2 dihydropyrimidinase- 0.0078 0.2899 −1.2 like 2 218156_s_at NM_018128 TSR1 TSR1, 20S rRNA 0.0411 0.6879 −1.2 accumulation, homolog (S. cerevisiae) 219420_s_at NM_023077 C1orf163 chromosome 1 0.0357 0.0712 −1.2 open reading frame 163 202945_at NM_004957 FPGS folylpolyglutamate 0.0044 0.0987 −1.2 synthase 203795_s_at NM_020993 BCL7A B-cell 0.0366 0.0812 −1.2 CLL/lymphoma 7A 203550_s_at NM_006589 C1orf2 chromosome 1 0.0123 0.4067 −1.2 open reading frame 2 220244_at NM_013343 LOH3CR2A loss of 0.0430 0.3328 −1.2 heterozygosity, 3, chromosomal region 2, gene A 201135_at NM_004092 ECHS1 enoyl Coenzyme A 0.0051 0.1455 −1.2 hydratase, short chain, 1, mitochondrial 218099_at NM_018469 TEX2 testis expressed 0.0413 0.2203 −1.2 sequence 2 214501_s_at AF044286 TLR4 /// toll-like receptor 4 0.0108 0.4608 −1.2 H2AFY /// H2A histone family, member Y 217729_s_at NM_001130 AES amino-terminal 0.0049 0.0782 −1.2 enhancer of split 212871_at NM_003668 MAPKAPK5 mitogen-activated 0.0160 0.1840 −1.2 protein kinase- activated protein kinase 5 219496_at NM_023016 ANKRD57 ankyrin repeat 0.0463 0.1807 −1.2 domain 57 219330_at NM_024062 VANGL1 vang-like 1 (van 0.0128 0.1514 −1.2 gogh, Drosophila) 219806_s_at NM_020179 C11orf75 chromosome 11 0.0311 0.2261 −1.2 open reading frame 75 201460_at AI141802 MAPKAPK2 mitogen-activated 0.0147 0.5934 −1.2 protein kinase- activated protein kinase 2 201763_s_at NM_001350 DAXX death-associated 0.0012 0.0157 −1.2 protein 6 211432_s_at U05682 TYRO3 TYRO3 protein 0.0329 0.2586 −1.2 tyrosine kinase 204493_at NM_001196 BID BH3 interacting 0.0129 0.1146 −1.2 domain death agonist 221267_s_at NM_031213 FAM108A1 family with 0.0178 0.3019 −1.2 sequence similarity 108, member A1 /// family with sequence similarity 108, member A1 212333_at AL049943 FAM98A family with 0.0206 0.0310 −1.2 sequence similarity 98, member A 206633_at NM_000079 CHRNA1 cholinergic 0.0127 0.2332 −1.2 receptor, nicotinic, alpha 1 (muscle) 201841_s_at NM_001540 HSPB1 /// heat shock 27 kDa 0.0034 0.2235 −1.2 MEIS3 protein 1 /// Meis1, myeloid ecotropic viral integration site 1 homolog 3 (mouse) 204044_at NM_014298 QPRT quinolinate 0.0416 0.8129 −1.2 phosphoribosyltransferase (nicotinate- nucleotide pyrophosphorylase (carboxylating)) 210011_s_at BC000527 EWSR1 Ewing sarcoma 0.0070 0.0721 −1.2 breakpoint region 1 218898_at NM_024792 FAM57A family with 0.0471 0.7205 −1.2 sequence similarity 57, member A 202518_at NM_001707 BCL7B B-cell 0.0264 0.2789 −1.2 CLL/lymphoma 7B 202069_s_at AI826060 IDH3A isocitrate 0.0224 0.4380 −1.2 dehydrogenase 3 (NAD+) alpha 220258_s_at NM_018081 WDR79 WD repeat domain 0.0225 0.2213 −1.2 79 201194_at NM_003009 SEPW1 selenoprotein W, 1 0.0162 0.1636 −1.2 201792_at NM_001129 AEBP1 AE binding protein 1 0.0193 0.1129 −1.2 204126_s_at NM_003504 CDC45L CDC45 cell 0.0253 0.5416 −1.2 division cycle 45- like (S. cerevisiae) 218961_s_at NM_007254 PNKP polynucleotide 0.0225 0.1313 −1.2 kinase 3′- phosphatase 209044_x_at BC004273 SF3B4 splicing factor 3b, 0.0014 0.3838 −1.2 subunit 4, 49 kDa 210415_s_at AF053970 ODF2 outer dense fiber of 0.0260 0.5497 −1.2 sperm tails 2 203210_s_at NM_007370 RFC5 replication factor C 0.0375 0.1357 −1.2 (activator 1) 5, 36.5 kDa 212271_at AA195999 MAPK1 mitogen-activated 0.0470 0.6623 −1.2 protein kinase 1 208696_at AF275798 CCT5 chaperonin 0.0242 0.9588 −1.2 containing TCP1, subunit 5 (epsilon) 218365_s_at AI765051 DARS2 aspartyl-tRNA 0.0157 0.2829 −1.2 synthetase 2 (mitochondrial) 218848_at NM_024339 THOC6 THO complex 6 0.0396 0.4185 −1.2 homolog (Drosophila) 218542_at NM_018131 CEP55 centrosomal 0.0061 0.5899 −1.2 protein 55 kDa 206845_s_at NM_014771 RNF40 ring finger protein 0.0244 0.1693 −1.2 40 202592_at NM_001487 BLOC1S1 biogenesis of 0.0112 0.6525 −1.2 lysosome-related organelles complex-1, subunit 1 218566_s_at NM_012124 CHORDC1 cysteine and 0.0484 0.3010 −1.2 histidine-rich domain (CHORD)- containing 1 200691_s_at BC000478 HSPA9 heat shock 70 kDa 0.0155 0.4830 −1.2 protein 9 (mortalin) 218187_s_at NM_023080 C8orf33 chromosome 8 0.0483 0.5066 −1.2 open reading frame 33 218120_s_at D21243 HMOX2 heme oxygenase 0.0440 0.6657 −1.2 (decycling) 2 221737_at AK024696 GNA12 guanine nucleotide 0.0258 0.4334 −1.2 binding protein (G protein) alpha 12 202828_s_at NM_004995 MMP14 matrix 0.0202 0.5070 −1.2 metallopeptidase 14 (membrane- inserted) 201357_s_at NM_005877 SF3A1 splicing factor 3a, 0.0267 0.0877 −1.2 subunit 1, 120 kDa 213696_s_at AA421957 MED8 mediator of RNA 0.0487 0.2629 −1.2 polymerase II transcription, subunit 8 homolog (S. cerevisiae) 204928_s_at NM_019848 SLC10A3 solute carrier 0.0039 0.2235 −1.2 family 10 (sodium/bile acid cotransporter family), member 3 217932_at NM_015971 MRPS7 mitochondrial 0.0014 0.1160 −1.2 ribosomal protein S7 201263_at NM_003191 TARS threonyl-tRNA 0.0302 0.0907 −1.2 synthetase 207121_s_at NM_002748 MAPK6 mitogen-activated 0.0064 0.1007 −1.2 protein kinase 6 217221_x_at AL137421 RBM10 RNA binding motif 0.0188 0.0866 −1.2 protein 10 202816_s_at AW292882 SS18 synovial sarcoma 0.0084 0.0541 −1.2 translocation, chromosome 18 1861_at U66879 BAD BCL2-antagonist 0.0380 0.5209 −1.2 of cell death 202108_at NM_000285 PEPD peptidase D 0.0178 0.2205 −1.2 204993_at NM_002073 GNAZ guanine nucleotide 0.0293 0.4344 −1.2 binding protein (G protein), alpha z polypeptide 201229_s_at BC000422 ARIH2 ariadne homolog 2 0.0395 0.3941 −1.2 (Drosophila) 213812_s_at AK024748 CAMKK2 calcium/calmodulin- 0.0294 0.3375 −1.2 dependent protein kinase kinase 2, beta 201298_s_at BC003398 MOBK1B MOB1, Mps One 0.0077 0.0700 −1.2 Binder kinase activator-like 1B (yeast) 213270_at AW450911 MPP2 membrane protein, 0.0039 0.0933 −1.2 palmitoylated 2 (MAGUK p55 subfamily member 2) 220688_s_at NM_016183 MRT4 mRNA turnover 4 0.0046 0.0441 −1.2 homolog (S. cerevisiae) 51176_at AA131335 CRSP8 cofactor required 0.0015 0.2747 −1.2 for Sp1 transcriptional activation, subunit 8, 34 kDa 201761_at NM_006636 MTHFD2 methylenetetrahydrofolate 0.0124 0.6250 −1.2 dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase 208682_s_at AF126181 MAGED2 melanoma antigen 0.0172 0.3256 −1.2 family D, 2 41160_at AC005943 MBD3 methyl-CpG 0.0031 0.0383 −1.2 binding domain protein 3 205661_s_at NM_025207 FLAD1 FAD1 flavin 0.0063 0.8074 −1.2 adenine dinucleotide synthetase homolog (S. cerevisiae) 208821_at J04564 SNRPB small nuclear 0.0050 0.0642 −1.2 ribonucleoprotein polypeptides B and B1 201303_at NM_014740 EIF4A3 eukaryotic 0.0079 0.9084 −1.2 translation initiation factor 4A, isoform 3 209581_at BC001387 HRASLS3 HRAS-like 0.0335 0.1759 −1.2 suppressor 3 48531_at AA522816 TNIP2 TNFAIP3 0.0131 0.4345 −1.2 interacting protein 2 201697_s_at NM_001379 DNMT1 DNA (cytosine-5-)- 0.0193 0.1580 −1.2 methyltransferase 1 218019_s_at NM_021941 PDXK pyridoxal 0.0044 0.0638 −1.2 (pyridoxine, vitamin B6) kinase 202338_at NM_003258 TK1 thymidine kinase 1, 0.0295 0.0858 −1.2 soluble 216232_s_at AI697055 GCN1L1 GCN1 general 0.0066 0.1082 −1.2 control of amino- acid synthesis 1- like 1 (yeast) 212250_at AV700332 MTDH metadherin 0.0380 0.1082 −1.2 214771_x_at AK025604 M-RIP myosin 0.0146 0.3146 −1.2 phosphatase-Rho interacting protein 200683_s_at BE964689 UBE2L3 ubiquitin- 0.0214 0.9367 −1.2 conjugating enzyme E2L 3 208152_s_at NM_004728 DDX21 DEAD (Asp-Glu- 0.0325 0.1335 −1.2 Ala-Asp) box polypeptide 21 /// DEAD (Asp-Glu- Ala-Asp) box polypeptide 21 203828_s_at NM_004221 IL32 interleukin 32 /// 0.0114 0.0452 −1.2 interleukin 32 208777_s_at AF001212 PSMD11 proteasome 0.0066 0.2440 −1.2 (prosome, macropain) 26S subunit, non- ATPase, 11 219862_s_at NM_012336 NARF nuclear prelamin A 0.0278 0.9051 −1.2 recognition factor 203827_at NM_017983 WIPI1 WD repeat domain, 0.0081 0.4544 −1.2 phosphoinositide interacting 1 219491_at NM_024036 LRFN4 leucine rich repeat 0.0160 0.3821 −1.2 and fibronectin type III domain containing 4 202115_s_at NM_015658 NOC2L nucleolar complex 0.0326 0.6859 −1.2 associated 2 homolog (S. cerevisiae) 212098_at AL134724 LOC151162 hypothetical 0.0094 0.4141 −1.2 protein LOC151162 203570_at NM_005576 LOXL1 lysyl oxidase-like 1 0.0023 0.0499 −1.2 210213_s_at AF022229 ITGB4BP integrin beta 4 0.0097 0.2297 −1.2 binding protein 32836_at U56417 AGPAT1 1-acylglycerol-3- 0.0161 0.0474 −1.2 phosphate O- acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) 201284_s_at NM_001640 APEH N-acylaminoacyl- 0.0120 0.0383 −1.2 peptide hydrolase 208689_s_at BC003560 RPN2 ribophorin II 0.0060 0.0452 −1.2 201307_at AL534972 11-Sep septin 11 0.0200 0.7860 −1.2 202757_at NM_015456 COBRA1 cofactor of BRCA1 0.0030 0.0278 −1.2 212480_at AB002374 SPECC1L SPECC1-like 0.0411 0.1914 −1.2 203233_at NM_000418 IL4R interleukin 4 0.0148 0.4358 −1.2 receptor 211630_s_at L42531 GSS glutathione 0.0411 0.1844 −1.2 synthetase /// glutathione synthetase 212400_at AL043266 FAM102A family with 0.0194 0.2054 −1.2 sequence similarity 102, member A 221704_s_at BC005882 VPS37B vacuolar protein 0.0045 0.6051 −1.2 sorting 37 homolog B (S. cerevisiae) /// vacuolar protein sorting 37 homolog B (S. cerevisiae) 209452_s_at AF035824 VTI1B vesicle transport 0.0357 0.4069 −1.2 through interaction with t-SNAREs homolog 1B (yeast) 218758_s_at NM_003683 D21S2056E DNA segment on 0.0362 0.3701 −1.2 chromosome 21 (unique) 2056 expressed sequence 201361_at NM_024092 TMEM109 transmembrane 0.0256 0.2193 −1.2 protein 109 209323_at AF081567 PRKRIR protein-kinase, 0.0063 0.0537 −1.2 interferon- inducible double stranded RNA dependent inhibitor, repressor of (P58 repressor) 204080_at NM_025077 TOE1 target of EGR1, 0.0179 0.7025 −1.2 member 1 (nuclear) 200708_at NM_002080 GOT2 glutamic- 0.0021 0.6983 −1.2 oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) 220155_s_at NM_023924 BRD9 bromodomain 0.0014 0.0804 −1.2 containing 9 211456_x_at AF333388 LOC645745 metallothionein 0.0037 0.0589 −1.2 1H-like protein 218460_at NM_017802 HEATR2 HEAT repeat 0.0180 0.7292 −1.2 containing 2 200793_s_at NM_001098 ACO2 aconitase 2, 0.0358 0.1897 −1.2 mitochondrial 203149_at NM_002856 PVRL2 poliovirus 0.0356 0.5506 −1.2 receptor-related 2 (herpesvirus entry mediator B) 201066_at NM_001916 CYC1 cytochrome c-1 0.0069 0.7513 −1.2 207707_s_at NM_030673 SEC13 SEC13 homolog 0.0025 0.4694 −1.2 (S. cerevisiae) 205351_at NM_000821 GGCX gamma-glutamyl 0.0093 0.8819 −1.2 carboxylase 214437_s_at NM_005412 SHMT2 serine 0.0054 0.2573 −1.2 hydroxymethyltransferase 2 (mitochondrial) 208863_s_at M72709 SFRS1 splicing factor, 0.0136 0.1920 −1.2 arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) 209501_at AL582414 CDR2 cerebellar 0.0186 0.1069 −1.2 degeneration- related protein 2, 62 kDa 206809_s_at NM_005758 HNRPA3P1 heterogeneous 0.0275 0.1782 −1.2 /// nuclear HNRPA3 ribonucleoprotein A3 pseudogene 1 /// heterogeneous nuclear ribonucleoprotein A3 205055_at NM_002208 ITGAE integrin, alpha E 0.0225 0.0929 −1.2 (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) 216977_x_at AJ130972 SNRPA1 small nuclear 0.0159 0.2202 −1.2 ribonucleoprotein polypeptide A′ 35617_at U29725 MAPK7 mitogen-activated 0.0203 0.2536 −1.2 protein kinase 7 205546_s_at NM_003331 TYK2 tyrosine kinase 2 0.0369 0.1604 −1.2 212953_x_at BE251303 CALR calreticulin 0.0294 0.1004 −1.2 211168_s_at D86988 UPF1 UPF1 regulator of 0.0155 0.0625 −1.2 nonsense transcripts homolog (yeast) 210046_s_at U52144 IDH2 isocitrate 0.0035 0.0383 −1.2 dehydrogenase 2 (NADP+), mitochondrial 219933_at NM_016066 GLRX2 glutaredoxin 2 0.0255 0.1890 −1.2 219081_at NM_024668 ANKHD1 ankyrin repeat and 0.0196 0.4240 −1.2 KH domain containing 1 200614_at NM_004859 CLTC clathrin, heavy 0.0237 0.4039 −1.2 chain (Hc) 209394_at BC002508 ASMTL acetylserotonin O- 0.0416 0.4632 −1.2 methyltransferase- like 49077_at AL040538 PPME1 protein 0.0049 0.8306 −1.2 phosphatase methylesterase 1 217933_s_at NM_015907 LAP3 leucine 0.0034 0.0252 −1.2 aminopeptidase 3 215411_s_at AL008730 TRAF3IP2 TRAF3 interacting 0.0099 0.0383 −1.2 protein 2 221904_at AI141670 C3orf40 chromosome 3 0.0459 0.2865 −1.2 open reading frame 40 206445_s_at NM_001536 PRMT1 protein arginine 0.0019 0.0740 −1.2 methyltransferase 1 207071_s_at NM_002197 ACO1 /// aconitase 1, soluble 0.0173 0.8523 −1.2 ANKRD15 /// ankyrin repeat domain 15 213205_s_at AU159543 RAD54L2 RAD54-like 2 (S. cerevisiae) 0.0124 0.1547 −1.2 207614_s_at NM_003592 CUL1 cullin 1 0.0268 0.9630 −1.2 208712_at M73554 CCND1 cyclin D1 0.0440 0.1233 −1.2 205224_at NM_017503 SURF2 surfeit 2 0.0311 0.9687 −1.2 202655_at NM_006010 ARMET arginine-rich, 0.0067 0.2238 −1.2 mutated in early stage tumors 201463_s_at NM_006755 TALDO1 transaldolase 1 0.0043 0.6019 −1.2 205588_s_at NM_007045 FGFR1OP FGFR1 oncogene 0.0246 0.0856 −1.2 /// C9orf4 partner /// chromosome 9 open reading frame 4 203746_s_at NM_005333 HCCS holocytochrome c 0.0080 0.3313 −1.2 synthase (cytochrome c heme-lyase) 202240_at NM_005030 PLK1 polo-like kinase 1 0.0224 0.0274 −1.2 (Drosophila) 207939_x_at NM_006711 RNPS1 RNA binding 0.0112 0.2149 −1.2 protein S1, serine- rich domain 202991_at NM_006804 STARD3 START domain 0.0198 0.5816 −1.2 containing 3 218337_at NM_022749 RAI16 retinoic acid 0.0370 0.4464 −1.2 induced 16 210821_x_at BC002703 CENPA centromere protein A 0.0221 0.0915 −1.2 200853_at NM_002106 H2AFZ H2A histone 0.0135 0.7942 −1.2 family, member Z 209464_at AB011446 AURKB aurora kinase B 0.0121 0.0981 −1.2 Cells were treated with 0.35 μM compound 1 for 6, 36 and 72 hours before harvest and subject to Affymetrix gene microarray analysis. Each sample was run in duplicates. A two-way ANOVA mixed model: (Intensity ~ Treatment + Time + Treatment × Time + Error) was utilized to identify drug treatment effect as well as treatment and time interaction on the expression of genes. The genes identified as modulated by the drug are those with FDR p value < 0.05 in either the Treatment effect or Treatment × Time interaction and the fold change between treatment group and DMSO control group is greater than 1.2 fold or less than −1.2 fold and total of 2056 probe sets were selected and only 1697 representative unique genes are listed in this Table with redundant probe sets removed.

TABLE 7 Proteins modulated by compound 1 treatment in Rh41 cells. International Protein Peptide FirstOfdescription Index Swiss-protein ID AFTGREFDELNPSAQR SWISS-PROT: P16615-1 IPI00219078.1 P16615-1 (SEQ ID NO: 146) REFSEQ_NP: NP_733765 ENSEMBL: ENSP00000324892 Tax_Id = 9606 Splice isoform SERCA2B of P16615 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 AHEGEIEDLALGPDGK REFSEQ_NP: NP_037520 IPI00033349.1 LVTVGR TREMBL: Q9UH94 (SEQ ID NO: 147) ENSEMBL: ENSP00000260643 Tax_Id = 9606 Prolactin regulatory element-binding protein AHIAQLCEK SWISS-PROT: Q00610 IPI00024067.1 Q00610 (SEQ ID NO: 148) REFSEQ_NP: NP_004850 ENSEMBL: ENSP00000269122 Tax_Id = 9606 Clathrin heavy chain 1 AITGASLADIMAK SWISS-PROT: P38663 IPI00220397.1 P38663 (SEQ ID NO: 149) REFSEQ_NP: NP_000977 ENSEMBL: ENSP00000265264 Tax_Id = 9606 60S ribosomal protein L24 ALGTEVIQLFPEK SWISS-PROT: O95831-2 IPI00186214.1 O95831-2 (SEQ ID NO: 150) REFSEQ_NP: NP_665812 ENSEMBL: ENSP00000316320 Tax_Id = 9606 Splice isoform 2 of O95831 Programmed cell death protein 8 mitochondrial precursor ALMAAEDK TREMBL: Q9Y427; Q07414 IPI00000230.1 Q9Y427; Q07414 (SEQ ID NO: 151) ENSEMBL: ENSP00000267996 Tax_Id = 9606 Hypothetical protein AMINLHIQK SWISS-PROT: Q9NZ45 IPI00020510.1 Q9NZ45 (SEQ ID NO: 152) REFSEQ_NP: NP_060934 ENSEMBL: ENSP00000242476 Tax_Id = 9606 Uncharacterized hematopoietic stem/progenitor cells protein MDS029 Uncharacterized hematopoietic stem/progenitor cells protein MDS029 AQSEAEKLAKERQEAE SWISS-PROT: P35240-7 IPI00220313.1 P35240-7 EAKEALLQASR ENSEMBL: ENSP00000314630 (SEQ ID NO: 153) Tax_Id = 9606 Splice isoform 7 of P35240 Merlin ASGDSARPVLLQVAES SWISS-PROT: Q9UJS0 IPI00007084.1 Q9UJS0 AYR REFSEQ_NP: NP_055066 (SEQ ID NO: 154) ENSEMBL: ENSP00000265631 Tax_Id = 9606 Calcium-binding mitochondrial carrier protein Aralar2 ASITALEAK SWISS-PROT: P35579 IPI00019502.1 P35579 (SEQ ID NO: 155) REFSEQ_NP: NP_002464 TREMBL: Q99529; Q9UMJ0 ENSEMBL: ENSP00000216181 Tax_Id = 9606 Myosin heavy chain nonmuscle type A AVTSANIQEFAGCKK SWISS-PROT: P04626 IPI00025072.1 P04626 (SEQ ID NO: 156) REFSEQ_NP: NP_004439 TREMBL: Q9UMK4; Q14256; Q9NP09 ENSEMBL: ENSP00000269571 Tax_Id = 9606 Receptor protein- tyrosine kinase erbB-2 precursor DDTIYEDEDVKEAIR SWISS-PROT: P14927 IPI00220416.1 P14927 (SEQ ID NO: 157) REFSEQ_NP: NP_006285 ENSEMBL: ENSP00000287022 Tax_Id = 9606 ubiquinol-cytochrome c reductase binding protein DGGQEYVVK SWISS-PROT: O60437 IPI00216295.1 O60437 (SEQ ID NO: 158) REFSEQ_NP: NP_002696 ENSEMBL: ENSP00000262369 Tax_Id = 9606 Periplakin DKQMELLENK REFSEQ_NP: NP_006401 IPI00107873.1 NP_006401 (SEQ ID NO: 159) TREMBL: O60520; Q9BUP3 ENSEMBL: ENSP00000227259 Tax_Id = 9606 Tat-interacting protein DLKPENLLLASK REFSEQ_NP: NP_751909 IPI00166707.1 NP_751909 (SEQ ID NO: 160) TREMBL: Q8N4I3 ENSEMBL: ENSP00000315599 Tax_Id = 9606 Calcium/calmodulin- dependent protein kinase DPIYFTGLASEPGAR SWISS-PROT: Q99523 IPI00016022.1 Q99523 (SEQ ID NO: 161) Tax_Id = 9606 Sortilin precursor DSIVHQAGMLK SWISS-PROT: O15144 IPI00005161.1 O15144 (SEQ ID NO: 162) REFSEQ_NP: NP_005722; NP_690601 TREMBL: Q9P1D4 ENSEMBL: ENSP00000327137 Tax_Id = 9606 ARP2/3 complex 34 kDa subunit DVSSSTPPSVTSK REFSEQ_NP: NP_036451 IPI00098365.1 NP_036451 (SEQ ID NO: 163) TREMBL: Q8IXR3; Q96HP5; Q13433 ENSEMBL: ENSP00000269187 Tax_Id = 9606 LIV-1 protein estrogen regulated EGVREVFETATR SWISS-PROT: P01121 IPI00000041.1 P01121 (SEQ ID NO: 164) REFSEQ_NP: NP_004031 ENSEMBL: ENSP00000272233 Tax_Id = 9606 Transforming protein RhoB ELASLHDK SWISS-PROT: O14662-2 IPI00220261.1 O14662-2 (SEQ ID NO: 165) REFSEQ_NP: NP_003754 ENSEMBL: ENSP00000287648; ENSP00000320106 Tax_Id = 9606 Splice isoform A of O14662 Syntaxin 16 ELISNSSDALDKIR SWISS-PROT: P07900 IPI00217479.1 P07900 (SEQ ID NO: 166) REFSEQ_NP: NP_005339 TREMBL: Q96HX7; Q8TBA7; O75322 ENSEMBL: ENSP00000216281 Tax_Id = 9606 heat shock 90 kDa protein 1 alpha ELVSLKQEQQAFKEAA REFSEQ_NP: NP_006816 IPI00141318.1 DTER TREMBL: Q07065 (SEQ ID NO: 167) ENSEMBL: ENSP00000312296 Tax_Id = 9606 P63 protein P63 protein EMIPFAVVGSDHEYQV TREMBL: Q9UHD8 IPI00155610.1 Q9UHD8 NGKR Tax_Id = 9606 MLL (SEQ ID NO: 168) septin-like fusion protein MSF-A MLL septin-like fusion protein MSF-A EQHGLQLQSEINQLHSK REFSEQ_NP: NP_003557 IPI00020647.1 (SEQ ID NO: 169) TREMBL: Q14221; Q15075 ENSEMBL: ENSP00000218310; ENSP00000317955 Tax_Id = 9606 Endosome-associated protein Endosome- associated protein FETEKNNGAGYFLEHL SWISS-PROT: P31930 IPI00013847.1 P31930 AFKGTK REFSEQ_NP: NP_003356 (SEQ ID NO: 170) TREMBL: Q96DD2 ENSEMBL: ENSP00000203407 Tax_Id = 9606 Ubiquinol-cytochrome C reductase complex core protein I mitochondrial precursor FEVIEKPQA SWISS-PROT: P18859 IPI00002521.1 P18859 (SEQ ID NO: 171) REFSEQ_NP: NP_001676 ENSEMBL: ENSP00000284971; ENSP00000318330 Tax_Id = 9606 ATP synthase coupling factor 6 mitochondrial precursor FFDEESYSLLRK SWISS-PROT: P51571 IPI00019385.1 P51571 (SEQ ID NO: 172) REFSEQ_NP: NP_006271 TREMBL: Q96BQ0 Tax_Id = 9606 Translocon-associated protein delta subunit precursor FHDVLGNERPSAYMR REFSEQ_XP: XP_086381 IPI00084819.2 XP_086381 (SEQ ID NO: 173) ENSEMBL: ENSP00000326482 Tax_Id = 9606 similar to 40S RIBOSOMAL PROTEIN P40 (C10 PROTEIN) FKMPEMHFKAPK SWISS-PROT: Q09666 IPI00021812.1 Q09666 (SEQ ID NO: 174) ENSEMBL: ENSP00000244934 Tax_Id = 9606 Neuroblast differentiation associated protein AHNAK FSAYIKNSNPALNDNL SWISS-PROT: O00299 IPI00010896.1 O00299 EK REFSEQ_NP: NP_001279 (SEQ ID NO: 175) ENSEMBL: ENSP00000211475 Tax_Id = 9606 Chloride intracellular channel protein 1 FSFKKPFK SWISS-PROT: P49006 IPI00220803.1 P49006 (SEQ ID NO: 176) REFSEQ_NP: NP_075385 ENSEMBL: ENSP00000310885 Tax_Id = 9606 MARCKS-like protein GADDAMESSKPGPVQ TREMBL: Q9UFL1; Q9BSE0 IPI00004806.1 Q9UFL1; Q9BSE0 VVLVQK Tax_Id = 9606 (SEQ ID NO: 177) Hypothetical protein GALHTVSHEDIRDIR REFSEQ_NP: NP_003617 IPI00164240.3 NP_003617 (SEQ ID NO: 178) TREMBL: Q13136; Q8N4I2; Q14567 ENSEMBL: ENSP00000310098 Tax_Id = 9606 PTPRF interacting protein alpha 1 isoform b GFFGYK TREMBL: Q15693 IPI00018949.1 Q15693 (SEQ ID NO: 179) Tax_Id = 9606 5C5 5C5 GPASPLDSTFYR SWISS-PROT: P04626 IPI00025072.1 P04626 (SEQ ID NO: 180) REFSEQ_NP: NP_004439 TREMBL: Q9UMK4; Q14256; Q9NP09 ENSEMBL: ENSP00000269571 Tax_Id = 9606 Receptor protein- tyrosine kinase erbB-2 precursor GPVGTVSEAQLAR SWISS- IPI00021048.1 Q9NZM1-1 (SEQ ID NO: 181) PROT: Q9NZM1-1 REFSEQ_NP: NP_038479 ENSEMBL: ENSP00000260690 Tax_Id = 9606 Splice isoform 1 of Q9NZM1 Myoferlin GTPGPPPAHGAALQPH SWISS-PROT: Q15654 IPI00018848.2 Q15654 PR REFSEQ_NP: NP_003293 (SEQ ID NO: 182) TREMBL: Q9BUE5; Q9BXP3 ENSEMBL: ENSP00000200457 Tax_Id = 9606 Thyroid receptor interacting protein 6 GVGIISEGNETVEDIAA SWISS-PROT: P05023-1 IPI00006482.1 P05023-1 RLNIPVSQVNPR REFSEQ_NP: NP_000692 (SEQ ID NO: 183) TREMBL: Q9UJ21 ENSEMBL: ENSP00000295598 Tax_Id = 9606 Splice isoform Long of P05023 Sodium/potassium- transporting ATPase alpha-1 chain precursor GYSFTTTAER SWISS-PROT: P02570 IPI00021439.1 P02570 (SEQ ID NO: 184) REFSEQ_NP: NP_001092 TREMBL: Q96DE1; Q96E67; Q9BTD2; Q9UE89; Q8WVW5; Q96FU6; Q96B34; Q9UMN3 ENSEMBL: ENSP00000158302 Tax_Id = 9606 Actin cytoplasmic 1 HMGLFDHAAR SWISS-PROT: P50213 IPI00030702.1 P50213 (SEQ ID NO: 185) REFSEQ_NP: NP_005521 TREMBL: Q9H3X0 ENSEMBL: ENSP00000299518 Tax_Id = 9606 Isocitrate dehydrogenase [NAP] subunit alpha mitochondrial precursor HSTFHGEDKLISVEDL REFSEQ_NP: NP_003147 IPI00166512.1 NP_003147 WK TREMBL: Q8N382 (SEQ ID NO: 186) ENSEMBL: ENSP00000300737 Tax_Id = 9606 Hypothetical protein Hypothetical protein HVIPMNPNTDDLFK SWISS-PROT: P13797 IPI00216694.1 P13797 (SEQ ID NO: 187) REFSEQ_NP: NP_005023 TREMBL: Q96HI1 ENSEMBL: ENSP00000289290 Tax_Id = 9606 plastin 3 IAAYAYSALSQIR REFSEQ_NP: NP_060377 IPI00016670.1 (SEQ ID NO: 188) TREMBL: Q9NWT0; Q8WZ09 ENSEMBL: ENSP00000278671 Tax_Id = 9606 Hypothetical protein Hypothetical protein IASQVAALDLGYKPGV SWISS-PROT: P28331 IPI00002871.1 P28331 EAIR Tax_Id = 9606 NADH- (SEQ ID NO: 189) ubiquinone oxidoreductase 75 kDa subunit mitochondrial precursor IEVEKPFAIAKE SWISS-PROT: P23284 IPI00107117.1 P23284 (SEQ ID NO: 190) REFSEQ_NP: NP_000933 TREMBL: Q9BVK5 ENSEMBL: ENSP00000300026 Tax_Id = 9606 Peptidylprolyl isomerase B IFVGGIKEDTEEHHLR REFSEQ_XP: XP_018399 IPI00042578.1 XP_018399 (SEQ ID NO: 191) ENSEMBL: ENSP00000267149 Tax_Id = 9606 similar to helix- destabilizing protein —rat IHEKLHYYEK REFSEQ_NP: NP_775767 IPI00217617.1 NP_775767 (SEQ ID NO: 192) TREMBL: Q8IY28 ENSEMBL: ENSP00000315639 Tax_Id = 9606 Similar to membrane protein palmitoylated 3 IINEPTAAAIAYGLDK SWISS-PROT: P34931 IPI00002965.2 P34931 (SEQ ID NO: 193) REFSEQ_NP: NP_005518 TREMBL: Q8NE72 REFSEQ_XP: XP_166348; XP_212623 ENSEMBL: ENSP00000259871 Tax_Id = 9606 Heat shock 70 kDa protein 1-HOM IISANGCK SWISS-PROT: P05023-1 IPI00006482.1 P05023-1 (SEQ ID NO: 194) REFSEQ_NP: NP_000692 TREMBL: Q9UJ21 ENSEMBL: ENSP00000295598 Tax_Id = 9606 Splice isoform Long of P05023 Sodium/potassium- transporting ATPase alpha-1 chain precursor IIYSHFTCATDTENIR SWISS-PROT: P50148 IPI00097511.1 P50148 (SEQ ID NO: 195) REFSEQ_NP: NP_002063 TREMBL: Q9BZB9 ENSEMBL: ENSP00000286548 Tax_Id = 9606 G alpha q protein INVYYNEATGGK SWISS-PROT: P05217 IPI00007752.1 P05217 (SEQ ID NO: 196) REFSEQ_NP: NP_006079 TREMBL: Q96HX0; Q9BUU9 Tax_Id = 9606 Tubulin beta-2 chain Tubulin beta-2 chain IPDVDIDSDGVFK SWISS-PROT: Q9NRX4 IPI00156269.1 Q9NRX4 (SEQ ID NO: 197) REFSEQ_NP: NP_054891 TREMBL: Q9P019 ENSEMBL: ENSP00000247665 Tax_Id = 9606 14 kDa phosphohistidine phosphatase ISVYYNEATGGKYVPR REFSEQ_NP: NP_001060 IPI00013475.1 (SEQ ID NO: 198) TREMBL: O43209; Q9UGA2; Q13885 ENSEMBL: ENSP00000259799 Tax_Id = 9606 Beta tubulin IYHTIAYLTPLPQPNR SWISS-PROT: P10620 IPI00021805.1 P10620 (SEQ ID NO: 199) REFSEQ_NP: NP_064696; NP_665707; NP_665734; NP_665735 ENSEMBL: ENSP00000010404; ENSP00000314356; ENSP00000314383; ENSP00000314466 Tax_Id = 9606 Microsomal glutathione S-transferase 1 KAHLTNQYMQR REFSEQ_XP: XP_210297 IPI00173545.1 (SEQ ID NO: 200) Tax_Id = 9606 similar to Polyadenylate-binding protein 4 (Poly(A) binding protein 4) (PABP 4) (Inducible poly(A)-binding protein) (iPABP) (Activated- platelet protein-1) (APP- 1) KALELDQER SWISS-PROT: P35241 IPI00017367.1 P35241 (SEQ ID NO: 201) REFSEQ_NP: NP_002897 TREMBL: Q9NST9 ENSEMBL: ENSP00000282281; ENSP00000310481 Tax_Id = 9606 Radixin Radixin KEPHESLGMTVAGGR SWISS-PROT: Q8N448 IPI00171047.1 Q8N448 (SEQ ID NO: 202) REFSEQ_NP: NP_699202 ENSEMBL: ENSP00000266952; ENSP00000325929 Tax_Id = 9606 Numb-binding protein 2 KGLDPYNVLAPK SWISS-PROT: P10606 IPI00021785.2 P10606 (SEQ ID NO: 203) REFSEQ_NP: NP_001853 TREMBL: Q99610 ENSEMBL: ENSP00000258424 Tax_Id = 9606 Cytochrome c oxidase polypeptide Vb mitochondrial precursor KIYEFTLQR SWISS-PROT: O43795 IPI00013980.2 O43795 (SEQ ID NO: 204) ENSEMBL: ENSP00000306382 Tax_Id = 9606 Myosin Ib KLMEECKR SWISS-PROT: Q9P0L0 IPI00170692.1 Q9P0L0 (SEQ ID NO: 205) REFSEQ_NP: NP_003565 ENSEMBL: ENSP00000217602 Tax_Id = 9606 Vesicle-associated membrane protein- associated protein A KMMLDLNKAK TREMBL: Q92799 IPI00023349.1 Q92799 (SEQ ID NO: 206) Tax_Id = 9606 Mitochondrial trifunctional protein beta subunit KPQYDIWGNTVNVASR SWISS-PROT: O95622 IPI00218608.1 O95622 (SEQ ID NO: 207) ENSEMBL: ENSP00000308685 Tax_Id = 9606 Adenylate cyclase type V KTGENVEDAFLEAAK SWISS-PROT: P35287 IPI00017508.1 P35287 (SEQ ID NO: 208) REFSEQ_NP: NP_057406 ENSEMBL: ENSP00000238339 Tax_Id = 9606 Ras-related protein Rab- 14 Ras-related protein Rab-14 KVEEENQGALEMIKR TREMBL: Q8N4U4; Q8WU84 IPI00102860.1 Q8N4U4; Q8WU84 (SEQ ID NO: 209) ENSEMBL: ENSP00000304043 Tax_Id = 9606 Hypothetical protein KWESPAQNTAHLDQF SWISS-PROT: P17612-1 IPI00219591.1 P17612-1 ER REFSEQ_NP: NP_002721 (SEQ ID NO: 210) TREMBL: Q15136 ENSEMBL: ENSP00000263389 Tax_Id = 9606 protein kinase cAMP- dependent catalytic alpha KYELGRPAANTK SWISS-PROT: P09058 IPI00216587.1 P09058 (SEQ ID NO: 211) REFSEQ_NP: NP_001003 TREMBL: Q9BS10 ENSEMBL: ENSP00000271105 Tax_Id = 9606 40S ribosomal protein S8 40S ribosomal protein S8 LAALQGRLEGLGSSEA REFSEQ_NP: NP_006816 IPI00141318.1 NP_006816 DQDGLASTVR TREMBL: Q07065 (SEQ ID NO: 212) ENSEMBL: ENSP00000312296 Tax_Id = 9606 P63 protein P63 protein LDHKFDLMYAK SWISS-PROT: P05215 IPI00007750.1 P05215 (SEQ ID NO: 213) REFSEQ_NP: NP_005991 ENSEMBL: ENSP00000248437 Tax_Id = 9606 Tubulin alpha-4 chain LDLRDDKDTIER SWISS-PROT: O14658 IPI00023138.1 O14658 (SEQ ID NO: 214) REFSEQ_NP: NP_005043 ENSEMBL: ENSP00000304283 Tax_Id = 9606 Ras-related C3 botulinum toxin substrate 3 LEKHELIEFR SWISS-PROT: Q00610 IPI00024067.1 Q00610 (SEQ ID NO: 215) REFSEQ_NP: NP_004850 ENSEMBL: ENSP00000269122 Tax_Id = 9606 Clathrin heavy chain 1 LESEGSPETLTNLR TREMBL: Q9NQA7 IPI00175830.1 Q9NQA7 (SEQ ID NO: 216) Tax_Id = 9606 B-ind1 protein B-ind1 protein LHSLKTAK SWISS-PROT: P20929 IPI00026247.2 P20929 (SEQ ID NO: 217) REFSEQ_NP: NP_004534 TREMBL: Q14215; Q14918; Q14214 ENSEMBL: ENSP00000172853 Tax_Id = 9606 Nebulin Nebulin LIVDEAINEDNSVVSLS SWISS-PROT: P55072 IPI00022774.1 P55072 QPK REFSEQ_NP: NP_009057 (SEQ ID NO: 218) TREMBL: Q9NTC4; Q96IF9; Q9HAP1; Q9HAP0 ENSEMBL: ENSP00000298001; ENSP00000312929; ENSP00000315065; ENSP00000318011 Tax_Id = 9606 Transitional endoplasmic reticulum ATPase LMVHTVATFNSIK SWISS-PROT: Q13813 IPI00015786.1 Q13813 (SEQ ID NO: 219) REFSEQ_NP: NP_003118 TREMBL: Q15324; Q9UG16 ENSEMBL: ENSP00000238302; ENSP00000306097; ENSP00000319196 Tax_Id = 9606 Spectrin alpha chain brain LNESLDENFKK TREMBL: Q96CV4; Q9Y2M8; IPI00179326.1 Q96CV4; Q9Y2M8; (SEQ ID NO: 220) Q9H5F5 Q9H5F5 ENSEMBL: ENSP00000005260 Tax_Id = 9606 Similar to RIKEN cDNA 1300006M19 gene Similar to RIKEN cDNA 1300006M19 gene LQQGYNAMGFSQGGQ SWISS-PROT: P50897 IPI00002412.1 P50897 FLR REFSEQ_NP: NP_000301 (SEQ ID NO: 221) ENSEMBL: ENSP00000253546 Tax_Id = 9606 Palmitoyl-protein thioesterase 1 precursor LQVELDNVTGLLSQSD SWISS-PROT: P35579 IPI00019502.1 P35579 SK REFSEQ_NP: NP_002464 (SEQ ID NO: 222) TREMBL: Q99529; Q9UMJ0 ENSEMBL: ENSP00000216181 Tax_Id = 9606 Myosin heavy chain nonmuscle type A LTVMTDLEDKNEWK SWISS-PROT: Q12907 IPI00009950.1 Q12907 (SEQ ID NO: 223) REFSEQ_NP: NP_006807 ENSEMBL: ENSP00000303366 Tax_Id = 9606 Vesicular integral- membrane protein VIP36 precursor MASGAANVVGPK SWISS-PROT: Q92520 IPI00021923.1 Q92520 (SEQ ID NO: 224) REFSEQ_NP: NP_055703 REFSEQ_XP: XP_208425 ENSEMBL: ENSP00000222764; ENSP00000310532 Tax_Id = 9606 Protein FAM3C precursor MKETAENYLGHTAK SWISS-PROT: P38646 IPI00007765.2 P38646 (SEQ ID NO: 225) REFSEQ_NP: NP_004125 TREMBL: Q8N1C8 ENSEMBL: ENSP00000297185 Tax_Id = 9606 Stress-70 protein mitochondrial precursor MNRPAPVEVTYK REFSEQ_NP: NP_003454 IPI00020164.1 NP_003454 (SEQ ID NO: 226) TREMBL: Q93096; O00648 ENSEMBL: ENSP00000229983 Tax_Id = 9606 Protein tyrosine phosphatase PTPCAAX1 MSQVMREWEEAERQAK SWISS-PROT: P05067-7 IPI00219187.1 P05067-7 (SEQ ID NO: 227) Tax_Id = 9606 Splice isoform L-APP733 of P05067 Amyloid beta A4 protein precursor NALLSLAK SWISS-PROT: P04083 IPI00218918.1 P04083 (SEQ ID NO: 228) REFSEQ_NP: NP_000691 ENSEMBL: ENSP00000257497 Tax_Id = 9606 annexin I NDITPLHVASK SWISS-PROT: Q12955 IPI00025770.2 Q12955 (SEQ ID NO: 229) REFSEQ_NP: NP_066267 TREMBL: Q8NAK2 ENSEMBL: ENSP00000280772; ENSP00000313984 Tax_Id = 9606 Ankyrin 3 NHPLHIRENR REFSEQ_NP: NP_006835 IPI00009963.2 NP_006835 (SEQ ID NO: 230) TREMBL: Q9UEB2; O43341; Q96F08 ENSEMBL: ENSP00000263383 Tax_Id = 9606 Acetolactate synthase Acetolactate synthase NIVHNYSEAEIK REFSEQ_NP: NP_060427 IPI00100282.1 NP_060427 (SEQ ID NO: 231) TREMBL: Q9NWK2; Q9H201 ENSEMBL: ENSP00000268933 Tax_Id = 9606 Epsin 3 Epsin 3 NLDSTTVAVHGEEIYCK SWISS-PROT: P21291 IPI00219674.1 P21291 (SEQ ID NO: 232) REFSEQ_NP: NP_004069 TREMBL: Q9BTA4 ENSEMBL: ENSP00000290286 Tax_Id = 9606 cysteine and glycine-rich protein 1 NLGSINTELQDVQR REFSEQ_NP: NP_004883 IPI00006865.1 NP_004883 (SEQ ID NO: 233) TREMBL: O75396 ENSEMBL: ENSP00000286336 Tax_Id = 9606 Vesicle trafficking protein SEC22B Vesicle trafficking protein SEC22B NVLSLTNK SWISS-PROT: P05556-2 IPI00107778.1 P05556-2 (SEQ ID NO: 234) REFSEQ_NP: NP_389647 Tax_Id = 9606 integrin beta 1 isoform 1B precursor PAVSKGDGMR SWISS-PROT: O94973 IPI00016621.1 O94973 (SEQ ID NO: 235) REFSEQ_NP: NP_036437 TREMBL: Q9UFK5 Tax_Id = 9606 Adapter- related protein complex 2 alpha 2 subunit PGTEPLGTTK SWISS-PROT: Q9Y6I9 IPI00006372.1 Q9Y6I9 (SEQ ID NO: 236) REFSEQ_NP: NP_057010 ENSEMBL: ENSP00000296478 Tax_Id = 9606 Putative secreted protein ZSIG11 precursor Putative secreted protein ZSIG11 precursor PIHPVGGLR SWISS-PROT: Q9HCU4 IPI00015346.1 Q9HCU4 (SEQ ID NO: 237) REFSEQ_NP: NP_001399 ENSEMBL: ENSP00000271332; ENSP00000319010 Tax_Id = 9606 Cadherin EGF LAG seven-pass G-type receptor 2 precursor QVLLAQAEAEK SWISS-PROT: Q14254 IPI00029625.1 Q14254 (SEQ ID NO: 238) REFSEQ_NP: NP_004466 ENSEMBL: ENSP00000254926 Tax_Id = 9606 Flotillin-2 QVTPDGESDEVGVIPS SWISS-PROT: Q15700 IPI00019328.1 Q15700 KR REFSEQ_NP: NP_001355 (SEQ ID NO: 239) ENSEMBL: ENSP00000280241 Tax_Id = 9606 Channel associated protein of synapse-110 RKVDWLTEK SWISS-PROT: P04765 IPI00025491.1 P04765 (SEQ ID NO: 240) REFSEQ_NP: NP_001407 TREMBL: Q9BRK6; Q9NZR9 ENSEMBL: ENSP00000293831 Tax_Id = 9606 Eukaryotic initiation factor 4A-I RLYWDDLKR SWISS-PROT: P02786 IPI00022462.1 P02786 (SEQ ID NO: 241) REFSEQ_NP: NP_003225 ENSEMBL: ENSP00000265238 Tax_Id = 9606 Transferrin receptor protein 1 RNELVIR SWISS-PROT: P11413-2 IPI00216008.1 P11413-2 (SEQ ID NO: 242) Tax_Id = 9606 Splice isoform Long of P11413 Glucose-6-phosphate 1- dehydrogenase RSNTENLSQHFR SWISS- IPI00008918.1 Q9UHB6-1 (SEQ ID NO: 243) PROT: Q9UHB6-1 REFSEQ_NP: NP_057441 ENSEMBL: ENSP00000293615 Tax_Id = 9606 Splice isoform Beta of Q9UHB6 Epithelial protein lost in neoplasm RTPVQPNPIVYMMK SWISS-PROT: O96000 IPI00220060.1 O96000 (SEQ ID NO: 244) REFSEQ_NP: NP_004539 TREMBL: Q96RX5 ENSEMBL: ENSP00000268668 Tax_Id = 9606 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 10 22 kDa SALLAEMDKVEGHVA SWISS-PROT: P33527-6 IPI00216265.1 P33527-6 IK Tax_Id = 9606 Splice (SEQ ID NO: 245) isoform Delexon-17-30 of P33527 Multidrug resistance-associated protein 1 SAVTTVVNPK SWISS-PROT: P05556-2 IPI00107778.1 P05556-2 (SEQ ID NO: 246) REFSEQ_NP: NP_389647 Tax_Id = 9606 integrin beta 1 isoform 1B precursor SEESVSRLPEEIR REFSEQ_NP: NP_006816 IPI00141318.1 NP_006816 (SEQ ID NO: 247) TREMBL: Q07065 ENSEMBL: ENSP00000312296 Tax_Id = 9606 P63 protein P63 protein SEHKVWSPLVTEEGKR SWISS-PROT: O00151 IPI00010414.2 O00151 (SEQ ID NO: 248) REFSEQ_NP: NP_066272 ENSEMBL: ENSP00000265995 Tax_Id = 9606 PDZ and LIM domain protein 1 SHEAEVLK SWISS-PROT: P16949 IPI00031736.1 P16949 (SEQ ID NO: 249) REFSEQ_NP: NP_005554 TREMBL: Q96CE4 ENSEMBL: ENSP00000236291 Tax_Id = 9606 Stathmin SKEPQLIAFYHK SWISS-PROT: P19634 IPI00020060.1 P19634 (SEQ ID NO: 250) REFSEQ_NP: NP_003038 REFSEQ_XP: XP_046881 ENSEMBL: ENSP00000263980 Tax_Id = 9606 Sodium/hydrogen exchanger 1 SLSLSKLEDPHVDIIR TREMBL: Q8TEP9 IPI00152791.1 Q8TEP9 (SEQ ID NO: 251) Tax_Id = 9606 FLJ00144 protein SLVNQQSFQDIKPMR SWISS-PROT: P17964 IPI00018364.2 P17964 (SEQ ID NO: 252) REFSEQ_XP: XP_209564 ENSEMBL: ENSP00000319096 Tax_Id = 9606 Ras-related protein RAP- 2b Ras-related protein RAP-2b SQVLDDEDSNNITVGS SWISS-PROT: Q9UGP8 IPI00218922.1 Q9UGP8 LVTVLVK REFSEQ_NP: NP_009145 (SEQ ID NO: 253) TREMBL: Q8IWL0 ENSEMBL: ENSP00000027474; ENSP00000317581 Tax_Id = 9606 SEC63 endoplasmic reticulum translocon component (S. cerevisiae) like SRKESYSVYVYK REFSEQ_XP: XP_169343 IPI00147570.1 (SEQ ID NO: 254) Tax_Id = 9606 similar to H2B histone family member S SSSLDDTEVKK SWISS-PROT: O95292-1 IPI00006211.1 O95292-1 (SEQ ID NO: 255) REFSEQ_NP: NP_004729 ENSEMBL: ENSP00000265619 Tax_Id = 9606 Splice isoform 1 of O95292 Vesicle- associated membrane protein-associated protein B/C STGPGASLGTGYDRK SWISS-PROT: O15551 IPI00007364.1 O15551 (SEQ ID NO: 256) REFSEQ_NP: NP_001297 ENSEMBL: ENSP00000297926 Tax_Id = 9606 Claudin-3 SWEQKLEEMR SWISS-PROT: Q16543 IPI00013122.1 Q16543 (SEQ ID NO: 257) REFSEQ_NP: NP_008996 ENSEMBL: ENSP00000222005 Tax_Id = 9606 Hsp90 co-chaperone Cdc37 TAPYKNVNIQNFHISWK SWISS-PROT: P12814 IPI00025845.1 P12814 (SEQ ID NO: 258) Tax_Id = 9606 Alpha- actinin 1 TAVVVGTITDDVR SWISS-PROT: Q07020 IPI00215719.1 Q07020 (SEQ ID NO: 259) REFSEQ_NP: NP_000970 ENSEMBL: ENSP00000084795 Tax_Id = 9606 60S ribosomal protein L18 60S ribosomal protein L18 TDLEKDIISDTSGDFRK SWISS-PROT: P07355 IPI00216240.1 P07355 (SEQ ID NO: 260) REFSEQ_NP: NP_004030 TREMBL: Q8TBV2 ENSEMBL: ENSP00000316276 Tax_Id = 9606 Annexin A2 Annexin A2 TDPVDIYK SWISS-PROT: P46940 IPI00009342.1 P46940 (SEQ ID NO: 261) REFSEQ_NP: NP_003861 TREMBL: Q96PA3 ENSEMBL: ENSP00000268182 Tax_Id = 9606 Ras GTPase-activating- like protein IQGAP1 TKTEISEMNR REFSEQ_NP: NP_778238 IPI00174775.1 NP_778238 (SEQ ID NO: 262) ENSEMBL: ENSP00000307014 Tax_Id = 9606 keratin 6 irs3 TVFDEAIR SWISS-PROT: P15154-2 IPI00219675.1 P15154-2 (SEQ ID NO: 263) REFSEQ_NP: NP_061485 ENSEMBL: ENSP00000258736 Tax_Id = 9606 Splice isoform B of P15154 Ras-related C3 botulinum toxin substrate 1 TVNMTWNK SWISS-PROT: P46939 IPI00009329.1 P46939 (SEQ ID NO: 264) REFSEQ_NP: NP_009055 TREMBL: Q9UJA7; Q8WYB8; Q8WYB7 ENSEMBL: ENSP00000282749 Tax_Id = 9606 Utrophin TVYSHLFDHVVNR SWISS-PROT: Q9UM54 IPI00008455.1 Q9UM54 (SEQ ID NO: 265) ENSEMBL: ENSP00000265377 Tax_Id = 9606 Myosin VI Myosin VI VKANLEK SWISS-PROT: P35579 IPI00019502.1 P35579 (SEQ ID NO: 266) REFSEQ_NP: NP_002464 TREMBL: Q99529; Q9UMJ0 ENSEMBL: ENSP00000216181 Tax_Id = 9606 Myosin heavy chain nonmuscle type A VKDASPNQVAEK SWISS-PROT: O43402 IPI00005740.1 O43402 (SEQ ID NO: 267) REFSEQ_NP: NP_006058 ENSEMBL: ENSP00000253457 Tax_Id = 9606 Neighbor of COX4 Neighbor of COX4 VKDRDDFPVVLVGNK SWISS-PROT: P10301 IPI00020418.1 P10301 (SEQ ID NO: 268) REFSEQ_NP: NP_006261 ENSEMBL: ENSP00000246792 Tax_Id = 9606 Ras-related protein R- Ras VKKEWEEAELQAK SWISS-PROT: Q06481-3 IPI00220978.1 Q06481-3 (SEQ ID NO: 269) ENSEMBL: ENSP00000263575 Tax_Id = 9606 Splice isoform 3 of Q06481 Amyloid-like protein 2 precursor VKLFYLDPDAQKLDFS SWISS-PROT: Q9BZ29-1 IPI00151888.2 Q9BZ29-1 SAEPEVK REFSEQ_NP: NP_056111 (SEQ ID NO: 270) TREMBL: Q9BZ26 ENSEMBL: ENSP00000304814 Tax_Id = 9606 Splice isoform 1 of Q9BZ29 Cdc42 guanine nucleotide exchange factor zizimin 1 VLAFTAVGDGPPSPTIQ REFSEQ_NP: NP_569707 IPI00107831.1 VK ENSEMBL: ENSP00000318349 (SEQ ID NO: 271) Tax_Id = 9606 protein tyrosine phosphatase receptor type F isoform 2 precursor VNGRPLEMIEPR SWISS-PROT: P17008 IPI00221092.1 P17008 (SEQ ID NO: 272) REFSEQ_NP: NP_001011 ENSEMBL: ENSP00000251453 Tax_Id = 9606 ribosomal protein S16 VPTSMVLTK TREMBL: Q9H1H3; Q9ULE9 IPI00020719.1 Q9H1H3; Q9ULE9 (SEQ ID NO: 273) REFSEQ_XP: XP_045472 ENSEMBL: ENSP00000319445 Tax_Id = 9606 Hypothetical protein KIAA1271 VSSLGKDWHK SWISS-PROT: P52943 IPI00006034.1 P52943 (SEQ ID NO: 274) REFSEQ_NP: NP_001303 Tax_Id = 9606 Cysteine-rich protein 2 WEVEEMKESK SWISS-PROT: P27824 IPI00020984.1 P27824 (SEQ ID NO: 275) REFSEQ_NP: NP_001737 ENSEMBL: ENSP00000247461 Tax_Id = 9606 Calnexin precursor WGKPHVASLSFR SWISS-PROT: P04920-1 IPI00026298.2 P04920-1 (SEQ ID NO: 276) Tax_Id = 9606 Splice isoform A of P04920 Anion exchange protein 2 WILSQTHNIFTQAGVR REFSEQ_NP: NP_598003 IPI00171632.1 (SEQ ID NO: 277) TREMBL: Q8TCH2; Q8NEW0 ENSEMBL: ENSP00000294731 Tax_Id = 9606 Zinc transporter ZnT-7 Zinc transporter ZnT-7 WKAGLYGLPRR REFSEQ_NP: NP_004095 IPI00107774.1 (SEQ ID NO: 278) TREMBL: Q96IT0; Q969R1; Q16702; Q96C68; Q13479; Q13587 ENSEMBL: ENSP00000304592; ENSP00000304718 Tax_Id = 9606 Fatty acid synthase YGPSLMPGGNKEAWP SWISS-PROT: P52209 IPI00219525.1 P52209 HIK REFSEQ_NP: NP_002622 (SEQ ID NO: 279) ENSEMBL: ENSP00000322397 Tax_Id = 9606 phosphogluconate dehydrogenase YKVEGFPTIYFAPSGD SWISS-PROT: P13667 IPI00009904.1 P13667 KK REFSEQ_NP: NP_004902 (SEQ ID NO: 280) ENSEMBL: ENSP00000286091 Tax_Id = 9606 Protein disulfide isomerase A4 precursor YMGDLSGGQVLKK SWISS-PROT: P30519 IPI00026824.1 P30519 (SEQ ID NO: 281) REFSEQ_NP: NP_002125 ENSEMBL: ENSP00000219700 Tax_Id = 9606 Heme oxygenase 2 YNGLIHRK SWISS-PROT: P46779 IPI00008411.2 P46779 (SEQ ID NO: 282) ENSEMBL: ENSP00000311213 Tax_Id = 9606 60S ribosomal protein L28 60S ribosomal protein L28 YQLSSEAAK SWISS-PROT: Q9NRW7 IPI00090327.1 Q9NRW7 (SEQ ID NO: 283) REFSEQ_NP: NP_009190 ENSEMBL: ENSP00000259149 Tax_Id = 9606 Vacuolar protein sorting- associated protein 45 YSALNVQHQMLK REFSEQ_NP: NP_055313 IPI00004962.1 (SEQ ID NO: 284) TREMBL: O00461 ENSEMBL: ENSP00000309893 Tax_Id = 9606 130 kDa golgi-localized phosphoprotein YSQVLANGLDNK SWISS-PROT: P25232 IPI00013296.1 P25232 (SEQ ID NO: 285) REFSEQ_NP: NP_072045 ENSEMBL: ENSP00000211372; ENSP00000313640 Tax_Id = 9606 40S ribosomal protein S18 YYPTEDVPRK SWISS-PROT: Q02878 IPI00027271.1 Q02878 (SEQ ID NO: 286) REFSEQ_NP: NP_000961 TREMBL: Q8N5Z7; Q9HBB3; Q8TBK5; Q8WW97 ENSEMBL: ENSP00000202773 Tax_Id = 9606 60S ribosomal protein L6 Cells were treated with 0.35 μM compound 1 for 6, 36 and 72 hours before harvest and subject to LC/MS based protein profiling. There are biological duplicates and technique duplicates. A two-way ANOVA mixed model was utilized to identify drug treatment effect as well as treatment and time interaction on the expression of peptide ions. The peptide ions identified as modulated by the drug are those with p value < 0.05 in either the Treatment effect or Treatment × Time interaction. FDR correction was not applied to the protein profiling data. Remarkably, these genes are mainly involved in apoptosis (AIFM1, ACIN1, BIRC2, BIRC5, BAD, BAG3, BAX, CARD10, CIAPIN1, DAP, DAXX, DAPK1, PDCD11 and PDCD4), cell growth and proliferation (Ki67, BOP1, GAS1 and ING3), cell cycles (cyclin family members of B, D, E, G, H, I, K, L; CDK 2 and 7; centromere protein A, B, M, N; CDKN3 and CDKN1B) and multiple tyrosine kinases such as ERBB3, PDGFR, FGFR1, 2 and 4, MET, EPH as well as the down-stream IGF1R signaling pathways: MAPK, PI3K and AKT. Interestingly, contrary to what was reported with IGF1R antibody (R. Baserga, Expert Opin. Ther. Targets; 9:753-68 (2005)), inhibition of kinase activity by compound 1 did not result in the receptor down-regulation, but rather induced the expression of IGF1R, insulin receptor substrate 2 (IRS2) and insulin-like growth factor binding protein 3 (IGFBP3). This could be one of the mechanisms by which cells attempt to compensate the reduced activity of the IGF1R caused by the inhibitor, and the feedback loop then restores the inhibited pathway activity. Genes Related to Acquired Resistance to IGF1R Inhibitor Compound 1:

Acquired resistance to anti-cancer agents is a major clinical problem. To study the mechanism of acquired resistance to IGF1R inhibitor, we derived resistance cells by culturing a compound 1 sensitive RMS cell line RD-1(IC₅₀=0.238 μM) in the presence of a gradually increased concentration of compound 1 in every other passage to reach the resistance level of plateau. The resulted resistant RD1 cells had IC₅₀=1.999 μM to compound 1, which is 8 fold higher than the IC₅₀ of the parent RD1. In order to identify markers that may contribute to acquired resistance to the IGF1R inhibitor, global gene expression profiles for both parental RD1 and resistant RD1 were analyzed using Affymetrix gene chip. A statistical analysis was conducted using GeneChip® Expression Analysis software MAS 5.0 to identify the genes differentially expressed between the sensitive and acquired resistant cells (Table 8).

TABLE 8 Genes related to acquired resistance to compound 1. Genes higher expressed in acquired resistant RD-1 cells 209278_s_at L27624 tissue factor pathway inhibitor 2 TFPI2 194 202820_at NM_001621 aryl hydrocarbon receptor AHR 157.6 216598_s_at S69738 chemokine (C-C motif) ligand 2 CCL2 104 209875_s_at M83248 secreted phosphoprotein 1 (osteopontin, SPP1 104 bone sialoprotein I, early T-lymphocyte activation 1) 201301_s_at BC000182 annexin A4 ANXA4 97 206785_s_at NM_002260 killer cell lectin-like receptor subfamily KLRC1 /// KLRC2 84.4 C, member 1 /// killer cell lectin-like receptor subfamily C, member 2 201427_s_at NM_005410 selenoprotein P, plasma, 1 SEPP1 84.4 213156_at BG251521 Homo sapiens, clone IMAGE: 4214654, — 64 mRNA 201005_at NM_001769 CD9 molecule CD9 59.7 220038_at NM_013257 serum/glucocorticoid regulated kinase SGK3 48.5 family, member 3 212681_at AI770004 erythrocyte membrane protein band EPB41L3 45.3 4.1-like 3 220014_at NM_016644 proline rich 16 PRR16 45.3 205563_at NM_002256 KiSS-1 metastasis-suppressor KISS1 42.2 211343_s_at M33653 collagen, type XIII, alpha 1 COL13A1 34.3 202555_s_at NM_005965 myosin, light chain kinase /// myosin, MYLK 32 light chain kinase 212909_at AL567376 LY6/PLAUR domain containing 1 LYPD1 29.9 206363_at NM_005360 v-maf musculoaponeurotic MAF 29.9 fibrosarcoma oncogene homolog (avian) 217967_s_at AF288391 family with sequence similarity 129, FAM129A 27.9 member A 209789_at BF939649 coronin, actin binding protein, 2B CORO2B 26 206693_at NM_000880 interleukin 7 IL7 26 206157_at NM_002852 pentraxin-related gene, rapidly induced PTX3 26 by IL-1 beta 206315_at NM_004750 cytokine receptor-like factor 1 CRLF1 24.3 222020_s_at AW117456 neurotrimin HNT 24.3 221884_at BE466525 ecotropic viral integration site 1 EVI1 22.6 205691_at NM_004209 synaptogyrin 3 SYNGR3 22.6 203888_at NM_000361 thrombomodulin THBD 21.1 214841_at AF070524 cornichon homolog 3 (Drosophila) CNIH3 17.1 210809_s_at D13665 periostin, osteoblast specific factor POSTN 17.1 203910_at NM_004815 Rho GTPase activating protein 29 ARHGAP29 16 214587_at BE877796 collagen, type VIII, alpha 1 COL8A1 14.9 214297_at BE857703 Chondroitin sulfate proteoglycan 4 CSPG4 14.9 (melanoma-associated) 204014_at NM_001394 dual specificity phosphatase 4 DUSP4 14.9 201163_s_at NM_001553 insulin-like growth factor binding IGFBP7 14.9 protein 7 221986_s_at AW006750 kelch-like 24 (Drosophila) KLHL24 14.9 204249_s_at NM_005574 LIM domain only 2 (rhombotin-like 1) LMO2 14.9 217901_at BF031829 Desmoglein 2 DSG2 13.9 204836_at NM_000170 glycine dehydrogenase GLDC 13.9 (decarboxylating) 204475_at NM_002421 matrix metallopeptidase 1 (interstitial MMP1 13.9 collagenase) 205858_at NM_002507 nerve growth factor receptor (TNFR NGFR 13.9 superfamily, member 16) 213716_s_at BF939675 secreted and transmembrane 1 SECTM1 13.9 214954_at BF977837 sushi domain containing 5 SUSD5 13.9 205110_s_at NM_004114 fibroblast growth factor 13 FGF13 13 207018_s_at NM_004163 RAB27B, member RAS oncogene RAB27B /// 13 family /// SH3 domain binding glutamic SH3BGR acid-rich protein 212912_at AI992251 ribosomal protein S6 kinase, 90 kDa, RPS6KA2 13 polypeptide 2 205862_at NM_014668 GREB1 protein GREB1 12.1 209870_s_at AW571582 amyloid beta (A4) precursor protein- APBA2 11.3 binding, family A, member 2 (X11-like) 212062_at AB014511 ATPase, Class II, type 9A ATP9A 11.3 213865_at AI378788 discoidin, CUB and LCCL domain DCBLD2 11.3 containing 2 205884_at NM_000885 integrin, alpha 4 (antigen CD49D, alpha ITGA4 11.3 4 subunit of VLA-4 receptor) 212188_at AA551075 potassium channel tetramerisation KCTD12 11.3 domain containing 12 /// potassium channel tetramerisation domain containing 12 202625_at AI356412 v-yes-1 Yamaguchi sarcoma viral LYN 11.3 related oncogene homolog /// v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 205538_at NM_003389 coronin, actin binding protein, 2A CORO2A 10.6 206638_at NM_000867 5-hydroxytryptamine (serotonin) HTR2B 10.6 receptor 2B 202718_at NM_000597 insulin-like growth factor binding IGFBP2 10.6 protein 2, 36 kDa 219181_at NM_006033 lipase, endothelial LIPG 10.6 209610_s_at BF340083 solute carrier family 1 SLC1A4 10.6 (glutamate/neutral amino acid transporter), member 4 214930_at AW449813 SLIT and NTRK-like family, member 5 SLITRK5 10.6 210095_s_at M31159 insulin-like growth factor binding IGFBP3 9.8 protein 3 209598_at AB020690 paraneoplastic antigen MA2 PNMA2 9.8 209859_at AF220036 tripartite motif-containing 9 TRIM9 9.8 213712_at BF508639 elongation of very long chain fatty ELOVL2 9.2 acids (FEN1/Elo2, SUR4/Elo3, yeast)- like 2 219093_at NM_017933 hypothetical protein FLJ20701 /// FLJ20701 8 hypothetical protein FLJ20701 202350_s_at NM_002380 matrilin 2 MATN2 8 204048_s_at AA551142 phosphatase and actin regulator 2 PHACTR2 8 206893_at NM_002968 sal-like 1 (Drosophila) SALL1 8 209591_s_at M60316 bone morphogenetic protein 7 BMP7 7.5 (osteogenic protein 1) 209167_at AI419030 glycoprotein M6B GPM6B 7.5 211959_at AW007532 insulin-like growth factor binding IGFBP5 7.5 protein 5 205825_at NM_000439 proprotein convertase subtilisin/kexin PCSK1 7.5 type 1 215856_at AK025833 CD33 molecule-like 3 CD33L3 7 205816_at NM_002214 integrin, beta 8 ITGB8 7 212092_at BE858180 paternally expressed 10 PEG10 7 207426_s_at NM_003326 tumor necrosis factor (ligand) TNFSF4 7 superfamily, member 4 (tax- transcriptionally activated glycoprotein 1, 34 kDa) 203940_s_at NM_014909 vasohibin 1 VASH1 7 221019_s_at NM_030781 collectin sub-family member 12 /// COLEC12 6.5 collectin sub-family member 12 206669_at NM_013445 glutamate decarboxylase 1 (brain, GAD1 /// LASS6 6.5 67 kDa) /// LAG1 homolog, ceramide synthase 6 (S. cerevisiae) 202755_s_at AI354864 glypican 1 GPC1 6.5 212314_at AB018289 KIAA0746 protein KIAA0746 6.5 215446_s_at L16895 lysyl oxidase LOX 6.5 202729_s_at NM_000627 latent transforming growth factor beta LTBP1 6.5 binding protein 1 207808_s_at NM_000313 protein S (alpha) PROS1 6.5 204198_s_at AA541630 runt-related transcription factor 3 RUNX3 6.5 212812_at AI700633 Serine incorporator 5 SERINC5 6.5 202935_s_at AI382146 SRY (sex determining region Y)-box 9 SOX9 6.5 (campomelic dysplasia, autosomal sex- reversal) 201925_s_at NM_000574 CD55 molecule, decay accelerating CD55 6.1 factor for complement (Cromer blood group) 221760_at BG287153 Mannosidase, alpha, class 1A, member 1 MAN1A1 6.1 211026_s_at BC006230 monoglyceride lipase /// monoglyceride MGLL 6.1 lipase 213906_at AW592266 v-myb myeloblastosis viral oncogene MYBL1 6.1 homolog (avian)-like 1 201110_s_at NM_003246 thrombospondin 1 THBS1 6.1 215034_s_at AI189753 transmembrane 4 L six family member 1 TM4SF1 6.1 44790_s_at AI129310 chromosome 13 open reading frame 18 C13orf18 5.7 219619_at NM_017594 DIRAS family, GTP-binding RAS-like 2 DIRAS2 5.7 202149_at AL136139 neural precursor cell expressed, NEDD9 5.7 developmentally down-regulated 9 204671_s_at BE677131 ankyrin repeat domain 6 ANKRD6 5.3 204456_s_at AW611727 growth arrest-specific 1 GAS1 5.3 209631_s_at U87460 G protein-coupled receptor 37 GPR37 5.3 (endothelin receptor type B-like) 213954_at AB020695 KIAA0888 protein KIAA0888 5.3 212298_at BE620457 neuropilin 1 NRP1 5.3 205593_s_at NM_002606 phosphodiesterase 9A PDE9A 5.3 204908_s_at NM_005178 B-cell CLL/lymphoma 3 BCL3 4.9 206932_at NM_003956 cholesterol 25-hydroxylase CH25H 4.9 218031_s_at NM_018589 checkpoint suppressor 1 CHES1 4.9 204072_s_at NM_023037 furry homolog (Drosophila) FRY 4.9 39549_at AI743090 neuronal PAS domain protein 2 NPAS2 4.9 218736_s_at NM_017734 palmdelphin PALMD 4.9 203708_at NM_002600 phosphodiesterase 4B, cAMP-specific PDE4B 4.9 (phosphodiesterase E4 dunce homolog, Drosophila) 214660_at X68742 Pelota homolog (Drosophila) PELO 4.9 221524_s_at AF272036 Ras-related GTP binding D RRAGD 4.9 208608_s_at NM_021021 syntrophin, beta 1 (dystrophin- SNTB1 4.9 associated protein A1, 59 kDa, basic component 1) 203476_at NM_006670 trophoblast glycoprotein TPBG 4.9 221156_x_at NM_004748 cell cycle progression 1 CCPG1 4.6 213230_at AI422335 cerebellar degeneration-related protein CDR2L 4.6 2-like 205100_at NM_005110 glutamine-fructose-6-phosphate GFPT2 4.6 transaminase 2 201141_at NM_002510 glycoprotein (transmembrane) nmb GPNMB 4.6 201656_at NM_000210 integrin, alpha 6 ITGA6 4.6 221584_s_at U11058 potassium large conductance calcium- KCNMA1 4.6 activated channel, subfamily M, alpha member 1 212190_at AL541302 serpin peptidase inhibitor, clade E SERPINE2 4.6 (nexin, plasminogen activator inhibitor type 1), member 2 201147_s_at BF347089 TIMP metallopeptidase inhibitor 3 TIMP3 4.6 (Sorsby fundus dystrophy, pseudoinflammatory) 213943_at X99268 twist homolog 1 TWIST1 4.6 (acrocephalosyndactyly 3; Saethre- Chotzen syndrome) (Drosophila) 221973_at AI983904 CDNA clone IMAGE: 5217021, with — 4.3 apparent retained intron 220658_s_at NM_020183 aryl hydrocarbon receptor nuclear ARNTL2 4.3 translocator-like 2 212992_at AI935123 chromosome 14 open reading frame 78 C14orf78 4.3 205379_at NM_001236 carbonyl reductase 3 CBR3 4.3 203139_at NM_004938 death-associated protein kinase 1 DAPK1 4.3 212641_at AL023584 human immunodeficiency virus type I HIVEP2 4.3 enhancer binding protein 2 205559_s_at NM_006200 proprotein convertase subtilisin/kexin PCSK5 4.3 type 5 212646_at D42043 raftlin, lipid raft linker 1 RFTN1 4.3 205383_s_at NM_015642 zinc finger and BTB domain containing ZBTB20 4.3 20 205390_s_at NM_000037 ankyrin 1, erythrocytic /// ankyrin 1, ANK1 4 erythrocytic 202888_s_at NM_001150 alanyl (membrane) aminopeptidase ANPEP 4 (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) 209962_at M34986 erythropoietin receptor EPOR 4 221245_s_at NM_030804 frizzled homolog 5 (Drosophila) /// FZD5 4 frizzled homolog 5 (Drosophila) 201125_s_at NM_002213 integrin, beta 5 ITGB5 4 211470_s_at AF186255 sulfotransferase family, cytosolic, 1C, SULT1C1 4 member 1 210512_s_at AF022375 vascular endothelial growth factor A VEGFA 4 202222_s_at NM_001927 desmin DES 3.7 205366_s_at NM_018952 homeobox B6 HOXB6 3.7 213424_at AB020702 KIAA0895 protein KIAA0895 3.7 209888_s_at M20643 myosin, light chain 1, alkali; skeletal, MYL1 3.7 fast 218162_at NM_020190 olfactomedin-like 3 OLFML3 3.7 202074_s_at NM_021980 optineurin OPTN 3.7 219304_s_at NM_025208 platelet derived growth factor D PDGFD 3.7 201739_at NM_005627 serum/glucocorticoid regulated kinase SGK 3.7 205856_at NM_015865 solute carrier family 14 (urea SLC14A1 3.7 transporter), member 1 (Kidd blood group) 202363_at AF231124 sparc/osteonectin, cwcv and kazal-like SPOCK1 3.7 domains proteoglycan (testican) 1 204236_at NM_002017 Friend leukemia virus integration 1 FLI1 3.5 202794_at NM_002194 inositol polyphosphate-1-phosphatase INPP1 3.5 205876_at NM_002310 leukemia inhibitory factor receptor LIFR 3.5 alpha 202161_at NM_002741 protein kinase N1 PKN1 3.5 218640_s_at NM_024613 pleckstrin homology domain PLEKHF2 3.5 containing, family F (with FYVE domain) member 2 203680_at NM_002736 protein kinase, cAMP-dependent, PRKAR2B 3.5 regulatory, type II, beta 204897_at AA897516 prostaglandin E receptor 4 (subtype PTGER4 3.5 EP4) 213325_at AA129716 poliovirus receptor-related 3 PVRL3 3.5 203217_s_at NM_003896 ST3 beta-galactoside alpha-2,3- ST3GAL5 3.5 sialyltransferase 5 215440_s_at AL523320 brain expressed X-linked-like 1 BEXL1 3.2 209081_s_at NM_030582 collagen, type XVIII, alpha 1 COL18A1 3.2 204036_at AW269335 endothelial differentiation, EDG2 3.2 lysophosphatidic acid G-protein- coupled receptor, 2 200878_at AF052094 endothelial PAS domain protein 1 EPAS1 3.2 213526_s_at BF215644 protein F25965 F25965 3.2 201631_s_at NM_003897 immediate early response 3 IER3 3.2 203474_at NM_006633 IQ motif containing GTPase activating IQGAP2 3.2 protein 2 201015_s_at NM_021991 junction plakoglobin JUP 3.2 203939_at NM_002526 5′-nucleotidase, ecto (CD73) NT5E 3.2 213075_at AL050002 olfactomedin-like 2A OLFML2A 3.2 205226_at NM_006207 platelet-derived growth factor receptor- PDGFRL 3.2 like 200986_at NM_000062 serpin peptidase inhibitor, clade G (C1 SERPING1 3.2 inhibitor), member 1, (angioedema, hereditary) 203167_at NM_003255 TIMP metallopeptidase inhibitor 2 TIMP2 3.2 215783_s_at X14174 alkaline phosphatase, liver/bone/kidney ALPL 3 213004_at AI074333 angiopoietin-like 2 ANGPTL2 3 212614_at BG285011 AT rich interactive domain 5B (MRF1- ARID5B 3 like) 221211_s_at NM_020152 chromosome 21 open reading frame 7 C21orf7 3 209906_at U62027 complement component 3a receptor 1 C3AR1 3 210026_s_at AY028896 caspase recruitment domain family, CARD10 3 member 10 201360_at NM_000099 cystatin C (amyloid angiopathy and CST3 3 cerebral hemorrhage) 217889_s_at NM_024843 cytochrome b reductase 1 CYBRD1 3 203791_at NM_005509 Dmx-like 1 DMXL1 3 202500_at NM_006736 DnaJ (Hsp40) homolog, subfamily B, DNAJB2 3 member 2 209343_at BC002449 EF-hand domain family, member D1 EFHD1 3 206307_s_at NM_004472 forkhead box D1 FOXD1 3 216033_s_at S74774 FYN oncogene related to SRC, FGR, FYN 3 YES 204115_at NM_004126 guanine nucleotide binding protein (G GNG11 3 protein), gamma 11 214104_at AI703188 G protein-coupled receptor 161 GPR161 3 203108_at NM_003979 G protein-coupled receptor, family C, GPRC5A 3 group 5, member A 218469_at NM_013372 gremlin 1, cysteine knot superfamily, GREM1 3 homolog (Xenopus laevis) 215933_s_at Z21533 homeobox, hematopoietically expressed HHEX 3 209185_s_at AF073310 insulin receptor substrate 2 IRS2 3 221011_s_at NM_030915 limb bud and heart development LBH 3 homolog (mouse) /// limb bud and heart development homolog (mouse) 201069_at NM_004530 matrix metallopeptidase 2 (gelatinase MMP2 3 A, 72 kDa gelatinase, 72 kDa type IV collagenase) 212096_s_at AL096842 mitochondrial tumor suppressor 1 MTUS1 3 205880_at NM_002742 protein kinase D1 PRKD1 3 217983_s_at NM_003730 ribonuclease T2 RNASET2 3 202636_at NM_005667 ring finger protein 103 RNF103 3 201286_at Z48199 syndecan 1 SDC1 3 216997_x_at AL358975 transducin-like enhancer of split 4 TLE4 3 (E(sp1) homolog, Drosophila) 213338_at BF062629 transmembrane protein 158 TMEM158 3 219296_at NM_019028 zinc finger, DHHC-type containing 13 ZDHHC13 3 209765_at Y13786 ADAM metallopeptidase domain 19 ADAM19 2.8 (meltrin beta) 212560_at AV728268 chromosome 11 open reading frame 32 C11orf32 2.8 218546_at NM_024709 chromosome 1 open reading frame 115 C1orf115 2.8 213492_at X06268 collagen, type II, alpha 1 (primary COL2A1 2.8 osteoarthritis, spondyloepiphyseal dysplasia, congenital) 218995_s_at NM_001955 endothelin 1 EDN1 2.8 201809_s_at NM_000118 endoglin (Osler-Rendu-Weber ENG 2.8 syndrome 1) 219683_at NM_017412 frizzled homolog 3 (Drosophila) FZD3 2.8 205462_s_at NM_002149 hippocalcin-like 1 HPCAL1 2.8 212830_at W68084 multiple EGF-like-domains 9 MEGF9 2.8 205054_at NM_004543 nebulin NEB 2.8 209324_s_at BF304996 regulator of G-protein signalling 16 RGS16 2.8 210365_at D43967 runt-related transcription factor 1 (acute RUNX1 2.8 myeloid leukemia 1; aml1 oncogene) 207413_s_at NM_000335 sodium channel, voltage-gated, type V, SCN5A 2.8 alpha (long QT syndrome 3) 201920_at NM_005415 solute carrier family 20 (phosphate SLC20A1 2.8 transporter), member 1 204981_at NM_002555 solute carrier family 22 (organic cation SLC22A18 2.8 transporter), member 18 204466_s_at BG260394 synuclein, alpha (non A4 component of SNCA 2.8 amyloid precursor) /// synuclein, alpha (non A4 component of amyloid precursor) 206258_at NM_013305 ST8 alpha-N-acetyl-neuraminide alpha- ST8SIA5 2.8 2,8-sialyltransferase 5 218424_s_at NM_018234 STEAP family member 3 STEAP3 2.8 214378_at BF109662 tissue factor pathway inhibitor TFPI 2.8 (lipoprotein-associated coagulation inhibitor) 212665_at AL556438 TCDD-inducible poly(ADP-ribose) TIPARP 2.8 polymerase 219736_at NM_018700 tripartite motif-containing 36 TRIM36 2.8 217823_s_at AL562528 ubiquitin-conjugating enzyme E2, J1 UBE2J1 2.8 (UBC6 homolog, yeast) 213429_at AW025579 CDNA FLJ26539 fis, clone KDN09310 — 2.6 215617_at AU145711 CDNA FLJ11754 fis, clone — 2.6 HEMBA1005588 60474_at AA469071 chromosome 20 open reading frame 42 C20orf42 2.6 202403_s_at AA788711 collagen, type I, alpha 2 COL1A2 2.6 201200_at NM_003851 cellular repressor of E1A-stimulated CREG1 2.6 genes 1 202481_at NM_004753 dehydrogenase/reductase (SDR family) DHRS3 2.6 member 3 218532_s_at NM_019000 hypothetical protein FLJ20152 FLJ20152 2.6 210220_at L37882 frizzled homolog 2 (Drosophila) FZD2 2.6 204137_at NM_003272 G protein-coupled receptor 137B GPR137B 2.6 205240_at NM_013296 G-protein signalling modulator 2 GPSM2 2.6 (AGS3-like, C. elegans) 212942_s_at AB033025 KIAA1199 KIAA1199 2.6 220940_at NM_025190 KIAA1641 KIAA1641 2.6 213248_at AL577024 hypothetical protein LOC221362 /// LOC221362 /// 2.6 similar to heterogeneous nuclear LOC730101 ribonucleoprotein A/B 40016_g_at AB002301 microtubule associated serine/threonine MAST4 2.6 kinase family member 4 208047_s_at NM_005966 NGFI-A binding protein 1 (EGR1 NAB1 2.6 binding protein 1) 217765_at NM_013392 nuclear receptor binding protein 1 NRBP1 2.6 209034_at AF279899 proline-rich nuclear receptor PNRC1 2.6 coactivator 1 209282_at AF309082 protein kinase D2 PRKD2 2.6 201481_s_at NM_002862 phosphorylase, glycogen; brain PYGB 2.6 219610_at NM_022448 Rho-guanine nucleotide exchange RGNEF 2.6 factor 219457_s_at NM_024832 Ras and Rab interactor 3 RIN3 2.6 206558_at NM_005069 single-minded homolog 2 (Drosophila) SIM2 2.6 215223_s_at W46388 superoxide dismutase 2, mitochondrial SOD2 2.6 204955_at NM_006307 sushi-repeat-containing protein, X- SRPX 2.6 linked 210612_s_at AF318616 synaptojanin 2 SYNJ2 2.6 209198_s_at BC004291 synaptotagmin XI SYT11 2.6 205122_at BF439316 transmembrane protein with EGF-like TMEFF1 2.6 and two follistatin-like domains 1 201690_s_at AA524023 tumor protein D52 TPD52 2.6 202893_at NM_006377 unc-13 homolog B (C. elegans) UNC13B 2.6 204254_s_at NM_000376 vitamin D (1,25-dihydroxyvitamin D3) VDR 2.6 receptor 208622_s_at AA670344 villin 2 (ezrin) VIL2 2.6 212993_at AA114166 MRNA; cDNA DKFZp667B1718 — 2.5 (from clone DKFZp667B1718) 221881_s_at AI638420 adducin 3 (gamma) /// chloride ADD3 /// CLIC4 2.5 intracellular channel 4 220092_s_at NM_018153 anthrax toxin receptor 1 ANTXR1 2.5 40148_at U62325 amyloid beta (A4) precursor protein- APBB2 2.5 binding, family B, member 2 (Fe65- like) 203576_at NM_001190 branched chain aminotransferase 2, BCAT2 2.5 mitochondrial 215509_s_at AL137654 BUB1 budding uninhibited by BUB1 2.5 benzimidazoles 1 homolog (yeast) 220975_s_at NM_030968 C1q and tumor necrosis factor related C1QTNF1 2.5 protein 1 /// C1q and tumor necrosis factor related protein 1 220918_at NM_025143 chromosome 21 open reading frame 96 C21orf96 2.5 208908_s_at AF327443 calpastatin CAST 2.5 204154_at NM_001801 cysteine dioxygenase, type I CDO1 2.5 212091_s_at AI141603 collagen, type VI, alpha 1 COL6A1 2.5 202517_at NM_001313 collapsin response mediator protein 1 CRMP1 2.5 201487_at NM_001814 cathepsin C CTSC 2.5 201279_s_at BC003064 disabled homolog 2, mitogen- DAB2 2.5 responsive phosphoprotein (Drosophila) 222101_s_at BF222893 dachsous 1 (Drosophila) DCHS1 2.5 202929_s_at NM_001355 D-dopachrome tautomerase DDT 2.5 203881_s_at NM_004010 dystrophin (muscular dystrophy, DMD 2.5 Duchenne and Becker types) 218225_at NM_016581 ECSIT homolog (Drosophila) ECSIT 2.5 217154_s_at AL035250 endothelin 3 EDN3 2.5 205738_s_at NM_004102 fatty acid binding protein 3, muscle and FABP3 2.5 heart (mammary-derived growth inhibitor) 201910_at BF213279 FERM, RhoGEF (ARHGEF) and FARP1 2.5 pleckstrin domain protein 1 (chondrocyte-derived) 207357_s_at NM_017540 UDP-N-acetyl-alpha-D- GALNT10 2.5 galactosamine:polypeptide N- acetylgalactosaminyltransferase 10 (GalNAc-T10) 216733_s_at X86401 glycine amidinotransferase (L- GATM 2.5 arginine:glycine amidinotransferase) 221577_x_at AF003934 growth differentiation factor 15 GDF15 2.5 203390_s_at NM_002254 kinesin family member 3C KIF3C 2.5 203130_s_at NM_004522 kinesin family member 5C KIF5C 2.5 204682_at NM_000428 latent transforming growth factor beta LTBP2 2.5 binding protein 2 219278_at NM_004672 mitogen-activated protein kinase kinase MAP3K6 2.5 kinase 6 206571_s_at NM_004834 mitogen-activated protein kinase kinase MAP4K4 2.5 kinase kinase 4 218890_x_at NM_016622 mitochondrial ribosomal protein L35 MRPL35 2.5 212365_at BF215996 myosin IB MYO1B 2.5 215073_s_at AL554245 nuclear receptor subfamily 2, group F, NR2F2 2.5 member 2 204622_x_at NM_006186 nuclear receptor subfamily 4, group A, NR4A2 2.5 member 2 210448_s_at U49396 purinergic receptor P2X, ligand-gated P2RX5 2.5 ion channel, 5 210139_s_at L03203 peripheral myelin protein 22 PMP22 2.5 209158_s_at BC004361 pleckstrin homology, Sec7 and coiled- PSCD2 2.5 coil domains 2 (cytohesin-2) 49306_at AI890191 Ras association (RalGDS/AF-6) RASSF4 2.5 domain family 4 204364_s_at BE535746 receptor accessory protein 1 REEP1 2.5 209568_s_at AF186779 ral guanine nucleotide dissociation RGL1 2.5 stimulator-like 1 209306_s_at AI139569 SWAP-70 protein SWAP70 2.5 209890_at AF065389 tetraspanin 5 /// tetraspanin 5 TSPAN5 2.5 213996_at NM_013313 yippee-like 1 (Drosophila) YPEL1 2.5 217783_s_at NM_016061 yippee-like 5 (Drosophila) YPEL5 2.5 212985_at BF115739 Full-length cDNA clone — 2.3 CS0DC015YK09 of Neuroblastoma Cot 25-normalized of Homo sapiens (human) 218795_at NM_016361 acid phosphatase 6, lysophosphatidic ACP6 2.3 205401_at NM_003659 alkylglycerone phosphate synthase AGPS 2.3 202587_s_at BC001116 adenylate kinase 1 AK1 2.3 202920_at BF726212 ankyrin 2, neuronal ANK2 2.3 210202_s_at U87558 bridging integrator 1 BIN1 2.3 200921_s_at NM_001731 B-cell translocation gene 1, anti- BTG1 2.3 proliferative 205308_at NM_016010 chromosome 8 open reading frame 70 C8orf70 2.3 200622_x_at AV685208 calmodulin 3 (phosphorylase kinase, CALM3 2.3 delta) 201850_at NM_001747 capping protein (actin filament), CAPG 2.3 gelsolin-like 220004_at NM_018665 DEAD (Asp-Glu-Ala-Asp) box DDX43 2.3 polypeptide 43 215482_s_at AJ011307 eukaryotic translation initiation factor EIF2B4 2.3 2B, subunit 4 delta, 67 kDa 219253_at NM_024121 family with sequence similarity 11, FAM11B 2.3 member B 209576_at AL049933 guanine nucleotide binding protein (G GNAI1 2.3 protein), alpha inhibiting activity polypeptide 1 221902_at AL567940 G protein-coupled receptor 153 GPR153 2.3 218603_at NM_016217 headcase homolog (Drosophila) HECA 2.3 221004_s_at NM_030926 integral membrane protein 2C /// ITM2C 2.3 integral membrane protein 2C 212492_s_at AW237172 jumonji domain containing 2B JMJD2B 2.3 219287_at NM_014505 potassium large conductance calcium- KCNMB4 2.3 activated channel, subfamily M, beta member 4 204334_at AA488672 Kruppel-like factor 7 (ubiquitous) KLF7 2.3 204584_at AI653981 L1 cell adhesion molecule L1CAM 2.3 203041_s_at J04183 lysosomal-associated membrane protein 2 LAMP2 2.3 208949_s_at BC001120 lectin, galactoside-binding, soluble, 3 LGALS3 2.3 (galectin 3) 204091_at NM_002601 phosphodiesterase 6D, cGMP-specific, PDE6D 2.3 rod, delta 211924_s_at AY029180 plasminogen activator, urokinase PLAUR 2.3 receptor /// plasminogen activator, urokinase receptor 206574_s_at NM_007079 protein tyrosine phosphatase type IVA, PTP4A3 2.3 member 3 207836_s_at NM_006867 RNA binding protein with multiple RBPMS 2.3 splicing 202898_at NM_014654 syndecan 3 (N-syndecan) SDC3 2.3 208127_s_at NM_014011 suppressor of cytokine signaling 5 SOCS5 2.3 212780_at AA700167 son of sevenless homolog 1 SOS1 2.3 (Drosophila) 216941_s_at AK026521 TATA box binding protein (TBP)- TAF1B 2.3 associated factor, RNA polymerase I, B, 63 kDa 203083_at NM_003247 thrombospondin 2 THBS2 2.3 212989_at AI377497 transmembrane protein 23 TMEM23 2.3 211300_s_at K03199 tumor protein p53 (Li-Fraumeni TP53 2.3 syndrome) 210609_s_at BC000474 tumor protein p53 inducible protein 3 TP53I3 2.3 202368_s_at AI986461 translocation associated membrane TRAM2 2.3 protein 2 202478_at NM_021643 tribbles homolog 2 (Drosophila) TRIB2 2.3 214023_x_at AL533838 tubulin, beta 2B TUBB2B 2.3 208998_at U94592 uncoupling protein 2 (mitochondrial, UCP2 2.3 proton carrier) 218807_at NM_006113 vav 3 oncogene VAV3 2.3 203855_at NM_014969 WD repeat domain 47 WDR47 2.3 221646_s_at AF267859 zinc finger, DHHC-type containing 11 ZDHHC11 2.3 215447_at AL080215 — — 2.1 205434_s_at AW451954 AP2 associated kinase 1 /// hypothetical AAK1 /// 2.1 protein LOC647217 LOC647217 210517_s_at AB003476 A kinase (PRKA) anchor protein AKAP12 2.1 (gravin) 12 214073_at BG475299 Aldehyde dehydrogenase 1 family, ALDH1A3 2.1 member A3 219637_at NM_025139 armadillo repeat containing 9 ARMC9 2.1 200070_at BC001393 chromosome 2 open reading frame 24 C2orf24 2.1 /// chromosome 2 open reading frame 24 209829_at AB002384 chromosome 6 open reading frame 32 C6orf32 2.1 204392_at NM_003656 calcium/calmodulin-dependent protein CAMK1 2.1 kinase I 209956_s_at U23460 calcium/calmodulin-dependent protein CAMK2B 2.1 kinase (CaM kinase) II beta 218309_at NM_018584 calcium/calmodulin-dependent protein CAMK2N1 2.1 kinase II inhibitor 1 212624_s_at BF339445 chimerin (chimaerin) 1 CHN1 2.1 206414_s_at NM_003887 development and differentiation DDEF2 2.1 enhancing factor 2 212503_s_at N22859 DIP2 disco-interacting protein 2 DIP2C 2.1 homolog C (Drosophila) 202196_s_at NM_013253 dickkopf homolog 3 (Xenopus laevis) DKK3 2.1 209365_s_at U65932 extracellular matrix protein 1 ECM1 2.1 220161_s_at NM_019114 erythrocyte membrane protein band 4.1 EPB41L4B 2.1 like 4B 221766_s_at AW246673 family with sequence similarity 46, FAM46A 2.1 member A 202949_s_at NM_001450 four and a half LIM domains 2 FHL2 2.1 218610_s_at NM_018340 hypothetical protein FLJ11151 FLJ11151 2.1 218880_at N36408 FOS-like antigen 2 FOSL2 2.1 219170_at NM_024333 fibronectin type III and SPRY domain FSD1 /// 2.1 containing 1 /// similar to fibronectin LOC731565 type III and SPRY domain containing 1 218204_s_at NM_024513 FYVE and coiled-coil domain FYCO1 2.1 containing 1 218070_s_at NM_013335 GDP-mannose pyrophosphorylase A GMPPA 2.1 214438_at M60721 H2.0-like homeobox 1 (Drosophila) HLX1 2.1 213150_at BF792917 homeobox A10 HOXA10 2.1 214434_at AB007877 heat shock 70 kDa protein 12A HSPA12A 2.1 201565_s_at NM_002166 inhibitor of DNA binding 2, dominant ID2 2.1 negative helix-loop-helix protein 201888_s_at U81379 interleukin 13 receptor, alpha 1 IL13RA1 2.1 204465_s_at NM_004692 internexin neuronal intermediate INA 2.1 filament protein, alpha 201189_s_at NM_002224 inositol 1,4,5-triphosphate receptor, ITPR3 2.1 type 3 212689_s_at AA524505 jumonji domain containing 1A JMJD1A 2.1 201776_s_at AK001487 KIAA0494 KIAA0494 2.1 213157_s_at BF115148 KIAA0523 protein KIAA0523 2.1 201596_x_at NM_000224 keratin 18 KRT18 2.1 204527_at NM_000259 myosin VA (heavy chain 12, myoxin) MYO5A 2.1 218231_at NM_017567 N-acetylglucosamine kinase /// N- NAGK 2.1 acetylglucosamine kinase 213568_at AI811298 odd-skipped related 2 (Drosophila) OSR2 2.1 203803_at N45309 prenylcysteine oxidase 1 PCYOX1 2.1 219126_at NM_018288 PHD finger protein 10 PHF10 2.1 209625_at BC004100 phosphatidylinositol glycan anchor PIGH 2.1 biosynthesis, class H 202732_at NM_007066 protein kinase (cAMP-dependent, PKIG 2.1 catalytic) inhibitor gamma 203896_s_at NM_000933 phospholipase C, beta 4 PLCB4 2.1 205934_at NM_006226 phospholipase C-like 1 PLCL1 2.1 203718_at NM_006702 patatin-like phospholipase domain PNPLA6 2.1 containing 6 205933_at NM_015559 SET binding protein 1 SETBP1 2.1 218720_x_at NM_012410 seizure related 6 homolog (mouse)-like 2 SEZ6L2 2.1 204362_at NM_003930 src kinase associated phosphoprotein 2 SKAP2 2.1 202855_s_at AL513917 solute carrier family 16, member 3 SLC16A3 2.1 (monocarboxylic acid transporter 4) 221041_s_at NM_012434 solute carrier family 17 (anion/sugar SLC17A5 2.1 transporter), member 5 220123_at NM_025181 solute carrier family 35, member F5 SLC35F5 2.1 209748_at AB029006 spastin SPAST 2.1 202786_at NM_013233 serine threonine kinase 39 STK39 2.1 (STE20/SPS1 homolog, yeast) 212625_at NM_003765 syntaxin 10 STX10 2.1 203310_at NM_007269 syntaxin binding protein 3 STXBP3 2.1 201079_at NM_004710 synaptogyrin 2 SYNGR2 2.1 215273_s_at AK024982 transcriptional adaptor 3 (NGG1 TADA3L 2.1 homolog, yeast)-like 205993_s_at NM_005994 T-box 2 TBX2 2.1 218996_at NM_013342 TCF3 (E2A) fusion partner (in TFPT 2.1 childhood Leukemia) 209118_s_at AF141347 tubulin, alpha 3 TUBA3 2.1 204141_at NM_001069 tubulin, beta 2A TUBB2A 2.1 219201_s_at NM_020648 twisted gastrulation homolog 1 TWSG1 2.1 (Drosophila) 214755_at AK022632 UDP-N-acteylglucosamine UAP1L1 2.1 pyrophosphorylase 1-like 1 210024_s_at AB017644 ubiquitin-conjugating enzyme E2E 3 UBE2E3 2.1 (UBC4/5 homolog, yeast) 209551_at BC004875 Yip1 domain family, member 4 YIPF4 2.1 201662_s_at D89053 acyl-CoA synthetase long-chain family ACSL3 2 member 3 201753_s_at NM_019903 adducin 3 (gamma) ADD3 2 201952_at AA156721 activated leukocyte cell adhesion ALCAM 2 molecule 212747_at AI990523 ankyrin repeat and sterile alpha motif ANKS1A 2 domain containing 1A 207076_s_at NM_000050 argininosuccinate synthetase 1 ASS1 2 213587_s_at AI884867 ATPase, H+ transporting V0 subunit e2 ATP6V0E2 2 202685_s_at AI467916 AXL receptor tyrosine kinase AXL 2 40093_at X83425 basal cell adhesion molecule (Lutheran BCAM 2 blood group) 219506_at NM_024579 chromosome 1 open reading frame 54 C1orf54 2 205575_at NM_006688 complement component 1, q C1QL1 2 subcomponent-like 1 204489_s_at NM_000610 CD44 molecule (Indian blood group) CD44 2 202910_s_at NM_001784 CD97 molecule CD97 2 204039_at NM_004364 CCAAT/enhancer binding protein CEBPA 2 (C/EBP), alpha 203973_s_at NM_005195 CCAAT/enhancer binding protein CEBPD 2 (C/EBP), delta 209357_at AF109161 Cbp/p300-interacting transactivator, CITED2 2 with Glu/Asp-rich carboxy-terminal domain, 2 211141_s_at AF180474 CCR4-NOT transcription complex, CNOT3 2 subunit 3 205229_s_at AA669336 coagulation factor C homolog, cochlin COCH 2 (Limulus polyphemus) 37892_at J04177 collagen, type XI, alpha 1 COL11A1 2 206100_at NM_001874 carboxypeptidase M CPM 2 221988_at AA463853 Cofactor required for Sp1 CRSP7 2 transcriptional activation, subunit 7, 70 kDa 215785_s_at AL161999 cytoplasmic FMR1 interacting protein 2 CYFIP2 2 215537_x_at AJ012008 dimethylarginine DDAH2 2 dimethylaminohydrolase 2 214027_x_at AA889653 desmin /// family with sequence DES /// FAM48A 2 similarity 48, member A 213420_at AA100250 DEAH (Asp-Glu-Ala-Asp/His) box DHX57 2 polypeptide 57 200664_s_at BG537255 DnaJ (Hsp40) homolog, subfamily B, DNAJB1 2 member 1 205248_at NM_005128 dopey family member 2 DOPEY2 2 204034_at NM_014297 ethylmalonic encephalopathy 1 ETHE1 2 219377_at NM_022751 family with sequence similarity 59, FAM59A 2 member A 213249_at AU145127 F-box and leucine-rich repeat protein 7 FBXL7 2 219208_at NM_025133 F-box protein 11 FBXO11 2 208378_x_at NM_004464 fibroblast growth factor 5 FGF5 2 208476_s_at NM_018027 FERM domain containing 4A FRMD4A 2 218084_x_at NM_014164 FXYD domain containing ion transport FXYD5 2 regulator 5 212891_s_at BF972185 growth arrest and DNA-damage- GADD45GIP1 2 inducible, gamma interacting protein 1 214510_at NM_005293 G protein-coupled receptor 20 GPR20 2 212822_at AA121502 HEG homolog 1 (zebrafish) HEG1 2 205453_at NM_002145 homeobox B2 HOXB2 2 204779_s_at NM_004502 homeobox B7 HOXB7 2 201841_s_at NM_001540 heat shock 27 kDa protein 1 /// Meis1, HSPB1 /// MEIS3 2 myeloid ecotropic viral integration site 1 homolog 3 (mouse) 211152_s_at AF184911 HtrA serine peptidase 2 HTRA2 2 201566_x_at D13891 inhibitor of DNA binding 2, dominant ID2 /// ID2B 2 negative helix-loop-helix protein /// inhibitor of DNA binding 2B, dominant negative helix-loop-helix protein 201315_x_at NM_006435 interferon induced transmembrane IFITM2 2 protein 2 (1-8D) 203336_s_at AL548363 integrin beta 1 binding protein 1 ITGB1BP1 2 202962_at NM_015254 kinesin family member 13B KIF13B 2 209234_at BF939474 kinesin family member 1B KIF1B 2 220253_s_at NM_013437 low density lipoprotein-related protein LRP12 2 12 201862_s_at NM_004735 leucine rich repeat (in FLII) interacting LRRFIP1 2 protein 1 212246_at BE880828 multiple coagulation factor deficiency 2 MCFD2 2 210087_s_at AF095727 myelin protein zero-like 1 MPZL1 2 202180_s_at NM_017458 major vault protein MVP 2 220319_s_at NM_013262 myosin regulatory light chain MYLIP 2 interacting protein 212843_at AA126505 neural cell adhesion molecule 1 NCAM1 2 212949_at D38553 non-SMC condensin I complex, subunit H NCAPH 2 203315_at BC000103 NCK adaptor protein 2 /// similar to NCK2 /// 2 NCK adaptor protein 2 LOC729030 200701_at NM_006432 Niemann-Pick disease, type C2 NPC2 2 219789_at AI628360 natriuretic peptide receptor C/guanylate NPR3 2 cyclase C (atrionatriuretic peptide receptor C) 209262_s_at BC002669 nuclear receptor subfamily 2, group F, NR2F6 2 member 6 214130_s_at AI821791 phosphodiesterase 4D interacting PDE4DIP /// 2 protein (myomegalin) /// similar to LOC727942 phosphodiesterase 4D interacting protein isoform 2 210041_s_at BC001258 phosphoglucomutase 3 PGM3 2 209803_s_at AF001294 pleckstrin homology-like domain, PHLDA2 2 family A, member 2 201860_s_at NM_000930 plasminogen activator, tissue PLAT 2 211668_s_at K03226 plasminogen activator, urokinase /// PLAU 2 plasminogen activator, urokinase 203467_at NM_002676 phosphomannomutase 1 PMM1 2 204284_at N26005 protein phosphatase 1, regulatory PPP1R3C 2 (inhibitor) subunit 3C 213093_at AI471375 protein kinase C, alpha PRKCA 2 219729_at NM_016307 paired related homeobox 2 PRRX2 2 202458_at NM_007173 protease, serine, 23 PRSS23 2 205128_x_at NM_000962 prostaglandin-endoperoxide synthase 1 PTGS1 2 (prostaglandin G/H synthase and cyclooxygenase) 205503_at NM_005401 protein tyrosine phosphatase, non- PTPN14 2 receptor type 14 34478_at X79780 RAB11B, member RAS oncogene RAB11B 2 family 210138_at AF074979 regulator of G-protein signalling 20 RGS20 2 221770_at BE964473 ribulose-5-phosphate-3-epimerase RPE 2 202497_x_at AI631159 solute carrier family 2 (facilitated SLC2A3 2 glucose transporter), member 3 209712_at AI769637 solute carrier family 35 (UDP- SLC35D1 2 glucuronic acid/UDP-N- acetylgalactosamine dual transporter), member D1 210001_s_at AB005043 suppressor of cytokine signaling 1 SOCS1 2 203509_at NM_003105 sortilin-related receptor, L (DLR class) SORL1 2 A repeats-containing 210218_s_at U36501 SP100 nuclear antigen SP100 2 202506_at NM_006751 sperm specific antigen 2 SSFA2 2 208992_s_at BC000627 signal transducer and activator of STAT3 2 transcription 3 (acute-phase response factor) 220761_s_at NM_016281 TAO kinase 3 TAOK3 2 219169_s_at NM_016020 transcription factor B1, mitochondrial TFB1M 2 202011_at NM_003257 tight junction protein 1 (zona occludens TJP1 2 1) 217730_at NM_022152 transmembrane BAX inhibitor motif TMBIM1 2 containing 1 208296_x_at NM_014350 tumor necrosis factor, alpha-induced TNFAIP8 2 protein 8 202704_at AA675892 transducer of ERBB2, 1 TOB1 2 212481_s_at AI214061 tropomyosin 4 TPM4 2 202124_s_at AV705253 trafficking protein, kinesin binding 2 TRAK2 2 215047_at AL080170 tripartite motif-containing 58 TRIM58 2 211701_s_at AF349720 trophinin /// trophinin TRO 2 213174_at BE675549 tetratricopeptide repeat domain 9 TTC9 2 209372_x_at BF971587 tubulin, beta 2A /// tubulin, beta 2B TUBB2A /// 2 TUBB2B 202663_at AI005043 WAS/WASL interacting protein family, WIPF1 2 member 1 218110_at NM_020196 XPA binding protein 2 XAB2 2 220748_s_at NM_016202 zinc finger protein 580 ZNF580 2 Genes higher expressed in the sensitive RD-1 cells: 204239_s_at NM_005386 neuronatin NNAT −29.9 202942_at NM_001985 electron-transfer-flavoprotein, beta ETFB −26 polypeptide 215731_s_at X98258 M-phase phosphoprotein 9 MPHOSPH9 −26 219271_at NM_024572 UDP-N-acetyl-alpha-D- GALNT14 −22.6 galactosamine:polypeptide N- acetylgalactosaminyltransferase 14 (GalNAc-T14) 219274_at NM_012338 tetraspanin 12 TSPAN12 −21.1 209656_s_at AL136550 transmembrane protein 47 TMEM47 −19.7 204439_at NM_006820 interferon-induced protein 44-like IFI44L −18.4 203510_at BG170541 met proto-oncogene (hepatocyte growth MET −18.4 factor receptor) 206228_at AW769732 paired box gene 2 PAX2 −18.4 207173_x_at D21254 cadherin 11, type 2, OB-cadherin CDH11 −17.1 (osteoblast) 206440_at NM_004664 lin-7 homolog A (C. elegans) LIN7A −17.1 205352_at NM_005025 serpin peptidase inhibitor, clade I SERPINI1 −17.1 (neuroserpin), member 1 218541_s_at NM_020130 chromosome 8 open reading frame 4 C8orf4 −14.9 206432_at NM_005328 hyaluronan synthase 2 HAS2 −13.9 202508_s_at NM_003081 synaptosomal-associated protein, SNAP25 −13 25 kDa 216005_at BF434846 Tenascin C (hexabrachion) TNC −13 220586_at NM_025134 chromodomain helicase DNA binding CHD9 −12.1 protein 9 219908_at NM_014421 dickkopf homolog 2 (Xenopus laevis) DKK2 −12.1 47560_at AI525402 latrophilin 1 LPHN1 −10.6 206459_s_at AB045117 wingless-type MMTV integration site WNT2B −10.6 family, member 2B 206385_s_at NM_020987 ankyrin 3, node of Ranvier (ankyrin G) ANK3 −9.8 207039_at NM_000077 cyclin-dependent kinase inhibitor 2A CDKN2A −9.8 (melanoma, p16, inhibits CDK4) 205003_at NM_014705 dedicator of cytokinesis 4 DOCK4 −9.8 214829_at AK023446 aminoadipate-semialdehyde synthase AASS −9.2 218775_s_at NM_024949 WW and C2 domain containing 2 WWC2 −9.2 209732_at BC005254 C-type lectin domain family 2, member CLEC2B /// −8.6 B /// CMT1A duplicated region CDRT15P transcript 15 pseudogene 202310_s_at K01228 collagen, type I, alpha 1 COL1A1 −8.6 36830_at U80034 mitochondrial intermediate peptidase MIPEP −8.6 215008_at AA582404 tolloid-like 2 TLL2 −8.6 200953_s_at NM_001759 cyclin D2 CCND2 −8 211155_s_at D32047 thrombopoietin (myeloproliferative THPO −8 leukemia virus oncogene ligand, megakaryocyte growth and development factor) 204470_at NM_001511 chemokine (C—X—C motif) ligand 1 CXCL1 −7.5 (melanoma growth stimulating activity, alpha) 215231_at AU144309 Protein kinase, AMP-activated, gamma PRKAG2 −7 2 non-catalytic subunit 214331_at AI796813 Ts translation elongation factor, TSFM −7 mitochondrial 206001_at NM_000905 neuropeptide Y NPY −6.5 213718_at BE222257 RNA binding motif protein 4 RBM4 −6.5 205498_at NM_000163 growth hormone receptor GHR −6.1 218717_s_at NM_018192 leprecan-like 1 LEPREL1 −6.1 205113_at NM_005382 neurofilament, medium polypeptide NEFM −6.1 150 kDa 204081_at NM_006176 neurogranin (protein kinase C substrate, NRGN −6.1 RC3) 207558_s_at NM_000325 paired-like homeodomain transcription PITX2 −6.1 factor 2 202659_at NM_002801 proteasome (prosome, macropain) PSMB10 −6.1 subunit, beta type, 10 205433_at NM_000055 butyrylcholinesterase BCHE −5.7 214045_at BF056778 lipoic acid synthetase LIAS −5.7 209267_s_at AB040120 solute carrier family 39 (zinc SLC39A8 −5.7 transporter), member 8 207850_at NM_002090 chemokine (C—X—C motif) ligand 3 CXCL3 −5.3 205132_at NM_005159 actin, alpha, cardiac muscle 1 ACTC1 −4.9 200897_s_at NM_016081 palladin, cytoskeletal associated protein PALLD −4.9 207119_at NM_006258 protein kinase, cGMP-dependent, type I PRKG1 −4.9 219498_s_at NM_018014 B-cell CLL/lymphoma 11A (zinc finger BCL11A −4.6 protein) 1405_i_at M21121 chemokine (C-C motif) ligand 5 CCL5 −4.6 217028_at AJ224869 chemokine (C—X—C motif) receptor 4 CXCR4 −4.6 219118_at NM_016594 FK506 binding protein 11, 19 kDa FKBP11 −4.6 213797_at AI337069 radical S-adenosyl methionine domain RSAD2 −4.6 containing 2 204268_at NM_005978 S100 calcium binding protein A2 S100A2 −4.6 213500_at AI307760 Coatomer protein complex, subunit beta COPB2 −4.3 2 (beta prime) 218676_s_at NM_021213 phosphatidylcholine transfer protein PCTP −4.3 211570_s_at BC004196 receptor-associated protein of the RAPSN −4.3 synapse, 43 kD 213591_at AU149534 Aldehyde dehydrogenase 7 family, ALDH7A1 −4 member A1 209774_x_at M57731 chemokine (C—X—C motif) ligand 2 CXCL2 −4 221667_s_at AF133207 heat shock 22 kDa protein 8 HSPB8 −4 205992_s_at NM_000585 interleukin 15 IL15 −4 220145_at NM_024826 microtubule-associated protein 9 MAP9 −4 220346_at NM_025001 methylenetetrahydrofolate MTHFD2L −4 dehydrogenase (NADP+ dependent) 2- like 210556_at U85430 nuclear factor of activated T-cells, NFATC3 −4 cytoplasmic, calcineurin-dependent 3 204589_at NM_014840 NUAK family, SNF1-like kinase, 1 NUAK1 −4 213817_at AL049435 CDNA FLJ13601 fis, clone — −3.7 PLACE1010069 219973_at NM_024590 arylsulfatase family, member J ARSJ −3.7 213880_at AL524520 leucine-rich repeat-containing G LGR5 −3.7 protein-coupled receptor 5 204597_x_at NM_003155 stanniocalcin 1 STC1 −3.7 208847_s_at M29872 alcohol dehydrogenase 5 (class III), chi ADH5 −3.5 polypeptide 212384_at AI282485 HLA-B associated transcript 1 BAT1 −3.5 211237_s_at AF202063 fibroblast growth factor receptor 4 FGFR4 −3.5 214604_at NM_021192 homeobox D11 HOXD11 −3.5 209099_x_at U73936 jagged 1 (Alagille syndrome) JAG1 −3.5 219582_at NM_024576 opioid growth factor receptor-like 1 OGFRL1 −3.5 207943_x_at NM_006718 pleiomorphic adenoma gene-like 1 PLAGL1 −3.5 202457_s_at AA911231 protein phosphatase 3 (formerly 2B), PPP3CA −3.5 catalytic subunit, alpha isoform (calcineurin A alpha) 212749_s_at AI096477 ring finger and CHY zinc finger domain RCHY1 −3.5 containing 1 215591_at AK025127 SATB family member 2 SATB2 −3.5 205609_at NM_001146 angiopoietin 1 ANGPT1 −3.2 202370_s_at NM_001755 core-binding factor, beta subunit CBFB −3.2 221521_s_at BC003186 GINS complex subunit 2 (Psf2 GINS2 −3.2 homolog) 201036_s_at NM_005327 hydroxyacyl-Coenzyme A HADH −3.2 dehydrogenase 213032_at AI186739 nuclear factor I/B NFIB −3.2 206653_at BF062139 polymerase (RNA) III (DNA directed) POLR3G −3.2 polypeptide G (32 kD) 213852_at BG289199 RNA binding motif protein 8A RBM8A −3.2 210432_s_at AF225986 sodium channel, voltage-gated, type III, SCN3A −3.2 alpha 221495_s_at AF322111 transcription factor 25 (basic helix- TCF25 /// MXRA7 −3.2 loop-helix) /// matrix-remodelling associated 7 220104_at NM_020119 zinc finger CCCH-type, antiviral 1 ZC3HAV1 −3.2 201067_at BF215487 — — −3 212126_at BG391282 CDNA clone IMAGE: 4842353 — −3 211148_s_at AF187858 angiopoietin 2 ANGPT2 −3 203264_s_at NM_015185 Cdc42 guanine nucleotide exchange ARHGEF9 −3 factor (GEF) 9 219023_at NM_018569 chromosome 4 open reading frame 16 C4orf16 −3 206070_s_at AF213459 EPH receptor A3 EPHA3 −3 214240_at AL556409 galanin GAL −3 220085_at NM_018063 helicase, lymphoid-specific HELLS −3 213359_at W74620 Heterogeneous nuclear HNRPD −3 ribonucleoprotein D (AU-rich element RNA binding protein 1, 37 kDa) 210112_at U96721 Hermansky-Pudlak syndrome 1 HPS1 −3 219213_at NM_021219 junctional adhesion molecule 2 JAM2 −3 222018_at AI992187 nascent-polypeptide-associated NACA /// NACAP1 −3 complex alpha polypeptide /// nascent- /// LOC389240 polypeptide-associated complex alpha polypeptide pseudogene 1 /// similar to nascent polypeptide-associated complex alpha polypeptide 219368_at NM_021963 nucleosome assembly protein 1-like 2 NAP1L2 −3 220741_s_at NM_006903 pyrophosphatase (inorganic) 2 /// PPA2 /// TRIM69 −3 tripartite motif-containing 69 203789_s_at NM_006379 sema domain, immunoglobulin domain SEMA3C −3 (Ig), short basic domain, secreted, (semaphorin) 3C 215389_s_at X79857 troponin T type 2 (cardiac) TNNT2 −3 203869_at AK024318 ubiquitin specific peptidase 46 USP46 −3 213790_at W46291 CDNA FLJ31066 fis, clone — −2.8 HSYRA2001153 219474_at NM_024616 chromosome 3 open reading frame 52 C3orf52 −2.8 209446_s_at BC001743 chromosome 7 open reading frame 44 C7orf44 −2.8 219555_s_at NM_018455 centromere protein N CENPN −2.8 208968_s_at BC002568 cytokine induced apoptosis inhibitor 1 CIAPIN1 −2.8 201733_at AA902971 chloride channel 3 CLCN3 −2.8 203498_at NM_005822 Down syndrome critical region gene 1- DSCR1L1 −2.8 like 1 222104_x_at AI569458 general transcription factor IIH, GTF2H3 −2.8 polypeptide 3, 34 kDa 209256_s_at AF277177 KIAA0265 protein KIAA0265 −2.8 209211_at AF132818 Kruppel-like factor 5 (intestinal) KLF5 −2.8 211042_x_at BC006329 melanoma cell adhesion molecule /// MCAM −2.8 melanoma cell adhesion molecule 208754_s_at AL162068 nucleosome assembly protein 1-like 1 NAP1L1 −2.8 219158_s_at NM_025085 NMDA receptor regulated 1 NARG1 −2.8 204105_s_at NM_005010 neuronal cell adhesion molecule NRCAM −2.8 201831_s_at BE875592 p21/Cdc42/Rac1-activated kinase 1 PAK1 /// VDP −2.8 (STE20 homolog, yeast) /// vesicle docking protein p115 209486_at BC004546 disrupter of silencing 10 SAS10 −2.8 219772_s_at NM_014332 small muscle protein, X-linked SMPX −2.8 205444_at NM_004320 ATPase, Ca++ transporting, cardiac ATP2A1 −2.6 muscle, fast twitch 1 212189_s_at AK022874 component of oligomeric golgi COG4 −2.6 complex 4 213546_at AL050378 hypothetical protein DKFZp586I1420 DKFZp586I1420 −2.6 212327_at AK026815 hypothetical protein DKFZP686A01247 −2.6 219237_s_at NM_024920 DnaJ (Hsp40) homolog, subfamily B, DNAJB14 −2.6 member 14 205061_s_at NM_005033 exosome component 9 EXOSC9 −2.6 207327_at NM_004100 eyes absent homolog 4 (Drosophila) EYA4 −2.6 202771_at NM_014745 family with sequence similarity 38, FAM38A −2.6 member A 219646_at NM_017702 hypothetical protein FLJ20186 FLJ20186 −2.6 205280_at NM_000824 glycine receptor, beta GLRB −2.6 200853_at NM_002106 H2A histone family, member Z H2AFZ −2.6 219863_at NM_016323 hect domain and RLD 5 HERC5 −2.6 218604_at NM_014319 LEM domain containing 3 LEMD3 −2.6 203740_at NM_005792 M-phase phosphoprotein 6 MPHOSPH6 −2.6 209519_at BG108193 nuclear cap binding protein subunit 1, NCBP1 −2.6 80 kDa 201939_at NM_006622 polo-like kinase 2 (Drosophila) PLK2 −2.6 212037_at BF508848 pinin, desmosome associated protein PNN −2.6 202541_at BF589679 small inducible cytokine subfamily E, SCYE1 −2.6 member 1 (endothelial monocyte- activating) 206529_x_at NM_000441 solute carrier family 26, member 4 SLC26A4 −2.6 201996_s_at AL524033 spen homolog, transcriptional regulator SPEN −2.6 (Drosophila) 209989_at AF317549 zinc finger protein 268 ZNF268 −2.6 201307_at AL534972 septin 11 11-Sep −2.5 221727_at AA456973 — — −2.5 221844_x_at AV756161 CDNA clone IMAGE: 6208446 — −2.5 221217_s_at NM_018723 ataxin 2-binding protein 1 A2BP1 −2.5 37577_at U79256 Rho GTPase activating protein 19 ARHGAP19 −2.5 203482_at AL133215 chromosome 10 open reading frame 6 C10orf6 −2.5 204521_at NM_013300 chromosome 12 open reading frame 24 C12orf24 −2.5 218447_at NM_020188 chromosome 16 open reading frame 61 C16orf61 −2.5 213436_at U73304 cannabinoid receptor 1 (brain) CNR1 −2.5 205931_s_at NM_004904 cAMP responsive element binding CREB5 −2.5 protein 5 201018_at AL079283 eukaryotic translation initiation factor EIF1AX −2.5 1A, X-linked 217820_s_at NM_018212 enabled homolog (Drosophila) ENAH −2.5 204422_s_at NM_002006 fibroblast growth factor 2 (basic) FGF2 −2.5 64900_at AA401703 hypothetical protein FLJ22167 FLJ22167 −2.5 213094_at AL033377 G protein-coupled receptor 126 GPR126 −2.5 215030_at AK023187 G-rich RNA sequence binding factor 1 GRSF1 −2.5 202934_at AI761561 hexokinase 2 HK2 −2.5 222040_at AI144007 heterogeneous nuclear HNRPA1 /// −2.5 ribonucleoprotein A1 /// hypothetical LOC728844 /// protein LOC728844 /// hypothetical LOC731172 protein LOC731172 212859_x_at BF217861 metallothionein 1E (functional) MT1E −2.5 221916_at BF055311 neurofilament, light polypeptide 68 kDa NEFL −2.5 218375_at NM_024047 nudix (nucleoside diphosphate linked NUDT9 −2.5 moiety X)-type motif 9 203060_s_at AF074331 3′-phosphoadenosine 5′-phosphosulfate PAPSS2 −2.5 synthase 2 214239_x_at AI560455 polycomb group ring finger 2 PCGF2 −2.5 213302_at AL044326 phosphoribosylformylglycinamidine PFAS −2.5 synthase (FGAR amidotransferase) 207469_s_at NM_003662 pirin (iron-binding nuclear protein) PIR −2.5 203737_s_at NM_015062 peroxisome proliferator-activated PPRC1 −2.5 receptor gamma, coactivator-related 1 218564_at BC002574 ring finger and WD repeat domain 3 RFWD3 −2.5 215009_s_at U92014 SEC31 homolog A (S. cerevisiae) SEC31A −2.5 219751_at NM_024860 SET domain containing 6 SETD6 −2.5 202524_s_at NM_014767 sparc/osteonectin, cwcv and kazal-like SPOCK2 −2.5 domains proteoglycan (testican) 2 206415_at AI769310 tolloid-like 1 TLL1 −2.5 213201_s_at AJ011712 troponin T type 1 (skeletal, slow) TNNT1 −2.5 212654_at AL566786 tropomyosin 2 (beta) /// peptidylprolyl TPM2 /// PPIL5 −2.5 isomerase (cyclophilin)-like 5 218505_at NM_024673 WD repeat domain 59 WDR59 −2.5 214714_at AK022360 zinc finger protein 394 ZNF394 −2.5 218981_at NM_020186 ACN9 homolog (S. cerevisiae) ACN9 −2.3 218868_at NM_020445 ARP3 actin-related protein 3 homolog ACTR3B −2.3 B (yeast) 219384_s_at NM_012091 adenosine deaminase, tRNA-specific 1 ADAT1 −2.3 201272_at NM_001628 aldo-keto reductase family 1, member AKR1B1 −2.3 B1 (aldose reductase) 202268_s_at NM_003905 amyloid beta precursor protein binding APPBP1 −2.3 protein 1 213892_s_at AA927724 adenine phosphoribosyltransferase APRT −2.3 209539_at D25304 Rac/Cdc42 guanine nucleotide ARHGEF6 −2.3 exchange factor (GEF) 6 212599_at AK025298 autism susceptibility candidate 2 AUTS2 −2.3 218264_at NM_016567 BRCA2 and CDKN1A interacting BCCIP −2.3 protein 208656_s_at AF135162 cyclin I CCNI −2.3 218803_at NM_018223 checkpoint with forkhead and ring CHFR −2.3 finger domains 200861_at NM_016284 CCR4-NOT transcription complex, CNOT1 −2.3 subunit 1 217726_at NM_016057 coatomer protein complex, subunit zeta 1 COPZ1 −2.3 203880_at NM_005694 COX17 cytochrome c oxidase assembly COX17 −2.3 homolog (S. cerevisiae) 220230_s_at NM_016229 cytochrome b5 reductase 2 CYB5R2 −2.3 204076_at AB002390 ectonucleoside triphosphate ENTPD4 −2.3 diphosphohydrolase 4 203806_s_at NM_000135 Fanconi anemia, complementation FANCA −2.3 group A /// Fanconi anemia, complementation group A 219901_at NM_018351 FYVE, RhoGEF and PH domain FGD6 −2.3 containing 6 205848_at NM_005256 growth arrest-specific 2 GAS2 −2.3 213129_s_at AI970157 glycine cleavage system protein H GCSH /// −2.3 (aminomethyl carrier) /// similar to LOC654085 /// Glycine cleavage system H protein, LOC730107 mitochondrial precursor /// similar to Glycine cleavage system H protein, mitochondrial precursor 214730_s_at AK025457 golgi apparatus protein 1 /// sema GLG1 /// SEMA6C −2.3 domain, transmembrane domain (TM), /// CDC42SE1 and cytoplasmic domain, (semaphorin) 6C /// CDC42 small effector 1 201348_at NM_002084 glutathione peroxidase 3 (plasma) GPX3 −2.3 211998_at AW138159 H3 histone, family 3B (H3.3B) H3F3B −2.3 214059_at BE049439 Interferon-induced protein 44 IFI44 −2.3 209760_at AL136932 KIAA0922 KIAA0922 −2.3 221219_s_at NM_017566 kelch domain containing 4 KLHDC4 −2.3 209840_s_at AI221950 leucine rich repeat neuronal 3 LRRN3 −2.3 203478_at NM_002494 NADH dehydrogenase (ubiquinone) 1, NDUFC1 −2.3 subcomplex unknown, 1, 6 kDa 218888_s_at NM_018092 neuropilin (NRP) and tolloid (TLL)-like 2 NETO2 −2.3 202432_at NM_021132 protein phosphatase 3 (formerly 2B), PPP3CB −2.3 catalytic subunit, beta isoform (calcineurin A beta) 221919_at AW450929 Protein tyrosine phosphatase, receptor PTPRU −2.3 type, U 206950_at NM_002977 sodium channel, voltage-gated, type IX, SCN9A −2.3 alpha 209897_s_at AF055585 slit homolog 2 (Drosophila) SLIT2 −2.3 213139_at AI572079 snail homolog 2 (Drosophila) SNAI2 −2.3 205406_s_at NM_017425 sperm autoantigenic protein 17 SPA17 −2.3 203046_s_at NM_003920 timeless homolog (Drosophila) TIMELESS −2.3 201377_at NM_014847 ubiquitin associated protein 2-like UBAP2L −2.3 209096_at U62136 ubiquitin-conjugating enzyme E2 UBE2V2 −2.3 variant 2 201760_s_at NM_018639 WD repeat and SOCS box-containing 2 WSB2 −2.3 209814_at BC004421 zinc finger protein 330 ZNF330 −2.3 220709_at NM_024967 zinc finger protein 556 ZNF556 −2.3 201425_at NM_000690 aldehyde dehydrogenase 2 family ALDH2 −2.1 (mitochondrial) 219649_at NM_013339 asparagine-linked glycosylation 6 ALG6 −2.1 homolog (S. cerevisiae, alpha-1,3- glucosyltransferase) 213905_x_at AA845258 biglycan /// teashirt family zinc finger 1 BGN /// TSHZ1 −2.1 218954_s_at AF298153 BRF2, subunit of RNA polymerase III BRF2 −2.1 transcription initiation factor, BRF1- like 202763_at NM_004346 caspase 3, apoptosis-related cysteine CASP3 −2.1 peptidase 221107_at NM_017581 cholinergic receptor, nicotinic, alpha 9 CHRNA9 −2.1 221139_s_at NM_015989 cysteine sulfinic acid decarboxylase CSAD −2.1 218970_s_at NM_015960 cutC copper transporter homolog (E. coli) CUTC −2.1 218102_at NM_015954 2-deoxyribose-5-phosphate aldolase DERA −2.1 homolog (C. elegans) 208810_at AF080569 DnaJ (Hsp40) homolog, subfamily B, DNAJB6 /// −2.1 member 6 /// similar to DnaJ (Hsp40) LOC387820 homolog, subfamily B, member 6 isoform a 212792_at AB020684 dpy-19-like 1 (C. elegans) DPY19L1 −2.1 205741_s_at NM_001392 dystrobrevin, alpha DTNA −2.1 201632_at NM_001414 eukaryotic translation initiation factor EIF2B1 −2.1 2B, subunit 1 alpha, 26 kDa 201437_s_at NM_001968 eukaryotic translation initiation factor EIF4E −2.1 4E 202973_x_at NM_014883 family with sequence similarity 13, FAM13A1 −2.1 member A1 218986_s_at NM_017631 hypothetical protein FLJ20035 FLJ20035 −2.1 53071_s_at AI885411 hypothetical protein FLJ22222 FLJ22222 −2.1 215143_at AL049437 Hypothetical protein FLJ36166 FLJ36166 −2.1 208841_s_at AB014560 GTPase activating protein (SH3 G3BP2 −2.1 domain) binding protein 2 205527_s_at NM_015487 gem (nuclear organelle) associated GEMIN4 −2.1 protein 4 206104_at NM_002202 ISL1 transcription factor, ISL1 −2.1 LIM/homeodomain, (islet-1) 203162_s_at NM_005886 katanin p80 (WD repeat containing) KATNB1 −2.1 subunit B 1 217956_s_at NM_021204 E-1 enzyme MASA −2.1 209585_s_at AF084943 multiple inositol polyphosphate MINPP1 −2.1 histidine phosphatase, 1 220615_s_at NM_018099 male sterility domain containing 1 MLSTD1 −2.1 204326_x_at NM_002450 metallothionein 1X MT1X −2.1 203212_s_at NM_016156 myotubularin related protein 2 MTMR2 −2.1 218568_at NM_018238 multiple substrate lipid kinase MULK −2.1 202431_s_at NM_002467 v-myc myelocytomatosis viral MYC −2.1 oncogene homolog (avian) 201304_at NM_005000 NADH dehydrogenase (ubiquinone) 1 NDUFA5 −2.1 alpha subcomplex, 5, 13 kDa 212808_at AI884627 nuclear factor of activated T-cells, NFATC2IP −2.1 cytoplasmic, calcineurin-dependent 2 interacting protein 219031_s_at NM_016101 nuclear import 7 homolog (S. cerevisiae) NIP7 −2.1 202188_at NM_014669 nucleoporin 93 kDa NUP93 −2.1 201013_s_at AA902652 phosphoribosylaminoimidazole PAICS −2.1 carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase 204873_at NM_000466 peroxisome biogenesis factor 1 PEX1 −2.1 213700_s_at AA554945 Pyruvate kinase, muscle PKM2 −2.1 204887_s_at NM_014264 polo-like kinase 4 (Drosophila) PLK4 −2.1 209434_s_at U00238 phosphoribosyl pyrophosphate PPAT −2.1 amidotransferase 201489_at BC005020 peptidylprolyl isomerase F (cyclophilin PPIF −2.1 F) 211737_x_at BC005916 pleiotrophin (heparin binding growth PTN −2.1 factor 8, neurite growth-promoting factor 1) /// pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 206290_s_at NM_002924 regulator of G-protein signalling 7 RGS7 −2.1 219154_at NM_024714 Ras homolog gene family, member F RHOF −2.1 (in filopodia) 214967_at AU146983 Sterile alpha motif domain containing SAMD4A −2.1 4A 221768_at AV705803 Splicing factor proline/glutamine-rich SFPQ −2.1 (polypyrimidine tract binding protein associated) 213505_s_at BG252853 splicing factor, arginine/serine-rich 14 SFRS14 −2.1 217289_s_at AF097831 solute carrier family 37 (glycerol-6- SLC37A4 −2.1 phosphate transporter), member 4 203580_s_at NM_003983 solute carrier family 7 (cationic amino SLC7A6 −2.1 acid transporter, y+ system), member 6 208920_at AV752215 sorcin SRI −2.1 208095_s_at NM_001222 signal recognition particle 72 kDa SRP72 −2.1 214597_at BC000256 somatostatin receptor 2 SSTR2 −2.1 207871_s_at NM_018412 suppression of tumorigenicity 7 ST7 −2.1 217914_at NM_017901 two pore segment channel 1 TPCN1 −2.1 218354_at NM_016209 trafficking protein particle complex 2- TRAPPC2L −2.1 like 205300_s_at NM_022717 U11/U12 snRNP 35K U1SNRNPBP −2.1 200667_at BF448062 ubiquitin-conjugating enzyme E2D 3 UBE2D3 −2.1 (UBC4/5 homolog, yeast) 209137_s_at BC000263 ubiquitin specific peptidase 10 USP10 −2.1 213256_at AW593996 membrane-associated ring finger 3-Mar −2 (C3HC4) 3 208838_at AB020636 — — −2 201872_s_at AI002002 ATP-binding cassette, sub-family E ABCE1 −2 (OABP), member 1 202422_s_at NM_022977 acyl-CoA synthetase long-chain family ACSL4 −2 member 4 214846_s_at AB037751 alpha-kinase 3 ALPK3 −2 219437_s_at NM_013275 ankyrin repeat domain 11 ANKRD11 −2 212211_at AI986295 ankyrin repeat domain 17 ANKRD17 −2 203350_at NM_001128 adaptor-related protein complex 1, AP1G1 −2 gamma 1 subunit 212536_at AB023173 ATPase, Class VI, type 11B ATP11B −2 208764_s_at D13119 ATP synthase, H+ transporting, ATP5G2 −2 mitochondrial F0 complex, subunit C2 (subunit 9) 208445_s_at NM_023005 bromodomain adjacent to zinc finger BAZ1B −2 domain, 1B 203796_s_at AI950380 B-cell CLL/lymphoma 7A BCL7A −2 201261_x_at BC002416 biglycan BGN −2 201032_at NM_006698 bladder cancer associated protein BLCAP −2 221776_s_at AI885109 bromodomain containing 7 BRD7 −2 64432_at W05463 chromosome 12 open reading frame 47 C12orf47 −2 204215_at NM_024315 chromosome 7 open reading frame 23 C7orf23 −2 218187_s_at NM_023080 chromosome 8 open reading frame 33 C8orf33 −2 219644_at NM_016122 coiled-coil domain containing 41 CCDC41 −2 203166_at NM_006324 craniofacial development protein 1 CFDP1 −2 218057_x_at NM_006067 COX4 neighbor COX4NB −2 202521_at NM_006565 CCCTC-binding factor (zinc finger CTCF −2 protein) 214743_at BE046521 cut-like 1, CCAAT displacement CUTL1 −2 protein (Drosophila) 201572_x_at NM_001921 dCMP deaminase DCTD −2 202577_s_at BC005162 DEAD (Asp-Glu-Ala-As) box DDX19A −2 polypeptide 19A 202534_x_at NM_000791 dihydrofolate reductase DHFR −2 205762_s_at NM_007016 dihydrouridine synthase 4-like (S. cerevisiae) DUS4L −2 201540_at NM_001449 four and a half LIM domains 1 FHL1 −2 218894_s_at NM_018048 mago-nashi homolog 2 FLJ10292 −2 209702_at U79260 fatso FTO −2 212847_at AL036840 Far upstream element (FUSE) binding FUBP1 −2 protein 1 209710_at AL563460 GATA binding protein 2 GATA2 −2 221028_s_at NM_030819 glucose-fructose oxidoreductase GFOD2 −2 domain containing 2 /// glucose- fructose oxidoreductase domain containing 2 200708_at NM_002080 glutamic-oxaloacetic transaminase 2, GOT2 −2 mitochondrial (aspartate aminotransferase 2) 214280_x_at X79536 heterogeneous nuclear HNRPA1 −2 ribonucleoprotein A1 215513_at AF241534 hydatidiform mole associated and HYMAI −2 imprinted 208937_s_at D13889 inhibitor of DNA binding 1, dominant ID1 −2 negative helix-loop-helix protein 203327_at N22903 insulin-degrading enzyme IDE −2 210881_s_at M17863 insulin-like growth factor 2 IGF2 /// INS-IGF2 −2 (somatomedin A) /// insulin-insulin- like growth factor 2 205070_at NM_019071 inhibitor of growth family, member 3 ING3 −2 203607_at NM_014937 inositol polyphosphate-5-phosphatase F INPP5F −2 200079_s_at AF285758 lysyl-tRNA synthetase /// lysyl-tRNA KARS −2 synthetase 213478_at AB028949 kazrin KIAA1026 −2 212714_at AL050205 La ribonucleoprotein domain family, LARP4 −2 member 4 217506_at H49382 Hypothetical protein LOC339290 LOC339290 −2 214109_at AI659561 LPS-responsive vesicle trafficking, LRBA −2 beach and anchor containing 204059_s_at NM_002395 malic enzyme 1, NADP(+)-dependent, ME1 −2 cytosolic 218654_s_at NM_016071 mitochondrial ribosomal protein S33 MRPS33 −2 203359_s_at AL525412 c-myc binding protein MYCBP −2 201468_s_at NM_000903 NAD(P)H dehydrogenase, quinone 1 NQO1 −2 210797_s_at AF063612 2′-5′-oligoadenylate synthetase-like OASL −2 219105_x_at NM_014321 origin recognition complex, subunit 6 ORC6L −2 like (yeast) 204004_at AI336206 PRKC, apoptosis, WT1, regulator PAWR −2 213227_at BE879873 progesterone receptor membrane PGRMC2 −2 component 2 219459_at NM_018082 polymerase (RNA) III (DNA directed) POLR3B −2 polypeptide B 202313_at NM_002717 protein phosphatase 2 (formerly 2A), PPP2R2A −2 regulatory subunit B (PR 52), alpha isoform 209049_s_at BC001004 protein kinase C binding protein 1 PRKCBP1 −2 212610_at U79291 protein tyrosine phosphatase, non- PTPN11 −2 receptor type 11 (Noonan syndrome 1) 203831_at NM_014925 R3H domain containing 2 R3HDM2 −2 218430_s_at NM_022841 regulatory factor X domain containing 2 RFXDC2 −2 204337_at AL514445 regulator of G-protein signalling 4 RGS4 −2 212191_x_at AW574664 ribosomal protein L13 RPL13 −2 213939_s_at AI871641 RUN and FYVE domain containing 3 RUFY3 −2 209127_s_at AW173076 squamous cell carcinoma antigen SART3 −2 recognized by T cells 3 204019_s_at NM_015677 SH3 domain containing, Ysc84-like 1 SH3YL1 −2 (S. cerevisiae) 202980_s_at AI953523 seven in absentia homolog 1 SIAH1 −2 (Drosophila) 221543_s_at AL442077 SPFH domain family, member 2 SPFH2 −2 212061_at AB002330 U2-associated SR140 protein SR140 −2 215772_x_at AL050226 succinate-CoA ligase, GDP-forming, SUCLG2 −2 beta subunit 222116_s_at AL157485 TBC1 domain family, member 16 TBC1D16 −2 212282_at BF038366 transmembrane protein 97 TMEM97 −2 214948_s_at AL050136 TATA element modulatory factor 1 TMF1 −2 202330_s_at NM_003362 uracil-DNA glycosylase UNG −2 213480_at AF052100 vesicle-associated membrane protein 4 VAMP4 −2 220917_s_at NM_025132 WD repeat domain 19 WDR19 −2 216350_s_at X52332 zinc finger protein 10 ZNF10 −2 209538_at U69645 zinc finger protein 32 ZNF32 −2 214761_at AW149417 zinc finger protein 423 ZNF423 −2 205739_x_at NM_016220 zinc finger protein 588 ZNF588 −2 206583_at NM_017776 zinc finger protein 673 ZNF673 −2 Gene expression profiles of compound 1 sensitive RMS cell line RD-1 (IC₅₀ = 0.238 μM) and the acquired resistant RD-1 cells has (IC₅₀ = 1.999 μM) which is more than 8 fold of the parental RD1 was compared and analyzed using using GeneChip ® Expression Analysis software MAS 5.0 to identify genes differentially expressed between these cells. A change call of “increase” or “decrease” in gene expression level was assigned for each probe set and the fold change between the resistant RD-1 cells and the parental sensitive cells was calculated. The redundant probes were removed and left one as the representative for the gene. The fold change is listed, the positive indicates higher expression in the resistant RD-1, and the negative indicates the higher expression in the sensitive parental RD-1. These genes may reflect the mechanism of acquired resistance to IGF1R inhibitor. Interestingly, several insulin-like growth factor binding proteins were expressed at higher level in the acquired resistant cells compared to the sensitive parent RD-1, such as IGFBP2 (10.6 fold), IGFBP3 (6.4 fold), IGFBPS (4.8 fold), IGFBP7 (15 fold), whereas, IGF2 had conversely expression pattern. SRC family members FYN and LYN also had increased expression levels in the acquired resistant cells. Comparison of the genes correlated with the intrinsic (de novo) resistance (Table 3) to the ones related to acquired resistance (Table 8), there are common genes, such as CAST, CD44, PLAUR, SP100, STK10, TFPI2 and THBS1 with higher expression in both de novo and acquired resistant cells, suggesting there may be some common mechanisms for both types of drug resistance. Thrombospondin 1 (THBS1) was reported to prevent camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells, this shed new light on a possible role for THBS 1 in drug resistance (G. Rath, et al., Biochim. Biophys. Acta., October;1763(10):1125-34 (2006)). THBS1 was up regulated by IGF stimulation to promote cell survival (data not shown) and over expressed in the resistant cells, and thus may involved in both de novo and acquired resistance to IGF1R inhibitors. Significant Differences in Multiple Pathways Between the Sensitive and Resistant Cell Lines at Basal Level:

Global pathway analysis on the basal gene expression of 28 cell lines using globaltest indicated that 75 out 183 tested pathways were significantly associated with the sensitive/resistant classification to compound 1 (FEW adjusted p value<0.05). Several interesting pathways including apoptosis pathway, and signaling pathways of MAPK, TGFβ, Jak-STAT, insulin, VEGF and natural killer cell mediated cytotoxicity were among those significant pathways that were different between the sensitive and resistant cell lines, while mTOR signaling pathway is different (p value=0.0005) yet slightly higher than the the significance cutoff (FWE adjusted p value=0.0559). Pathway analysis of expression data for the compound 1 treated Rh41 cell compared to that for the untreated control cells, above mentioned pathways are also different between the cells treated with or without the drug with p value all less than 0.01 but not reach the statistical significant cutoff based on the FWE adjusted p values.

Ingenuity pathway analysis on the 497 probe sets that significantly correlated with the sensitivity of compound 1 in the 28-cell line panel were performed, over expression of multiple kinases (e.g., EGFR, MET, TGFβR2) in the compound 1 resistant cell lines was observed in the most significant network. This may explain why these cell lines are still proliferating and surviving even in presence of the drug, since they use alternative growth signal pathways instead of IGF1R. In this specific situation, targeting multiple pathways may be necessary to sufficiently inhibit the growth of these cells and synergistic effects with the combination of inhibitors targeting these kinases could be possible.

Synergistic Activity Between Inhibitors of IGF1R and Other Kinases:

IGF signaling through IGF1R has also been shown to protect cancer cells from the cytotoxic effects of chemotherapy and radiation, and this may be an important factor in tumor cell drug resistance (J. Gooch, et al., Breast Cancer Res. Treat., 56(1): 1-10 (1999), B. Turner, et al., Cancer Res, 57(15):3079-83 (1997)). Recent evidence suggests that resistance to Herceptin® in some forms of breast cancer may be due to activation of IGF1R signaling in those cancers (Y. Lu, et al., J. Natl. Cancer Inst., 93(24):1852-7 (2001)). Tumor cells rely on alternative receptors for activation of critical signaling pathways, therefore, strategies designed to block signaling from multiple receptors may be advantageous. Due to the wide expression of IGF1R and the potential cross-talk between the IGF1R pathway and the other signaling pathways implicated in oncogenesis (EGFR, Her2 and mTOR), IGF1R inhibitors may have potential to be combined with other therapies in a wide range of tumors to increase the overall survival of patients. Through ingenuity pathway analysis, the overexpression of multiple kniases (EGFR, MET, TGFR) in the compound 1 resistant cell lines was observed to be within the top network. Given the important roles of IGF1R, EGFR and Her2 in cell cycle progression, we carried out combination studies to investigate whether inhibition of multiple targets might result in enhanced inhibition of tumor growth. Table 9 summarizes the data for in vitro combination studies in multiple types of tumor cell lines and indicated that the drug combinations resulted in synergistic effects between IGF1R inhibitor compound 1 and various inhibitors of EGFR, including both Her 1 and/or Her2 inhibitors in the forms of either antibody (cetuximab) or small molecules (gefitnib, erlotinib and lapatinib).

TABLE 9 In vitro combination study of compound 1 with other anti-tumor agents in multiple cell lines: IGF1R- sal, Colo205, RD1, HT-29, WiDr, GEO, MDA-PCa-2b, MCF-7, H3396, N-87, BT474, and SKBR3 cell lines. Class/Compound Combination Result HER1/HER2 Inhibitor cetuximab Synergy gefitnib Synergy erlotinib Synergy lapatinib Synergy Other targets dasatinib Synergy Cytotoxic paclitaxel Additive cisplatin Additive VP-16 Additive ADR Additive vincristine Additive The combination results were analyzed by Isobolograms. These results confirmed our hypothesis based on the pathway analysis. In vivo synergistic effects were also observed in selected xenograft models (data not shown). In addition, combination between multiple cytotoxic agents and compound 1 also resulted in additive activity.

Increased expression level of SRC family members FYN (3 fold) and LYN (11 fold) in the compound 1 acquired resistant RD-1 cells may suggest SRC family members act as an alternative signal pathway to play an important role in growth and survival of the acquired resistant cells, and targeting IGF1R in this case is not sufficient enough. Targeting multiple pathways could be one of ways to prevent the acquired resistance. The results in Table 9 also demonstrated that synergistic effect observed between IGF1R inhibitor compound 1 and dasatinib, a novel, oral, multi-targeted kinase inhibitor that targets important oncogenic pathways, including SRC family kinases, BCR-ABL, PDGFR, c-KIT and EPHA2 (L. Lombardo, et al., J. Med. Chem.;47:6658-61 (2004), A. Todd, et al., PNAS; 102;11011-11016 (2005)).

Discussion

The development of trastuzumab and EGFR tyrosine kinase inhibitors have demonstrated that careful measurement of biomarkers is necessary when only a small percentage of patients have receptor-driven tumors. Identification of molecular markers predictive of response to IGF1R inhibitors could assist in clinical development by selecting patients most likely to derive clinical benefit. In the present study, by utilizing both microarray gene expression profiling and LC/MS based “bottom-up” protein profiling technologies and a panel of 29 sarcoma and neuroblastoma cell lines, we identified genes and proteins that differentially expressed between the sensitive and resistant cell lines to IGF1R inhibitors compound 2 and compound 1. Realizing the sensitivity/resistance demarcation in the panel of the cell lines is arbitrarily defined and its relevance to the peak range of the drug concentrations in plasma of patients treated with the clinical achievable dose is unclear, we applied Pearson correlation analysis of expression levels with IC₅₀ values to identify genes/protein correlated with the sensitivity of the drugs in combination with two-sample t-test.

There is a correlation between sensitive/resistant classification to IGF1R inhibitors and different sub-types of cell lines. Notably, most of neuroblastoma, Ewing's and RMS cell lines are sensitive to the inhibitors, making these cell types as the preferred targeting population for IGF1R inhibitors. However, it may create potential possibility of the markers identified are the ones reflecting the specific cell types rather than reflecting the sensitivity of cells to the IGF1R inhibitors. This is not the case for two reasons: first, the sensitive cell lines are consisted of three cell types rather than a single one, and vise visa for the resistant cell llines; second, comparing the drug sensitivity markers identified in this study with the signatures for specific subtypes of sarcomas further excluded the possibility.

A number of gene expression profiling studies of soft tissue tumors have identified the signatures for specific subtypes of sarcomas (C. Baer, et al., Int. J. Cancer,110(5):687-94 (2004), K. Baird, et al., Cancer Res., 65: (20)9226-35 (2005), T. Nielsen, et al., Lancet, 359(9314):1301-7 (2002)). For example, the top discriminators for Ewing's sarcoma include FVT1, DCC, DKK2, PAX3 and JAK1; for fibrosarcoma are PMP22, PTPRZ1, FN1; for RMS are MYL4, FGFR4, TNN11, ACTC, FLNC, and CDH15; for liposarcoma are PPARG, FABP4, FALCS, SH3KBP1, HOXAS and AIM1, for leiomyosarcoma MYLK, CCN1, PBX1 and SLMAP. The comparison results indicated that none of the subtype specific markers are among the intrinsic sensitivity markers we identified.

Since IGF1R plays a role in cell survival and in resistance to the anti-HER2 monoclonal antibody trastuzumab, the expression patterns of the components of IGFs/IGF1R system were evaluated in this study to see if they have any correlation with the intrinsic sensitivity/resistance to IGF1R inhibitors in the panel of cell lines. The results showed that IGF1R expression level was not significantly correlated to the sensitivity of compound 2 and/or compound 1 in the 29 sarcoma cell lines even through some of the sensitive cell lines had higher IGF1R expression, this does not exclude the possibility that the sensitive cell lines have elevated activity of IGF1R or IGF1R is the major player for the growth of these cell lines. On the other hand, one member of the IGF-binding proteins (IGFBPs), IGFBP6, was significantly higher (>10 fold) in the group of resistant cell lines at basal level. Intriguingly, in the compound 1 acquired resistant RD-1 cells, IRS2 was 2 fold and IGFBP2, IGFBP 3, IGFBP 5 and IGFBP 7 were 7 to 15 fold elevated compared to the parent sensitive cells. IRS2 is the substrate for IGF1R and can enhance the IGF1R activity associated with a metastatic phenotype which correlated with increased migration and motility (J. Jackson, et al., Oncogene, 20(50): 7318-25 (2001)). IGFBPs influenced IGF signaling by modulate the bioavailability and bioactivity of the IGFs. Several IGFBPs are implicated in drug resistance. IGFBP3 and IGFBP5 were reported to be significantly higher from ovarian cancer non-response patients to aromatase inhibitor letrozole compared with responders (G. Walker, et al., Clin. Cancer Res., 13(5):1438-44 (2007)). IGFBP-2 mRNA and protein level were found to be overexpressed in resistant cell lines to antiestrogen Faslodex/Fulvestrant, tamoxifen or RU 58,668 (A. Juncker-Jensen, et al., Growth Horm. IGF. Res., 16(4):224-39 (2006)). IGFBPs' actions can be modulated by IGFBP proteases, such as cathepsins that cleave IGFBPs. Higher basal expression level (4 to 12 fold) of lysosomal cysteine protease cathepsin B, L and Z and lysosomal aspartyl protease cathepsin D were observed in the resistant cell lines. In cancer patients, elevated cathepsin B activity correlates to poor therapy outcome. Several studies have shown that levels of cathepsin B and/or cathepsin L are correlated with drug-resistance (e.g., adriamycin) (M. Osmak, et al., Anticancer Res., 21(1A):481-3 (2001), P. Scaddan, et al., Invasion Metastasis., 13(6):301-13 (1993)). Cathepsin L acts as a cell survival molecule responsible for initiation of resistance to chemotherapy, inhibition of cathepsin L with siRNA facilitates induction of senescence and reversal of drug resistance (A. Juncker-Jensen, et al., Growth Horm. IGF Res., 16(4):224-39 (2006)). The association between drug-resistance and cathepsin D was also studied in nine cervical and laryngeal carcinoma cell lines resistant to different cytostatics, and all drug resistant cell lines had increased concentration of cathepsin D (M. Osmak, et al., Anticancer Res., July-August;19(4B):3193-7 (1999)).

Another group of genes involved in the intrinsic (de novo) drug resistance to

IGF1R inhibitors was metallothionein family members (1F, G, H, M, X, 2A), with over-expression (4 to 9 fold) in resistant cell lines. Metallothionein family members are cysteine-rich proteins that involved in many pathophysiological processes such as metal ion homeostasis and detoxification, protection against oxidative damage, cell proliferation and apoptosis, chemo-resistance (platinum agents, tamoxifen) and radiotherapy resistance (M. Ebadi, et al., Gen Pharmacol., 25(7):1297-310 (1994)). The basal level overexpression of these family members was also observed in a group of colon cancer lines that are resistant to compound 1 compared to the sensitive cell lines, suggesting the role of metallothionein family members in IGF1R inhibitor drug resistance.

Inhibition of oncogenic protein kinases by small molecule inhibitors has proven to be a valuable strategy for the directed and target-specific treatment of an ever-increasing number of cancer types. Unfortunately, initially successful therapy is often hampered by relatively rapid onset of resistance to the drug and subsequent relapse, particularly in patients with advanced disease. In addition to deriving mutations, loss of target dependence due to the activation of parallel signaling pathways has been also reported as cause for acquired drug resistance. Therefore, novel therapeutic approaches are based on concepts to prevent or circumvent drug resistance, e.g., with target-specific novel drugs interfering with signaling and apoptotic pathways. Revelation of mechanistic details of drug resistance also provides the basis for the development of therapies with novel or conventional antitumor drugs in combination with specific inhibitors to re-establish chemosensitivity. From the present study, it is noteworthy that in the cell lines with de novo resistant to IGF1R inhibitors, other tyrosine kinases such as Met and EGFR were overexpressed. Furthermore, SRC family members FYN and LYN also increased expression levels in the compound 1 acquired resistant cells. These observations may suggest that loss of IGF1R dependence due to overexpression of other kinases and activation of different signal pathways plays an important role as one of the possible mechanisms in the de novo and acquired resistances to IGF1R inhibitors. It is possible that in the IGF 1R inhibitor resistant cell lines, MET and EGFR pathways are presumably more activated and are major factors for the growth signaling, so targeting only IGF1R is not sufficient enough to inhibit growth of these cells.

The same hypothesis could be applied to the IGF1R inhibitor acquired resistant cells because SRC family members FYN and LYN elevated their expression level after the IGF1R inhibitor treatment. Based on these observations, we hypothesize that there should be a potential sensitize activity between IGF1R inhibitors and inhibitors for Met, EGFR or SRC pathways. The combination studies in several tumor cell lines (Table 9) actually demonstrated the synergy effects between IGF1R inhibitor compound 1 and multiple HER1/HER2 inhibitors or dasatinib, a multi-targeted kinase inhibitor that targets important oncogenic pathways including SRC family kinases. The same synergy effects were also observed for IGF1R inhibitor compound 2 (data not show). The results further support the observation that co-inhibition of IGF1R and EGFR synergistically sensitizes cancer cells to induce apoptosis (A. Camirand, et al., Breast Cancer Res., 7(4):R570-9 (2005), J. Steinbach, et al., Biochem. Biophys. Res. Commun., 321(3):524-30 (2004)).

Because the mutations in tyrosine receptor kinases have been linked to the efficacy of the inhibitors targeting these kinases, it is reasonable to ask whether mutations or/and single nucleotide polymorphisms (SNPs) in IGF1R would correlate with the response to the IGF1R inhibitors, compound 2 and compound 1. Sequencing of the IGF1R in Rh41 and RD-1 (sensitive lines), Rh36 (primary resistant line) and resistant RD-1 (acquired resistant line) has shown no mutations or/and SNPs exist that might cause resistance to the IGF1R inhibitors. Interestingly, no specific mutations in IGF receptors or ligands have been identified in human cancers, but there is clear evidence of epigenetic alterations such as the loss of imprinting (LOI) of IGF-II in a variety of human tumors (S. Ranier, et al., Hum. Mol. Genet., 3(2):386 (1994), S. Zhan, et al., Clin. Invest., 94(1): 445-8 (1994)). Furthermore, no SNPs that cause amino acid changes in the IGF1R protein have been reported in the NCBI dbSNP database, the Japanese SNP database or the Incyte Foundation database. In addition, no human inherited disorders are attributed to mutations in IGF1R. In order to further evaluate potential IGF1R mutations in human cancers, we sequenced the human IGF1R gene from a panel of genomic DNA derived from 24 tumor-derived cell lines and from 48 human primary lung tumors and no germline variations or somatic mutations were identified in these tumor/cell line samples during tumorigenesis, although amplification of the IGF1R locus has been reported in a small number of breast cancer and melanoma specimens (A. Almeida, et al., Genes Chromosomes Cancer, 11(1): 63-5 (1994)).

From protein profiles of the baseline expression in 29 cell lines, a strikingly large number of the proteins identified are involved in cell adhesion and cell motility and extracellular signaling regulated processes. Most actin binding proteins found were present in lower levels in the IGF1R sensitive cell lines. The overall goal of this study is to understand the difference in the proteomic signatures of resistant and sensitive cell lines. The pattern emerging from these data is a profile of sensitive cell lines with lower levels of cytoskeleton binding proteins, and overall higher levels of DNA and RNA binding proteins found in the nucleus. The open question is how these features confer the sensitivity to IGF1R inhibitors on the sarcoma cell lines studied here.

There is differential sensitivity of compound 2 and compound 1 in a pair of human RMS cells that are sensitive (Rh41) or resistant (Rh36) to the drugs in a cellular proliferation assay (Table 1). These two cell lines have different chromosomal translocations: Rh41 cells harbor a PAX3-FKHR translocation, t(2;13)(q35;q14), whereas Rh36 cells harbor a EWS-FLI-1 translocation, t(11;22)(q24;q12). Gene expression revealed that Rh41 cells have a significant higher level of IGF1R but limited expression of IR, the results were confirmed by RT-PCR measurements (IGF1R/IR ratio=445) and by FACS analysis (data not shown). No mutations in the IGF1R were apparent in both cell lines. In general, the level of IGF1R expression has not been correlated with increased sensitivity in multiple cell lines, thus the sensitivity might be due to differential signaling pathways in these cells. In order to better understand the mechanism of the differential sensitivity, the two cell lines were evaluated by drug treatment and global gene/protein profiling to monitor the differential changes in gene/protein expression. Overall, in Rh36 cells the drug had little, to no effect especially at later time points, 36 and 72 hrs. This makes sense considering the drug concentration of compound 1 used in the study, Rh36 is highly resistant. However, in the sensitive cell Rh41, 30% of genes have significant expression changes upon the drug treatment. These genes are mainly involved in apoptosis, cell growth and proliferation, cell cycles and multiple tyrosine kinases pathways as well as the down-stream IGF1R signaling pathways: MAPK, PI3K and AKT. The expression level of survivin was significantly reduced especially at 36 and 72 hours and programmed cell death 4 (PDCD4) was up-regulated by compound 1 treatment in the sensitive Rh41 cells, but not in resistant Rh36 cells. PDCD4 is a tumor suppressor protein and its expression is strongly induced during apoptosis in a number of cell types (0. Afonja, et al., Oncogene, 23(49):8135-45 (2004)). Thus, up-regulation of PDCD4 expression may suggest apoptosis induced by compound 1 in sensitive cell lines only. This is in agreement with Western blot analysis showed both Rh41 and Rh36 cell lines have high expression of pBad, but only Rh41 cells showed significant reduction in pBad activity by 6 hrs of drug treatment. The reduction in pBad activity was accompanied by an increase in apoptosis when cells were exposed to the drugs for 24-48 hrs, followed by a G1 arrest. Remarkable but not complete decrease of Ki-67 in compound 1 treated cells may suggest the inhibitor with the cytostatic rather than cytotoxic effect. The inhibitor may induce apoptosis and lower the survival threshold of cancer cells thereby augmenting a second apoptotic stimulus by another agent in a combination therapy.

There are 41% of 183 total tested KEGG pathways significantly different between the sensitive and resistant cell lines to IGF1R inhibitor. This provides a general clue on what are the main differences conferring the cell's sensitivity to IGF1R inhibitor. For example, apoptosis pathway is one of the differences, many genes promoting apoptosis have higher expression levels in the resistant cell lines. Detailed dissection of the pathway is needed to get insights for whether resistant cell lines have higher threshold to be apoptotic due to presence of other growth signaling pathways (e.g., EGFR, MET) in addition to IGF1R pathway, whereas in the sensitive cell lines, IGF1R is probably the dominant growth and survival driver.

In conclusion, molecular characterization of a panel of soft tissue sarcoma cell lines lead to identified signatures or candidate markers correlating with the intrinsic sensitivity in vitro to IGF1R inhibitors, compound 1 and compound 2. Whether these signatures or markers have the utility in predicting the response to IGF1R inhibitors in the patients with sarcoma needs to be tested in clinic. The possible mechanisms for both intrinsic and acquired drug resistances were explored and could be due to the alternative activation of other parallel signaling pathways besides IGF1R. Based on these possible mechanisms, the combination strategies to target multiple pathways was proposed and tested, synergistic activity of inhibitors for IGF1-R and EGFR, or SRC was observed. This provides some clues on the strategies for developing IGF1R inhibitor and possible combination therapies in clinical trials to achieve synergy between inhibitors for IGF1R and other kinases.

Example 2 Production of Antibodies Against the Biomarkers

Antibodies against the biomarkers can be prepared by a variety of methods. For example, cells expressing an biomarker polypeptide can be administered to an animal to induce the production of sera containing polyclonal antibodies directed to the expressed polypeptides. In one aspect, the biomarker protein is prepared and isolated or otherwise purified to render it substantially free of natural contaminants, using techniques commonly practiced in the art. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity for the expressed and isolated polypeptide.

In one aspect, the antibodies of the invention are monoclonal antibodies (or protein binding fragments thereof). Cells expressing the biomarker polypeptide can be cultured in any suitable tissue culture medium, however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented to contain 10% fetal bovine serum (inactivated at about 56° C.), and supplemented to contain about 10 g/l nonessential amino acids, about 1,00 U/ml penicillin, and about 100 μg/ml streptomycin.

The splenocytes of immunized (and boosted) mice can be extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line can be employed in accordance with the invention, however, it is preferable to employ the parent myeloma cell line (SP2/0), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (1981, Gastroenterology, 80:225-232). The hybridoma cells obtained through such a selection are then assayed to identify those cell clones that secrete antibodies capable of binding to the polypeptide immunogen, or a portion thereof.

Alternatively, additional antibodies capable of binding to the biomarker polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens and, therefore, it is possible to obtain an antibody that binds to a second antibody. In accordance with this method, protein specific antibodies can be used to immunize an animal, preferably a mouse. The splenocytes of such an immunized animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones that produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce the formation of further protein-specific antibodies.

Example 3 Immunofluorescence Assays

The following immunofluorescence protocol may be used, for example, to verify IGF1R biomarker protein expression on cells or, for example, to check for the presence of one or more antibodies that bind IGF1R biomarkers expressed on the surface of cells. Briefly, Lab-Tek II chamber slides are coated overnight at 4° C. with 10 micrograms/milliliter (μg/ml) of bovine collagen Type II in DPBS containing calcium and magnesium (DPBS++). The slides are then washed twice with cold DPBS++ and seeded with 8000 CHO-CCRS or CHO pC4 transfected cells in a total volume of 125 μl and incubated at 37° C. in the presence of 95% oxygen/5% carbon dioxide.

The culture medium is gently removed by aspiration and the adherent cells are washed twice with DPBS++ at ambient temperature. The slides are blocked with DPBS++ containing 0.2% BSA (blocker) at 0-4° C. for one hour. The blocking solution is gently removed by aspiration, and 125 μl of antibody containing solution (an antibody containing solution may be, for example, a hybridoma culture supernatant which is usually used undiluted, or serum/plasma which is usually diluted, e.g., a dilution of about 1/100 dilution). The slides are incubated for 1 hour at 0-4° C. Antibody solutions are then gently removed by aspiration and the cells are washed five times with 400 μl of ice cold blocking solution. Next, 125 μl of 1 μg/ml rhodamine labeled secondary antibody (e.g., anti-human IgG) in blocker solution is added to the cells. Again, cells are incubated for 1 hour at 0-4° C.

The secondary antibody solution is then gently removed by aspiration and the cells are washed three times with 400 μl of ice cold blocking solution, and five times with cold DPBS++. The cells are then fixed with 125 μl of 3.7% formaldehyde in DPBS++ for 15 minutes at ambient temperature. Thereafter, the cells are washed five times with 400 μl of DPBS++ at ambient temperature. Finally, the cells are mounted in 50% aqueous glycerol and viewed in a fluorescence microscope using rhodamine filters. 

What is claimed is:
 1. A method for predicting the likelihood a patient will respond therapeutically to a method of treating cancer comprising administering an IGF1R inhibitor, said method comprises: (a) measuring the expression level of the IGFBP6 biomarker in a biological cancer sample of said patient; (b) determining whether said sample has an increased level of said biomarker in said cancer sample that is at least 2-fold higher relative to a predetermined level of said biomarker, (c) classifying said patient as having an increased likelihood of responding therapeutically to said method of treating cancer if said patient has a decreased level of said biomarker, and (d) administering (2S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-2-pyrrolidinecarboxamide to said patient.
 2. The method of claim 1 further comprising the measurement of at least one additional biomarker selected from Table
 2. 3. The method of claim 1 wherein said biological sample is a tissue sample comprising cancer cells and said tissue is fixed, paraffin-embedded, fresh, or frozen.
 4. A method for predicting the likelihood a patient will respond therapeutically to a method of treating cancer comprising administering an IGF1R inhibitor, said method comprises: (a) measuring the expression level of the IGFBP6 biomarker in a cancer sample of said patient; (b) administering an IGF1R inhibitor to said patient; (c) following the administering step (b), measuring in said sample of said patient the expression level of said biomarker, and (d) classifying said patient as having a decreased likelihood of responding therapeutically to said method of treating cancer if said patient has an increased level of said biomarker measured in step (c) that is at least 2-fold higher than the level of said biomarker measured in step (a), wherein said IGF1R inhibitor is (2S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-2-pyrrolidinecarboxamide.
 5. The method according to claim 4, further comprising the step of selecting the optimal dose of said IGF1R inhibitor to achieve a therapeutic response.
 6. The method according to claim 4, further comprising the step of administering said IGF1R inhibitor in combination with another agent to achieve a therapeutic response.
 7. The method according to claim 6, wherein said other agent is an EGFR inhibitor. 